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Abstract 
Kinase drug discovery has been a relatively successful endeavour: since the approval of imatinib 
in 2001, another 51 kinase inhibitors have been approved for treating patients by targeting these 
signalling proteins when they are implicated in disease. That said, more than 80% of the near 
600 human protein kinases lack suitably potent and selective compounds to validate their role 
in biology. 
The limited availability of such compounds is reflected in research output where a lot of the 
published work on kinases has been done on a relatively small number of targets. This thesis 
work is part of a collaborative effort with the Structural Genomics Consortium to provide 
suitable chemical probes for the, so-called, “dark kinome” to find the drug targets of the future. 
The aim of this PhD project was to develop a suitable chemical probe for a relatively 
understudied kinase, protein kinase N2 (PKN2). PKN2 is an AGC kinase that has reported roles in 
cell cycle, adhesion and transport amongst others. It has also been postulated as a target of 
interest in several cancers, heart failure and inflammation, but currently lacks selective 
inhibitors to convincingly validate its role in these various diseases. 
The European Molecular Biology Laboratory (EMBL) ChEMBL database literature screen has 
record of 1200 compounds from across the literature with biological activity data against PKN2. 
Following a triage of the data, three relatively small but potent PKN2 inhibitors were identified 
(10, 11 and 12). The Structure Activity Relationships of these compounds were explored by 
synthesis of a chemical library resulting in three series of compounds. The potencies and 
selectivities of these compounds within the PKN kinase family were evaluated using TR-FRET 
assay experiments. Selectivity within the wider kinome was investigated using the commercial 
DiscoverX KINOMEscan® panel containing nearly 500 kinases. 
This work showed it is possible to potently and selectively drug PKN2 within the PKN kinase 
family and the wider kinome. One compound (187) shows Ki = 2.7 nM in vitro potency towards 
PKN2, 5-fold selectivity for PKN2 over PKN1 and inhibits just 9/400 wild-type kinases in the 
DiscoverX screen above 70%. This compound was further optimised to yield a compound (312) 
with PKN2 Ki = 6.7 nM with 18-fold selectivity over PKN1 – with wider selectivity data pending at 
time of writing. This is a major step towards delivering a suitable probe for this relatively 
neglected kinase to validate its potential as a new drug target. 
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Chapter 1 Introduction 
1.1 Chemical Probes 
Chemical probes, also known as chemical tools, are selective small molecules designed to enable 
scientists to solve mechanistic biological questions. Drug molecules, on the other hand, are 
designed with the aim of producing a desired clinical response.1 Chemical probes thus need not 
possess all of the desirable physiochemical properties of a drug candidate (e.g. off-target hERG 
inhibition, bioavailability and metabolic stability)2 but often make excellent starting points for 
drug discovery programmes to facilitate the elucidation and validation of disease pathways.  
Chemical probes are designed to modulate the function of a protein, nucleic acid or other 
biomolecule. They are used in combination with genetic approaches such as small interfering 
RNAs (siRNA) and CRISPR-Cas9 methods to validate that the intended change in the biochemical 
pathway elicits a particular biological response e.g. inhibition of a particular protein halts 
proliferation of a specific cancer cell line.3 
A good quality probe enables the further understanding of both physiological and pathological 
pathways. They can also enable drug discovery programmes because probes can confirm 
whether a potential drug target is involved in disease or not and can be used to set up assay 
experiments. 
The general characteristics of a good quality chemical probe have been summarised in multiple 
reviews1–3 which suggest using the following guiding parameters: a suitable probe must have 
less than 100 nM in vitro potency at the target protein; have at least 30-fold selectivity over 
sequence related proteins of the same target family; be profiled against an “industry standard” 
panel of pharmacologically relevant off-target proteins; and less than 1 μM in cellular potency. 
They also suggest a complementary inactive analogue that can be used as a negative control 
compound.4  
 
Figure 1.1 Target-based vs. probe-based discovery process sequences3 
TARGET-
BASED 
APPROACH
1. Target ID
2. Target 
Validation
3. Medicinal 
Chemistry
4. Preclinical 
studies
PROBE-
BASED 
APPROACH
1. Medicinal 
Chemistry
2. Target ID
3. Target 
Validation
4. Preclinical 
studies
2 
 
The conventional series of events in a drug discovery programme involve identifying a drug 
target and validating that target with biogenetic techniques before carrying out iterative rounds 
of medicinal chemistry to optimise a candidate before pre-clinical studies (Figure 1.1). This can 
be referred to as “target-based discovery”.  
This sequence of processes outlined in the top schematic in Figure 1.1 can be reordered to form 
a so-called “probe-based discovery” strategy, whereby the bulk of the medicinal chemistry 
happens first. Once a suitably selective and potent probe is made, it can be used in combination 
with biogenetic techniques to facilitate target identification and validation before entering 
preclinical studies. 
Genetic tools such as RNA interference (RNAi)5,6 have transformed how we modify genes and 
the protein functions they code for. While useful techniques, they have some disadvantages 
compared to small molecule inhibitors. For example, generation of knockdown cell lines is 
generally a time consuming process. The removal of one gene can sometimes cause another 
gene to upregulate and mask the effect of the initial gene knockdown. Sometimes it is not 
possible to achieve full gene knockdown e.g. when using conditional genetic techniques. The 
delivery of nucleic acids into cells can also be more challenging than dosing with small molecules 
in solution. Off-target effects, known as the “interferon response” can occur due to the cell 
detecting the presence of certain nucleic acids.  
Additionally, changes in transcription levels of messenger RNA (mRNA) do not always correlate 
with the amount of expressed protein in a cell7 and removing a protein altogether is not always 
equivalent to inhibiting one with a small molecule. When dealing with multifunctional proteins, 
certain ligands may only modulate a portion of that protein and inhibit one of multiple functions, 
whereas RNAi-facilitated gene silencing removes the entire protein which is different to 
pharmacological intervention via an inhibitor compound.8 Having a biochemical technique to 
complement siRNA-based validation techniques can save time and resources in the long-term 
when seeking drug candidates of the future. 
 
Figure 1.2 Staurosporine (1)9 
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Probes should be of high selectivity and potency as the use of low-quality probes can lead to 
misleading conclusions. For example, staurosporine (1) (Figure 1.2) is a natural product derived 
from bacteria10 that, while initially reported as a selective protein kinase C (PKC) inhibitor, has 
proven to be a pan-kinase inhibitor so it not useful for defining pathways involving more than 
one kinase.11 That said, promiscuous probes like staurosporine are still used incorrectly in tens 
of thousands of studies1 to explore specific mechanistic questions, although its use as a control 
compound remains appropriate when comparing it with other kinase inhibitors. 
 
Figure 1.3 LY294002 (2)12 
Similarly, LY294002 (2) (Figure 1.3) was described as a selective phosphoinositide 3-kinase (PI3K) 
inhibitor in 199412 which was later disproven13 and, whilst better PI3K inhibitors have since been 
synthesised and characterised,14 the compound still features in over 1200 publications from the 
last five years alone according to a PubMed search for “LY294002 and PI3 kinase” in March 
2020.15 
Selectivity is not the defining characteristic of a poor chemical probe. Other features such as the 
appearance of chemically reactive motifs (e.g. acrylates and multiple halides) or molecular 
fragments known as pan-assay interference compounds (PAINs)16. These can give rise to false 
positives across common biochemical assays can be missed by researchers who do not have a 
background in chemistry or a research group that lacks the input of a synthetic or medicinal 
chemist.1–3 
The reasons why low quality probes continue to be used can be put down to any number of 
factors, from commercial vendors choosing to omit up to date information about their products 
in their catalogues and websites to unsuspecting clients; to a lack of chemistry support within a 
research team who might otherwise spot issues with a probe.1 
Resources such as the Protein Kinase Inhibitor Sets (PKIS/PKIS2)17,18, Chemical Probes Portal19 
and Structural Genomics Consortium Probes Database4 have been created as peer-reviewed 
information deposits in order to combat the wave of poor quality probe use in academia. Various 
review articles1–3 have been written specifically warning against the use of deficient probes.  
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The authors’ motives behind these articles were to ensure time and resources are not wasted in 
progressing drug discovery projects that may ultimately fail if the underlying biology is not 
sufficiently well understood. Drug discovery projects developed in academic labs frequently fail 
when they reach in vivo studies20 because the move from a relatively simple in vitro model to a 
more complex in vivo model often reveals a lack of selectivity for a given compound.1–3,21–23 
If high quality tools are available, research into the proteins they target is more likely to be 
carried out, and thus the development of new chemical tools is vital in drug discovery 
research.1,24 Figure 1.4 plots the number of PubMed25 literature search hits found in April 2019 
for over 500 human protein kinases. The skewed results show that a lot of published work is 
carried out on a very small number of kinases. This is likely due to there being more information 
available about the pathways that small number of kinases are involved in and an unavailability 
of reagents (e.g. inhibitors, genetic tools, modified cell lines) for the majority of those kinases. 
 
Figure 1.4 Plot of kinase target vs number of PubMed literature search hits25 
An example of a high impact probe is the bromodomain extra terminal motif (BET) inhibitor (+)-
JQ-1 (3) (Figure 1.5). A collaboration between James E. Bradner of Harvard and the Structural 
Genomics Consortium’s University of Oxford team began in January 2010 and resulted in the 
development of compound 3 which was published in Nature in December of that same year, as 
it was recognised as a first-in-class selective BET inhibitor.26  
Following this publication, compound 3 was distributed to over 100 laboratories who requested 
use of the compound and in 2011 alone, links were established between this bromodomain and 
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acute myeloid leukaemia (AML)27 and multiple myeloma28 (MM) cancers. A slightly modified 
version of this compound, molibresib (4) (Figure 1.5), then entered first-in-human studies in 
2012.29 This series of events covered just over two years from lab to patient which shows the 
potential power good chemical probes can have in accelerating the drug discovery process. 
Usually this process can take several years. 
 
Figure 1.5 Chemical structures of (+)-JQ-1 and optimised molibresib 
Other examples of high quality probes that catalysed research areas in the past include the 
mTOR allosteric inhibitor, rapamycin;1 liver X receptor-α/β agonist, GW683965;30 GNF-5, an 
allosteric inhibitor of kinase breakpoint cluster region-Abelson murine leukaemia viral oncogene 
(BCR-ABL);31 and BET bromodomain inhibitors I-BET and PFI-1.23 
1.2 Kinase Drug Discovery 
Achieving selectivity across the 518 known human protein kinases32 continues to present a 
significant challenge to drug discovery scientists working on projects involving these cell 
signalling proteins.33 At present, less than 20% of the human kinome is believed to have been 
investigated with small molecule inhibitors (Figure 1.4) and an even smaller fraction of those 
compounds meet the previously described criteria4 for being used as chemical probes.34 
Protein kinases facilitate the transfer of a phosphate group from adenosine triphosphate (ATP) 
(6) to a specific hydroxyl-containing amino acid residue (serine (5)/threonine/tyrosine) in a 
target protein substrate. Scheme 1.1 outlines a general mechanism for this catalytic 
biotransformation.35  
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Scheme 1.1 Mechanism of serine phosphorylation event 
The addition of a negatively charged phosphate to a protein often induces a conformational 
change in the shape of the protein36 which can activate or deactivate that protein’s function 
(Figure 1.6). Protein kinases are thus involved in many signalling pathways, as are phosphatase 
enzymes which carry out the reverse process of dephosphorylation.35 The protein kinases can in 
general be divided into those that phosphorylate serine or threonine residues, and those that 
phosphorylate tyrosine residues, along with a small number of dual-specificity kinases as well as 
a number of further sub-categories such as histidine and lipid kinases.37 
 
Figure 1.6 Exemplar conformational changes in a protein induced by phosphorylation36 
Until the 1950s, casein, phosvitin and a few other related proteins involved in embryonic 
development were the only known phosphoproteins. Following work on better understanding 
the action of glycogen phosphorylase, the discovery of c-AMP dependent protein kinase (PKA) 
by Walsh et al. in 196838 gave rise to rapid discovery of many distinct kinase proteins involved in 
cell signalling processes.39 
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Figure 1.7 General kinase topology with ATP in the binding site40 
A typical structure of a protein kinase contains several characteristics (Figure 1.7) such as a large 
C-terminal domain which mainly consists of α-helices and a smaller N-terminal domain which 
possesses a 5-stranded β-sheet.41 Between the N- and C-domains lies a cleft which is the site 
where ATP binds. This binding site is covered by a glycine-rich activation loop (P-loop/G-loop),42 
a relatively unstructured length of peptide chain that lies outside the active site and 
distinguishes between  serine/threonine and tyrosine residues on protein substrates. The start 
of the activation loop is marked by the DFG motif, a characteristic trio of aspartate (D), 
phenylalanine (F) and glycine (G) amino acid residues.37  
The aspartate coordinates with a Mg2+ ion which holds the β- and γ-phosphates of ATP in place 
to aid phosphate transfer (Scheme 1.1).43,44 The conformation of this loop, and the orientation 
of the DFG-aspartate residue indicates whether the kinase is in its active (DFG-Din) or inactive 
(DFG-Dout) state  and usually coverts between the two via the 
phosphorylation/dephosphorylation of one or more residues on this loop. 43,45,46 
Figure 1.8 outlines the four main sub-types of kinase inhibitor. Type I inhibitors bind to the ATP 
site of an active (DFG-Din) kinase, while type II inhibitors fit into the ATP site, such that the kinase 
is in its inactive conformation (DFG-Dout). Type III and type IV inhibitors bind allosterically to 
other regions of the kinase.47,48  
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Figure 1.8 Overview of type I–IV kinase inhibitor classes14 
This project involved isosteric inhibitors that target the ATP-site. The precise type I/II inhibition 
is unknown due to a lack of crystallographic information. Selectivity is harder to achieve with 
ATP-isosteric inhibitors over allosteric inhibitors because ATP is the common substrate across all 
kinases, although it is generally thought that it is possible to achieve selective type I/II inhibition 
by taking advantage of unoccupied hydrophobic spaces within the ATP-binding site (Figure 
1.9).40 
 
Figure 1.9 Illustration of ATP (6) binding to a length of peptide representing the hinge region of a kinase via 
hydrogen bonding interactions (shown in red) and vacant hydrophobic regions in the kinase active site outlined40 
The approval of imatinib (9) (Figure 1.10),49 the first FDA-approved kinase inhibitor, in 2001 was 
a milestone event in kinase drug discovery history. It primarily targets a tyrosine kinase called 
BCR-ABL which is particularly prevalent in chronic myeloid leukaemia (CML), making it a first-in-
class monogenic cancer drug.  
 
Figure 1.10 Imatinib, the first approved kinase inhibitor (9)36 
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Since then, a further 51 kinase inhibitors have been approved by the FDA for treating cancers 
and other autoimmune, cardiovascular, inflammatory and nervous system diseases.46 Bringing 
over fifty drugs to market around a particular drug class in twenty years shows just how fruitful 
pursuing kinases has been for academic and industrial drug discovery laboratories. 
That said, the 52 approved kinase inhibitors do not cover 52 distinct kinases. Only 20 kinases are 
primarily targeted by these drugs while a further 15–20 targets are currently under investigation 
in clinical trials.46 This constitutes less than 10% of the human kinome which comprises 518 
kinases. The reasons for this include well intentioned efforts to bring through second- and third-
line treatment options in the event of drug resistance, but also because it is easier to develop 
marginally improved drugs for established and well-studied targets.46 While such admirable 
efforts give more options to patients with diseases that involve this sub-set of well-studied 
kinases, there are still many hundreds of kinases with poorly understood roles in both 
physiological and pathological biology.50 
It has been estimated that less than 4% of the human genome51 has suitable tools available for 
probing the roles of proteins coded for within the genome. Within that, 2% of all coding genes 
in the human genome are linked to protein kinases.52  Less than 20% of those kinases34 have 
suitably selective and potent inhibitors. Up to a third of drug discovery efforts are carried out on 
kinase proteins but only a select number of those signalling enzymes. New chemical entities are 
needed to probe the, so-called, “dark kinome” in order to find processes that can be targeted 
to treat diseases in the future.33,34,46,50 
1.3 Structural Features of Protein Kinase N 2 
Protein kinase N 2 (PKN2) (Figure 1.7) is one of the relatively understudied kinases of the so-
called “dark kinome”. In the above PubMed literature search from April 2019 (Figure 1.4), only 
24 literature hits were found with PKN2 in the title compared to the many thousands of papers 
published about more readily researched kinases like PKA, BCR-ABL and PI3K kinases.25  
PKN2 is an AGC serine/threonine protein kinase (Figure 1.11). Of the 518 known protein kinases 
in the human kinome (Figure 1.11),32 61 protein kinases and 2 pseudo-kinases are classified as 
AGC kinases. The term “AGC” arises from the similarity in structure between the c-AMP-
dependent kinase, (PKA), the c-GMP-dependent kinase (PKG) and the protein kinase C (PKC) 
families.  
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Figure 1.11 Location of PKN2 and related PKN kinases within the human kinome phylogenetic tree highlighted in 
red. Illustration reproduced courtesy of Cell Signalling Technology, Inc.53 
PKN2 falls into the PKN/PRK sub-family (Figure 1.12), closely related to the PKC sub-family, and 
is one of three homologues (PKN1/2/3).54 It has a number of pseudonyms: Protein-Kinase C-
Related Kinase 2 (PRK2), Protein Kinase C-like 2 (PRKCL2), Cardiolipin-Activated Protein Kinase, 
PRO2042, STK7, PAK2.55  
 
 
 
Figure 1.12 A) AGC kinase family within the human kinome; B) evolution tree within the AGC kinase family. PLK 
and Aurora pseudo-kinases appear in grey41 
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In 1994 Palmer et al.56 carried out a polymerase chain reaction (PCR) based screening of two 
complementary deoxyribonucleic acid (cDNA) libraries derived from human monoblastoid U937 
cells which led to the discovery of PKN2. Redundant oligonucleotide primers that correspond to 
the catalytic domain of PKC (a highly conserved region across AGC kinases) were used to identify 
the protein. Mukai et al.57 also isolated PKN cDNA from a human hippocampal cDNA library in 
the same year. Following this a number of groups have isolated and sequenced PKN2 and its 
other isoforms.58,59  
PKN2’s catalytic domain shares 87% sequence similarity with PKN1, 70% with PKN360 and 50% 
with PKC61 kinases. There is less chain similarity in the N-terminal regions (48% between PKN1/2 
and 40% between PKN2/3). Other AGC kinases, e.g. the ROCK sub-family possess a 34% similarity 
in chain sequence to PKN2.60 
PKN1 is the most studied of the three PKN kinases. In the protein data base (PDB) there are six 
crystal structures of PKN1 domains available (4OTD, 4OTG, 4OTH, 4OTI, 2RMK, 4NKG) with 
different ligands bound. Meanwhile, there is only one structure of the PKN2 kinase domain 
bound to ATPγS (4CRS) (Figure 1.13)  and none available of PKN3. PKN3 is less well understood 
and it is found in fewer tissues than PKN1 and PKN2.62 
 
Figure 1.13 PRK2 with some annotated structural features (4CRS)63 
The above mentioned X-ray crystal structure of PKN2 (Figure 1.13) shows that ATP-γ-S, an 
analogue of ATP, interacts with the hinge region (blue) of PKN2 via two hydrogen bonds: with 
the primary amine of the adenine acting as a hydrogen bond donor to an alanine residue 
(Ala684) and the 1-nitrogen as a hydrogen bond acceptor with a tyrosine (Tyr739).  
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The C-terminus of most AGC kinases contains two specific phosphorylation sites: the 
hydrophobic motif (HM) that binds in a groove on the N-terminal lobe of the kinase and a 
turn/zipper motif.41 AGC kinases possess a hydrophobic region of six amino acids between the 
C-terminus and the catalytic core. The hydrophobic motif follows the general sequence pattern 
F/Y-X-X-F/Y-S/T/D/C-F-Y (where X represents any amino acid residue). The activation loop is 
phosphorylated by an upstream AGC kinase, PDK1 (Scheme 1.2) while another kinase 
phosphorylates the HM. The HM is also referred to as the PDK1 Interacting fragment/peptide 
(PIFtide). Secondly, there is the turn/zipper motif which has various roles in different AGC 
kinases. In PKN2 it carries the HM over to the PIF pocket and also enables the release of PKN2 
when it is docked with PDK1.54,41 
The hydrophobic motif is connected to the, so-called, “PIF pocket”, a conserved allosteric site in 
the small lobe which interacts with the PIFtide of PDK1 and other kinases in order to regulate 
ATP-binding, activity and substrate interaction.64 The PIFtide/PIF pocket complementarity allows 
PKN2 to self-inhibit itself by forming dimers/oligomers. This is thought to be a unique inhibition 
mechanism compared to the rest of the AGC family and a two-step mechanism has been 
suggested (Scheme 1.2).54,41  
First of all, once synthesised, PKN2 needs to be phosphorylated by PDK1 and does so by 
interacting with the upstream kinase. The turn-motif is phosphorylated and this process releases 
PKN2 from PDK1. Next, the phosphorylated PKN2 in its active state can be deactivated by 
forming a dimer with another PKN2 protein. The inter-molecular inhibition can be reversed 
through the binding of lipid/Rho-activators which stabilise the active monomer state of 
PKN2.41,54,64–67  
 
Scheme 1.2 Representation of the two-stage mechanism of activation of PKN241 
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1.4 Functional Roles of PKN2 
1.4.1 Physiological Roles of PKN2 
PKN2 is activated by PDK1 and Rho GTPases. It has reported functionality in regulation of 
cytoskeleton, migration, cell adhesion, embryonic development, cell cycle, apoptosis and DNA 
translation regulation.68 It is found in the cell nucleus, cytosol, cytoskeleton and plasma 
membrane.55 This is a seemingly diverse set of proposed physiological roles which requires a 
good quality chemical probe to verify. Generally, genetic methods have been mainly used to 
postulate these functions of PKN2 so far and are detailed below.  
PKN2 and Rho 
The Rho family are a set of signalling G proteins, forming part of the Ras superfamily and act as 
molecular switches. Mukai et al.69 in 1996 expressed PKN kinases with Rho in bovine brain 
membrane cells, COS-7 and Swiss 3T3 cell lines to investigate their dependency on each other 
for cell signalling. In the same year, Watanabe et al.70 published similar work correlating PKN2 
to Rho using a yeast two hybrid system, a common genetic technique for detecting interacting 
proteins in living yeast cells.71,72  
Flynn et al.73 later reported that Rho and another kinase, phosphoinositide-dependent kinase-1 
(PDK1) were involved in the activation of PKN2. They expressed kinase domains of PKN2 as well 
as PKN1 and monitored the phosphorylation rates in the presence of wild-type and mutant 
forms of Rho, PKN2 and PDK1 to establish structural areas of importance to function. They also 
used PI3K inhibitor LY294002 (2) to confirm this relationship because of PI3K’s link to PKB and 
other AGC kinases but did not use any other inhibitors in their study.  
Cytoskeleton regulation and cell migration 
Regarding work carried out on investigating PKN2’s role in cytoskeleton regulation, Vincent et 
al.74 published work in 1997 where they made microinjections of wild-type and mutant forms of 
PKN2 into different cell lines to see what effect addition of the kinase had on actin microfilament 
arrangement. They also transfected cDNA fragments into cells and their findings were a 
probable but indefinite correlation between PKN2 and Rho on microfilament organisation. No 
inhibitors were used in this work.  
In 2000, Dong et al.75 used a yeast two-hybrid genetic system to find proteins that interacted 
with PDK1. This was to better understand how PDK1 responds to insulin-controlled signals 
regarding actin cytoskeleton arrangement. They also carried out pull down experiments in rat 
cell lines to investigate the effect of deleting PKN2. In their phosphorylation studies, cells were 
treated with insulin, but no small molecules were used.  
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Bourguignon et al.76 later transfected cDNA fragments correlating to PKN2 and used wound 
healing assays to measure the effect certain proteins like PKN2 had on cell migration in 
astrocytes, specialised glial cells that support neuron cells in the central nervous system.35 No 
compound inhibitors were used in this study. 
RNAi techniques were used by Wallace et al.77 in 2011 to deplete PKN2 in bronchial epithelial 
cells and found the cells were unable to form apical junctions – specific cytoskeleton structures 
formed as a result of communication between cell signalling proteins and cytoskeletal 
components, known as cell polarisation. They also introduced a mutated form of PKN2 into the 
cell line by transfecting mRNAs to ensure PKN2 was a direct target of RhoA within the Rho family. 
Cell adhesion 
Calautti et al.78 published work in 2002 on the interaction between Fyn, a tyrosine kinase, and 
Rho and PKN2. The proteins were believed to be involved in adhesion between keratinocyte 
cells in the outer layers of the skin. They created a PKN2 expressing adenovirus that could be 
added to cells to induce over expression of PKN2. Mutant forms of Rho were also transfected 
into cells to see if PKN2 interacted with only wild-type Rho. PKN2 did not interact with the 
mutant for of Rho. No inhibitors were used in this study. 
Embryonic development 
Work by Quétier et al.79 sought to remove PKN2 from mouse embryos using gene knockdown 
techniques. The embryos did not survive this gene deletion experiment. They also used a 
conditional genetic knockdown technique that involved dosing improved Cre recombinase (iCre) 
treated cells with tamoxifen in order to induce loss of PKN2 and saw a similar essential role of 
the kinase in embryonic development. 
Cell cycle 
Misaki et al.80 used recombinant viruses like Calautti et al. to introduce additional PKN2 into 
HeLa cells. They also used microinjection techniques as well. Their aim was to investigate the 
effect PKN2 had on the activity of Wee1 kinase and cell division cycle 25 (Cdc25), a dual-
specificity phosphatase, during mitosis – the most common form of cell division.35  PKN2 did not 
enhance Wee1 activity but was shown to phosphorylate Cdc25, both in vitro.  
Apoptosis 
PKN2 has also been linked to apoptosis, programmed cell death.35 In 1998, Takahashi et al.81 
used DNA plasmids and mutagenesis recombinant caspase enzymes to investigate if PKN kinases 
were activated during apoptosis. Koh et al.82 later used yeast two-hybrid assays and PKN2 
hybrids to investigate similar roles of the kinase in programmed cell death. The substrates used 
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in their work were histone 2B (H2B) and tumour necrosis factor, the latter used to induce 
apoptosis and linked PKN2 to PI3K, but no small molecules were used to probe the role of PKN2.  
Transcriptional regulation 
In 2005, Chang et al. carried out an expression screen by transfecting DNA constructs into cell 
lines in order to find kinases that phosphorylated histone deacetylase (HDAC) enzymes and 
found PKN2 might be an activator of this class of protein. HDACs catalyse the removal of acetyl 
groups from lysine residues residing in histone and other proteins involved in control of DNA 
expression.83  
Harrison et al.84 later demonstrated in 2010 that PKN2 phosphorylates HDAC5 by using DNA 
transfection methods into heart tissue and carrying out phosphorylation studies. No compounds 
were used to validate the interaction of these proteins. 
1.4.2 Pathological Roles of PKN2 
PKN2 has been linked to multiple cancer sub-types, namely prostate,85 colon,86 head,87 neck87 
and breast88,89 cancers. It has other reported roles in inflammation,90 hepatitis C91 and 
cardiovascular processes,92 all of which will be summarised below. 
Prostate cancer 
With regards to PKN2’s role in prostate cancers, O’Sullivan et al.85 reported in 2015 that PKN1 
and PKN2 were potential mediators in the release of prostanoids, eicosanoid compounds related 
to prostaglandins involved in the body’s pain response. Prostanoids specifically control 
constriction of blood vessels (vasoconstriction),35 a notable response in certain prostate 
cancers.85 O’Sullivan et al.93 later reported in 2017 that they had found that PKN2 may form a 
complex with T prostanoid receptors in prostate cancer progression. Yang et al.94 also reported 
in 2017 that PKN2 was involved in prostate motility pathways and influences differentiation of 
prostate cell types. 
Colon cancer 
In 2018, Cheng et al.86 reported that PKN2 was involved in signalling pathways for the 
transformation of macrophage cells into their pathogenic form, known as polarisation.95 This 
polarisation process is involved in the progression of colon cancer. They found that there was 
high expression of PKN2 in early stage colon cancer cells but that as the disease progressed, the 
presence of PKN2 reduced tumour-associated macrophage association and overall tumour 
growth.86 
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Head and neck cancer 
While smokers are predominantly prone to lung cancers,96 Rajagopalan et al.87 reported in 2018 
that smokers prone to head and neck cancers following long-term exposure to cigarette smoke 
possessed high levels of PKN2 across a panel of cell lines that had been exposed to cigarette 
smoke for twelve months. They depleted PKN2 in those cell lines and found that doing so 
reduced the rate of colony formation, cell invasion and migration. 
Breast cancer 
Most recently, PKN2’s role in triple negative breast cancer (TNBC) has been postulated by Patel 
et al.89 in 2020 building on previous work by Lin et al.88 They found that depleting PKN1 and 
PKN2 in mouse and human TNBC cells reduced the rate of cell proliferation and growth of 
spheroid tumours. High PKN2 expression is correlated to poor patient outcome and has also 
been reported to support the growth of this sub-type of breast cancer – known to be particularly 
difficult to treat due to a lack of hormone receptors on the cancer cells’ surface.97  
Hepatitis C and inflammation 
Outside of cancer, PKN2 also shows promise as an anti-viral target due to its role in 
phosphorylating and activating NS5B, a RNA polymerase with a crucial role in the Hepatitis C 
disease pathway.91,98 The kinase also has other potential roles in inflammation due to the 
reported role PKN1 and PKN2 have in phosphorylating the pyrin inflammasome following 
activation by arachidonic acid.90,99,100 In the study carried out by Park et al.99 staurosporine and 
PKC412, referred to as “potent PKN inhibitors” in their study, were used. Both of these 
compounds may be potent but they are not selective PKN inhibitors9,101 and could have given 
misleading results about the precise roles of PKN kinases in these processes. 
Heart failure 
Finally, in the area of cardiovascular function, PKNs have been linked to signalling processes 
during heart formation and dysregulation in certain cardiac pathologies but these relationships 
were deemed by the authors to be less well understood than those of their closely related 
homologues, PKC proteins.92,102 In the Sakaguchi study,102 PKN1/2 were not directly inhibited. 
Instead a Rho inhibitor was used to halt the phosphorylation of the PKNs by inhibiting the 
upstream Rho protein that would otherwise activate the PKNs. 
1.5 Project Aims 
The main aim of the project was to deliver a high-quality chemical probe that showed sufficient 
potency and selectivity for PKN2 within the PKN kinase family and wider kinome to facilitate 
validation of its role in physiological and pathological biochemical pathways. The parameters set 
for the probe were those suggested by the Structural Genomics Consortium4 whereby an ideal 
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probe should exhibit less than 100 nM IC50 in vitro potency; at least 30-fold selectivity over other 
kinases; less than 1 μM IC50 in cellulo potency and have a suitable inactive analogue for use as a 
control compound. 
Three literature compounds (10, 11 and 12) (Figure 1.14) were selected in-house from a data 
triage of 1200 compounds reported in the literature as inhibitors of PRK2. The ChEMBL literature 
database103 was used to find these compounds through a search for compounds with known 
bioactivities against PKN2, which were then ranked by their potency. 
Compounds 10–12 were selected for their high potency and promising initial selectivity, with 
the exception of 12 due to lack of available data against other kinase targets. Each series will be 
discussed in a separate results chapter which will cover the similarities of the compounds to 
existing FDA-approved kinase inhibitors; synthesis of those initial hits and subsequent analogues 
for structural activity relationship (SAR) studies as well as the biological evaluation of the 
resulting compound libraries. The rationalisation of the compounds’ biological activity using 
computational drug design (CDD) methods will also be discussed. 
 
Figure 1.14 Compounds 10, 11 and 12 selected from the ChEMBL screen103–106 
This project was carried out in collaboration between SDDC and GDSC at University of Sussex 
and the SGC in order to add a PKN2 probe to their database.4 Work was carried out by the SGC 
between University of Oxford, UK and University of Campinas, Brazil to develop TR-FRET 
biochemical assay methods for these compounds against PKN2 and PKN1. Compounds with 
promising potency and selectivity between the two PKN kinases were sent for wider kinome 
screening via the commercial KINOMEscan® platform.107 The SGC also carried out 
crystallographic studies to obtain a structure of PKN2 with an inhibitor bound at the ATP site.  
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Chapter 2 Series A – Benzimidazoles 
This chapter seeks to outline the work carried out in optimising compound 10, a benzimidazole 
(Figure 2.1). The chemistry used to prepare this compound and other analogues will be discussed 
as well as the biological evaluation of the inhibitory potencies of those compounds against PKN2 
and other kinases. Attempts to rationalise said biological activity using computational studies 
will also be outlined. Most of the work covered in this chapter was recently published in the 
journal Bioorganic and Medicinal Chemistry Letters.108 
 
Figure 2.1 Original compound for series A109 
2.1 Hit Origin 
Benzimidazoles are popular scaffolds in medicinal chemistry.110 Two of the current list of 52 FDA-
approved kinase inhibitors, abemaciclib (13) and binimetinib (14) (Figure 2.2), contain 
benzimidazoles while thirteen others contain similar 6,5-aromatic heterocycles.46  
 
Figure 2.2 Chemical structure of benzimidazole-containing FDA-approved kinase inhibitors46 
Benzimidazoles are bioisosteres of the adenine portion of ATP (6) (Figure 2.3), the common 
phosphate-transferring molecule of kinases, making it a common motif explored in kinase 
inhibitor design.111 The combination of the hydrogen bond donor and accepting nitrogen atoms 
allows for multiple interactions within the kinase hinge region and the fused benzene ring 
incorporated into the structure can potentially form hydrophobic and π-π stacking 
intermolecular interactions with pockets within the catalytic site.  
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Figure 2.3 ATP (6) structure 
One such benzimidazole was identified in the previously described triage of 1200 compounds in 
the ChEMBL database reported to have biological activities against PKN2. Compound 10 (Figure 
2.1) was initially developed as a PARP inhibitor,104,112–115 but was shown to be more potent 
towards PKN2 than its intended target in a published kinase panel screen of Abbott’s compound 
library.109 The benzimidazole core is linked to a 4’-pyridyl ring at the 2-position and a primary 
amide at the 4-position. It was deemed an attractive starting point for a selective PKN2 probe 
because of its low reported potency of Ki 40 nM against PKN2 and in terms of selectivity, 
inhibited only PKN1 and CLK4 with Ki values below 100 nM out of 137 kinases with reported 
bioactivities.109  
2.2 Chemistry 
2.2.1 Synthesis of original hit 
  
 
Scheme 2.1 CDI amide coupling conditions to 17116 
Compound 10 was successfully synthesised using a 4-step synthesis. First, 2-amino-3-nitro-
benzoic acid (15) underwent an amide coupling with ammonia using 1,1'-carbonyldiimidazole 
(CDI) (16) as a coupling reagent (Scheme 2.1). Scheme 2.2 proposes a mechanism for the 
transformation.  
Deprotonation of the acid function forms a nucleophile (18) that attacks the carbonyl of the CDI 
(16), resulting in the loss of imidazole. This imidazole then attacks the carbonyl adjacent to the 
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benzene ring (19) which in turn eliminates carbon dioxide and another equivalent of imidazole. 
The combination of imidazole being a good leaving group and that the carbonyl carbon (20) is 
now sufficiently delta positive means that carbon undergoes nucleophilic attack by ammonia, 
and, for a third time, loss of imidazole occurs to yield intermediate 21. Finally, this imidazole 
deprotonates the nitrogen to form amide 17. 
 
Scheme 2.2 CDI amide coupling mechanism117 
Yields for this reaction typically ranged from 32–58% and usually two crops of amide 17 were 
isolated by filtration. The second batch was isolated from the filtrate after being left overnight 
to further crystallise. Typically, orange crystals formed.  
 
Scheme 2.3 Nitro-reduction conditions using sodium dithionite118 
Next, the nitro-functionality of 17 was reduced to form dianiline 22 using sodium dithionate 
(Scheme 2.3).118 It was found that 10 equivalents of the reducing agent were required for full 
conversion due to the tendency of sodium dithionite to degrade upon heating in aqueous 
solutions.119 Following work-up with ethyl acetate extraction and flash chromatography, 
dianiline 22 was isolated in 44% yield. This was thought to be due to the slow elution from the 
column during purification. The drop in yield was taken into account in later attempts of this 
step by carrying it out at larger scale to ensure enough of this key dianiline intermediate was 
isolated to get to the end of the synthesis. 
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Scheme 2.4 The conversion of 22 to 25104,120 
The third step of the synthesis in the literature procedure104 called for isonicotinic acid (23) to 
be coupled with 22 in the presence of TEA and DMAP (Scheme 2.4). This was attempted twice 
with no success. Converting 23 to the corresponding acid chloride (14) and then using the same 
conditions was also unsuccessful when trying to make amide 25. Table 2.1 summarises the 
chemistry attempted. 
Table 2.1 Summary of reaction conditions attempted to make amide 25104,120 
Coupling partner Other reagents Solvent Temperature Time Yield 
23 TEA, DMAP THF RT 18 h 0% 
24 TEA, DMAP THF RT 2 h 0% 
23 HATU, DIPEA DCM RT 18 h 99% 
 
HATU-facilitated coupling conditions120 using intermediate 22, isonicotinic acid (23), HATU (26) 
and N,N-diisopropylethylamine (DIPEA) were successful, isolating amide 25 in quantitative 
yields. Scheme 2.5 outlines the mechanism for an amide bond formation using HATU (26) as a 
coupling agent.  
 
 
Scheme 2.5 General HATU coupling mechanism117 
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Once the acid is deprotonated (27), it can attack the δ+ iminium carbon of the HATU (26) adjacent 
to three nitrogens. The resulting azabenzotriazole (28) can then attack the δ+ carbon of the 
carbonyl of intermediate 29 to activate the acid group, such that amine 31 can then act as a 
nucleophile to attack the activated ester (30). The zwitterionic intermediate (32) is stabilised by 
a hydrogen bonding interaction between an N-H and nitrogen acceptor within the HATU-acid-
amine tetrahedral intermediate which breaks down to again release azabenzotriazole (33) as a 
side product to give the amide product (34). 
It was found in most cases that amide 25 and its derivatives could simply be isolated from the 
reaction mixture by filtration and the crude carried forward without further purification. This 
was done because in some first attempts, carrying out aqueous work-up to isolate 25 proved 
difficult – up to a litre of solvent was required to dissolve/transfer around 100 mg product 
resulting in very low yields in one attempt. For derivative amide intermediates that did not 
precipitate out of the reaction mixture standard work-up and purification practices were used 
to isolate the intermediate. 
 
Scheme 2.6 Acid-catalysed cyclisation conditions to form benzimidazole 10104 
The benzimidazole product (10) was formed by stirring amide 25 in acetic acid with heating 
(Scheme 2.6). Scheme 2.7 outlines a possible mechanism. 
 
Scheme 2.7 Proposed mechanism for the acid-catalysed cyclisation of 25 to benzimidazole 10 
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Activation of amide 25 via reversible protonation of the carbonyl oxygen sufficiently polarises 
the carbonyl bond such that the free primary aniline attacks the δ+ carbon of intermediate 35. 
The resulting intramolecular bond formation yields cationic intermediate 36. The hydroxyl group 
picks up an additional proton to promote water loss from intermediate 37 to give benzimidazole 
10. 
For the majority of analogues, the reaction was complete within a couple of hours and 
observable by TLC and LCMS analysis. The reaction mixture was concentrated and directly 
purified by flash chromatography to remove any residual starting material and acetic acid. 
Compound 10 was successfully isolated in 24% yield. 
The isolation procedure was optimised which removed the need for a column in most cases. 
Instead, the acidic reaction mixture was neutralised by adding saturated aqueous sodium 
hydrogen carbonate which caused the product to precipitate out of solution. This was isolated 
by filtration and dried in a vacuum oven overnight to yield the benzimidazole. When preparation 
of 10 was repeated, e.g. for preparing N-alkylated analogues, isolation by this method increased 
the reaction yield from 24% to 60%. Occasionally the isolated product required further 
purification via flash column chromatography, as outlined in individual procedures in the 
experimental section which resulted in lower yields as expected. 
1H NMR confirmed the amide 25 had been converted to benzimidazole 10 because one of the 
two N-H peaks had disappeared from the spectra and characteristic singlet peaks for 
benzimidazole exchangeable N-H proton were observed around δ 7.84. 
2.2.2 Preparation of analogues 
Pyridyl variation 
It was hypothesised that the 4’-pyridyl function was the hinge-binder in 10 so initial efforts were 
made to vary this ring. Three analogues with the nitrogen in the 3’-position (38), addition of 
another nitrogen with a 5’-pyrimidine (39) and incorporating an adjacent electron-donating 
methoxy group (40) were successfully prepared using the above synthesis by varying the acid 
used in the HATU coupling step (Figure 2.4).120 
 
Figure 2.4 Analogues of 10 by varying pyridyl function 
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The 2’-pyridyl (42) and 6’-pyrimidine (44) analogues (Scheme 2.8) proved difficult to prepare in 
the final step. This was thought to be due to a potential intramolecular hydrogen bond as shown 
in Scheme 2.8.  Heating both reactions to 150 °C and further to 200 °C in the microwave for 30 
minutes to disrupt those intramolecular bonds did not force the reaction to completion which 
suggests this is not why the reaction did not progress. It may be possible that the ortho azo 
nitrogen has an inductive effect making the amide less susceptible to reaction.   
 
Scheme 2.8 Analogues of 10 that could not be prepared thought due to possible hydrogen bonding interactions 
(in red) 
Other attempts to exchange the six-membered ring with other heterocycles such as indazoles 
(47/50) or an amino-pyridine (53) were unsuccessful (Scheme 2.9). This was thought to be due 
to unprotected amines in the reaction mixture which were also reacting with the acids during 
the amide coupling step. Protection of the free N-H in the indazole-5-carboxylic acid (45) and 
indazole-6-carboxylic acid (48) starting materials with Boc121 and THP122 protecting groups was 
attempted but was unsuccessful at the purification stage.  
 
Scheme 2.9 Failed preparation of analogues 47, 50 and 53 due to unprotected amines (highlighted in blue)120 
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Amide variation 
Another region of interest for SAR in 10 was the amide. Generating amide libraries is generally 
straightforward when a fairly short synthesis has been established. Ideally, the amide should be 
varied at the end of the synthetic route, but this protocol often required the amide to be formed 
in the first step before nitro-reduction steps. Due to its relatively short length of four steps and 
reproducibility it was decided to stick with the existing method and the amide was introduced 
at the beginning of the synthesis.  
Benzimidazole 56 which lacked the amide moiety was successfully synthesised using 
commercially available O-phenylenediamine (54) with notably higher yields than the typical 25% 
yield for isolating 10 (Scheme 2.10).  
 
Scheme 2.10 Synthesis to benzimidazole 56 from commercially available O-phenylenediamine (54)104,120 
Removing the amide completely changed the 1H NMR aromatic region. Instead of the usual two 
doublets and triplets observed denoting the three aromatic protons of the benzimidazole in 
different environments, three peaks, two integrating to one proton (either side of the 
exchangeable N-H hence the slightly different magnetic environments) and one integrating to 
two were seen due to the increased symmetry in this analogue (Figure 2.5). 
 
Figure 2.5 Excerpt of 1H NMR spectrum of compound 56 
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The mono-methylated (60) and di-methylated (67) amide derivatives were attempted by 
coupling methylamine/dimethylamine in the first step of the synthesis outlined in Scheme 2.11. 
The mono-methylated analogue (60) was prepared in 6% yield in the final step. It was not 
possible to sufficiently purify amide 63 for taking to the last step of the synthesis.  
 
Scheme 2.11 Synthesis summary of methylated analogues 60 and 63 by usual chemistry procedures104,116,118,120 
In the initial CDI amide coupling step, it was particularly difficult to remove the imidazole, even 
after purification by column chromatography. Intermediates 57 and 61 were taken through 
without further purification, and this did not seem to severely affect later steps. 
 
Scheme 2.12 Synthetic scheme to dimethylated analogue 67104,120,123 
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Synthesising the corresponding 4-methyl ester benzimidazole analogue (66) and cleaving that 
ester with 2 eq. 2 M aqueous sodium hydroxide solution, followed by coupling dimethylamine 
via HATU coupling conditions was also unsuccessful. Substituting the 2 M dimethylamine in THF 
solution for the chloride salt did not cause the reaction to progress either. Using 
propylphosphonic acid anhydride (T3P, 68) allowed the dimethylated amide analogue (67) to be 
isolated in 32% yield (Scheme 2.12). T3P (68) is a cyclic trimer which activates carboxylic acids 
for reactions with amines, as outlined in the mechanism in Scheme 2.13. 
 
Scheme 2.13 T3P-facilitated amide coupling mechanism124 
Upon deprotonation, nucleophile 27 cleaves the T3P (68) ring via nucleophilic attack of one of 
the phosphonate groups. The diffuse nature of the electron distribution in phosphorus and 
strength of the P=O bond means the P-O bond is directly cleaved cf. a carbonyl-based 
substitution. Species 69 has a sufficiently activated ester to react with amine 31 to produce 
cationic intermediate 70, whose charge is neutralised via deprotonation by triethylamine to 
form the amide product (34).  
Confirmation of the mono- (60) and di-methylated (67) versions of 10 were confirmed by 
observation of the expected larger masses (m/z 253 and 267, respectively cf. 239) and 
appearance of additional peaks in the aliphatic region of their 1H NMR spectra (Figure 2.6). For 
compound 60, an additional singlet integrating to three protons was observed at δ 3.02 ppm 
while two additional singlet peaks appeared in the 1H NMR spectrum of 67, both integrating to 
three protons each, at δ 3.11 and 2.87 ppm. Two peaks arise due to the relative rigidity around 
the C-N amide bond due to the adjacent electron-withdrawing carbonyl in a relatively polar 
solvent, DMSO-d6 (ΔGǂ rotation of C-N in dimethylacetamide in DMSO = 76.5 kJ mol-1).117 
Additional carbon peaks were also observed in both compounds’ respective 13C NMR spectra. 
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Figure 2.6 1H NMR spectra of compounds 60 and 67 with peaks corresponding to methyl groups circled in blue 
Varying the position of the branching amide (78) was attempted using a similar synthetic 
strategy (Scheme 2.15) with the corresponding benzimidazole with a 5-ethyl ester (62) but the 
product could not be cleanly isolated. An in-house procedure using 1,5,7-triazabicyclo[4,4,0]dec-
5-ene (TBD) (71) (for mechanism see Scheme 2.14) or HATU (26) coupling agents to form the 5-
position amide yielded no product or product of a low purity, respectively (Scheme 2.15).  
 
Scheme 2.14 TBD-facilitated amide coupling general mechanism125 
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Scheme 2.15 Unsuccessful attempts at producing benzimidazole 78 from benzimidazole 77 
The 5-ethyl ester benzimidazole (77) was tested as an analogue in its own right but unfortunately 
converting the ester to an amide as per 67, did not yield the desired product (78) in sufficient 
yield and purity. Instead, the compound was made using the usual original route (Scheme 2.16) 
from commercially available 4-amino-3-nitrobenzamide (79) in order to deliver compound 78 in 
13% yield but of sufficient purity for biological evaluation. 
 
Scheme 2.16 Synthesis to 78 from 4-amino-3-nitrobenzamide 
It was possible to exchange the primary amide for other functional groups using various 
commercially available di-anilines and nitro-anilines. In total, five other analogues (Figure 2.7) 
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were prepared with ester (66 and 77), cyano (83), and nitro (82 and 84) moieties vectoring from 
the 4- or 5-position of the benzimidazole.  
 
Figure 2.7 Structures of a selection of benzimidazole analogues prepared that lack an amide 
Appearance of a strong peak at 2216 cm-1 in the IR spectrum confirmed the presence of a nitrile 
group in benzimidazole 83, as well as a peak in the 13C NMR spectrum at 120.9 ppm in lieu of the 
usual carbonyl peak observed around δ 160–220 ppm. Similarly, the loss of carbonyl signals in 
13C NMR and IR spectra for nitro-containing analogues 82 and 84 helped to conclude the 
preceding amide intermediates had fully cyclised to the respective benzimidazoles. For the 
derivatives containing esters, 66 and 77, two peaks attributed to carbonyl carbons were 
observed for the penultimate amide intermediates in the 13C NMR spectra. 
Attempts were made to produce the 4-amino derivative of 10 (87) in order to see what 
difference was made by removing the hydrogen bond acceptor but keeping the two donors. 
First, a one-pot cyclisation-reduction test reaction was carried out using 3-nitrobenzene-1,2-
diamine (85), 4-pyridinecarboxaldehyde (86) and sodium hydrosulfite but even with 30 
equivalents of the sodium hydrosulfite, the reaction did not go to completion. Similarly, reducing 
the nitro-containing match pair (82) using sodium hydrosulfite was unsuccessful as neither 
starting material nor product mass ions could be observed in the LCMS spectrum (Scheme 2.17). 
 
Scheme 2.17 Unsuccessful attempts of preparing 4-amino analogue of 10118 
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Additional ring systems 
In an attempt to explore building off the 6-position of this set of compounds, a bromine moiety 
was introduced at the 6-position to facilitate Suzuki coupling of aromatic groups. The key 
bromine-containing benzimidazole (92) was successfully synthesised from commercially 
available 2-amino-5-bromo-3-nitrobenzoic acid (88) (Scheme 2.18). Alternative amide coupling 
conditions using HOBt and EDC126 instead of HATU120 were required for the penultimate step. 
Appearance of two peaks in mass spectrometry experiments of m/z [M+H] and [M+H+2] in a 1:1 
ratio indicated the presence of the bromine atom across the synthesis.127 
 
Scheme 2.18 Synthesis of Br-containing analogue 92104,116,118,126 
Unfortunately, various Pd-catalysed couplings were tried with bromo-containing intermediates 
88, 89 and 90 but none resulted in a successful reaction. The conditions are summarised in Table 
2.2. It is thought that the free N-H in the benzimidazole was interfering with the catalytic cycle 
and would need protecting in order to carry out such steps. 
Table 2.2 Summary of Suzuki conditions attempted on bromine-containing intermediates 
Starting 
material 
Catalyst Solvent system Temp. Time 
Heating 
method 
Product 
m/z in 
LCMS? 
88 Pd(dppf)Cl2·CH2Cl2 3:1 dioxane:water 100 °C 4 h Hot plate No 
88 Pd(dppf)Cl2·CH2Cl2 3:1 dioxane:water 100 °C 1.5 h Microwave No 
89 Pd(dppf)Cl2·CH2Cl2 3:1 dioxane:water 100 °C 1.5 h Microwave No 
90 Pd-118 
4:1 
acetonitrile:water 
100 °C 1.5 h Microwave No 
90 Pd(PPh3)2Cl2 
4:1 
acetonitrile:water 
100 °C 18 h Hot plate No 
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Alkylation of benzimidazole 
Attempts were also made to cap the benzimidazole N-H of 10 (94) using typical methylating 
conditions128 using sodium hydride as a base and methyl iodide as the source of the methyl 
group (Scheme 2.19). Despite numerous attempts and careful execution of the reaction under 
inert conditions, the dimethylated salt (93) seemed to form preferentially leaving unreacted 
starting material rather than reacting once with the benzimidazole N-H to form desired 
compound 94. Instead, it is believed that the 4’-pyridyl nitrogen was the next likely position at 
which the methyl iodine would react. The observation was of m/z 268 in the reaction’s LCMS 
profile instead of the desired m/z 253 expected for a compound of 252 Da, as was the 
appearance of two methyl peaks in the 1H NMR spectrum. 
One of the literature sources128 for the alkylation reaction showed a variety of alkyl groups being 
substituted at the N-H centre of a benzimidazole. Unfortunately, the paper only gave 
experimental data for the combination of methyl bromoacetate (95) with the benzimidazole 
(96), and not simply methyl iodide, although it was implied that the chemistry had been used to 
produce the equivalent analogue. The chemistry was repeated using the methyl bromoacetate 
and the ester-capped benzimidazole (96) was successfully isolated (Scheme 2.19).  
 
Scheme 2.19 N-Alkylation attempts to benzimidazole 93128 
Compound 96 is not an ideal match pair with 10 because the ester is a larger point change than 
that of a simple methyl group. It was still tested in the biochemical assay to compare with 10 in 
the absence of the simpler methylated analogue (94). 
Overall, these methods provided a relatively straight forward way to synthesise fifteen 
benzimidazoles for exploring the SAR around compound 10 (Figure 2.8). But the library is 
relatively narrow in scope and it was unfortunate that the other planned 2’-position aryl, 6-
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position aryl-coupled and 1-position N-methylated analogues could not be synthesised within 
the timeframe dedicated to this series.   
 
 
Figure 2.8 Summary of Series A compounds synthesised 
2.3 Biological evaluation 
2.3.1 TR-FRET 
This project is being carried out in collaboration with the Structural Genomics Consortium, who 
agreed to test the compounds synthesised against PKN1 and PKN2 in a binding-displacement 
assay using a time resolved fluorescence resonance energy transfer (TR-FRET) assay readout. 
The assay work described below was carried out by Dr. Angela Maria Fala at the State University 
of Campinas, Brazil. 
The assay is based on the displacement of a fluorescent tracer molecule from the ATP binding 
site of a kinase (Figure 2.9). When the fluorescent tracer molecule is bound to the kinase there 
is a TR-FRET signal due to an energy transfer from a europium- or terbium-cryptate FRET donor 
that is attached to the kinase via the high affinity streptavidin-biotin interaction. In the presence 
of an inhibitor that binds to the same site in the kinase, the TR-FRET signal is non-existent. 
Varying concentrations of inhibitors (typically 50 μM to 0.85 nM over 12 data points) were added 
to displace the Kinase Tracer 236 (Thermofisher) from the ATP binding site and decrease the 
FRET signal from Streptavidin bound to the biotin tag in the C-terminal of the kinase. IC50 values 
are measured for the specific inhibitor and Ki values are calculated using the Cheng Prusoff 
equation129 and the previously determined dissociation constant (Kd) of the tracer . The IC50 value 
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is the half-maximal inhibitory concentration.8 Staurosporine, a commonly used pan kinase 
inhibitor,9 was used as an assay control. 
 
Figure 2.9 Overview of TR-FRET experiment 
Two biological replicates of the experiments were carried out in triplicate. The data was 
normalised to 0–100% inhibition values and fitted to a four-parameter dose-response curve 
using GraphPad 7 Software (version 7.04). The results of the TR-FRET assay for this series are 
summarised in Table 2.3. Ki values are given in micromolar concentration (μM). 
Table 2.3. Structure activity relationships for benzimidazoles binding to PKN2 and PKN1. Calculated Ki values for 
PKN2 and PKN1 are shown in μM. The assay Z’ factor was 0.7 < Z’ < 0.9; n = 2. 
 
# R R1 R2 X Ar 
PKN2 PKN1 
Ki (μM) Ki (µM) 
10 CONH2 H H H 4-py 0.03 0.54 
96 CONH2 H H 
 
4-py 2.69 25.9 
38 CONH2 H H H 3-py 8.19 32.5 
39 CONH2 H H H 5-pyrimidine 23.8 67.7 
40 CONH2 H H H 3-methoxy-4-py 6.90 30.2 
60 CONHMe H H H 4-py 1.06 5.20 
67 CONMe2 H H H 4-py 19.4 27.8 
78 H CONH2 H H 4-py 8.11 48.8 
56 H H H H 4-py 3.85 22.4 
82 NO2 H H H 4-py 1.25 28.9 
66 COOMe H H H 4-py 15.6 19.1 
77 H COOEt H H 4-py 21.1 27.8 
83 H C≡N H H 4-py 2.51 18.9 
84 H NO2 H H 4-py 12.9 53.7 
92 CONH2 H Br H 4-py 0.08 2.19 
Benzimidazole 10 was confirmed as an inhibitor of PKN2 (Ki 30 nM) with 18-fold selectivity over 
PKN1 (Ki 540 nM). Capping the benzimidazole N-H (96) resulted in loss of activity. As discussed 
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previously, this is not as useful a point change as a simple methylated benzimidazole would have 
given but it potentially suggests that this group is too large for binding or that removing the 
basicity of that nitrogen is detrimental for bioactivity, or that N-H is needed for binding. 
The 4’-pyridyl appears to be the hinge-binding motif of the molecule because exchanging it for 
the 3’-pyridyl (38) or a 5’-pyrimidine (39) results in a large drop in the IC50. Similarly, introducing 
a methoxy-group at the 3-position (40) reduced the activity of the compound, likely due to 
disrupting steric access to the 4’-pyridyl nitrogen. 
The primary amide also proved to be an essential component of the compound because the 
methylated (60) and dimethylated (67) analogues were less potently active than the original 
compound (10). A crystal structure would assist in determining whether the methyl groups cause 
steric hindrance with the kinase pocket. A similar result was observed in the analogue that 
removed the amide altogether (56) showing that the carbonyl hydrogen bond acceptor was also 
required. 
The amide was moved to the adjacent 5-position (78) and despite this small structural change 
there was a large loss of bioactivity, likely due to the different conformation of the amide moiety. 
Similarly, exchanging the amide at the 4-position for a nitro (82) or methyl ester (66), or an ethyl 
ester (77), nitrile (83) or nitro (84) group at the 5-positon, resulted in loss of activity. 
Compound 92 was the only analogue of 10 that had relatively potent inhibition against PKN2. 
Introduction of a bromine atom at the 6-position was not a significant structural change and 
resulted in a nearly equipotent compound (Ki 80 nM). That said, a great loss of activity was 
observed for PKN1 (Ki  2.19 μM) which meant the compound was 27-fold selective for PKN2 over 
PKN1, despite the overall loss in potency. The larger size of the bromine atom, in addition to its 
weak electron-withdrawing effects, must have slightly disrupted the binding mode of the 
benzimidazole. 
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2.4 Computational Studies 
 
Figure 2.10 Labelled X-Ray Crystal Structure of PKN2 (PDB code 4CRS) 
One X-ray crystal structure of PKN2 (Figure 2.10) was deposited in the PDB in 2014 which allowed 
computational studies to be carried out in order to complement and rationalise the previously 
discussed biological results. It suggests that ATP-γ-S, an analogue of ATP, interacts with the hinge 
region of PKN2 via two hydrogen bonds: primary amine of the adenine function acting as a H-
bond donor to an alanine residue (Ala684) and the 1-nitrogen as a hydrogen bond acceptor with 
tyrosine (Tyr739).  
2.4.1 Benzimidazole kinase ligands in the Protein Data Bank 
A search for kinase ligands containing pyridyl benzimidazoles and benzimidazoles was carried 
out in the PDB and three crystal structures were found (Figure 2.11–2.13) that could be used to 
hypothesise the binding mode of 10. The crystal structures were imported into Schrodinger 
Maestro (version 2018-1)130 and prepared using the Protein Preparation application to set 
parameters such as missing residues. 
 
Figure 2.11 Benzimidazole ligand interacting with the hinge region of CK1GS (PDB code 4HGS); 
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Figure 2.12 Benzimidazole ligand interacting with the hinge region of PIM1 (PDB code 5KGD); 
  
Figure 2.13 Benzimidazole ligand interacting with the hinge region of PKA-S6K1 complex (PDB code 4C35) 
Figure 2.11 shows a benzimidazole similar to 10 that binds to a leucine residue (Leu119) within 
the hinge region of kinase CK1GS through a hydrogen bond between the 4’-pyridyl nitrogen 
acceptor and an amide N-H donor. In Figure 2.12, a benzimidazole with a 3’-pyridyl function (cf. 
38 and 56) does not interact with the hinge of the kinase in structure 5KGD. Instead the 3’-
pyridyl nitrogen of the ligand forms a hydrogen bond with the N-H of a lysine residue (Lys67). 
Figure 2.13 is a crystal structure of a PKA-S6K1 complex with a benzimidazole that contains a 
primary amide like that of 10. The amide points towards the hinge region of the kinase, 
particularly in the direction of a glutamine (Glu121) and tyrosine (Tyr122) residue. 
2.4.2 Docking Experiments 
All of the aforementioned benzimidazole compounds based around compound 10, including 
those that could not be synthesised, were docked into a prepared receptor grid defined in the 
hinge region of the existing structure of PKN2 (4CRS) using Schrodinger Maestro’s Receptor Grid 
Generator application130 by the author. The ligands were prepared in all possible conformations 
using the Schrodinger LigPrep function. Three docking studies were run with varying levels of 
constraints added, in terms of hydrogen bonding interactions that had to be met:  
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1. Ala684 and Tyr739 both interact with the ligand 
2. Either Ala684/Tyr739 interact with the ligand 
3. No constraints 
Only one series A compound was successfully docked into the protein across these three 
experiments. The 5-amide analogue (78) which suggested the amide formed hydrogen bonds 
with Ala740 and Glu738 (Figure 2.14).  
 
Figure 2.14 PKN2 hinge region interacting with docked 4-pyridyl nitrogen of 1 
This unfortunately does not correlate with biological data as this compound was shown to be 
relatively inactive compared to 10 and any experimentally potent compounds could not be 
docked in this particular experiment. Dr. Ben Wahab, a computational chemist, ran repeat 
docking experiments instructing the compounds to bind with the hinge via the 4’-pyridyl and 
obtained similar results with biologically inactive compounds being docked in the ATP site. Thus, 
it was deemed that the 4CRS crystal structure was not representative of PKN2 under 
physiological conditions and these computational chemistry experiments could not add value to 
the experimental data obtained for the project thus far.  
 
Figure 2.15 Compound 10 docked into PKN2 using MOE software 
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Further docking experiments carried out by Dr. Angela Maria Fala at the SGC using MOE software 
successfully docked 10 into PKN2 (Figure 2.15). The binding mode suggests the pyridine portion 
of the compound interacts with an alanine residue in the hinge region  (Ala740) and the primary 
amide has another key, but different, interaction with a lysine residue (Lys686). This docking 
experiment was only carried out on a small number of compounds for use in publications 
associated with this series so it is unclear whether this computational method would have been 
of use for directing medicinal chemistry efforts if it had been more complementary to the 
experimental data obtained for this series. 
2.5 Chapter 2 Summary 
This portion of work focused on optimising benzimidazole 10, a repurposed PARP inhibitor that 
showed affinity for PKN2. The compound was re-synthesised using a four-step synthesis and was 
confirmed as an inhibitor of PKN2 with Ki 30 nM and 18-fold selectivity over PKN1 (Ki 540 nM). 
Subsequent analogues were prepared to explore SARs between portions of the compound e.g. 
the primary amide, 4’-pyridyl which were deemed critical for potent binding to PKN2 (Figure 
2.16). The necessity of the benzimidazole N-H could not be determined from the analogues 
synthesised. 
In total 15 compounds were isolated and unfortunately none, with the exception of 92 improved 
on the PKN2/1 selectivity of the original compound (27-fold cf. 18-fold). Additionally, attempts 
to use computer assisted docking did not match experimental data so it was not extensively 
used to guide chemistry efforts for this series. A short communication of this work has been 
published in the journal Bioorganic and Medicinal Chemistry Letters.108 
 
Figure 2.16 SAR summary for Series A based on compound 10 
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Chapter 3 Series B – Pyrrolopyridinone   
This chapter seeks to outline the work carried out in optimising compound 11, a 
pyrrolopyridinone (Figure 3.1). The chemistry used to prepare this compound and other 
analogues will be discussed as well as the biological evaluation of the inhibitory potencies of 
those compounds against PKN2 and other kinases. Attempts to rationalise said biological activity 
using computational studies will also be outlined.  
 
Figure 3.1 Original compound for series B 
3.1 Hit Origin 
6,7-Dihydro-5H-pyrrolo[3,2-c]pyridin-4-one (11) (Figure 3.1) was identified as a potent PKN2 
inhibitor (Ki = 4 nM)105 via a ChEMBL103 data mining effort as described in Section 2.1. It was 
previously made for research efforts developing inhibitors for various kinases such as CDKs131–
135 and MK-2.105 According to the ChEMBL database, it inhibits 22 out of 157 kinases with a Ki 
less than 100 nM, including PKN2. This reasonable selectivity and high potency made it a good 
starting point for a developing a more selective PKN2 inhibitor. 
The pyrrolopyridinone structure is particularly unusual, exhibited by the observation that none 
of the current 52 FDA-approved kinase inhibitors possess the core within their structures, 
although sunitinib (97), a multi-receptor tyrosine kinase inhibitor, contains a pyrrole ring (Figure 
3.2). Unfortunately, most pyrrole-containing motifs are classified as pan-assay interference 
compounds (PAINs)16 due to their tendency to interfere with bioassays because they are easily 
oxidizable and can act as nucleophiles. Pyrroles also contain a relatively acidic proton (pKa ≈ 
16.5117) which can react with weak basic reagents used in assay protocols. It was hoped that 
suitable modifications could be made to 11 to improve its properties as a PKN2 chemical probe. 
 
Figure 3.2 Sunitinib (97) 
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Work on this series was carried out in part by a University of Sussex MChem student, Mihaela 
Paula-Ficu, as part of her dissertation research project. 
3.2 Chemistry 
3.2.1 Synthesis of original hit 
 
Scheme 3.1 Synthesis to 11 
4-(Bromoacetyl)pyridine (98) and piperidin-2,4-dione (99) were stirred in ethanol with 
ammonium acetate at room temperature (Scheme 3.1) to make compound 11. The reaction 
involves a nucleophilic addition step followed by enamine formation then a dehydration 
reaction (see Scheme 3.2 for mechanism). 
 
Scheme 3.2 Mechanism for addition condensation step to form compound 11 
First, acetate deprotonates a relatively acidic proton from piperidin-2,4-dione (pKa ≈ 10136) (98). 
The resulting enolate (100) attacks 99 via the α-carbon to displace the bromoketone bromine 
atom to form intermediate 101. Ammonia then attacks the carbonyl carbon adjacent to the 
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pyridyl to form charged intermediate 102. Loss of water from 103 encourages the formation of 
iminium 104 and subsequent proton exchange yields enamine 105. Upon activation of the 
ketone carbonyl by protonation, enamine 105 cyclises at this carbon to form species 107 which, 
upon loss of another molecule of water, yields pyrrolopyridinone 11. 
While the original procedure105 stated the reaction would be complete after an hour, it was 
found that leaving the reaction to stir overnight at room temperature improved the reaction 
profile, with a higher percentage of the product observed in a sample taken from the reaction 
mixture by LCMS. Following aqueous work-up and purification, compound 11 was successfully 
isolated in 28% yield (cf. 71% reported yield105). LCMS indicated a mixture of intermediate 106 
and product 11 tended to form. Attempts to improve the conversion to 11 such as changing the 
solvent; order of addition and/or adding a catalytic quantity of concentrated hydrochloric acid 
to encourage the loss of water from 106 via 107 did not improve on the reaction yield. 
Despite the fairly poor yield for a one-step synthesis, the affordability of the commercial starting 
materials meant suitable quantities of the product could be isolated if carried out at sufficient 
scale. The reaction was repeated at 2 g scale to afford 598 mg (37%) of 11 for preparing 
analogues  
LCMS (m/z 214) and 1H NMR confirmed formation of the product. The same pair of doublets in 
the aromatic region correlate to the 4’-pyridyl ring were observable for 11 as in 10 as well as 
two broad N-H singlets at δ 11.95 and 7.08 ppm for the pyrrole and amide protons; a sharper 
singlet at δ 7.00 ppm for the 3-position C-H and two upfield triplet/multiplet peaks each 
integrating to two protons for the aliphatic protons at the 6- and 7-positions. 
3.2.2 Preparation of analogues 
Pyridyl variation 
The first analogues of 11 that were prepared were variants at the pyridyl portion of the molecule 
because compound 11 has a similar general shape to benzimidazole 10 and the 4’-pyridyl group 
was critical for activity in series A. The 3’- (109) and 2’-pyridyl (111) derivatives were successfully 
prepared (in 28% and 9% yields, respectively) using the corresponding α-haloketones (Scheme 
3.3) (108 and 110, respectively). Preparation of the aryl-derivative (113) using phenacyl bromide 
(112) enabled the synthesis of 113 in 13% yield. 
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Scheme 3.3 Preparations of pyridyl analogues of 11 
The aromatic regions of the 1H NMR spectra for these compounds were used to distinguish 
between the analogues. The aromatic region of the original hit (11) contained two doublets due 
to the symmetrical 4’-pyridyl ring, while 109 had four peaks integrating to four protons in total 
– a singlet, two doublets and a double doublet. The 2’-pyridyl moiety of compound 111 was 
identifiable by a doublet and two multiplets with a similar combined integration of four protons 
and, finally, the phenyl derivative (113) had the characteristic doublet and two triplets that 
represent the five benzene hydrogens.  
Lactam variation 
It was possible to modify individual components of the amide by exchanging piperidin-2,4-dione 
for 1,3-cyclohexanedione and tert-butyl 4-oxopiperidine-1-carboxylate to produce the cyclo-
ketone (114) and cyclo-amine (115), respectively (Figure 3.3).  
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Scheme 3.4 Syntheses to compounds 114 and 115 
Typical Boc-deprotection conditions were used to give 115 by stirring the protected analogue of 
the compound (115a) in trifluoroacetic acid (TFA) (see Scheme 3.5 for mechanism). Activation 
of the carbamate carbonyl oxygen of 116 by acidified protonation encourages the loss of a 
proton from the tert-butyl group of 117. This subsequently triggers the loss of isobutene from 
117 and carbon dioxide from 118 to yield the unprotected amine (119).117 
 
Scheme 3.5 Boc deprotection mechanism117 
Alongside expected changes in the mass observed in the LCMS and HRMS spectra, 1H NMR was 
used to confirm the structural changes from the lactam in 11 to the ketone (114) and cyclic 
amine (115) (Figure 3.3). 
 
Figure 3.3 Structures of compounds 11, 114 and 115 with selected 1H NMR chemical shift values highlighted in 
ppm 
The loss of the amide N-H peak at δ 9.11 ppm from the 1H NMR spectrum for 11 indicated that 
only the C=O was present in 114. Similarly,  the appearance of a new aliphatic C-H peak 
integrating to two hydrogens at δ 4.32 ppm in the 1H NMR confirmed the removal of the nitrogen 
in 114. An additional peak was also observed in the 13C NMR spectrum which corresponds to the 
additional carbon atom.  
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When characterising compound 115, a lack of C=O peaks in the IR spectra and 13C NMR were 
observed. Additionally, the N-H peak in the 1H NMR shifted from δ 7.08 to 9.11 ppm and a new 
peak was present at δ 2.36 ppm which correlated to the other aliphatic hydrogens (by COSY 
NMR) confirmed the isolation of compound 115 as a TFA salt.  
Alkylation of pyrrole  
 
 
Figure 3.4 Alkylated analogues 120–125 prepared in Series B library 
Replacing ammonium acetate with an alkyl amine enabled simple alkylation of the pyrrole N-H 
(Scheme 3.6) without having to carry out traditional alkylation reactions with air-sensitive agents 
such as sodium hydride.137 Methyl (120), ethyl (121), n-propyl (122) and i-propyl (123) groups 
were easily introduced to cap the N-H from their respective amines, either added neat or in 
combination with acetic acid in order to mimic the ammonium acetate used to prepare 
compound 11. 
 
Scheme 3.6 Synthesis to compounds 120-125 
Additional peaks in the higher end of the aliphatic region of 13C and 1H NMR spectra were used 
to confirm the incorporation of the alkyl groups, as well as an expected increase in molecular 
weight observed by LCMS. In all cases, the N-H peak observed at δ 11.95 in the 1H NMR spectrum 
for 11 disappeared due to a lack of hydrogen present at that 1-position nitrogen. 
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Similarly, it was possible to introduce a terminal alcohol (124) by using ethanolamine. A new 
peak was observed at δ 4.98 in the 1H NMR spectrum due to the hydroxyl proton present in the 
molecule. 
In order to observe the effect of incorporating a bulky aromatic group into the compound, benzyl 
amine was used to make compound 125. Three new peaks were observed in the aromatic region 
at δ 7.32, 7.25 and 7.15 ppm collectively integrating to the five protons present in the benzyl 
group, as well as a new peak in the aliphatic region integrating to two protons at δ 5.05. 
Alkylation of lactam 
It was also possible to further alkylate the amide portion of 121 by using a combination of 
sodium hydride and alkyl iodides to produce the methyl- (126) and n-propyl-capped (127) 
amides, respectively (Scheme 3.7).138 1H NMR confirmed alkylation at this centre because the 
amide N-H peak at δ 7.08 disappeared and new aliphatic peaks appeared corresponding to their 
respective methyl and n-propyl moieties. 
 
Scheme 3.7 Alkylation conditions used to synthesise compounds 126 and 127138 
Scheme 3.8 outlines the mechanism of this chemical transformation. The hydride anion 
deprotonates amide 128 which allows resulting nucleophile 129 to attack the alkyl halide’s α-
carbon displacing the iodide via a SN2 mechanism. This converts the secondary amide to a 
tertiary amide (130). 
 
Scheme 3.8 Alkylation mechanism involving sodium hydride and alkyl halides 
The same chemistry was deployed to try and synthesise a derivative of 11 with a free pyrrole N-
H and a methylated amide (133) (Scheme 3.9) by methylating 125 to form 132 and then remove 
the benzyl group to yield the free pyrrole (133). Similar to the issues experienced with alkylation 
reactions for series 2 in section 2.2, carrying out this reaction produced a product with m/z 332 
[M + CH3]+, instead of m/z 318 [M + H]+. This was presumed to be the methyl iodide reacting at 
47 
 
the 4’-pyridyl nitrogen as well as the amide (131). Care was taken to ensure stoichiometric 
quantities of sodium hydride and methyl iodide were slowly added at low temperature but after 
multiple attempts, this analogue was abandoned due to time constraints to focus on other 
aspects of the project. 
 
Scheme 3.9 Attempts to alkylate the lactam N-H of 125138 
Additional ring systems 
Simultaneous attempts were made to introduce a benzyl or phenyl group at the 6-position of 
the lactam ring with varying success (Scheme 3.10). 3-(Tert-Butoxycarbonylamino)-4-phenyl-
butanoic acid (134) was combined with 2,2-dimethyl-1,3-dioxane-4,6-dione (135) using N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC·HCl) as a coupling agent139 to 
produce compound 136, but this reaction was abandoned because the product could not be 
sufficiently purified and the latter, phenyl-containing analogue (138) was successfully isolated 
by another method which was being carried out in parallel. 
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Scheme 3.10 Chemistry used to incorporate an additional aromatic group at the 6-position105,139 
More success was had using the phenyl-containing equivalent, commercially available 6-
phenylpiperidine-2,4-dione (138) using the original chemistry route,105 and 139 was isolated in 
23% yield. The disappearance of one of the four aliphatic C-H peaks, replaced by three additional 
peaks in the aromatic region in the 1H NMR, confirmed the isolation of 139. The benzyl analogue 
(137) was not reattempted because 139 was deemed a suitable match pair for 11 that had an 
additional aromatic ring incorporated into its structure at that particular vector. If the compound 
had particularly promising bioactivity, synthesis of the single enantiomers would have been 
attempted, but this was not the case. 
 
Figure 3.5 Summary of SAR explored around compound 11 
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In total, fourteen analogues of 11 were prepared (Figure 3.5). It was possible to remove portions 
of the amide, manoeuvre the pyridyl nitrogen, as well as remove the pyridyl nitrogen all 
together. The pyrrole and amide nitrogen atoms were capped with various small alkyl groups, 
and it was also possible to introduce additional benzyl and phenyl groups at the 1- and 6-
positions respectively. 
3.3 Biological evaluation 
3.3.1 TR-FRET 
The compounds were sent for biological evaluation at the SGC using the TR-FRET assay 
previously described in Section 2.3. Table 3.1 summarises the calculated Ki values for PKN1 and 
2. Ki values were calculated as before using the Cheng-Prusoff equation.129 
 
Table 3.1 TR-FRET bioanalysis of series B compounds for PKN2 and PKN1 with calculated Ki nM potency; Z value > 
0.70 < 0.90; n = 2 
Structure 
PKN2 PKN1 
Ki (nM) Ki (nM) 
 Ar 
11 
 
4-py 8 156 
109 3-py 1616 10267 
111 2-py 45120 144757 
113 Ph 62225 16487 
 R 
120 
 
Me 129 2275 
121 Et 8 108 
122 n-Pr 7 64 
123 i-Pr 73 922 
124 (CH2)2OH 15 222 
125 Bn 323 1529 
  R’   
114 
 
- 33 653 
115 
 
- 1123 10140 
126 
 
Me 178 4780 
127 n-Pr 1296 14125 
139 
 
- 27 260 
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Compound 11 was confirmed as an inhibitor of PKN2 with Ki = 8 nM against PKN2 and 20-fold 
selectivity over PKN1. An ideal molecule should have at least 30-fold selectivity over other 
kinases, so this was a promising start to have this level of selectivity in the original compound4 
Much like series 2, altering the 4’-pyridyl by either moving (109/111) or removing (113) the 
nitrogen resulted in the largest loss of potency across the series. This suggests the hinge region 
of the kinase specifically interacts with this portion of the molecule. 
When the pyrrole N-H bond was replaced by a N-methyl group (115), there was a 16-fold 
decrease in potency for PKN2. However, when an ethyl (121) or n-propyl (122) group was added, 
these compounds were equipotent with 11; however there was a decrease in selectivity 
between PKN2/PKN1 – 14-fold and 9-fold for compounds 121 and 122, respectively. This 
suggests that the pyrrole N-H is not as well tolerated in PKN1 and is not essential for binding in 
PKN2 either. Removing this hydrogen bond donor increases the compounds’ affinities for PKN1 
which is undesirable for a PKN2 chemical probe within the context of this project. 
As the substituent became bulkier, this effect was lost: the isopropyl (123) and benzyl (125) 
analogues resulted in 9-fold and 40-fold less potent compounds, respectively. 
Extending the hydrogen bond donor by replacing the ammonia source with ethanolamine (124) 
halved the potency of the compound, and slightly reduced the selectivity between PKN2/PKN1 
from 20-fold to 15-fold. 
Removing the carbonyl group from the amide (115) resulted in 140-fold loss in potency. This 
indicates the hydrogen bond acceptor forms a more important interaction within PKN2 than the 
hydrogen bond donor with regards to the amide N-H portion of 11. On the other hand, removing 
the amide N-H (114), only resulted in a negligible 4-fold loss of potency towards PKN2, but held 
the 20-fold selectivity between PKN2 and PKN1. 
Capping the amide and pyrrole nitrogen atoms (126 and 127) resulted in larger losses of potency. 
This dissuaded any further attempts to build off that particular vector because this structural 
change was detrimental to the compound’s ability to bind to PKN2.  
Introducing the additional phenyl group (139) resulted in a slight 3-fold reduction in potency for 
PKN2 and effectively halved the selectivity of the compound between PKN2/1 to 10-fold, down 
from 20-fold. This implies that the bulky phenyl group can be accommodated within the PKN2 
pocket.4  
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In summary, it was possible to synthesise two equipotent PKN2 inhibitor analogues (121 and 
122) with PKN2 Ki values matching that of 11. However, the selectivity of 20-fold between PKN2 
and PKN1 for 11 could not be improved upon in compounds 121 and 122. All other compounds 
resulted in loss of potency. Attempts to remove hydrogen bond donors and acceptors generally 
resulted in loss of potency and selectivity, most notably altering the 4’-pyridyl portion of the 
compound, suggesting this is where the compound interacts with the hinge of the kinase. 
3.3.2 Kinome Selectivity Evaluation 
Due to the promising ca. 18-20-fold PKN2/1 selectivity of analogues 114 and 121, these two 
compounds were sent for wider kinome selectivity analysis by the commercial Thermo Fisher 
Scientific SelectScreen Kinase Profiling Service. The compounds are dosed at a single 1 μM dose 
in a LanthaScreen™ Eu Kinase TR-FRET Binding Assay (Figure 3.6) across a selected panel of 
kinases.140 The 50 kinase panel used was mostly composed of other AGC kinases and particularly 
undesirable off-target kinases such as GSK3β which is involved in energy metabolism and 
neurological processes.141 
Briefly, an ATP-competitive Alexa FluorTM tracer, is attached to the kinase of choice. This 
conjugate binding is detected by the addition of a europium-labelled anti-tag antibody. The 
interaction is observed by a resulting FRET signal. When the tracer is displaced by a more 
competitive inhibitor, there is a reduction in this signal readout.140 
 
Figure 3.6 Overview of TR-FRET LanthaScreenTM Eu Kinase Binding Assay140 
Figure 3.7 and Figure 3.8 show % inhibition values for those 50 kinases for compounds 114 and 
121 dosed at 1 μM. Compound 114 was shown to inhibit 6/50 kinases above 75%, with PKN2 
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ranking the highest in terms of potency, along with CDK8, GSK3β, PRKG2, STK17A and DYRK1A. 
It also inhibited three other kinases above 50% (MINK1, ROCK1 and RIPK2) (Figure 3.7). 
 
Figure 3.7 Bar graph of SelectScreen kinase panel targets against % inhibition for compound 114 assayed at 1 μM 
On the other hand, compound 121, the ethylated analogue of 11, was more selective. It inhibited 
five kinases (CDK8, GSK3β, PKN2, PRKG2 and STK17A) above 75% and two others, DYRK1A and 
MINK1 ≥ 50%. While PKN2 is not the most inhibited target by compound 121 – in this case it is 
CDK8 – the same kinases appear in the top tier of targets inhibited by both compounds (Figure 
3.8).  
 
Figure 3.8 Bar graph of SelectScreen kinase panel targets against % inhibition for compound 121 assayed at 1 μM 
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This drop in potency across the majority of targets for 121 is thought to be due to the loss of the 
pyrrole N-H hydrogen bond donor. While this did not prove to be useful for achieving PKN2/1 
selectivity, at least across this particular kinase panel, it had a more dramatic effect in reducing 
potency across the wider kinome. 
The original compound (11) and the 1-N-methylated analogue (120) were also sent for wider 
kinome selectivity analysis via the commercial KINOMEscan® panel provided by DiscoverX. At 
the time of testing (Q4 2018), the KINOMEscan®107 panel was composed of 469 kinases, 
comprised of 400 wild types and 69 mutants. This number has since increased to 489 kinase 
targets and it provides a good indicator of how the compound behaves across around 80% of 
the human kinome. The full results from this kinase panel can be found in the Appendix 1. 
The experiment involves a competition binding-assay (Figure 3.9). Firstly, DNA-tagged kinases 
are mixed with test compound and a known ligand immobilised on a solid support. After 
equilibration, the solid support is washed to remove unbound kinase. Test compounds that bind 
to the kinase compete with the immobilised ligand and if sufficiently potent and present at high 
enough concentration are able to prevent kinase binding to the immobilised ligand. This reduces 
the quantity of kinase on the solid bead support. If a compound does not bind well to a kinase, 
that kinase remains on the solid support. qPCR is then used to quantify the associated DNA-label 
of the kinases left on the support. A “hit” compound is defined as one where the kinase level 
remaining is lower than that of the DMSO control sample.  
 
Figure 3.9 Overview of KINOMEscan® Competitive Binding Assay using DNA-tagged Kinases142 
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Compound 11 was shown to bind relatively potently (i.e. > 70%) to 20 out of the 400 wild-type 
kinases while 120 was similarly selective, inhibiting 19 kinases to the same extent. Figure 3.10 
summarises these data for compounds 11 and 120.  
 
Figure 3.10 Labelled phylogenetic kinome trees highlighting the remaining % of immobilised ligand on each kinase 
for compounds 11 (left) and 120 (right) assayed at 1 μM in KINOMEscan® experiment. Kinase sub-family 
classifications are colour coded. 
Alkylating the pyrrole N-H (120) appears to reduce potency for tyrosine kinases (TK, in pink); 
CAMK kinases (purple); and ROCK kinases within the AGC kinase family (green). See the kinome 
phylogenetic trees in Figure 1.11 and Figure 1.12 for sub-classes within kinase families. 
Generally, compounds 11 and 120 inhibit PKN2 and a few other AGC kinases (green), such as the 
PKC sub-family. This is understandable given the structural similarity of these kinases. The 
compounds also inhibit some CK1 kinases (blue), STE kinases (olive), CMGC kinases (mustard), 
in particular, the DYRK sub-family, and non-classified kinases like FLT3 (centre of the tree). Figure 
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3.11 and 
 
Figure 3.12 detail the 24 kinase targets inhibited the most by compounds 11 and 120, including 
PKN2. 
 
Figure 3.11 Bar graph showing where PKN2 sits in the top 24 kinases inhibited by compound 11 in the DiscoverX 
KINOMEscan® experiment assayed at 1 μM 
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Figure 3.12 7 Bar graph showing where PKN2 sits in the top 24 kinases inhibited by compound 120 in the 
DiscoverX KINOMEscan® experiment assayed at 1 μM 
The change in kinome selectivity is too small to say that the capping of the N-H significantly 
changes the selectivity profile of the compound, as there are often false positives in these single 
point experiments. Hits are usually confirmed by carrying out further Kd experiments on a 
selected number of targets. Such experiments were not carried out for compounds 11 and 120 
in this series because they were not deemed the most selective compounds in this overall work 
(see Chapter 4). That said, it was encouraging to see that these two compounds only affect 
around 5% of the human kinome potently in this effort to find a selective probe for PKN2. 
3.4 Computational chemistry 
3.4.1 Pyrrole-containing ligands in the Protein Data Bank 
There is one example of compound 11 bound to a kinase in the PDB (Figure 3.13). Crystal 
structure 4F9B suggests that the 4’-pyridyl of 11 points towards a tyrosine residue (Tyr136) 
within the hinge region of cyclin-dependent kinase 7 (CDK7). It also shows the lactam oxygen 
interacting with a neighbouring lysine residue (Lys90). This binding conformation agrees with 
the experimental data for 11 against PKN2 that shows the largest loss of potency across the 
series was when the 4’-pyridyl motif was altered, suggesting this interaction is key for binding. 
CDK7 is one of the targets shown to bind to 11 in Figure 3.11. 
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Figure 3.13 Crystal structure of compound 11 in CDK7 (PDB code 4F9B). Image prepared using Schrodinger 
Maestro (v 2020.1). PKN2 hinge in yellow, N-domain in blue. 
3.4.2 Docking Experiments 
Single Target Docking 
The majority of synthesised series B compounds along with a series of hypothetical derivatives 
were docked into PKN2 as previously described in section 2.4 by the author. The 2’-pyridyl 
analogue (111) and the ethylated derivative of the same compound (140) (Figure 3.14) were the 
only two of the compound set that were successfully docked into PKN2 with the two previously 
described binding constraints enforced. No compounds docked with one or no constraints were 
applied.  
Both compounds were shown to interact with the hinge region of PKN2 via the lactam moiety 
(Figure 3.15), as seen for Series A in the previous chapter. This does not correlate with the TR-
FRET data as 111 was shown to be over 5000-fold less potent than compound 11.  Additionally, 
compound 114 which contained a ketone instead of a lactam showed potency towards PKN2 so 
this does not explain that retainment of potency. 
 
Figure 3.14 Series B analogue compounds successfully docked into PKN2 
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Figure 3.15 PKN2 hinge region interacting with lactam of compound 111 
Multi-Target Docking 
After analysing the KINOMEscan® selectivity data regarding compounds 11 and 120, the two 
compounds were applied to a cross docking experiment using the XGlide application in 
Schrodinger (version 2019.1).130,143 Cross docking involves docking one compound against 
multiple targets rather than the more common docking  experiments involving multiple 
compounds docked into a single protein. The proteins, ligands and receptor grids were prepared 
using the same methods as described previously in chapter 2. Two studies were carried out: 
1. Compounds 11 and 120 were docked into the binding pockets of a selection of 
physiologically relevant kinase crystal structures (PI3Ka, ROCK1, GSK3, VEGFR2, JNK1, 
p38, AurA, MELK, FLT3, PKN2) that were structurally similar to PKN2 – as evaluated by a 
BLAST protein sequence alignment. 
2. Compounds 11 and 120 were docked into a selection of physiologically relevant kinase 
crystal structures (CHEK2, RSK1 (Kin. Dom.1-N-terminal), LIMK1, CDK2, FAK, PIK3CA 
(H1047Y), PAK6, MET (M1250T), PIM2, MELK, ERK5/MAPK7, KIT (L576P)) from the 
DiscoverX KINOMEscan® panel that all six compounds (two from series B, four from 
series C) inhibited above 90%. 
A full list of the crystal structures used can be found in Appendix 2. The outcome of the docking 
experiments across the 24 targets as well as the motif of the compound that interacted with the 
hinge of the respective kinases were logged and summarised in the pie charts below (Figure 3.16 
and Figure 3.17). For the original compound (11) (Figure 3.16), there was a roughly equal number 
of poses where the compounds orientated either the 4’-pyridyl or the lactam portion of the 
compound towards the hinge, which does not provide a convincing hypothesis for either binding 
mode.  It may be that these two hinge motifs mean the compound has multiple binding 
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conformations. This contradicts the experimentally observed TR-FRET data, which suggests the 
pyridyl is far more important for binding than the lactam. 
 
Figure 3.16 Distribution of binding modes in cross docking experiment with compound 11 
 
Figure 3.17 Distribution of binding modes in cross docking experiment with compound 120 
These inconclusive results suggest using computational methods to justify the binding 
hypothesis of this set of compounds is not a suitable method to use for this series because of 
the ambiguous binding modes that the compound can adopt via the lactam or 4’-pyridyl. 
Experimentally, removal of the amide portion of compound 11 was less detrimental to binding 
compared to the 4’-pyridyl. 
Unfortunately, the Glide dock used to rationalise the experimental data did not match up with 
that observed in the TR-FRET assay. Removing one of the hydrogen-bond forming motifs from 
the compound resulted in loss of potency and selectivity, so it was not possible to force the 
compound to bind in a single conformation in order to achieve selectivity within the kinome. As 
a result, docking experiments across PKN2 and other kinases give ambiguous binding poses 
because the compound set contains multiple functional groups that mimic ATP in a kinase active 
site. 
3.5 Chapter 3 Summary 
Fifteen compounds were successfully synthesised in series B, based on a previously developed 
MAPK inhibitor (11) that showed high affinity for PKN2 (Figure 3.18). Compared to series A, this 
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series of pyrrolopyridinones proved to be a more promising set of compounds in terms of their 
potency and selectivity towards PKN2, PKN1 and the wider kinome.  
 
Figure 3.18 SAR explored around compound 11. *Indicates loss of both amide N-H and pyrrole N-H results in loss 
of activity, but this is not the case in the absence of one or other 
The best compound was once again the original hit, 11, with Ki = 8 nM for PKN2 and with 20-fold 
selectivity over PKN1. It was also found to inhibit 19 other kinases above a nominal threshold of 
70% in the commercial KINOMEscan® of 400 distinct kinase targets. Two equipotent compounds 
(120 and 121 which capped the pyrrole N-H with ethyl and n-propyl groups respectively) were 
not as selective as 11 against PKN1, despite improved selectivity within the context of the wider 
kinome. 
Attempts to alter the pyridyl, lactam and pyrrole portions of the compound resulted in loss of 
potency and/or selectivity between the PKNs. Interestingly, the alkylated derivates of 11 showed 
slightly better selectivity within the wider kinome, likely due to the lack of hydrogen bond donor 
by loss of the pyrrole N-H, but this was not enough to significantly improve on the existing 
compound. 
Computational studies of series B compounds yielded results which did not line up with 
experimental data. Cross docking compounds 11 and 120 across multiple kinases yielded 
ambiguous results which did not give any decisive rationale for the binding mode of this set of 
compounds. 
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Chapter 4 Series C – Naphthyridines, Quinazolines and 
Isoquinolines 
This chapter seeks to outline the work carried out in optimising compound 12, a 2,7-
naphthyridine (Figure 4.1). The chemistry used to prepare this compound and other analogues 
will be discussed as well as the biological evaluation of the inhibitory potencies of those 
compounds against PKN2 and other kinases. IUPAC numbering will not be used for this series to 
allow for consistent numbering across the different ring systems used. Attempts to rationalise 
the biological activity using computational studies will also be outlined. This series proved to be 
the most productive in terms of the optimised chemical route and biological activity of the 
compounds. Thus this chapter constitutes the majority of the work involved in this project.  
 
Figure 4.1 Labelled structure of compound 12103,106 
4.1 Hit Origin 
Compound 12 (Figure 4.1) was identified in the previously described ChEMBL data mining 
effort103 as a potent inhibitor of PKN2 (PKN2 IC50 7 nM). This compound comes from work106 
carried out to identify an inhibitor of protein kinase D (PKD), and was likely not further 
developed by the researchers involved due to its poor selectivity profile.  
In terms of selectivity, this compound had not been tested against as many targets as the lead 
compounds of the previous chapters. Compound 12 is only reported to inhibit eleven out of 
seventeen other kinases with IC50 potency below 100 nM according to ChEMBL.103 The low PKN2 
potency of 12 made this compound an attractive starting point for tuning in PKN selectivity in 
order to produce a high quality probe for validating PKN2 as a potential drug target. 
Naphthyridines are 6,6-heterocycles composed of two fused aromatic rings made up of eight 
carbons and two nitrogen atoms with the nitrogen atoms distributed across the rings. While 
none of the current FDA-approved inhibitors contain the 2,7-naphthyridine core of 12, other 
similar N-containing fused heterocycles feature on the list of approved drugs (Figure 4.2). 
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Figure 4.2 Quinazoline- and quinoxaline-containing FDA approved inhibitors46 
Quinazolines are isomers of naphthyridines and have the two nitrogen atoms on only one of the 
rings, whereas as naphthyridines have one nitrogen on each ring. They are particularly common 
within the current list of 52 FDA-approved kinase inhibitors, likely due to their ability to mimic 
the hydrogen bond donor/acceptor motif of the adenine portion of ATP (Figure 2.3). Five drugs 
– afatinib (141), dacomitinib (142), erlotinib (143), gefitinib (144), lapatinib (145) possess a 
quinazoline core. Erdafitinib (146) contains a closely related quinoxaline core (Figure 4.2).  
Quinolines and isoquinolines are bioisosteres for naphthyridines and quinazolines but only 
possess one nitrogen atom in their heterocycle. Three approved kinase inhibitor drugs contain 
a quinoline motif, bosutinib (147), lenvatinib (148) and neratinib (149), while netarsudil (150) 
contains an isoquinoline core (Figure 4.3).  
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Figure 4.3 Quinoline- and isoquinoline-containing FDA approved kinase inhibitors 
4.2 Chemistry 
4.2.1 Synthesis of original hit 
The initial hit, compound 12, was synthesised by the same 8-step synthesised used by Meredith 
et al.106 First, isonicotinic acid (23) underwent an amide coupling with tert-butyl amine using 
ethyl chloroformate (151) under basic conditions (Scheme 4.1). The best attempt of this reaction 
yielded amide 152 in 68% yield.  
 
Scheme 4.1 Amide coupling conditions to form 152106 
A proposed mechanism for this step is outlined in Scheme 4.2. First, triethylamine (TEA) 
deprotonates the isonicotinic acid (23) then resulting nucleophile 153 attacks the carbonyl 
carbon of ethyl chloroformate (151), with the loss of a chloride leaving group. The mixed 
anhydride intermediate (154) is now susceptible to nucleophilic attack by tert-butylamine, with 
loss of carbon dioxide and ethoxide. A final deprotonation of 155 by TEA yields the amide (152).  
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Scheme 4.2 Proposed mechanism for amide coupling under ethyl chloroformate conditions to compound 152 
The presence of the tert-butyl amide moiety in 152 was confirmed by two singlets in the 1H NMR, 
one occurring at δ 1.47 ppm integrating to the nine protons in the tert-butyl group and one at δ 
5.98 ppm, integrating to the hydrogen in the amide. The desired mass ion (m/z 179.1 [M+H]+) 
was also observed by LCMS (LCQ). 
Compound 152 was methylated to form intermediate 156 (Scheme 4.3) using strong base n-
butyl lithium (n-BuLi) to deprotonate one of the carbon atoms positioned ortho to the amide. 
Scheme 4.4 outlines the mechanism for this transformation. 
 
Scheme 4.3 Methylation conditions for preparation of intermediate 156106 
 
Scheme 4.4 Proposed mechanism for methylation step to 156 
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A minimum of two equivalents of n-BuLi were required because the more acidic amide N-H 
proton (pKa ≈ 20)117 preferentially deprotonates over one of the pyridyl protons (pKa ≈ 35)144 to 
give 157. The directed ortho metalation mechanism encourages the electrophile to attach 
exclusively to the ortho-carbon because of the coordination with the amide carbonyl group.  
Methyl iodide provides the methyl source for the product and was added after dianion 158 
formed at low temperature. Following quenching of species 159 with aqueous ammonium 
chloride solution and purification, amide 156 was isolated in 87% yield.  
1H NMR was used to determine whether 152 had been methylated at the 3-position (156) over 
the 2-position, relative to the pyridyl nitrogen. The 1H NMR of 152, the starting material, 
included two doublets, each integrating to two protons (Figure 4.4), representing the pairs of 
protons in the symmetrical ring. The chemical shift values of 152 are higher than the equivalent 
values of the reference 1H chemical shift values of pyridine (160) due to the electron-
withdrawing amide.127 The two equivalent peaks of product 156 appear slightly lower than the 
starting material and pyridine due to increased electron shielding by addition of an electron 
donating methyl group to the aromatic ring.  
 
Figure 4.4 Observed 1H chemical shifts of aromatic protons in pyridine (160),127 152 and 156 
Additionally, a new singlet integrating to three protons at δ 2.37 indicated the introduction of a 
methyl group to molecule 156. The relative integration of the doublet with the higher chemical 
shift to the doublet with the lower chemical shift increased from 1:1 in 152 to 2:1 in 156. This 
meant there was only one proton ortho to the amide as the other had been methylated, and 
two meta-protons, confirming the formation of 156 (Figure 4.5).  
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Figure 4.5 Exemplar 1H NMR showing the change in relative chemical shift and integration of aromatic peaks 
between intermediates 152 (left) and 156 (right) 
n-BuLi was also used in the third step to deprotonate the new methyl carbon to allow a 
displacement reaction to take place between 156 and ethyl isonicotinate (161) (Scheme 4.5). 
Scheme 4.6 outlines the mechanism to compound 162.  
 
Scheme 4.5 Acylation of 156 to form ketone 162106 
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Scheme 4.6 Proposed mechanism for acylation step to form 162 
Similar to the previous step, 2.1 equivalents of n-BuLi were required to form dianion 164 so that 
the methyl anion could form after the amide proton was removed (163) and attack the carbonyl 
of ethyl isonicotinate (161) to form intermediate 165, with loss of ethoxide. Quenching and 
purification of the reaction mixture yielded ketone 162 in 55% yield. 
The formation of two new correlating doublets in the aromatic region of the 1H NMR confirmed 
the introduction of a second pyridyl moiety to the molecule, as did LCMS where a mass ion of 
m/z 298.04 [M+H]+ was observed which conformed to the product 162’s molecular weight of 
297. 
 
Scheme 4.7 Cyclisation conditions to form lactone 166106 
Next, ketone 162 underwent a cyclisation reaction by being heated in the microwave (mv) in 
DMF at 220 °C (Scheme 4.7). The product, lactone 166, precipitated out in solution as a pale pink 
solid. Reheating the filtrate caused more product to precipitate but the combined yield of this 
step could not be pushed beyond 49%. The formation of product 166 was confirmed by the 
correct mass ion (m/z 225 [M+H]+) by LCMS (LCQ). By 1H NMR, the loss of the aliphatic C-H peaks 
in the 1H NMR and observation of six peaks instead of five in the aromatic region of the spectrum 
also confirmed the product had formed. 
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The mechanism for this particular step could not be fully elucidated. It is unusual in that it 
involves the loss of a bulky tert-butyl amine group, by definition a poor leaving group. That said, 
the reaction is taking place under harsh conditions (220 °C, microwave heating) so any tert-butyl 
amine lost from the compound would be expected to boil off from the reaction mixture, which 
may drive the transformation but this reaction was carried out in a sealed microwave tube so 
this is not the case. This reaction is thought to be less feasible if the amide and ketone functions 
were in separate molecules. As this is an intramolecular cyclisation, reactions that aren’t usually 
energetically favourable can become more so when brought into closer proximity. The change 
in enthalpy (ΔH) will be roughly the same for 162 and 166 and intramolecular reactions do not 
result in a negative change in entropy (ΔS). The reaction is also carried out at high temperature 
(T) which increases the product value of TΔS. This means overall, the change in Gibbs Free Energy 
(ΔG), defined as,  
∆𝐺 =  ∆𝐻 − 𝑇∆𝑆 
will result in a negative value so the equilibrium of the reaction will preferentially lean towards 
the product 166 over intermediate 162.117,145  
 
Scheme 4.8 Conditions for converting lactone 162 to lactam 166106 
Conversion of lactone 166 to lactam 167 was achieved by stirring 166 in an excess of ammonia 
in methanol for 2 h (Scheme 4.8) and isolating the product by filtration in 96% yield. Scheme 4.9 
outlines the mechanism.  
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Scheme 4.9 Proposed mechanism for the conversion of lactone 166 to lactam 167 
Ammonia attacks at the carbonyl carbon of 166 to hydrolyse the ester. After a series of reversible 
proton exchanges, the newly formed primary amide nitrogen in 170 acts as a nucleophile to 
attack the resulting ketone within its structure to form the hydroxyl-containing amide 
intermediate (167). 
 
Figure 4.6 Predicted structure (172) after reaction of lactone 166 with ammonia (left), actual structure of 167 
(right) with molecular weights listed 
Initially it was thought a fully unsaturated intermediate (172) formed (Figure 4.6) but 1H NMR 
showed a set of ABq peaks127 in the aliphatic region between δ 3.0–3.5 ppm, indicating the 
presence of two diastereotopic protons belonging to a saturated carbon within the molecule 
(Figure 4.7). This and the mass ion by LCMS being m/z 242 [M+H2O]+ instead of m/z 224 [M+H]+ 
were used to deduce that the hydroxy-containing product (167) with a molecular weight of 241 
had formed instead of 172. 
70 
 
 
Figure 4.7 1H NMR of lactam 167 highlighting ABq peaks indicating degree of saturation in product 
The formation of the key bromide/chloride naphthyridine intermediates 173 and 174 was 
achieved by heating 167 in neat phosphoryl bromide/chloride (POBr3/POCl3), followed by 
quenching and isolation by flash chromatography (Scheme 4.10). Both were prepared because 
Meredith et al.106 who originally made the compound used the bromide for the preparation of 
12 and the chloride for other derivatives. A mechanism is outlined in Scheme 4.11.  
 
Scheme 4.10 Conditions for bromination/chlorination of lactam 167106
 
Scheme 4.11 Proposed mechanism of chlorination by POBr3/POCl3 to form 181 
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The lone pair on the amide nitrogen of 167 delocalises to encourage a C-O carbonyl bond to 
break to form a new O-P bond with the corresponding phosphoryl halide, displacing a halide 
anion. The diffuse nature of the p-orbitals in phosphorus and the high strength of a P=O bond 
(575 kJ mol-1)117 means there is no breaking and reforming of the P-O bond, as would otherwise 
be seen in a carbonyl under nucleophilic attack. The halide anion can then attack species 175 to 
yield intermediate 176 where loss of a phosphinic halide results in intermediate 177. Following 
deprotonation of 177, the hydroxyl group oxygen lone pair of 178 acts as a nucleophile to attack 
another phosphoryl halide molecule to give species 179. Loss of a proton from 180 to restore 
aromaticity drives loss of another phosphinic halide to yield product 181. 
This step usually led to a significant drop in yield (typical yields 30–61%) which was undesirable 
at this point in the synthesis. The largest scale attempt of the synthesis started with 5 g 
isonicotinic acid yet only 484 mg of 174 was isolated after six steps.  
The 1H NMR was consistent with that expected for the product because the amide N-H, hydroxyl 
and aliphatic ABq peaks of the starting material disappeared and six aromatic peaks remained. 
The LCMS (LCQ) spectra also exhibited the expected 1:1 and 3:1 splitting pattern for 173 and 
174 with the relative abundances 79Br and 81Br/35Cl and 37Cl isotopes respectively.146,147  
Bromide 173 was used to prepare the intermediate 183, the penultimate intermediate to make 
12, by undergoing a nucleophilic aromatic substitution (SNAr) reaction with the Boc-protected 
ethylenediamine (182), heated in dioxane for 72 h (Scheme 4.12). 183 was isolated in 18% yield 
despite being left for the allotted time (cf. 71% reported yield106). Scheme 4.13 proposes a 
general mechanism for this SNAr transformation.  
 
Scheme 4.12 Conditions for SNAr to prepare penultimate intermediate 183106 
 
Scheme 4.13 Proposed mechanism for SNAr transformation to form 183 
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The lone pair associated with the unprotected nitrogen in Boc-ethylene diamine (182) attacks 
the δ+ carbon of 173, displacing a bromide anion and shuffling electrons between that carbon 
and the adjacent nitrogen. The presence of the sodium hydroxide in the reaction deprotonates 
resulting intermediate 184 to yield product 183. 
1H NMR confirmed introduction of the Boc-protected ethylene diamine moiety to 173 by the 
appearance of two triplet peaks in the aliphatic region which each integrated to two protons as 
well as a further upfield singlet integrating to nine protons, representing the nine tert-butyl 
protons in the Boc-group. 
In later attempts of this synthesis, the chloride (174) was used to prepare analogues of 12 
because the chloride intermediate is more reactive than the bromide and thus required less 
harsh conditions.148  
Compound 12 was prepared by removal of the protecting group from the terminal amine by 
stirring 183 in trifluoroacetic acid (TFA), as shown in Scheme 4.14. The mechanism for this 
transformation was previously described in section 3.1.1. 12 was isolated in 95% yield as the 
trifluoroacetate salt. Disappearance of the singlet integrating to nine protons indicated the 
removal of the Boc-group. The multiplicity of the two aliphatic peaks changed from two triplets 
seen for 183 to a triplet and quadruplet because of the different number of protons adjacent to 
the ethylene carbons. 
 
Scheme 4.14 De-protection conditions to prepare compound 12106 
4.1.2 Preparation of analogues 
Amine variation 
 
Scheme 4.15 General scheme for initial analogue synthesis for series 1 
Four other amines were coupled with 174 to identify the SAR relating to the free-moving ethyl 
amine (Scheme 4.15). 187 was prepared with the two nitrogens fixed in position by stirring 174 
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with Boc-protected piperazine (185) in DMF at 90 °C for 5 h. After work-up and purification the 
Boc-group was removed by stirring the intermediate in TFA. Compound 187 was isolated as the 
trifluoroacetate salt and then converted to the equivalent free base by purification through an 
SCX cartridge by elution with methanol then 2 M NH3 in methanol (Scheme 4.16). The 
appearance of two singlets in the aliphatic region, each integrating to 4 protons confirmed the 
introduction of the piperazine function to the compound, as did the new broad singlet at δ 9.09 
integrating to one proton, indicative of the presence of a secondary amine. 
 
Scheme 4.16 Preparation of compound 187 from 174106 
The terminal nitrogen was also removed in the preparation of analogue 189 by introducing 
piperidine (188) to the molecule (Scheme 4.17). The appearance of three multiplets, two 
integrating to 4 protons and one integrating to two protons between δ 1.51–3.50 ppm 
confirmed the piperidine group had successfully coupled with the naphthyridine. The correct 
mass ion (m/z 291.33) was observed by LCMS (LCQ) corresponding to the molecular weight of 
the compound (290.36).  
 
Scheme 4.17 Conditions for SNAr involving chloride 174 and piperidine (188) to make compound 189106 
Further questions can be answered about how the two amino groups are involved in binding by 
methylation of the nitrogen atoms to see if removing hydrogen-bond donors affects how the 
compound fits into the active site. The analogue with the dimethylated terminal nitrogen (191) 
was successfully isolated in 61% yield but attempts to fully methylate both basic nitrogens by 
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reductive amination of 191 to make 192 were unsuccessful (Scheme 4.18). The lack of peak 
corresponding to -NH2 compared to the 1H NMR spectrum for 12 and the appearance of  a singlet 
at δ 2.24 ppm integrating to six protons confirmed formation of product 191. 
 
Scheme 4.18 SNAr and reductive amination conditions attempted to form 191 and 192 respectively106,149 
Another analogue of 12 where the ethylene diamine moiety is truncated to a methyl group 
was successfully prepared by reacting 174 with methyl amine, isolating 193 in 38% yield 
(Scheme 4.19).  
 
Scheme 4.19 SNAr conditions to prepare 193106 
This initial set of five 2,7-naphthyridine compounds (Figure 4.8) provided some useful point 
changes around the amine region of the molecule. Due to the length of the synthesis (7–8 steps), 
it was decided to investigate whether the naphthyridine core could be replaced in order to 
simplify and shorten the synthetic route to access other analogues. This is because any changes 
to the pyridyl portion of the compound had to be introduced at the third step, while any change 
to the amine portion required sufficient quantities of an intermediate made using six chemical 
transformations. There were no suitable intermediates available from commercial vendors with 
this naphthyridine core.  
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Figure 4.8 Series 1 compounds synthesised with 2,7-naphthyridine core 
Quinazoline analogues 
A quinazoline core was chosen to explore and compare with the 2,7-naphthyridine core of 12 
due to the commercial availability of 1,3-dichloroquinazoline (194) in order to optimise the 
length of the synthesis – the 2,6-naphthyridine equivalent is not commercially available. This 
enabled the rapid generation of quinazoline-containing analogues via SNAr and Suzuki coupling 
steps (Scheme 4.20). 
  
Scheme 4.20 General synthetic route to quinazoline analogues150,151 
The first step involved SNAr coupling conditions that coupled methylamine to 1,3-
dichloroquinazoline (194), summarised in Scheme 4.20.150 These conditions were transferable 
for all five amines previously used and a set of chloroquinazoline intermediates (198–202) were 
synthesised (Figure 4.9). 
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Figure 4.9 Quinazoline-containing intermediates and yields 
The amines are believed to selectively attack at the 1-position chlorine of 194 due to the 
stabilising resonance effects of the tetrahedral intermediate that forms. Scheme 4.21 shows the 
possible resonance forms that can potentially arise by nucleophilic attack at the 1-position 
(red/pink) and the 3-position (blue). More resonance forms exist for the intermediate that 
occurs from addition at the 1-position (204–206). This means this intermediate is more stable 
and thus formed selectively over a 3-substituted product. 
 
Scheme 4.21 Resonance structures with nucleophilic attack mechanistic pathways proposed for the 1-chlorine 
(red/pink) and 3-chlorine (blue) 
NOESY NMR was used to check the amine substituted with the desired chlorine of 194. An 
exemplar spectrum of 202 (Figure 4.10) shows correlation between the methylamine N-H and 
the 9-position hydrogen on the quinazoline ring, indicating the amine had substituted at the 1-
position. If it had substituted at the 3-position, no correlation with the aromatic protons would 
have been observed because of the nitrogen atoms at the 2- and 4-positions. 
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Figure 4.10 Zoomed portion of NOESY NMR spectrum for compound 202 highlighting correlation between 
methylamine proton (HA) and 9-C proton (HE) in red 
Palladium-catalysed couplings152 are one of the most commonly used transformations in 
medicinal chemistry.153 Such couplings are used to form carbon-carbon bonds between aryl 
rings. Some Suzuki conditions (Scheme 4.20)151 were found to efficiently introduce the pyridyl 
moiety to intermediates 198–202. Scheme 4.22 outlines a typical mechanism for a Suzuki 
reaction. 
 
Scheme 4.22 General mechanism for a Suzuki coupling154 
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Following activation of the palladium catalyst (210) to yield a Pd(0) source (212), the palladium 
is oxidised by donating two electrons to form a new Pd-C bond with the aryl group of an aryl 
halide, e.g. an aryl bromide (213). After formation of 214, transmetalation occurs which 
transfers a second nucleophilic aryl group from a boronic acid (215) to the palladium (217). 
Reductive elimination from the palladium yields the combined aryl groups (218) and regenerates 
the palladium (212) ready to be used again in this catalytic transformation.152,154 
A set of Suzuki conditions using (dppf)2PdCl2 found in the literature did not work when first 
attempted. Conditions that are commonly used in-house21 with a different catalyst, Pd(PPh3)2Cl2, 
were more successful to prepare compounds 220 and 222–225 (Scheme 4.23). 
 
Scheme 4.23 Final quinazoline match pairs with yields for Suzuki and Boc-deprotection steps 
1H NMR was used to distinguish between the 2,7-naphthyridine and quinazoline cores. For the 
former, two singlets and two multiplets were typically observed (e.g. 12 in Figure 4.11) while for 
a quinazoline core, two triplets and two doublets were observed instead due to all four aromatic 
protons being on the same ring adjacent to one another (e.g. 220 in Figure 4.11). COSY and 
NOESY NMR were used to fully assign the intermediates and final products.  
In some cases the 1H NMR peaks of aromatic C-Hs overlapped, and the COSY NMR was 
sufficiently ambiguous that it was difficult to confirm which aromatic protons were which. Such 
compounds have been assigned as fully as possible in the experimental section. 
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Figure 4.11 Aromatic region of 1H NMR spectra for compounds 12 and 220. Correlation from COSY NMR shown 
with coloured lines. 
Isoquinoline analogues 
The SNAr conditions150 used to prepare chloroquinazolines 198–202 were unsuccessful in the 
preparation of isoquinoline match pairs, likely due to the less electrophilic nature of the 
isoquinoline ring so harsher conditions were required.  
 
Scheme 4.24 Synthetic route to isoquinoline analogues151,155 
An alternative set of conditions155 (Scheme 4.24) where the 1,3-dichloroisoquinoline (225) was 
heated overnight at 100 °C instead of 1 h at 0 °C were found to be successful and used to bring 
through the equivalent five isoquinoline-containing intermediates (228–232) in good yield 
(Figure 4.12). 
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Figure 4.12 Chloroisoquinoline intermediates 228–232 prepared via SNAr transformation 
NOESY NMR was again used to confirm that the amine had displaced the desired 1-chlorine over 
the 3-chlorine. Figure 4.13 shows a zoomed NOESY NMR spectrum for compound 232. The 
correlation between peaks A and B confirm that the amine coupled at the 1-position. Had the 
amine substituted at the 3-position, correlation would be observed between peaks B and F, 
which is not the case. 
 
Figure 4.13 Zoomed portion of NOESY NMR spectrum for compound 232 highlighting correlation between 
methylamine proton (HB) and 9-C proton (HA) in red 
The Suzuki conditions used for the quinazoline analogues in Scheme 4.20 did not work for 
preparing the equivalent isoquinoline intermediates. A small reaction condition screen was set 
up whereby 50 mg scale reactions were run with different Pd-catalysts. The reactions were 
followed by LCQ LCMS (Table 4.1). Microwave and hotplate heating methods were compared as 
were time (15 minutes vs. overnight) and temperature (140 °C and 100 °C) parameters. 
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Table 4.1 Suzuki optimisation summary with most successful conditions highlighted in green 
Catalyst 
Reaction 
Time 
Temp. 
Heating 
apparatus 
Observed m/z values (LCQ LCMS) and predicted 
products formed 
Pd(dba)2 15 min 140 °C Microwave 
  
Pd(dppf)2Cl2 15 min 140 °C Microwave m/z 322/324 (228) and 266 (233) 
Pd-118 15 min 140 °C Microwave 
 
Pd(PPh3)4 15 min 140 °C Microwave m/z 322/324 (228) and 266 (233) 
Pd(dba)2 overnight 100 °C Hot plate m/z 322/324 (228) and 366 (234) 
Pd(dppf)2Cl2 overnight 100 °C Hot plate m/z 322/324 (228) and 266 (233) 
Pd-118 overnight 100 °C Hot plate m/z 366 (234), 309 (235) and 266 (233) 
Pd(PPh3)4 overnight 100 °C Hot plate Indecipherable mixture of compounds 
 
It was found that Pd-118 was a suitable replacement for Pd(PPh3)Cl2 and facilitated the synthesis 
of compounds 234–240 (Scheme 4.25). Again, intermediates were deprotected using TFA where 
necessary (95 and 97). 
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Scheme 4.25 Isoquinoline analogues with yields for Suzuki and Boc-deprotection steps 
To compare the removal of the 2-nitrogen from the quinazoline core, the 4-quinoline derivative 
of 12 and 233 (245) was attempted. Unfortunately using the previously successful synthetic 
route of reactions did not work because the disubstituted product (242) formed in the SNAr step 
(LCMS m/z 446 with no chlorine splitting pattern instead of 321/323). The reaction was repeated 
with a 1:1 ratio of 1,3-dichloro-4-quinoline and ethylene diamine (normally an excess of amine 
was still added) but a mixture of unreacted starting material (241) and compound 242 formed.  
 
Scheme 4.26 Attempted and optimised synthetic routes to compound 108 
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This was thought to be due to the difference in reactivity of the relative 1- and 3-position carbon 
atoms of the quinazoline (247), isoquinoline (248) and quinoline (249) rings due to the electronic 
effects affected by the relatively more electronegative nature of nitrogen (3.04)117 compared to 
carbon (2.55)117 atoms (Figure 4.14.). Carbons adjacent to nitrogens are more susceptible to 
nucleophilic attack whereas the 1-carbon of 249 is only adjacent to other carbons atoms, making 
it less delta positive for attracting a nucleophile. 
 
Figure 4.14 Comparison of relative literature 1-position and 3-position 13C NMR shift values for protons in 
quinazoline (247), isoquinoline (248) and quinoline (249)156 
Instead, the Suzuki step was attempted first. This successfully introduced the pyridyl group in 
place of the 3-position chlorine to make 246 in near quantitative yield. The amine (182) was 
successfully coupled to 246 through Buchwald Hartwig coupling conditions157 and removal of 
the Boc-group yielded compound 245 in 43% yield across three steps.  
Scheme 4.27 outlines the mechanism for the Buchwald-Hartwig transformation. Oxidative 
addition of an aryl bromide (253) to a Pd(0) complex (252), followed by coordination of an amine 
(255) catalyses the reductive elimination of the N-coupled aryl group (259). 
 
Scheme 4.27 Mechanism for Buchwald-Hartwig Amination158 
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There were observable general differences between the 1H NMR spectra when comparing the 
2,6-naphthyridine (e.g. 12) and its quinazoline (220), isoquinoline (233) and quinoline (245) 
match pairs (Figure 4.15). Due to the lack of nitrogen in the left fused ring of 220, 233 and 245, 
additional correlation is seen between four aromatic protons instead of just two in 1 (orange). 
In 1, two singlets and two doublets were observed while for 220, 233 and 245, two doublets and 
two triplets were generally observed. For 233 and 245 an additional singlet was observed 
compared to 220 because of the removal of the nitrogen.  
 
Figure 4.15 Comparison of aromatic regions of 1H NMR spectra for compounds 12, 220, 233 and 245 
Pyridyl variation 
When TR-FRET evaluation of the aforementioned 2,7-naphthyridine, quinazoline, isoquinoline 
and quinoline compounds confirmed it was possible to retain potency for PKN2 for certain core 
and amine combinations (see Section 4.3.1), further structural changes were made to the 
compound set. The next region of SAR investigation focused on the 4’-pyridyl moiety within 
compound 12.  
Due to the slightly shorter SNAr reaction time for the quinazoline (1 h) compared to the 
isoquinoline series (overnight), the quinazoline series was used to observe this structural point 
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change. The 3’-pyridyl analogues of 220 (260) and 222 (261) were prepared using the chemistry 
described in Scheme 4.20 but 3-pyridylboronic acid was used instead of 4-pyridylboronic acid 
(196) Figure 4.16. For 260, the yields of the Suzuki and deprotection steps were 46% and 86%, 
respectively and for 261 the transformations yielded 37% and 86% of product, respectively. 
 
Figure 4.16 3'-Pyridyl analogues of compounds 220 and 222 
1H NMR was used to confirm the 3’-pyridyl analogues had been prepared. Instead of observing 
two doublets to reflect the symmetrical nature of the four 4’-pyridyl protons, four peaks each 
integrating to a single proton correlated to the unsymmetrical nature of a 3’-pyridyl motif. For 
260, this was observable as a singlet at δ 9.61; two doublets at δ 8.75 and δ 8.68 ppm; and a 
fourth peak overlapping with other aromatic peaks associated with the quinazoline structure 
between δ 7.58–7.45 ppm. 
Similarly, for the piperazine match-pair (261), two multiplets were observed at δ 9.66–9.54 and 
7.62–7.50 ppm, as well as two double triplets at δ 8.76 and 8.70 ppm. Each peak corresponded 
to a single proton within the 3’-pyridyl structure and COSY NMR was used to assign the pyridyl 
hydrogens of compounds 260 and 261. 
Further amine variation 
Similar to above, the quinazoline core was primarily used to further explore changes to the 
amine portion of compound 220 due to the relatively short reaction time. Larger structural 
changes were made to compound 220 by introduction of a morpholine ring (262) and extending 
beyond the ethylene diamine function by addition of a piperidine (263), piperazine (264) and 
morpholine ring (265) at the end of the two carbon chain (Figure 4.17). 
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Figure 4.17 Piperidine-, piperazine- and morpholine-containing analogues 262–265 with yields for SNAr, Suzuki 
(and for 264, Boc—deprotection) steps, respectively 
For morpholine analogue 262, a shift in the positions of the aliphatic 1H NMR peaks was 
observed compared to 222 containing a piperazine ring. Two overlapping doublets, giving the 
appearance of a double doublet was observed at δ 3.86 ppm compared to the two distinct triplet 
peaks observed at δ 3.94 and 3.23 ppm for compound 222. There was also no N-H peak in the 
1H NMR spectrum of 262. 
For the extended amines (263–265) on the other hand, additional peaks were observed in the 
1H NMR spectrum to the two ethylene diamine peaks each integrating to two protons. Three 
additional broad singlets were observed at δ 2.48, 1.50 and 1.38 ppm with integrations of four, 
four and two protons respectively in the 1H NMR spectrum for 263. The lack of multiplicity is 
thought to be due to the relative flexibility of the piperidine ring system.  
For 264, there were only two broad singlets each integrating to four protons at 2.75 and 2.48 
and while no N-H peak was observable in the 1H NMR, LCMS analysis gave m/z 335 for 264, 
corresponding to a molecular weight of 334. A similar 1H NMR spectrum was observed for 265 
but a higher m/z of 336 was observed in the LCMS spectrum, indicating the presence of an 
oxygen instead of a nitrogen in 265.  
This chemistry was also utilised to prepare pyrrolidine (266) and dimethylamine (267) analogues 
of 220 (Figure 4.18). For 266, a broad singlet and a multiplet were observed in the 1H NMR 
spectrum at δ 4.00 and 2.08–1.93 ppm respectively. Both peaks integrated to four protons each, 
confirming reduction in ring size compared to piperidine-containing analogue 223. In the 1H 
NMR spectrum for compound 267, a singlet integrating to six protons at δ 3.46 indicated the 
dimethylamine had been successfully coupled to the quinazoline ring.  
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Figure 4.18 Compounds 266 and 267, with reported yields for SNAr and Suzuki steps, respectively 
Attempts to extend the ethylene diamine chain resulted in the synthesis of compound 275 with 
five carbon atoms between the two amine functions. The propylene analogue (272) was 
prepared in part, but purification of 271 proved difficult partly due to its solubility (it could not 
be dissolved in DCM, methanol, ethyl acetate, DMSO and combinations of these solvents) and it 
was of insufficient purity to carry out the final deprotection step. Scheme 4.28 summarises the 
attempted syntheses of the two compounds.  
 
Scheme 4.28 Attempted syntheses of 272 and 275 
The synthesis of 272 was later reattempted but was abandoned due to time constraints within 
the project. Isolation of only compound 275 was deemed a suitable matched pair for comparing 
the bioactivity of a compound with an extended chain against 220 in the absence of 272. 
Removal of phenyl ring 
Attempts to synthesise respective pyrimidine and pyridine analogues of 220 and 222 without a 
fused benzene ring proved unsuccessful. An exemplar scheme of the chemistry intended to 
make 279 is summarised in Scheme 4.29. Solubility was the main issue in trying to make these. 
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The formed products preferred to dissolve in the aqueous phase rather than the organic phase, 
even when using a polar 2:1 chloroform:propan-2-ol solvent mixture as the organic phase so 
compound 277 could not be isolated. Thin Layer Chromatography (TLC) analysis of the reaction 
mixture also indicated flash column chromatography would not be a suitable method to purify 
this reaction mixture due to the polarity of the reaction and the number of other closely running 
side products.  
Any samples of 277 and similar analogues that were isolated were not of sufficient quantity or 
purity to carry forward in the synthesis. A 250 mg sample of an unprotected version of 277 was 
purchased and while the Suzuki transformation was successful by LCMS, the compound could 
not be isolated, again due to its solubility. Purchasing larger quantities of this intermediate was 
not economically viable so the synthesis of other possible analogues was investigated. 
 
Scheme 4.29 Attempted synthesis to 279 
Instead, a comparison was made between two matched pairs where an already substituted 
intermediate was available commercially, to check the Suzuki chemistry worked. These were the 
pyrrolidine and morpholine containing entities which were made from commercially available 
2-chloro-4-(1-pyrrolidinyl)pyrimidine (280) and 4-(2-chloro-4-pyrimidinyl)morpholine (282) 
which only required a single Suzuki reaction step to make products 281 and 283, respectively 
(Scheme 4.30).  
 
Scheme 4.30 Syntheses to 281 and 283 
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The 1H NMR profiles of 281 and 283 were similar to their quinazoline, counterparts 266 and 262 
respectively, but there were two fewer aromatic peaks due to the removal of the benzene ring. 
While the yields were relatively low, sufficiently pure sample was prepared in quantities 
adequate for use in the TR-FRET assay. 
While it would have been useful to have prepare the ethylene diamine and piperazine 
analogues, these compounds should provide a useful matched pair with 262 and 266 to see what 
effect removing the phenyl ring from the quinazoline has on the potency against PKN2 (Figure 
4.19). 
 
Figure 4.19 Quinazoline and pyrimidine core match pairs 
Returning to a naphthyridine core 
After receiving kinome selectivity data on 2,7-naphthyridines 187, 191 and quinazolines 220  and 
222 (see section 4.3.2), the 2,7-naphthyridine core was shown to have better selectivity across 
the human kinome than the quinazoline cores. This was a disappointing result because 
quinazoline-containing compounds like 220 had a shorter synthetic route (2–3 steps) than the 
other three compounds (7–8 steps).  
It was decided to return to a naphthyridine core to see what effect shifting the 7-nitrogen to the 
6-position had on potency and selectivity because of the commercial availability of 1,3-dichloro-
2,6-naphthyridine (284). If these compounds exhibited similar PKN2/1 selectivity, the 2,6-
naphthyridine core would be used to prepare further analogues with finer structural changes 
made in order to further optimise a chemical probe for PKN2. 
Scheme 4.31 outlines the SNAr, Suzuki and deprotection chemistry conditions used to produce 
the 2,6-naphthyridine analogues of 12 and 187–287 and 290, respectively. These conditions 
were the same used for preparing isoquinoline analogues. 
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Scheme 4.31 Synthetic route for preparing 2,6-naphthyridine analogues 
The general changes in 1H NMR splitting pattern observed going from a 2,7- to a 2,6-
naphthyridine were loss of a singlet peak and the gain of a triplet/multiplet peak correlating to 
two other peaks as there were now three aromatic protons adjacent to one another. Figure 4.20 
gives an example comparison between the spectra of compounds 12 and 287. Correlation was 
generally observable between aromatic hydrogens at the 7- and 8-positions as well as the pyridyl 
hydrogens. 
 
Figure 4.20 Comparison of aromatic region of 1H NMR spectra for compounds 12 and 287 
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Finer structural changes to piperazine 
Potency for PKN2 and selectivity against PKN1 were retained for compounds 287 and 290  which 
indicated the 2,6-naphthyridine core was suitable to use (see Section 4.3.1). This resulted in the 
rapid synthesis of analogues related to 290, due to the high kinome selectivity of its 2,7-
naphthyridine analogue, 187.  
The analogues in Figure 4.21 contain electron-withdrawing groups adjacent to one of the basic 
nitrogen atoms. 286 and 289 are Boc-protected intermediates produced during the synthesis of 
287 and 290  while compounds 291 and 292 contain less bulky amide groups. 293 contains a 
lactam moiety and 294 is a N-methylated derivative of 293. These were prepared using 
commercially available amides which were coupled using the same SNAr conditions outlined in 
Scheme 4.31. The reaction yields when preparing these analogues were generally high (70–
100%) due to the removed basicity of one of the amines present which made purification by 
flash column chromatography on acidic silica gel relatively straightforward. 
 
Figure 4.21 Structures of 2,6-naphthyridine analogues with electron-withdrawing modifications with yields for 
SNAr and Suzuki steps, respectively 
It was also relatively simple to produce alkylated analogues of 290 using the same chemistry 
with commercially available piperazines, removing the need for an alkylation step. The methyl 
(295), iso-propyl (296) and phenyl (297) capped piperazine analogues (Figure 4.22) were 
prepared using the previously described SNAr and Suzuki chemistry in Scheme 4.31.  
92 
 
 
Figure 4.22 N-substituted analogues of 290 with yields for SNAr and Suzuki steps, respectively 
1H NMR spectra for these compounds lacked an N-H peak and gained peaks associated with the 
alkyl species capping the piperazine, in addition to the usual pairs of peaks observed for the 
piperazine protons. Generally, these compounds required a more polar solvent system during 
flash column chromatography purification, typically dichloromethane:methanol over petroleum 
ether:ethyl acetate because of their increased polarity compared to the compounds in Figure 
4.21. 
Similarly, it was also possible to investigate the addition of branching moieties on the piperazine 
carbons (Figure 4.23). A series of mono- and di-methylated piperazines (298–302 and 306–307) 
were attempted and all but one were successfully isolated. A suitably pure sample of the 
opposite diastereoisomer of 298 was not successfully isolated within the timeframe of the 
project but it was thought the difference in bioactivity would be negligible given the small size 
of the methyl group. 
It was possible to introduce a geminal dimethyl group next to the N-H (307) but not adjacent to 
the 2,6-naphthyridine ring, likely due to steric hindrance occurring during the SNAr step. 
Similarly, 306 was successfully prepared using tert-butyl (2R,6S)-2,6-dimethylpiperazine-1-
carboxylate but a similar reaction using tert-butyl (3R,5S)-3,5-dimethylpiperazine-1-carboxylate 
with the two methyl groups on the carbons nearest the naphthyridine was unsuccessful. Larger 
isopropyl (303), isobutyl (304) and benzyl (305) groups were also introduced to the terminal end 
of the piperazine ring to compare with 290 using commercially available amines with the alkyl 
groups already substituted onto the piperazine ring. It was also possible to substitute the 
piperazine for a simple bicycle in 308 using commercial reagent (1R,4R)-5-Boc-2,5-
diazabicyclo[2.2.1]heptane.  
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Figure 4.23 Analogues of 290 with additional alkyl groups and yields for SNAr, Suzuki and Boc-deprotection steps, 
respectively 
The observable changes in the 1H NMR spectra for these compounds was generally in the lower 
shift aliphatic region. One or more of the piperazine C-H peaks would either disappear or would 
half in size corresponding to the loss of piperazine protons that had been substituted by alkyl 
groups. New peaks would be observed corresponding to the group introduced to the ring. Little 
difference was seen in chemical shift between diastereoisomers e.g. for 298 and 299, a methyl-
related peak was observed at δ 1.31 and 1.17 ppm, respectively. At times due to overlapping 
peaks and overall flexibility of the ring system, it was difficult to fully assign peaks due to the 
appearance of broad singlets and these have been assigned as far as possible in the experimental 
section. 
Converting the flexible ethylene diamine of 12 to a relatively more rigid piperazine ring (187) 
was one example of restricting the relative position of the terminal hydrogen bond donating N-
H to the naphthyridine core. Other rigidified ring systems involving Boc-protected amino 
pyrrolidines were reacted with 284 using the usual chemistry in Scheme 4.31 to yield compounds 
309 –312 (Figure 4.24) in addition to bicycle 308 shown in Figure 4.23. It was possible to verify 
the incorporation of these ring systems into the compound using COSY NMR which showed how 
the aliphatic C-H protons correlated to the various amine groups. 
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Figure 4.24 Pyrrolidine analogues of 290 with yields for SNAr, Suzuki and Boc-deprotection steps, respectively 
For example, in the aliphatic region of the COSY NMR for compound 312 (Figure 4.25), two 
connected ring systems could be elucidated, starting from tertiary proton 12, in order to 
distinguish between the less polar 16-C protons and the slightly more polar C-15/13 protons. 
The C-15/13 protons which were adjacent to the pyrrolidine N-H meaning they had a higher δ 
value than peaks corresponding to 16-C protons which were between two carbon atoms. Two 
sets of peaks were observable for protons 13, 15 and 16 because each carbon was bound to two 
protons, each in distinct magnetic environments. 
 
Figure 4.25 Zoomed aliphatic region of COSY NMR spectrum for compound 312 showing two ring systems (red 
and blue) and their corresponding protons on structure of 312. 
Unexplored SAR 
Beyond the 2,6-naphthyridine core chemistry work, no other cores were explored. This was due 
to the general unavailability of equivalent commercial reagents possessing chlorines at the 1-, 
3- and other positions, that would have otherwise facilitated efficient synthesis of modular 
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compounds. A small number of compounds do exist as commercial agents but were not available 
in quantities that were useful for the previously described syntheses. It would have otherwise 
been interesting to investigate the effect of growing off other vectors within the compounds, 
for example, the 5–8-positions on the naphthyridine ring, on the activity of the compound 
against PKN2. 
In total, 52 analogues of compound 12 were prepared (Figure 4.26), most using an optimised 
synthetic route by altering the central core of the molecule. Naphthyridine, quinazoline and 
isoquinoline cores were reacted with amines and boronic acids in order to vary the modular 
components of compound 12, primarily focusing on the amine moiety at the 1-position of the 
central core of the molecule.  
 
 
Figure 4.26 SAR explored around compound 12 
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4.3 Biological evaluation 
4.3.1 TR-FRET 
The compounds were tested by the SGC using the commercial TR-FRET technology assay 
previously described in section 2.3.1. Due to the size of compound library compared to Series A 
and Series B, similar chemical species have been grouped into individual results tables to outline 
the SAR explored around compound 12. Some of the TR-FRET measurements are missing for 
PKN1. This is due to a lack of sufficiently purified PKN1 protein at the time of testing. 
Compound 12 was confirmed to be a potent inhibitor of PKN2 (Ki = 12 nM), however exhibited 
only 5-fold selectivity over PKN1. Table 4.2 shows that these particular variations of the amine 
at the 1-position of 12 largely retain potency for PKN2 but can tune selectivity between PKN2 
and PKN1. Rigidifying the ethylene diamine group to a piperazine (187) also shows a gain in 
potency although no improvement on selectivity. Removing the terminal N-H of 187 in 
piperidine analogue 189 results in a negligible doubling of potency. Capping the primary amine 
in 12 with two methyl groups in 191 suggests the presence of a terminal primary amide is not 
essential for binding in PKN2 but is more desirable for achieving potency in PKN1. Finally, 
removal of most of the amine to a methylamine moiety in 193 results in a large loss in potency 
suggesting the terminal nitrogen in 12, 187 and 191 is important for binding to PKN2. 
Table 4.2 Structure activity relationships for 2,7-naphthyridine-containing compounds binding to PKN2 and PKN1. 
Calculated Ki values for PKN2 and PKN1 are shown in nM. The assay Z’ factor was 0.7 < Z’ < 0.9; n = 2. 
 
# R PKN2 Ki (nM) PKN1 Ki (nM) 
12 
 
12 56 
187 
 
2.7 15 
189 
 
25 140 
191 
 
14 120 
193 -NHMe 5400 23000 
Table 4.3 compares the different central cores investigated compared to compound 1. Switching 
to a 2,6-naphthyridine (287) from a 2,7-naphthyridine (12) has little impact on potency, but 
PKN2/1 selectivity improves slightly from 5-fold (12) to 12-fold. This improvement drove the 
decision to focus on making 2,6-naphthyridines in the latter stages of the project. 
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Switching to the quinazoline core (220) results in a slight loss of potency (3-fold) but also 
improves the PKN2/1 selectivity (16-fold). This suggests the 6-position nitrogen in the 
naphthyridine ring is not essential for PKN2 binding if it can be moved or removed. 233, the 
isoquinoline derivative of 12 has similar potency and selectivity to 12 (7-fold). The 4-isoquinoline 
(245), on the other hand, results in 34-fold loss of potency for PKN2 highlighting the importance 
of having a nitrogen at the 2-position in the central core of this set of compounds. 
Table 4.3 Structure activity relationships for ethylene diamine-containing compounds binding to PKN2 and PKN1. 
Calculated Ki values for PKN2 and PKN1 are shown in nM. The assay Z’ factor was 0.7 < Z’ < 0.9; n = 2. 
 
# X PKN2 Ki (nM) PKN1 Ki (nM) 
12 
 
12 56 
287 
 
11 130 
220 
 
30 480 
233 
 
8.4 58 
245 
 
410 4600 
 
A similar comparison is made between piperazine-containing analogues in Table 4.4. Switching 
to the 2,6-naphthyridine (290) compared to the 2,7-naphthyridine (187) results in a slight 7-fold 
loss of potency but maintains selectivity between PKN2 and PKN1 (7-fold cf. 6-fold for 187). Due 
to the promising wider kinome selectivity of 187 (see Section 4.3.2), the medicinal chemistry 
moved towards a focused library around piperazine- and 2,6-naphthyridine-containing 
compounds, as outlined in the latter portion of section 4.2. 
A quinazoline core with both nitrogen atoms on the one ring (222) slightly reduced the potency 
of the compound for PKN2 by 10-fold but maintained PKN2/1 selectivity at 7-fold difference in 
Ki between the two kinases. Isoquinoline 237, on the other hand, had a less drastic effect on 
potency compared to 222 but reduced the selectivity to 3-fold, less than that of 12. As with the 
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ethylene diamine library above in Table 4.3, the naphthyridine cores are advantageous over 
quinazoline and isoquinoline cores for these compounds. 
Table 4.4 Structure activity relationships for piperazine-containing compounds binding to PKN2 and PKN1. 
Calculated Ki values for PKN2 and PKN1 are shown in nM. The assay Z’ factor was 0.7 < Z’ < 0.9; n = 2. 
 
# X PKN2 Ki (nM) PKN1 Ki (nM) 
187 
 
2.7 15 
290 
 
19 135 
222 
 
32 210 
237 
 
8.4 28 
 
Table 4.5 compares the bioactivities of quinazolines 220 and 222 with their 3’-pyridyl matched 
pairs, 260 and 261, respectively, as well as their preceding Boc-protected intermediates (219 
and 221, respectively). Both Boc-protected analogues result in large loss of potency indicating 
the importance of the free terminal basic amine in 220 and 222. Similarly, compounds 260 and 
261 indicate that the 3’-pyridyl is detrimental to PKN2 potency, as has been the case for 
compounds in Series B and Series C, suggesting it may be interacting with the hinge region of 
PKN2. For this reason, no further changes were made to the pyridyl region of the series.  
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Table 4.5 Structure activity relationships for pyridyl-containing compounds binding to PKN2 and PKN1. Calculated 
Ki values for PKN2 and PKN1 are shown in nM. The assay Z’ factor was 0.7 < Z’ < 0.9; n = 2. 
 
# Ar R PKN2 Ki (nM) PKN1 Ki (nM) 
220 4’-py 
 
30 480 
260 3’-py 
 
35000 - 
119 4’-py 
 
99763 - 
222 4’-py 
 
32 210 
261 3’-py 
 
4000 15000 
221 4’-py 
 
31549 31548 
 
Table 4.6 shows the data in preceding tables combined with the other quinazoline and 
isoquinoline derivatives of the initial five compounds isolated containing the 2,7-naphthyridine 
core. It appears that removing or moving the 7-nitrogen atom from 12 and 220 has a generally 
negligible effect on the potency of the quinazoline and isoquinoline analogues but when the 
amine is neither ethylene diamine or piperazine, there is loss of potency when the core changes 
to a quinazoline or isoquinoline. 
For piperidine containing compounds, there is 125-fold and 917-fold loss of potency when 
moving from the 2,7-naphthyridine (189) to the quinazoline (223) or isoquinoline (238) core, 
respectively. This suggests 189 is not binding via the pyridyl group but in another conformation, 
which is no longer possible by removal of the 7-nitrogen. For 193, a truncated version of 12, 
there is loss of activity across the three cores. Compound 267, the dimethyl derivative of 225 
shows similar inactivity compared to 220 indicating it is the loss of the terminal amine has a 
larger effect on potency than whether the nitrogen attached to the 1-postion of the core has a 
hydrogen bond donor. The 2,6-naphthyridine analogues containing piperidine, methylamine 
and N,N-dimethylethylene diamine were not synthesised due to a focus on piperazine-based 
analogues. 
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Table 4.6 Structure activity relationships for a selection of series C compounds binding to PKN2 and PKN1. 
Calculated Ki values for PKN2 and PKN1 are shown in nM. The assay Z’ factor was 0.7 < Z’ < 0.9; n = 2. 
 
# Core R PKN2 Ki (nM) PKN1 Ki (nM) 
12 A 
 
12 56 
220 B 30 480 
233 C 8.4 58 
187 A 
 
2.7 15 
222 B 32 210 
237 C 8.4 28 
189 A 
 
25 140 
223 B 1500 13000 
238 C 11000 36000 
193 A 
-NHMe 
5400 23000 
225 B 1200 4800 
240 C 600 2600 
267 B -NMe2 1400 7000 
191 A 
 
14 120 
224 B 520 5200 
239 C 251 tbc 
 
Table 4.7 compares quinazoline 220 with attempts to extend the ethylene diamine moiety. 
Removing the terminal nitrogen with a piperidine ring (263) results in 83-fold loss of PKN2 
potency due to steric effects or loss of the hydrogen bond donor N-H. Attaching a piperazine 
ring (264) on the other hand, which effectively extends the terminal hydrogen bond donating N-
H by a length of three atoms, results in a smaller 13-fold loss of potency. This suggests a terminal 
hydrogen bond donor (e.g. N-H) protruding away from the central core of the compound is 
beneficial for binding to PKN2. Meanwhile, capping with a morpholine (265) results in a greater 
230-fold drop in Ki showing an oxygen atom is not a suitable replacement for the secondary 
amine.  
Extending the carbon chain to five atoms in compound 275 results in 4-fold loss of potency 
towards PKN2. This suggests there is an optimal distance for either a N-H or -NH2 to occupy 
within the PKN2 site. Retrospectively, it was disappointing that the propylene diamine analogue 
(273) could not be isolated for reasons previously described as this finer point change would 
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have been interesting to investigate given the result for its pentylene derivative. None of these 
compounds improved on compound 220. 
Table 4.7 Structure activity relationships for quinazoline compounds binding to PKN2 and PKN1. Calculated Ki 
values for PKN2 and PKN1 are shown in nM. The assay Z’ factor was 0.7 < Z’ < 0.9; n = 2. 
 
# R PKN2 Ki (nM) PKN1 Ki (nM) 
220 
 
30 480 
263 
 
2500 16000 
264 
 
390 2100 
265 
 
6900 36000 
275  130 820 
 
Table 4.8 shows the effect of removing the phenyl ring from the quinazoline structure. As 
previously described in section 4.2.2, it was not possible to isolate the ethylene diamine- or 
piperazine-containing analogues with a pyrimidine core due to the polarity of the SNAr reaction 
product. Instead, intermediates containing already substituted pyrimidine rings with 
morpholine (283) and pyrrolidine (281) functions were used because they only required a Suzuki 
step to get to the product. When compared with the quinazoline counterparts (262 and 266 
respectively), loss of potency is observed between 262/283 and 262/266.  It can be postulated 
that a similar loss of activity would be observed for an ethylene diamine analogue like 220 
confirming the importance of the second ring for PKN2 potency.  
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Table 4.8 Structure activity relationships for quinazoline- and pyrimidine-containing compounds binding to PKN2 
and PKN1. Calculated Ki values for PKN2 and PKN1 are shown in nM. The assay Z’ factor was 0.7 < Z’ < 0.9; n = 2. 
# Structure R 
PKN2 Ki 
(nM) 
PKN1 Ki (nM) 
262 
 
 
1200 7500 
266 
 
2100 18000 
283 
 
 
5100 42000 
281 
 
14000 7100000 
Table 4.9 shows the full set of compounds synthesised with an isoquinoline and quinoline core. 
As previously discussed, the piperidine (238), N,N-dimethyl ethylene diamine (239) and 
methylamine (240) analogues exhibit a loss of potency with this core, unlike their 2,7-
naphthyridine counterparts (see Table 4.6), as does removing the basicity of the terminal 
ethylene diamine (234) or piperazine (236) nitrogen by use of the carbamate in the Boc 
protecting group. For completeness, 245, the quinoline analogue of 12 was also synthesised and 
was 48-times less potent than the isoquinoline 233 and the original compound, 12 (Ki = 12 nM). 
Table 4.9 Structure activity relationships for isoquinoline- and quinoline-containing compounds binding to PKN2 
and PKN1. Calculated Ki values for PKN2 and PKN1 are shown in nM. The assay Z’ factor was 0.7 < Z’ < 0.9; n = 2. 
                                             
# X Y R PKN2 Ki (nM) PKN1 Ki (nM) 
233 
N C-H 
 
8.4 58 
234 
 
25060 79245 
237 
 
8.4 28 
236 
 
99763 199054 
238 
 
11000 36000 
239 
 
251 tbc 
240 -NHMe 600 2600 
245 C-H N 
 
4100 4600 
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The library becomes more focused beyond this point, predominantly around 2,6-naphthyridine- 
and piperazine-containing compounds, with reference to 290. Table 4.10 details the three 
compounds isolated that capped the piperazine N-H using a methyl (295), isopropyl (296) and 
phenyl (297) groups. 295 was 4-times less potent than 290; and as group size increased, loss in 
potency also increased. In terms of selectivity, 295 and 296 have comparable PKN2/1 selectivity 
cf. 290 and the selectivity of  297 is irrelevant given its drop in potency for PKN2. This set of 
results indicates capping the terminal N-H of the piperazine is undesirable for achieving PKN2 
potency and selectivity. 
Table 4.10 Structure activity relationships for N-alkylated compounds binding to PKN2 and PKN1. Calculated Ki 
values for PKN2 and PKN1 are shown in nM. The assay Z’ factor was 0.7 < Z’ < 0.9; n = 2. 
 
# R PKN2 Ki (nM) PKN1 Ki (nM) 
290 
 
19 135 
295 
 
83 410 
296 
 
130 760 
297 
 
18000 190000 
 
Analogues were prepared that sought to remove basicity from the terminal primary amine in 
compound 287 and the secondary amine in the piperazine ring of 290 (Table 4.11). Addition of 
a carbamate (286 and 289) or acetate (291 and 292) group resulted in loss of potency. Swapping 
the piperazine ring for a piperazinone (293) and methylating the N-H of the oxopiperazine (294) 
also decreased the activity of the compound compared to 290 (PKN2 Ki = 19 nM). 
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Table 4.11 Structure activity relationships for 2,6-naphthyridine-containing compounds binding to PKN2 and 
PKN1. Calculated Ki values for PKN2 and PKN1 are shown in nM. The assay Z’ factor was 0.7 < Z’ < 0.9; n = 2. 
 
# R PKN2 Ki (nM) PKN1 Ki (nM) 
286 
 
7925 19906 
291 
 
1500 6900 
292 
 
1991 31548 
289 
 
12000 29000 
293 
 
730 15000 
294 
 
2800 23000 
 
Table 4.12 shows structural changes made elsewhere on the piperazine ring. Compound 298 is 
equipotent with 290 with little improvement on PKN2/1 selectivity. Diastereoisomers 299 and 
302 are roughly similar in their potency and selectivity. Thus the same result could be expected 
for the diastereoisomer of 298.   
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Table 4.12  Structure activity relationships for 2,6-naphthyridine-containing compounds binding to PKN2 and 
PKN1. Calculated Ki values for PKN2 and PKN1 are shown in nM. The assay Z’ factor was 0.7 < Z’ < 0.9; n = 2. 
 
# R PKN2 Ki (nM) PKN1 Ki (nM) 
290 
 
19 135 
298 
 
18 170 
299 
 
29 310 
302 
 
36 420 
303 
 
360 1400 
304 
 
32 150 
305 
 
300 1000 
307 
 
18 190 
300 
 
15 130 
301 
 
590 2500 
306 
 
64 680 
 
Increasing the protruding alkyl group from a methyl (302) to an isopropyl (303) group reduces 
PKN2 potency by 10-fold while, surprisingly, the slightly larger isobutyl (304) group is equipotent 
with 302 but is less selective between PKN2 and PKN1. The i-butyl group potentially 
accommodates a cavity in the ATP binding site of PKN2 better than an i-propyl group does. The 
benzylated analogue (305) on the other hand, is 16-fold less potent than 290. 
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Incorporating a second additional methyl group into the piperazine ring gave different results. 
When present on the same carbon in a geminal arrangement (307), PKN2 potency was 
comparable to 290 and there was a slight improvement in selectivity from 7-fold to 10-fold. 
Diastereoisomers 300 and 301 gave different results based on the 3D conformation of the two 
methyl groups spaced three carbons apart in a trans conformation. Compound 300  had similar 
potency and selectivity cf. 290 but 301 was 31-fold less potent than 290 towards PKN2. This 
suggests the space the piperazine ring occupies is relatively small but can accommodate two 
methyl groups branching from the ring if they are in the right conformation.  
Moving the methyl groups slightly closer together in a symmetrical cis-conformation adjacent 
to the amine (306) resulted in 3-fold loss of PKN2 potency but PKN2/1 selectivity increased from 
7-fold to 10-fold compared to 290.  
Table 4.13, the last of TR-FRET results, details the potencies of the fused ring systems 
synthesised compared to the flexible terminal amine in 12 and 287. Bicycle 308 is 12-fold less 
potent than 287. Pyrrolidines 309  and 310 are 3–4 times less potent than 287 with similar 
selectivity over PKN1. Reversing the branched pyrrolidine such that the branching amine is 
coupled with the 2,5-naphthyridine core gave more contrasting results: 311 was 20-fold less 
potent towards PKN2 but its diastereoisomer 312 nearly doubled the potency towards PKN2. It 
also exhibited 18-fold selectivity over PKN1, the highest of any compound in this series.  
The Boc-protected version of 312, compound 313 was also tested and was shown to be 1000-
fold less active towards PKN2 than 312 like other Boc-containing compounds. In combination 
with 312, it provides a useful matched pair for use as a control in target validation experiments. 
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Table 4.13 Structure activity relationships for 2,6-naphthyridine-containing compounds binding to PKN2 and 
PKN1. Calculated Ki values for PKN2 and PKN1 are shown in nM. The assay Z’ factor was 0.7 < Z’ < 0.9; n = 2. 
 
# R PKN2 Ki (nM) PKN1 Ki (nM) 
287 
 
11 130 
290 
 
19 135 
308 
 
130 970 
309 
 
48 680 
310 
 
28 320 
311 
 
200 3000 
312 
 
6.7 120 
313 
 
7400 19000 
 
4.3.2 Kinome Selectivity Evaluation  
Compounds 187, 191, 220, and 222 were sent for screening against the DiscoverX kinase panel 
previously described in Section 3.3.2. These compounds were picked for their reasonable 
potency and selectivity for PKN2 over PKN1 – using a single run of TR-FRET data which differed 
slightly from the averaged data in the section 4.3.1. Figure 4.27–Figure 4.31 show the inhibited 
kinases on the kinome phylogenetic tree with varying sizes of circle, corresponding to 
percentage inhibition by the compound. These will be discussed in order of increasing PKN2 
selectivity. The full data can be viewed in Appendix 1. 
Figure 4.27 and shows that 1 μM concentration of compound 191 inhibits 4 out of 400 distinct 
kinase targets above a nominal threshold of 70%. Unfortunately, PKN2 does not feature in that 
set of four kinases. Instead it is the 24th most inhibited kinase from the panel used in this 
experiment (Figure 4.28). The kinases that were inhibited by 191 were ROCK1, ROCK2, HASPIN 
and YSK4. ROCK kinases lie within the AGC family and share structural similarity with PKNs, so it 
is not surprising that compound 191 inhibits these kinases. It should be noted that false positives 
are possible in this experiment given the single dose and vast quantity of targets. 
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Figure 4.27 Kinome selectivity of compound 191 @ 1 μM 
 
Figure 4.28 Bar graph showing where PKN2 sits in the top 24 kinases inhibited by compound 191 @ 1 μM  in the 
DiscoverX KINOMEscan® experiment dosed at 1 μM. PKN2 highlighted in green. 
A small number of large red spots in Figure 4.29 suggests 220 has a similar selectivity profile to 
compound 191. 220 was shown to inhibit 2 out of 400 targets in this experiment, neither of 
which were PKN2. PKN2 is ranked 176th in terms of the most inhibited kinase in this set, while 
HASPIN and FLT3 kinases have the lowest % of immobilised ligand remaining in the experiment. 
The AGC family is highlighted in green and some degree of inhibition but nothing that suggests 
the compound is particularly selective for PKNs. 
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Figure 4.29 Kinome selectivity of compound 220 @ 1μM 
Similarly, compound 222 in Figure 4.30 appears to not inhibit any of the kinases in this 
experiment above the nominal threshold of 70% when dosed at 1 μM.  PKN2 was ranked 176th 
out of 469 wild-type and mutant kinase domains used in the experiment. AMPK-α is the most 
inhibited kinase but only had a measured inhibition of 56% when dosed with 1 μM 222. While 
some binding is observed predominantly in the mustard yellow CMGC branch of the kinome, 
this shows this compound would not be ideal as a tool compound for PKN2. This discrepancy 
compared to the TR-FRET will be discussed further below. 
 
Figure 4.30 Kinome selectivity of compound 222 @ 1 μM 
The most promising result for this experiment regards compound 187. In Figure 4.31, 187 is 
shown to have bound potently (indicated by large red circles) to several AGC kinases located on 
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the green branch of the kinome phylogenetic tree. Specifically, 187 was shown to bind to 9 out 
of 400 kinase targets above 70% inhibition.  
 
Figure 4.31 Kinome selectivity of compound 187 @ 1 μM 
The other kinases more potently inhibited by this compound were ROCK1, ROCK2 and HASPIN 
as seen for compounds 191 and 220 as well as PRKCE, MEK5, HIPK2, CIT and PRKG2. Some 
activity is also seen in the DYRK regions of the mustard yellow branches of the CMGC kinase 
family. Activity across the AGC kinase family is to be expected for a compound designed to target 
an AGC kinase. 
 
Figure 4.32 Bar graph showing where PKN2 sits in the top 24 kinases inhibited by compound 187  in the DiscoverX 
KINOMEscan® experiment dosed at 1 μM. PKN2 highlighted in green. 
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DiscoverX data often contains false positives because testing these four compounds at single 
dose concentration (1 μM) against over 400 kinases resulted in over 1600 data points. Perceived 
“hits” from a DiscoverX selectivity screen are usually followed up by testing the top hits from 
the KINOMEscan® in a dose-response measurement in order to obtain IC50 values for the off-
targets as well as the desired targets. This work has not been completed for these compounds 
thus far. 
There is also the possibility of false negatives, as seen here for compounds 57, 80 and 82 which 
appeared to be potent PKN2 inhibitors by the TR-FRET assay but not by the KINOMEscan®. An 
example of such an inhibitor is the SPHINX31 SRPK1 inhibitor.159 The DiscoverX SRPK1 assay 
showed other SRPK1 inhibitors to be potent but not SPHINX31. It may be possible that certain 
inhibitors bind along with the immobilised ligand but generally these discrepancies have not 
been rationalised. The TR-FRET experiment is a more reliable method for showing compounds 
bind to PKN2 and PKN1 and this kinase panel screen is more useful as a general guide about 
selectivity.  
After receiving these data, the decision was taken to focus on further optimising 187, the most 
potent and selective of these four compounds. Attempts were made to investigate if returning 
to the 2,7,naphthyridine could be avoided because of the length of the synthetic route.  
The 2,6-naphthyridine analogue (290) showed similar potency and PKN2/1 selectivity to 187 as 
previously described and a library of compounds related to 290 were prepared to see if the 
wider kinome selectivity could be maintained, or even improved upon with this small structural 
change.  
4.4 Computational chemistry 
4.4.1 Similar ligands in the Protein Data Bank 
In the PDB there is one example of a similar compound bound to PKCη (Figure 4.33), a geminal 
dimethyl analogue of 12  (314) (Figure 4.34). The pyridyl nitrogen of this compound, is shown to 
interact with the N-H of a valine residue (Val436) via a hydrogen bonding interaction in crystal 
structure 3TXO in Protein Kinase C-η (PKCη). Given the general similarity of PKC kinases to PKN 
kinases, this supports the pyridyl-based binding hypothesis associated with this series of 
compounds. 
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Figure 4.33 Compound 314 interacting with hinge region (mint green) of PKCη (PDB code 3TXO).160 Figure made 
with Schrodinger Maestro 19-4. 
 
Figure 4.34 Geminal dimethyl analogue of 12 
Searches for similar pyridine-containing structures with 2,6-naphthyridine, quinazoline, 
isoquinoline and quinoline cores yielded no hits. More crystal structures with these core 
heterocycles are deposited in the PDB e.g. 533 structures co-crystallised with quinazoline-
containing ligands, but these lacked the experimentally determined essential pyridyl ring also 
needed for binding in this series of compounds. 
4.4.2 Docking Experiments 
A selection of synthesised and hypothetical Series C compounds were docked into PKN2 as 
previously described in section 2.4 by the author. While in the previous two chapters, 
experimentally inactive compounds were docked and vice versa, more compounds from this 
series were successfully docked by this method. 
Figure 4.35 shows five compounds (12, 315–318) that were successfully docked into the ATP 
binding site of PKN2 with one of the two bonding constraints applied regarding the alanine 
(Ala740) and Tyrosine (Tyr739) residues shown to form hydrogen bonds with ATP-γS in a 
structure of PKN2 (PDB code 4CRS).  
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Figure 4.35 Compounds successfully docked via one binding constraint 
Unfortunately, the compounds did not correspond to the experimentally elucidated bonding 
hypothesis. Compounds 12 and 315–317 were shown to interact with Ala740 within the kinase 
hinge region (yellow) via the 7-position nitrogen hydrogen bond acceptor. None of the 
compounds bound via the 4’-position nitrogen acceptor in the pyridyl ring (Figure 4.36).  
Compound 318 is the phenyl derivative of 12. While this was not synthesised, the 3’-pyridyl 
quinazoline analogue (260) was shown to be experimentally inactive in section 4.3.1. It is 
assumed a phenyl group would have given a similar result, as per the set of series B compounds 
synthesised in section 3.3.1.  
  
Figure 4.36 PKN2 hinge region (yellow) with compounds 2, 315–317 stacked. Figure made with Schrodinger 
Maestro 19-4. 
The theoretical 2,9-naphthyridine (318), which was not synthesised, was the only one of this set 
of compounds shown to bind via the 4’-pyridyl to Ala740 within the hinge of PKN2 (yellow) 
(Figure 4.37). Compound 318 does not have a nitrogen at the 7-position like the other four 
compounds in Figure 4.35 which may be why the 4’-pyridyl nitrogen became the preferential 
hinge binder. 
Figure 4.37 shows an overlay of the two docked binding poses of compound 318 in the 
constrained and unconstrained docking experiments. There is little change in the overall 
114 
 
positioning of the compound. An additional interaction is shown whereby the terminal amine 
forms a hydrogen bond with an aspartate (Asp 744) residue in the C-domain of the kinase. It 
may be possible that the piperazine N-H of 54 and the pyrrolidine N-H of 167 occupy more 
desirable orientations to interact with this residue. 
 
Figure 4.37 Overlay of compound 318 in PKN2 from single and zero constricted experiments interacting with 
hinge (lime green) of PKN2. Figure made with Schrodinger Maestro 19-4. 
Generally, it is difficult to carry out docking studies without a crystal structure containing a 
molecule from the same series of compounds because a kinase conformation usually changes 
when it is inhibited by ATP-competitive ligands. Using this crystal structure of PKN2 as the basis 
for the docking model did not correlate that with experimental data but assuming the binding 
conformation of 318 was correct, it was possible to justify some of the experimental changes in 
SAR. Many of the compounds that proved to be active by biochemical assay were not 
successfully docked into the protein.  
Cross-docking experiments 
Following return of the DiscoverX data for compounds 187, 191, 220 and 222, these compounds 
underwent similar cross docking experiments described in section 3.4.2. As per the series B 
compounds, ambiguous binding modes were observed for the compounds across the different 
kinase targets, fully outlined in Appendix 2. 
When compound 191 was docked across the two kinase sets with high inhibition in the 
DiscoverX screen and had structural similarity to PKN2 (Figure 4.38), two thirds of the docking 
experiments were ambiguous (grey), in that the compound did not bind to the hinge region or 
bound via an unusual conformation such as the aliphatic amine. This was expected as the crystal 
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structures chosen for the various kinases in this cross-docking study contained a variety of 
chemotypes of ligands that were not necessarily naphthyridine-based. 
 
Figure 4.38 Distribution of binding modes in cross-docking experiment with compound 191 
Of the successful cross-docking experiments, just over half bound to the hinge via the 4’-pyridyl 
nitrogen (orange) while the remaining cases bound via the nitrogen at the 6-position (green) in 
the naphthyridine ring. These are the two most expected binding conformations for this 
compound so although only a third of the kinases successfully accommodated the compound 
using this method, it highlights the ambiguity in potential binding mode. 
All of the docking experiments using compound 220 were successful (Figure 4.39). Just under 
half of those showed the compound bound to the kinase via the 4’-pyridyl (orange) of those that 
successfully docked into their respective kinases. 
 
Figure 4.39 Distribution of binding modes in cross docking experiment with compound 220 
The other binding conformations were classified as “other” (grey), meaning the compound 
either bound elsewhere in the kinase or they bound via the amine or other portion of the 
molecule in an inconsistent way. This suggests that removing the 6-nitrogen from compound 12 
to the 4-position removes the ability of the compound to bind to the kinase in the alternative 
conformation seen for compound 12. 
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Compound 222 is the piperazine analogue of 220. While there was a small number of cases 
where the compound did not dock (yellow), around a quarter docked via the 4’-pyridyl nitrogen 
(orange). There was a case where the 4-position nitrogen in the quinazoline core interacted with 
the hinge (blue), but this was not seen across other kinases. The majority of binding modes were 
unclassifiable (Figure 4.40). 
 
Figure 4.40 Distribution of binding modes in cross docking experiment with compound 222 
Finally, for compound 187, the 2,7-naphthyridine equivalent of 222 showed similar ambiguous 
binding modes seen for the other compounds (Figure 4.41). In this case, half of the docking 
experiments showed the kinases forming hydrogen bonding interactions with the 6-position 
nitrogen (green) and around just under a quarter of cases with the 4’-pyridyl nitrogen (orange). 
 
Figure 4.41 Distribution of binding modes in cross docking experiment with compound 187 
The cross docking studies suggest 2,7-napthyridine-contaiing compounds have more possible 
binding conformations than quinazoline and isoquinoline cores.  This is thought to be due to 
having a nitrogen on both rings within the central heterocycle core of the molecule. These 
studies suggest it be possible to reduce binding ambiguity by removing this nitrogen through the 
use of an alternative heterocycle like a quinazoline or isoquinoline. Reducing the number of ATP-
like motifs in a compound is a reasonable strategy to prevent the compounds binding to more 
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kinases. There was also an instance where the dock was unsuccessful (yellow) and around a 
quarter of cases where the compound bound to the kinase in other ways (grey) such as the 
piperazine interacting with the hinge over the aromatic rings.  
Overall, the docking experiments did show that the compounds bound via the pyridyl ring 
(orange) in some, but not all cases. While ambiguous binding modes outside of the hinge region 
were the most common binding type, it was possible to see the effect removing the 6-nitrogen 
had on forcing the binding conformation towards the pyridyl-led interaction. Unfortunately 
removing this nitrogen did not improve the selectivity experimentally so a nitrogen is required 
in that region for PKN2 potency.  
Due to the inconclusive nature of the docking experiments, with multiple binding modes 
suggested, computational docking was not deemed a suitable tool using this particular model 
for guiding chemistry for this series of molecules. Experimental results showed that loss of the 
4’-pyridyl ring resulted in the greatest loss of potency, suggesting this hydrogen bond accepter 
at this particular arrangement was involved in the key interaction with the kinase hinge.  
4.5 Crystallography 
Dr. Angela Fala (SGC) managed to successfully co-crystallise compound 187 with PKN2 (Figure 
4.42). This is the first crystal structure of PKN2 bound to a non-ATP-type ligand. Compared to 
the existing structure of PKN2 bound to ATPγS (PDB code: 4CRS), the structure of PKN2 with 187 
bound shows that it binds to the hinge region of the PKN2 via the 4’pyridyl nitrogen which forms 
a hydrogen bond with an alanine residue (Ala740). The 7-nitrogen also forms a hydrogen bond 
with a lysine in the N-terminal region (Lys686). The aromatic rings lie parallel to each other but 
the piperazine extends almost perpendicular to the naphthyridine ring to make an interaction 
with an aspartate residue (Asp786). 
 
Figure 4.42 Crystal structure of PKN2 co-crystallised with compound 187 with zoomed section on binding site 
showing key interactions with residues. Figure produced by Angela Fala using MOE. 
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Figure 4.43 shows the aligned PKN2 structures and highlights the binding sites of the two 
structures individually. It appears that Asp744 interacts with both a hydroxyl group in the sugar 
portion of ATP and with the piperazine N-H. The 5-nitrogen and 4-amino functions of the 
adenine portion of ATP form an acceptor donor motif with the hinge of the motif while 
compound 187 only requires a single hydrogen bonding interaction with an alanine residue in 
the hinger (A/Ala740). The lysine residue that interacts with the 7-nitrogen of 187 also interacts 
with the central phosphate group in ATP. The lack of disparity between the two structures in the 
hinge region suggests that compound 187 occupies a similar space to ATP in that it mimics three 
key interactions with PKN2. A tartrate molecule has also crystallised with the structure and 
interacts with lysine (Lys/K784) and arginine (Arg/R665) residues at the exterior of the PKN2 ATP 
site due to the conditions used to grow the crystal (see section 6.2.3). 
While the docking studies discussed in section 4.4.2 did not show this binding conformation for 
compound 12, a 2,9-naphthyridine analogue (318) did occupy the ATP site of PKN2 in a similar 
orientation, with the 4’pyridyl nitrogen forming a hydrogen bond with the alanine (Ala740) 
residue in the hinge and the terminal amine with an aspartate residues Asp744 and Asp786. 
Docking studies should be reattempted using this new crystal structure to see if compound 12 
and other 2,7- and 2,6-naphthyridine analogues dock into the kinase with a similar conformation 
as 318. 
 
Figure 4.43 Alignment of PKN2 crystal structures with ATPγS and compound 187 bound and zoomed sections of 
individual binding sites and key residues highlighted. Figure produced by Angela Fala using MOE. 
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Crystallisation studies with compound 312 are underway but it is possible to postulate that the 
branched pyrrolidine in 312 provides a more optimal angle for the terminal amine to protrude 
away from the naphthyridine ring to form a stronger interaction with aspartate residue 
(Asp744). Compounds with longer amine branches such as 264 and 275 may be too large to form 
an ideal interaction with this residue (Figure 4.44). 
 
Figure 4.44 Compounds 264, 275 and 312’s SAR can be rationalised with the crystal structure of 187 in PKN2 
The attainment of this crystal structure confirms the importance of the pyridyl ring and the 
necessary inclusion of a second nitrogen in the central ring across this series of compounds. It 
can be proposed that the quinazoline and isoquinoline analogues could not participate in the 
same hydrogen bonding interaction with Lys686 but were still able to occupy the ATP site, taking 
advantage of nearby hydrophobic residues to accommodate the less polar fused phenyl ring. 
4.6 Chapter 4 Summary 
Series C proved to be the most successful of the three series of compounds for optimising a 
PKN2 chemical probe. The original hit, a reported PKC/PKD inhibitor,106,161 was synthesised via 
an 8-step synthesis and was confirmed as a potent inhibitor of PKN2 (Ki 12 nM) but had only 5-
fold selectivity over PKN1. Exchanging the core, amine and pyridyl rings established the 6/7-
position nitrogen and pyridyl ring were required for potency and selectivity (Figure 4.45) and 
confirmed a shorter chemical route could be used to make an optimised compound using a 2,6-
naphthyridine instead of a 2,7-naphthyridine.  
 
Figure 4.45 SAR summary regarding compound 12 
Piperazine analogue 187 was shown to inhibit 9/400 kinases above 70% when dosed at 1 μM in 
the commercial DiscoverX scheme but had the same 5-fold selectivity as 12 (PKN2 Ki 2.9 nM, 
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PKN1 Ki 15 nM). Further optimisation of this compound led to compound 312 (Figure 4.46), 
whereby the fused pyrrolidine system improved the potency to PKN2 Ki 6.7 nM and the 
selectivity to 18-fold over PKN1. Further kinome selectivity studies on 312 are currently pending. 
Compound 313, the Boc-protected analogue of 312 also serves as a suitable inactive probe for 
use in experimental controls. 
While computational studies could not fully rationalise compound 12’s potency for PKN2 or 
other kinases, crystallographic studies around this series yielded the first crystal structure of 
PKN2 with a non-ATP analogue ligand bound. The structure confirmed the binding mode of 
compound 187 with the 4’-pyridyl binding with the hinge of the compound and other critical 
SAR for further compound optimisation. 
 
Figure 4.46 Optimisation of compound 12 to compound 312 
  
121 
 
Chapter 5 Conclusions and Future Work 
Chemical probes are drug-like compounds used in early-stage drug discovery projects. They are 
designed to be sufficiently potent and selective against a desired biological target, usually a 
protein, in order to answer mechanistic questions in physiological and pathological biology. 
While kinase drug discovery has impressively brought 52 drugs to market over the past 20 years, 
more than 80% of the, so called, “dark kinome” lacks good quality small molecule inhibitors.  
PKN2 is one of those understudied kinases with several postulated roles across normal cell 
biology, from cytoskeleton regulation to cell cycle amongst others. The AGC kinase is of interest 
as a potential drug target for its apparent role in several sub-types of cancer, inflammation and 
heart failure.  
This PhD project sought to repurpose and optimise existing kinase inhibitors identified from a 
ChEMBL literature screen. The main aim was to investigate where it was possible to achieve 
potency and selectivity with one or more of the compounds within the PKN sub-family and wider 
human kinome through a collaboration with the SGC.  
A triage of 1200 reported PKN2 inhibitors resulted in the prioritisation of three potent 
compounds (10, 11 and 12) (Figure 5.1). This thesis aimed to outline the work undertaken to 
synthesise these compounds, confirm their bioactivities as inhibitors of PKN2, and explore SAR 
in order to improve on their selectivity for PKN2 over PKN1 and the wider kinome. 
 
Figure 5.1 Compounds 10, 11 and 12 selected from the ChEMBL screen with reported potencies and 
selectivities103–106  
Chapter 2 summarised work concerning series A, around benzimidazole 10, synthesised in four 
steps. It was not possible to improve on the original compound’s potency but a more selective 
(27-fold) analogue (92), containing a bromine at the 6-position, was successfully isolated and 
tested against PKN2 and PKN1 along with the other compounds in series A using a TR-FRET assay 
(Scheme 5.1). 
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Scheme 5.1 Attempted  optimisation of compound 10 
Chapter 3 focused on series B, based around pyrrolopyridinone 11. This compound was 
successfully made in a one-step addition-condensation reaction, with additional conditions used 
to alkylate the various free N-H bonds present in the compound. Two equipotent compounds, 
121 and 122, were made by alkylating the pyrrole N-H with ethyl and n-propyl respectively, but 
they were less selective over PKN1 cf. 11 (Scheme 5.3).  
 
Scheme 5.2 Attempted  optimisation of compound 11 
When these compounds were tested in focused (50 kinases) and diverse (469 wild-type and 
mutant) kinase panels for their selectivity, it was found that alkylating the pyrrole N-H improved 
some degree of selectivity across the kinome because of the lost hydrogen bond donor, but the 
compounds of series B did not prove to be the most selective series. 
Chapter 4 discusses the most promising of the three series, series C. The starting compound, 12, 
a 2,7-naphthyridine was successfully synthesised using a previously reported 8-step synthesis. 
Exchanging the 2,7-naphthyridine for other N-containing-fused heterocycles optimised the 
synthesis to 2–3 steps, depending on if the amine coupled at the 1-position required 
deprotection or not. 12 was confirmed as a potent but relatively unselective PKN2 inhibitor. 
Close analogue, 187, containing a piperazine moiety had improved potency and was shown to 
inhibit only 9/469 wild-type and mutant kinases above 70% at 1 μM in the commercial DiscoverX 
panel.  
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Scheme 5.3 Optimisation of compound 12 to yield compounds 187 and 312 
This result was used to guide further chemistry around 2,6-naphthyridine compounds containing 
rigidified amines and the best compound of the series was compound 312, with Ki 6.7 nM 
potency for PKN2 and 18-fold selectivity over PKN1. While this compound has the desired in 
vitro  potency (< 100 nM), its selectivity falls short (30-fold) and its in cellulo activity is still to be 
tested. Despite this, it provides a significant step towards a good quality PKN2 chemical probe. 
Computational studies generally did not add value to the experimental work. This was primarily 
because the only crystal structure available of PKN2 available had an ATP-like ligand which 
meant the kinase was not in the conformation it would otherwise be in if bound to a more 
similarr chemotype of ligand. Towards the end of this work, a structure of PKN2 in an alternative 
conformation co-crystallised with 187 was successfully produced by Dr. Angela Fala and provides 
a useful tool for further exploring how to drug this kinase. 
In specific terms of future work, knowing the wider selectivity of 92 and 312 will help to direct 
future chemistry efforts. The new crystal structure can be used for fully rationalising the SAR of 
the series C compounds synthesised thus far and can provide the basis for docking studies to 
support and guide future compound design and syntheses. Further characterisation of these 
probes and their ability to engage with PKN2 in cells using target engagement assays such as 
NanoBRET would also be beneficial. 
Previous research carried out on PKN2 has, for the most part, utilised genetic tools and 
techniques to elucidate the function of this kinase. This work is believed to be the first concerted 
effort to design small molecule inhibitors specifically for PKN2, as oppose to serendipitously 
finding potent and selective PKN2 inhibitors while targeting other kinases. The work around the 
three series of compounds has shown it is indeed possible to drug PKN2 with a reasonable 
degree of selectivity over its close homologue PKN1 and the wider human kinome. 121 novel 
compounds were synthesised as part of this project. If an appropriate probe can be developed, 
it will be possible to validate whether PKN2 could be a useful drug target of the future.  
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Chapter 6 Experimental Methods 
6.1 Chemistry 
All commercial reagents were purchased from Sigma-Aldrich, Alfa Aesar, Apollo Scientific, Fisher 
Scientific, Fluorochem, Tokyo Chemical Industry or Manchester Organics and were of the highest 
available purity. Unless otherwise stated, chemicals were used as supplied without further 
purification. Anhydrous solvents were purchased from Acros (AcroSeal™) or Sigma-Aldrich 
(SureSeal™) and were stored under nitrogen. Anhydrous solvents and reagents were used as 
purchased. Petroleum ether refers to the fraction with a boiling point between 40 °C and 60 °C. 
Reactions were magnetically stirred and monitored by liquid chromatography mass 
spectrometry (LCMS) or thin layer chromatography (TLC) using aluminium-supported thin layer 
chromatography sheets with Merck silica gel 60 F254. For TLC, the eluent was as stated (where 
this consisted of more than one solvent, the ratio is stated as volume: volume). Visualisation was 
by absorption of UV light (νmax 254 or 365 nm). 
Flash column chromatography was carried out using either: commercial pre-packed silica 
columns from Biotage (SNAP and Zip), Isco (RediSep), Grace (Reveleris) or filled with Merck silica 
gel 60 (40-63 μm); C18 silica (Biotage SNAP KP-C18-HS, Grace Reveleris C18); amino silica 
(Biotage SNAP KP-NH or Grace Reveleris Amino) on an ISCO Combiflash Rf or a Biotage Isolera 
Prime. 
1H and 13C NMR spectra were recorded at 500 or 600 MHz on a Varian VNMRS 500/600 MHz 
spectrometer (at 30 °C), using residual isotopic solvent as an internal reference. The chemical 
shift data for each signal are given as δ in units of parts per million (ppm). Each spectrum is 
corrected to the appropriate solvent reference; δ (CHCl3) = 7.27/77 ppm or δ (DMSO) = 
2.50/39.52 ppm for 1H/13C NMR respectively. The multiplicity of each δ signal is indicated by: s 
(singlet); br s (broad singlet); d (doublet); t (triplet); q (quartet); or m (multiplet). The number of 
protons (n) for a given resonance signal is indicated by nH. Coupling constants (J) are quoted in 
Hz and are recorded to the nearest 0.1 Hz. Identical proton coupling constants (J) are averaged 
in each spectrum and reported to the nearest 0.1 Hz. The coupling constants are determined by 
analysis using MestreNova version 10 software. 
LCMS (LCQ) data was recorded on a Waters 2695 HPLC using a Waters 2487 UV detector and a 
Thermo LCQ ESI-MS. Samples were eluted through a Phenomenex Luna 3 μ C18 50 mm × 4.6 
mm column, using water and acetonitrile acidified by 0.1% formic acid at 1.5 mL/min and 
detected at 254 nm. 
125 
 
LCMS (MDAP) data was recorded on a Shimadzu Prominence Series coupled to a LCMS-2020 ESI 
and EI mass spectrometer. Samples were eluted through a Phenomenex Gemini 5 μ C18 110 Å 
250 mm × 4.6 mm column, using water and acetonitrile acidified by 0.1% formic acid at 1 mL/min 
and detected at 254 nm. 
High resolution mass spectrometry: HRMS data (ESI+) was recorded on Bruker Daltonics, Apex 
III, ESI source: Apollo ESI with methanol as spray solvent. Only molecular ions, fractions from 
molecular ions and other major peaks are reported as mass/charge (m/z) ratios. 
Known intermediates have previous literature referenced where available and were only 
characterised by 1H NMR, LCMS and HRMS when ionisation by MDAP/LCQ LCMS was not 
possible. Final compounds and novel intermediates were further characterised, as follows. 
Rf values were obtained via Thin Layer Chromatography, as previously described. 
Infra-red spectra were recorded on a Perkin Elmer FT-IR Spectrum One spectrometer as a 
neat sample. Absorption maxima are reported in wavenumber (cm-1). Distinguishable and 
significant absorptions were recorded in wave numbers (cm-1), with key stretches 
identified in brackets. 
Melting points were recorded using a FisherbrandTM Digital Melting Point Apparatus with 
samples in 2 mm glass capillary tubes. 
6.1.1 Preparation of compounds described in Chapter 2 
General Method A (CDI amide coupling)116 
1,1'-Carbonyldiimidazole (CDI) (16) (1 eq.) was added portion-wise to the corresponding benzoic 
acid (1 eq.) in tetrahydrofuran (20 mL/g) at room temperature. The reaction mixture was heated 
to reflux for 30 min to facilitate the coupling of the CDI (16) to the acid, allowed to cool and then 
the corresponding amine (1.1 eq.) was added in one portion. The reaction was stirred at room 
temperature overnight resulting in the formation of an orange suspension. The product was 
isolated as per specification. 
General Method B (nitro reduction)118 
The corresponding nitroaniline (1 eq.) was added to 50% aqueous ethanol (5 mL/g) at room 
temperature and heated to reflux. Sodium dithionite (10 eq.) was added portion-wise. The 
reaction was heated under reflux for 30 min. TLC confirmed consumption of starting material 
(100% ethyl acetate, UV). The cooled reaction mixture was extracted four times with ethyl 
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acetate (4 × 10 mL/g) and the combined organic phases were dried over MgSO4, filtered and 
concentrated under reduced pressure. The product was isolated as per specification. 
General Method C (HATU amide coupling)120 
The corresponding dianiline (1 eq.), the corresponding aromatic acid (1.1 eq.), HATU (1.1 eq.) 
and N,N-diisopropyl-ethylamine (2 eq.) in dichloromethane (2 mL/g) was stirred overnight at 
room temperature. The product was isolated as per specification. 
General Method D (acid-catalysed cyclisation)104 
The corresponding amide (1 eq.) was dissolved in acetic acid (excess ca. 140 eq.) and heated to 
120 °C. The reaction was monitored by TLC and after 1.5 h, all of the starting material had been 
consumed. The product was isolated as per specification. 
2-Amino-3-nitro-benzamide (17)162–164 
 
Compound 17 was prepared via General Method A using 2-amino-3-nitro-benzoic acid (10) 
(10 g, 54.91 mmol) and  13.4 M aqueous ammonia solution (41 mL, 549.1 mmol).  The reaction 
mixture was filtered giving 2-amino-3-nitro-benzamide (17) (2.24 g, 21%) as a fine orange solid. 
The filtrate was partially concentrated under reduced pressure, left overnight and a further crop 
of 2-amino-3-nitro-benzamide (17) (3.91 g, 37% yield) was isolated by filtration as a fine orange 
solid.  
1H NMR (500 MHz, DMSO-d6) δ 8.47 (s, 2H, H-9), 8.25–8.07 (m, 2H, H-4 and H-10), 8.01–7.86 (m, 
1H, H-6), 7.62 (s, 1H, H-10), 6.67 (t, J = 7.4Hz, 1H, H-5); HRMS m/z (ESI+) [Found: 204.0382, 
C7H7N3O3Na requires (M+Na)+ 204.1390]; LCMS (MDAP) Rt = 24.9 min (Ana 9–95), not ionisable 
by LCQ/MDAP LCMS.  
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2,3-Diaminobenzamide (22)165–167 
 
Compound 22 was prepared via General Method B using 2-amino-3-nitro-benzamide (17) (6 g, 
31.47 mmol). The crude was purified via flash column chromatography (100 g silica, ethyl 
acetate:methanol, 100:0 to 90:10) to give 2,3-diaminobenzamide (22) (2.21 g, 44%) as a light 
brown solid.  
1H NMR (500 MHz, DMSO-d6) δ 7.63 (s, 1H, H-10), 7.00 (s, 1H, H-10), 6.90 (d, J = 8.0 Hz, 1H, H-6), 
6.62 (d, J = 7.5 Hz, 1H, H-4), 6.35 (t, J = 7.7 Hz, 1H, H-5), 6.08 (s, 2H, H-9), 4.63 (s, 2H, H-11); HRMS 
m/z (ESI+) [Found: 174.0638, C7H9N3ONa requires (M+H)+ 174.1560]; LCMS (MDAP) Rt = 19.3 min 
(Ana 9–95), not ionsable by LCQ/MDAP LCMS. 
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N-(2-Amino-3-carbamoyl-phenyl)pyridine-4-carboxamide (25)  
 
Compound 25 was prepared via General Method C using 2,3-diaminobenzamide (22) (150 mg, 
0.94 mmol) and isonicotinic acid (128 mg, 1.04 mmol). The reaction mixture was filtered giving 
N-(2-amino-3-carbamoyl-phenyl)-pyridine-4-carboxamide (25) (245 mg, 96%) as an off-white 
solid.  
1H NMR (500 MHz, DMSO-d6) δ 9.91 (s, 1H, H-11), 8.77 (d, J = 5.3 Hz, 2H, H-2'and H-6'), 7.91 (d, 
J = 5.5 Hz, 2H, H-3'and H-5'), 7.87 (s, 1H, H-10), 7.53 (d, J = 7.9 Hz, 1H, H-6), 7.26 (d, J = 7.6 Hz, 
1H, H-4), 7.23 (s, 1H, H-10), 6.57 (t, J = 7.8 Hz, 1H, H-5), 6.52 (s, 2H, H-9); HRMS m/z (ESI+) [Found: 
256.9010, C13H12N4O2 requires (M)+ 256.2595]; LCMS (LCQ) Rt = 0.8 min (4 min method), not 
ionisable by LCQ/MDAP LCMS.  
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2-(4-Pyridyl)-1H-benzimidazole-4-carboxamide (10)109,112,114,115,168  
 
Compound 10 was prepared via General Method D using N-(2-amino-3-carbamoyl-
phenyl)pyridine-4-carboxamide (25) (330 mg, 1.29 mmol). The reaction mixture was 
concentrated under reduced pressure to give a pale yellow crude solid (37 mg). The crude was 
purified via flash column chromatography (11 g amino silica, ethyl acetate:methanol, 100:0 to 
85:15) to give 2-(4-pyridyl)-1H-benzimidazole-4-carboxamide (10) (193 mg, 60%) as a yellow 
solid.  
Rf 0.50 (9:1 ethyl acetate:methanol); MP > 250 °C; νmax (thin film)/cm-1 3347 (N-H, b), 1650 (C=O, 
s), 1609 (C=C, s), 756 (N-H, s); 1H NMR (500 MHz, DMSO-d6) δ 9.19 (s, 2H, H-10), 8.80 (d, J = 4.3 
Hz, 2H, H-2'and H-6'), 8.19 (d, J = 4.3 Hz, 2H, H-3' and H-5'), 7.91 (d, J = 7.3 Hz, 1H, H-7), 7.84 (s, 
1H, H-1), 7.81 (d, J = 7.9 Hz, 1H, H-5), 7.41 (t, J = 7.7 Hz, 1H, H-6); 13C NMR (126 MHz, DMSO-d6) 
δ 170.8 (C-7), 166.5 (C-3a), 151.0 (C-2' and C-6'), 150.0 (C-4'), 136.7 (C-2), 123.9 (C-7), 123.6 (C-
5), 123.2 (C-6), 121.2 (C3' and C-5'), 116.4 (C-7a); HRMS m/z (ESI+) [Found: 239.0924, C13H10N4O 
requires (M+H)+ 239.0927]; LCMS (LCQ) Rt = 0.6 min (4 min method), not ionisable by LCQ. 
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N-(2-Amino-3-carbamoyl-phenyl)pyridine-3-carboxamide 
 
The intermediate was prepared via General Method C using 2,3-diaminobenzamide (22) 
(150 mg, 0.94 mmol) and nicotinic acid (128 mg, 1.04 mmol). N-(2-Amino-3-carbamoyl-phenyl) 
pyridine-3-carboxamide (229 mg, 85%) was isolated by filtration as a light brown solid.  
Rf 0.66 (9:1 ethyl acetate:methanol); m.p. 170–174 °C; 3441 (N-H, m), νmax (thin film)/cm-1 3355 
(N-H, s), 3173 (C-H, m), 1643 (C=O, s), 1517 (N-H/C-C, s); 1H NMR (500 MHz, DMSO-d6) δ 9.84 (s, 
1H, H-11), 9.16 (s, 1H, H-6’), 8.78–8.70 (m, 1H, H-2’), 8.33 (d, J = 7.8 Hz, 1H, H-4’), 7.88 (s, 1H, 
H-10), 7.60–7.47 (m, 2H, H-6 and H-3’), 7.27 (d, J = 7.4 Hz, 1H, H-4), 7.23 (s, 1H, H-10), 6.56 (m, 
3H, H-5 and 2 × H-9); 13C NMR (126 MHz, DMSO-d6) δ 171.7 (C-7), 164.9 (C-12), 152.4 (C-2’), 
149.4 (C-6’), 146.1 (C-5’), 136.0 (C-4’), 131.1 (C-4), 130.58 (C-1), 127.6 (C-3’), 124.2 (C-2), 123.8 
(C-6), 115.9 (C-3), 114.3 (C-5); HRMS m/z (ESI+) [Found: 257.1032, C13H12N4O2 requires (M+H)+ 
257.1033]; LCMS (LCQ) Rt = 0.6 min (4 min method), m/z (ESI+) 257.08 (M+H)+.  
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2-(3-Pyridyl)-1H-benzimidazole-4-carboxamide (38)112,115,169 
 
Compound 38 was prepared via General Method D using N-(2-Amino-3-carbamoyl-
phenyl)pyridine-3-carboxamide (179 mg, 0.70 mmol). The reaction mixture was concentrated 
under reduced pressure to give a pale-yellow crude solid (37 mg). The crude was purified via 
flash column chromatography (11 g amino silica, ethyl acetate:methanol, 100:0 to 90:10) to give 
2-(3-pyridyl)-1H-benzimidazole-4-carboxamide (38) (45 mg, 26%) as an off-white solid.  
Rf 0.29 (9:1 ethyl acetate:methanol); m.p. 293–295 °C; νmax (thin film)/cm-1 2998 (C-H, b), 1685 
(C=O, s), 1634 (C=C, s), 3376 (C-N, s), 1120 (C-N, s); 1H NMR (500 MHz, DMSO-d6) δ 13.62 (s, 1H, 
H-1), 9.42 (s, 1H, H-6’), 9.29 (s, 1H, H-10), 8.72 (d, J = 7.1 Hz, 1H, H-7), 8.59 (d, J = 7.1 Hz, 1H, H-
5), 7.94–7.87 (d, J = 7.9 Hz, 1H, H-2’), 7.83 (s, 1H, H-10), 7.78 (d, J = 7.5 Hz, 1H, H-4’), 7.62 (t, J = 
7.5 Hz, 1H, H-6), 7.38 (t, J = 7.0 Hz, 1H, H-5’); 13C NMR (126 MHz, DMSO-d6) δ 166.0 (C-8), 151.1 
(C-7), 149.6 (C-7a), 147.9 (C-6’), 141.3 (C-3a/4), 135.3 (C-2), 134.4 (C-5), 125.3 (C-5’), 124.1 (C-
6), 123.2 (C-2’), 122.8 (C-3’), 115.2 (C-4’), C-4/3a peak missing; HRMS m/z (ESI+) [Found: 
239.0924, C13H10N4O requires (M+H)+ 239.0927]; LCMS (LCQ) Rt = 0.6 min (4 min method), m/z 
(ESI+) 239.0 (M+H)+.  
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N-(2-Amino-3-carbamoyl-phenyl)pyrimidine-5-carboxamide 
 
The intermediate was prepared via General Method C using 2,3-diaminobenzamide (22) 
(150 mg, 0.94 mmol) and pyrimidine-5-carboxylic acid (117 mg, 0.94 mmol). N-(2-amino-3-
carbamoyl-phenyl)pyrimidine-5-carboxamide (240 mg, 94%) was isolated by filtration as a pale 
brown solid. The crude was taken on without further purification.  
Rf  0.72 (9:1 ethyl acetate:methanol); m.p. 171–173 °C; νmax (thin film)/cm-1 3427 (N-H, m), 3213 
(C-H/N-H, br), 1355 (C=O, s). 1502 (C-H, m), 713 (N-H, s); 1H NMR (500 MHz, DMSO-d6) δ 10.09 
(s, 1H, H-11), 9.34 (s, 1H, H-2'), 9.32 (s, 2H, H-4' and H-6'), 7.89 (s, 1H, H-10), 7.54 (d, J = 7.4 Hz, 
1H, H-6), 7.28 (d, J = 7.1 Hz, 1H, H-4), 7.23 (s, 1H, H-10), 6.64 (s, 2H, H-9), 6.57 (t, J = 7.4 Hz, 1H, 
H-5); 13C NMR (126 MHz, DMSO-d6) δ 171.6 (C-7), 163.2 (C-12), 160.4 (C-2'), 156.8 (C-4' and 6'), 
146.1 (C-2), 131.1 (C-4), 128.6 (C-5'), 127.8 (C-6), 123.6 (C-3), 115.7 (C-1), 114.2 (C-5); HRMS m/z 
(ESI+) [Found: 280.0812, C12H11N5NaO2 requires (M+H+Na)+ 280.0805]; LCMS (LCQ) Rt = 0.7 min 
(4 min method), m/z (ESI+) 257.98 (M+H)+.  
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2-Pyrimidin-5-yl-1H-benzimidazole-4-carboxamide (39) 
 
Compound 39 was prepared via General Method D using N-(2-amino-3-carbamoyl-phenyl)-pyri-
midine-5-carboxamide (140 mg, 0.54 mmol). The reaction mixture was concentrated under 
reduced pressure and was purified via flash column chromatography (11 g amino silica, ethyl 
acetate:methanol 100:0 to 85:15) to give 2-pyrimidin-5-yl-1H-benzimidazole-4-carboxamide 
(39) (90 mg, 66%) as a yellow solid.  
Rf 0.51 (9:1 ethyl acetate:methanol); m.p. > 300 °C; νmax (thin film)/cm-1 3308 (N-H, br), 3218 (N-
H, br), 1650 (C=O, m), 1559 (aromatic C-C, s), 718 (N-H, s); 1H NMR (500 MHz, DMSO-d6) δ 9.57 
(s, 2H, H-4' and H-6'), 9.30 (s, 1H, H-2'), 9.09 (s, 2H, H-10), 7.90 (d, J = 7.3 Hz, 1H, H-5), 7.84–7.72 
(m, 2H, H-1 amd H-7), 7.37 (t, J = 7.7 Hz, 1H, H-6); 13C NMR (151 MHz, DMSO-d6) δ 166.0 (C-8), 
158.7 (C-2'), 154.8 (C-4' and 6'), 146.9 (C-2), 140.0 (C-3a), 136.5 (C-4), 123.8 (C-7), 123.1 (C-5), 
122.5 (C-6), 122.2 (C-7a), 116.1 (C-5'); HRMS m/z (ESI+) [Found: 262.0705, C12H9N5NaO requires 
(M+H+Na)+ 262.0699]; LCMS (LCQ) Rt = 0.6 min (4 min method), m/z (ESI+) 239.99 (M+H)+. 
  
134 
 
N-(2-Amino-3-carbamoyl-phenyl)-2-methoxy-pyridine-4-carboxamide 
 
The intermediate was prepared via General Method C using 2,3-diaminobenzamide (22) 
(150 mg, 0.94 mmol) and 2-methoxyisonicotinic acid (159 mg, 1.04 mmol). N-(2-Amino-3-
carbamoyl-phenyl)-2-methoxy-pyridine-4-carboxamide (242 mg, 81%) was isolated by filtration 
as a pale brown solid.  
Rf 0.77 (9:1 ethyl acetate:methanol); m.p. 282–284 °C; νmax (thin film)/cm-1 3424 (N-H, w), 3330 
(N-H, br), 1639 (C=O, s), 1520 (C-H, m); 1H NMR (500 MHz, DMSO-d6) δ 9.84 (s, 1H, H-11), 8.33 
(d, J = 5.3 Hz, 1H, H-6'), 7.87 (s, 1H, H-10), 7.53 (d, J = 8.0 Hz, 1H, H-4), 7.48 (d, J = 5.3 Hz, 1H, 
H-5), 7.37 (s, 1H, H-3'), 7.27–7.18 (m, 2H, H-10 and H-6), 6.57 (t, J = 7.8 Hz, 1H, H-5), 6.51 (s, 2H, 
H-9), 3.91 (s, 3H, H-7'); 13C NMR (126 MHz, DMSO-d6) δ 171.6 (C-7), 164.5 (C-12), 147.7 (C-6'), 
145.8 (C-2), 145.2 (C-2'), 130.8 (C-4), 127.7 (C-6), 124.0 (C-1), 116.1 (C-4'), 115.6 (C-5'), 114.4 
(C-5), 109.5 (C-3'), 53.9 (C-7'), C-3 peak missing; HRMS m/z (ESI+) [Found: 309.0963, 
C14H14N4NaO3 requires (M+H+Na)+ 309.0958]; LCMS (LCQ) Rt = 0.6 min (4 min method), m/z 
(ESI+) 286.96 (M+H)+. 
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2-(2-Methoxy-4-pyridyl)-1H-benzimidazole-4-carboxamide (40) 
 
Compound 40 was prepared via General Method D using N-(2-amino-3-carbamoyl-phenyl)-2-
methoxy-pyridine-4-carboxamide (190 mg, 0.66 mmol). The reaction mixture was concentrated 
under reduced pressure. The crude was purified via flash column chromatography (11 g amino 
silica, ethyl acetate:methanol, 100:0 to 90:10) to give 2-(2-methoxy-4-pyridyl)-1H-
benzimidazole-4-carboxamide (40) (152 mg, 81%) as a pale yellow solid.  
Rf 0.34 (100% ethyl acetate); m.p. 290–293 °C; νmax (thin film)/cm-1 3459 (N-H, w), 3170 (N-H, br), 
3135 (N-H, br), 1667 (C=O, s), 736 (N-H, s); 1H NMR (500 MHz, DMSO-d6) δ 13.64 (s, 1H, H-1), 
9.22 (s, 1H, H-10), 8.35 (d, J = 4.7 Hz, 1H, H-6'), 7.91 (d, J = 6.7 Hz, 1H, H-5), 7.83 (s, 1H, H-1), 
7.82–7.76 (m, 2H, H-7 and H-5'), 7.61 (s, 1H, H-3'), 7.40 (t, J = 7.3 Hz, 1H, H-6), 3.92 (s, 3H, H-7'); 
13C NMR (126 MHz, DMSO-d6) δ 166.3 (C-8), 164.8 (C-2'), 149.7 (C-2), 148.5 (C-6'), 141.5 (C-3a), 
139.6 (C-4'), 135.6 (C-4), 124.0 (C-5), 123.7 (C-6), 123.4 (C-7a), 115.9 (C-7), 114.8 (C-5'), 108.0 
(C-3'), 54.0 (C-7'); HRMS m/z (ESI+) [Found: 291.0857, C14H12N4NaO2 requires (M+H+Na)+ 
291.0852]; LCMS (LCQ) Rt = 0.6 min (4 min method), m/z (ESI+) 269.01 (M+H)+.  
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N-(2-Aminophenyl)pyridine-4-carboxamide (55) 
 
Intermediate 55 was prepared via General Method C using O-phenylenediamine (54) (100 mg, 
0.92 mmol) and isonicotinic acid (23) (125 mg, 1.02 mmol). The reaction mixture was filtered 
giving N-(2-aminophenyl)pyridine-4-carboxamide (55) (156 mg, 75%) as an off-white solid.  
1H NMR (500 MHz, DMSO-d6) δ 9.90 (s, 1H, H-8), 8.76 (d, J = 4.6 Hz, 2H, H-2' and H-6'), 7.89 (d, 
J = 4.6 Hz, 2H, H-3' and H-5'), 7.16 (d, J = 7.6 Hz, 1H, H-3), 6.99 (t, J = 7.5 Hz, 1H, H-5), 6.78 (d, J = 
7.9 Hz, 1H, H-6), 6.59 (t, J = 7.4 Hz, 1H, H-4), 5.01 (s, 2H, H-7); LCMS (LCQ) Rt = 0.7 min (4 min 
method), m/z (ESI+) 214.11 (M+H)+. 
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2-(4-Pyridyl)-1H-benzimidazole (56)170–172  
 
Compound 56 was prepared via General Method D using N-(2-aminophenyl)pyridine-4-
carboxamide (54) (100 mg, 0.47 mmol). TLC (9:1 ethyl acetate:methanol) showed reaction was 
complete after 2 h. The reaction mixture was concentrated under reduced pressure to give an 
off-white solid (181 mg). The crude was purified by flash column chromatography (5 g amino 
silica, ethyl acetate:methanol, 100:0 to 90:10) to give 2-(4-pyridyl)-1H-benzimidazole (56) 
(64 mg, 66%) as a white solid. 
Rf 0.51 (9:1 ethyl acetate:methanol); m.p. 212–214 °C; νmax (thin film)/cm-1 3249 (br, NH), 3066 
(m, aromatic CH), 1642 (m, C=C), 1509 (s, aromatic CH), 1066 (s, C-N), 656 (s, N-H)1H NMR (500 
MHz, DMSO-d6) δ 13.28 (s, 1H, H-1), 8.76 (d, J = 5.7 Hz, 2H, H-2' and H-6'), 8.10 (d, J = 5.8 Hz, 2H, 
H-3' and H-5'), 7.73 (s, 1H, H-5/8), 7.61 (s, 1H, H-8/5), 7.27 (s, 2H, H-6 and H-7); 13C NMR (126 
MHz, DMSO-d6) δ 150.5 (C-2' ad C-6'), 148.8 (C-2), 143.6 (C-7a), 137.1 (C-4'), 135.0 (C-3a), 123.5 
(C-6), 122.2 (C-5), 120.3 (C-3' and C-5'), 119.4 (C-7), 111.8 (C-4).; HRMS m/z (ESI+) [Found: 
196.0871, C12H10N3 requires (M+H)+ 196.0869]; LCMS (LCQ) Rt = 0.6 min (4 min method), m/z 
(ESI+) 196.27 (M+H)+. 
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2-Amino-N-methyl-3-nitro-benzamide (57) 
 
Intermediate 57 was prepared via General Method A using 2-amino-3-nitro-benzoic acid (15) 
(2 g, 10.98 mmol) and 13.4 M aqueous methylamine (6 mL, 12.08 mmol). The reaction mixture 
was concentrated under reduced pressure. The crude was purified via flash column 
chromatography (30 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give a 1:2 mixture of 
2-amino-N-methyl-3-nitro-benzamide (57) (2.00 g, 32%) and imidazole. The product was carried 
forward without further purification. 
1H NMR (500 MHz, CDCl3) δ 8.25 (d, J = 8.5 Hz, 1H, H-4), 8.21 (s, 2H, H-11), 7.67 (d, 1H, H-6), 6.60 
(t, J = 8.0 Hz, 1H, H-5), 2.99 (d, J = 4.7 Hz, 3H, H-10); LCMS (LCQ) Rt = 0.8 min (4 min method), 
m/z (ESI+) 195.92 (M+H)+. 
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2,3-Diamino-N-methyl-benzamide (58) 
 
Intermediate (58) was prepared via General Method B using 2-amino-N-methyl-3-nitro-
benzamide (57) (1 g, 5.12 mmol). The crude was purified via flash column chromatography (10 g 
silica, ethyl acetate:methanol, 100:0 to 90:10) to give 2,3-diamino-N-methyl-benzamide (58) 
(357 mg, 34%) as a yellow oil.  
1H NMR (500 MHz, CDCl3) δ 7.58 (s, 1H, H-9), 7.03 (s, 1H, H-11), 6.88 (d, J = 7.9 Hz, 1H, H-6), 6.77–
6.68 (m, 1H, H-4), 6.64 (s, 1H, H-11), 6.55 (t, J = 7.8 Hz, 1H, H-5), 5.15 (s, 2H, H-12), 2.89 (d, J = 
4.8 Hz, 3H, H-10); LCMS (LCQ) Rt = 0.5 min (4 min method), m/z (ESI+) 195.92. 
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N-[2-Amino-3-(methylcarbamoyl)phenyl]pyridine-4-carboxamide (59) 
 
Intermediate 59 was prepared via General Method C using 2,3-diamino-N-methyl-benzamide 
(58) (140 mg, 0.85 mmol) and isonicotinic acid (23) (115 mg, 0.93 mmol). N-[2-Amino-3-
(methylcarbamoyl)-phenyl]pyridine-4-carboxamide (59) (123 mg, 46%) was isolated by filtration 
as an off-white solid.  
Rf 0.62 (9:1 ethyl acetate:methanol); m.p. 299–300 °C; νmax (thin film)/cm-1 3407 (N-H, br) 3309 
(N-H, m), 3229 (N-H, br), 1625 (C=O, m), 1639 (C=O, s), 1406 (aromatic C-C, s), 714 (N-H, s); 1H 
NMR (500 MHz, DMSO-d6) δ 9.93 (s, 1H, H-12), 8.77 (d, J = 5.2 Hz, 2H, H-2' and H-6'), 8.33 (s, 1H, 
H-9), 7.91 (d, J = 5.3 Hz, 2H, H-3' and H-5'), 7.44 (d, J = 7.5 Hz, 1H, H-6), 7.26 (d, J = 7.3 Hz, 1H, 
H-4), 6.60 (t, J = 7.6 Hz, 1H, H-5), 6.35 (s, 2H, H-11), 2.75 (d, J = 4.3 Hz, 3H, H-10); 13C NMR (126 
MHz, DMSO-d6) δ 169.2 (C-7), 164.0 (C-12), 150.1 (C-2' and C-6'), 144.9 (C-2), 141.6 (C-4'), 130.2 
(C-4), 126.4 (C-6), 123.52 (C-1), 121.8 (C-3' and 5'), 116.6 (C-3), 114.2 (C-5), 26.1 (C-10); HRMS 
m/z (ESI+) [Found: 293.1015, C14H14N4NaO2 requires [M+H+Na]+ 293.1009]; LCMS (LCQ) Rt = 0.6 
min (4 min method), m/z (ESI+) 271.05 (M+H)+. 
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N-Methyl-2-(4-pyridyl)-1H-benzimidazole-4-carboxamide (60) 
 
Compound 60 was prepared via General Method D using 2,3-diamino-N-methyl-benzamide (59) 
(100 mg, 0.37 mmol). The reaction mixture was concentrated under reduced pressure. The 
crude was purified via flash column chromatography (11 g amino silica, ethyl acetate:methanol, 
100:0 to 90:10) to give N-methyl-2-(4-pyridyl)-1H-benzimidazole-4-carboxamide (60) (11 mg, 
6%) as a pale yellow solid.  
Rf 0.21 (100% ethyl acetate); m.p. >300 °C; νmax (thin film)/cm-1 3170 (N-H, br), 1648 (C=O, s), 
1608 (aromatic C=C, s), 1526 (aromatic C-H, m), 1501 (aromatic C-C), 750 (N-H, s); 1H NMR (500 
MHz, DMSO-d6) δ 13.76 (s, 1H, H-1), 9.67 (s, 1H, H-10), 8.95–8.70 (m, 2H, H-2' and H-6'), 8.30–
8.17 (m, 2H, H-3' and H-5'), 7.92 (s, 1H, H-7), 7.80 (d, J = 7.8 Hz, 1H, H-5), 7.41 (t, J = 7.5 Hz, 1H, 
H-6), 3.02 (s, 3H, H-11); 13C NMR (151 MHz, DMSO-d6) δ 164.9 (C-8), 150.6 (C-2' and C-6'), 149.4 
(C-2), 140.7 (C-3a), 136.1 (C-4'), 135.3 (C-4), 123.4 (C-6), 123.3 (C-7), 122.8 (C-7a), 120.8 (C-3' 
and C-5'), 115.3 (C-5), 26.2 (C-11); HRMS m/z (ESI+) [Found: 275.0912, C14H12N4NaO requires 
(M+H+Na)+ 275.0903]; LCMS (LCQ) Rt = 0.7 min (4 min method), m/z (ESI+) 253.16 (M+H)+. 
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2-Amino-N,N-dimethyl-3-nitro-benzamide (61) 
 
Intermediate 61 was prepared via General Method A using 2-amino-3-nitro-benzoic acid (15) 
(2.00 g, 10.98 mmol) and 13.4 M aqueous dimethylamine (6.6 mL, 13.33 mmol). The crude was 
purified by flash column chromatography (30 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) 
to give a 3:1 mixture of 2-amino-N,N-dimethyl-3-nitro-benzamide (61) (2.72 g, 89%) 
and imidazole side product from the 1,1'-carbonyldiimidazole. The product was carried forward 
without further purification. 
1H NMR (500 MHz, CDCl3) δ 8.15 (d, J = 8.5 Hz, 1H, H-4), 7.32 (d, J = 7.0 Hz, 1H, H-6), 6.85 (s, 2H, 
H-11), 6.68 (t, J = 7.9 Hz, 1H, H-5), 3.05 (s, 3H, H-10), 3.04 (s, 3H, H-10);  LCMS (LCQ) Rt = 0.6 min 
(4 min method), m/z (ESI+) 209.91 (M+H)+.  
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Methyl 3-amino-2-(pyridine-4-carbonyl-amino)benzoate (65) 
 
Intermediate 65 was prepared via General Method C using 2,3-diaminobenzoic acid methyl ester 
(64) (2 g, 1.20 mmol) and isonicotinic acid (23) (163 mg, 1.32 mmol). The reaction mixture was 
concentrated under reduced pressure and water (100 mL) was added to the residue. The 
aqueous solution was extracted three times with ethyl acetate (3 × 100 mL). The combined 
organic phases were dried over MgSO4, filtered and concentrated under reduced pressure to 
give an orange oil (692 mg). The crude was purified via flash column chromatography (24 g silica, 
ethyl acetate:methanol, 100:0 to 90:10) to give methyl 3-amino-2-(pyridine-4-
carbonylamino)benzoate (65) (3.42 g, 94%) as an orange oil which crystallised upon standing to 
form a pale orange solid. The product was taken forward without further purification. 
1H NMR (500 MHz, DMSO-d6) δ 9.99 (s, 1H, H-7), 8.78 (d, J = 4.4 Hz, 2H, H-2' and H-6'), 7.92 (d, 
J = 4.4 Hz, 2H, H-3' and H-5'), 7.74 (d, J = 8.0 Hz, 1H, H-4), 7.37 (d, J = 7.4 Hz, 1H, H-6), 6.63 (d, 
J = 8.6 Hz, 3H, H-10), 3.82 (s, 3H, H-14); HRMS m/z (ESI+) [Found: 272.0200, C14H13N3O3 requires 
(M+H)+ 271.2708]; LCMS (LCQ) Rt = 0.8 min (7 min method), m/z (ESI+) 272.02 (M+H)+. 
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Methyl 2-(4-pyridyl)-1H-benzimidazole-4-carboxylate (66) 
 
Compound 66 was prepared via General Method D using methyl 2-amino-3-(pyridine-4-
carbonylamino) benzoate (65) (139 mg, 0.51 mmol). The reaction mixture was concentrated 
under reduced pressure. The crude was purified via flash column chromatography (11 g amino 
silica, ethyl acetate:methanol, 100:0 to 90:10) to give methyl 2-(4-pyridyl)-1H-benzimida-zole-4-
carboxylate (66) (118 mg, 86%) as a pale yellow solid. 
Rf 0.24 (100% ethyl acetate); m.p. 85–87 °C; νmax (thin film)/cm-1 3447 (N-H, br), 3206 (N-H, br), 
1619 (C=O, s), 1509 (aromatic C-H, s), 1479 (aliphatic C-H, m), 1464 (aliphatic C-H, s), 674 (N-H, 
s); 1H NMR (500 MHz, DMSO-d6) δ 8.76 (d, J = 4.2 Hz, 2H, H-2' and H-6'), 8.26 (d, J = 4.1 Hz, 2H, 
H-3' and H-5'), 8.01 (d, J = 7.8 Hz, 1H, H-7), 7.88 (d, J = 7.3 Hz, 1H, H-5), 7.37 (t, J = 7.5 Hz, 1H, 
H-6), 3.97 (s, 3H, H-10); 13C NMR (126 MHz, DMSO-d6) δ 165.6 (C-8), 151.0 (C-2), 150.2 (C-2' and 
C-6'), 143.6 (C-4), 136.7 (C-4'), 135.4 (C-3a), 125.4 (C-5), 123.8 (C-7), 122.1 (C-6), 121.5 (C-3' and 
C-5'), 115.4 (C-7a), 52.2 (C-10); HRMS m/z (ESI+) [Found: 276.0746, C14H11N3NaO2 requires 
[M+Na]+ 276.0743]; LCMS (LCQ) Rt = 0.7 min (7 min method), m/z (ESI+) 254.0 (M+H)+. 
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N,N-Dimethyl-2-(4-pyridyl)-1H-benzimidazole-4-carboxamide (67)123 
 
2 M aqueous sodium hydroxide solution (9 mL, 17.93 mmol) was added to methyl 2-(4-pyridyl)-
1H-benzimidazole-4-carboxylate (66) (2.39 g, 8.97 mmol) in methanol (1 mL). The resulting 
mixture was refluxed at 100 °C overnight. The mixture was concentrated under reduced 
pressure and sodium 2-(4-pyridyl)-1H-benzimidazole-4-carboxylate (3.38 g) was taken forward 
without further purification. Triethylamine (1 ml, 7.66 mmol), 2 M dimethylamine (0.19 ml, 0.38 
mmol) in tetrahydrofuran, sodium 2-(4-pyridyl)-1H-benzimidazole-4-carboxylate (100 mg, 0.38 
mmol) and 50% propylphosphonic anhydride in ethyl acetate (0.34 ml, 1.15 mmol) were stirred 
together in N,N-dimethylformamide (5 ml) at RT overnight. The reaction mixture was 
concentrated under reduced pressure and the resulting crude yellow mixture (734 mg) was 
purified via flash column chromatography (30 g silica, ethyl acetate:methanol, 100:0 to 90:10) 
to give N,N-dimethyl-2-(4-pyridyl)-1H-benzimidazole-4-carboxamide (67) (34 mg, 32%) as an off-
white solid. 
Rf 0.38 (9:1 dichloromethane:methanol); m.p. 234–236 °C; νmax (thin film)/cm-1 3258 (N-H, br), 
3054 (C-H, w), 2956 (C-H, w), 1604 (C=C, s), 1440 (C-H); 1H NMR (600 MHz, DMSO-d6) δ 13.34 (s, 
1H, H-1), 8.92–8.59 (m, 2H, H-2' and H-6'), 8.14 (s, 2H, H-3' and H-5'), 7.70 (s, 1H, H-7), 7.32 (t, 
J = 7.5 Hz, 1H, H-6), 7.22 (d, J = 7.2 Hz, 1H, H-5), 3.11 (s, 3H, H-11), 2.87 (s, 3H, H-11); 13C NMR 
(151 MHz, DMSO-d6) δ 168.8 (C-8), 150.9 (C-2' and C-6'), 150.0, 140.4, 137.3 (C-3' and C-5'), 
135.5, 128.8, 123.7, 121.1, 113.1, 38.8 (C-11), 35.0 (C-11), insufficient sample quantity to obtain 
good quality HSQC and HMBC NMR; HRMS m/z (ESI+) [Found: 267.1241, C15H15N4O requires 
(M+H)+ 267.1240]; LCMS (LCQ) Rt = 0.6 min (4 min method), m/z (ESI+) 267.0 (M+H)+. 
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Ethyl 4-amino-3-(pyridine-4-carbonyl-amino)benzoate (76) 
 
Intermediate 76 was prepared via General Method C using ethyl 3,4-diaminobenzoate (75) 
(100 mg, 0.55 mmol) and isonicotinic acid (23) (75 mg, 0.61 mmol).  The reaction mixture was 
concentrated under reduced pressure and water (5 mL) was added to the residue. The aqueous 
solution was extracted three times with ethyl acetate (3 × 5 mL). The combined organic phases 
were dried over MgSO4, filtered and concentrated under reduced pressure to give an orange oil 
(191 mg). The crude was purified via flash column chromatography (12 g silica, ethyl 
acetate:methanol, 100:0 to 90:10) to give ethyl 4-amino-3-(pyridine-4-carbonyl-
amino)benzoate (76) (151 mg, 91%) as a pale orange solid.  
Rf 0.63 (9:1 ethyl acetate:methanol); m.p. 132–135 °C; νmax (thin film)/cm-1 3439 (N-H, w), 3208 
(aromatic C-H, m), 1629 (C=O, s), 1606 (C=O, s), 1530 (aromatic C-H, m), 1498 (aliphatic C-H, s), 
763 (N-H, s); 1H NMR (500 MHz, DMSO-d6) δ 9.92 (s, 1H, H-12), 8.77 (d, J = 4.2 Hz, 2H, H-2' and 
H-6'), 7.91 (d, J = 4.4 Hz, 2H, H-3' and H-5'), 7.75 (s, 1H, H-2), 7.61 (d, J = 8.5 Hz, 1H, H-6), 6.77 
(d, J = 8.5 Hz, 2H, H-5), 5.93 (s, 2H, H-15), 4.22 (q, J = 7.1 Hz, 2H, H-10), 1.42–0.97 (m, 3H, H-11); 
13C NMR (126 MHz, DMSO-d6) δ 165.6 (C-13), 164.3 (C-7), 150.1 (C-2' and C-6'), 148.6 (C-4), 141.5 
(C-4'), 129.1 (C-2), 128.8 (C-6), 121.8 (C-3' and C-5'), 120.9 (C-3), 116.3 (C-1), 114.5 (C-5), 59.8 
(C-10), 14.3 (C-11); HRMS m/z (ESI+) [Found: 308.1007, C15H15N3NaO3 requires (M+Na)+ 
308.1006]; LCMS (LCQ) Rt = 0.6 min (4 min method), m/z (ESI+) 286.1 (M+H)+. 
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Ethyl 2-(4-pyridyl)-1H-benzimidazole-5-carboxylate (77)173,174  
 
Compound 77 was prepared via General Method D using ethyl 4-amino-3-(pyridine-4-carbonyl-
amino) benzoate (130 mg, 0.46 mmol).  The reaction mixture was concentrated under reduced 
pressure to give an off-white solid (170 mg). The crude was purified via flash column 
chromatography (5 g amino silica, ethyl acetate:methanol, 100:0 to 90:10) to give ethyl 2-(4-
pyridyl)-1H-benzimidazole-5-carboxylate (77) (50 mg, 58%) as a white solid.  
Rf 0.42 (100% ethyl acetate); m.p. degrades > 240 °C; νmax (thin film)/cm-1 3246 (N-H, m, br), 3067 
(aromatic C-H, m, br), 2843 (aliphatic C-H, w), 1642 (C=O, m), 1509 (aromatic C-H, s), 1472 
(aliphatic C-H, m), 750 (N-H, s); 1H NMR (500 MHz, DMSO-d6) δ 8.72 (d, J = 4.7 Hz, 2H (H-2' and 
H-6'), 8.24 (s, 1H, H-4), 8.16 (d, J = 4.9 Hz, 2H, H-3' and H-5'), 7.80 (d, J = 8.4 Hz, 1H, H-6), 7.69 
(d, J = 8.4 Hz, 1H, H-7), 4.32 (q, J = 7.0 Hz, 2H, H-11), 1.34 (t, J = 7.1 Hz, 3H, H-12); 13C NMR 
(126 MHz, DMSO-d6) δ 166.5 (C-8), 153.5 (C-2), 150.3 (C-2' and C-6'), 144.3 (C-7a), 141.1 (C-5), 
138.3 (C-4'), 123.1 (C-3a), 122.7 (C-6), 120.7 (C-3' and C-5'), 118.0 (C-4), 115.4 (C-7), 60.3 (C-11), 
14.3 (C-12); HRMS m/z (ESI+) [Found: 290.0904, C15H13N3NaO2 requires (M+Na)+ 290.0900]; LCMS 
(LCQ) Rt = 0.6 min (4 min method), m/z (ESI+) 268.15 (M+H)+. 
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3,4-Diaminobenzamide (80) 
 
Intermediate 80  was prepared via General Method B using 4-amino-3-nitrobenzamide (79) 
(500 mg, 2.76 mmol). 3,4-Diaminobenzamide (249 mg, 57%) was isolated as an off-white solid.   
1H NMR (600 MHz, DMSO-d6) δ 7.36 (s, 1H, H-9), 7.05 (s, 1H, H-2), 6.97 (d, J = 8.0 Hz, 1H, H-6), 
6.69 (s, 1H, H-9), 6.45 (d, J = 8.0 Hz, 1H, H-5), 4.92 (s, 2H, H-10), 4.49 (s, 2H, H-11); HRMS m/z 
(ESI+) [Found: 152.0900, C7H10N3O requires (M+H)+ 151.1665]; LCMS (LCQ) Rt = 0.5 min (4 min 
method), m/z (ESI+) 152.07 (M+H)+. 
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N-(2-Amino-5-carbamoyl-phenyl)pyridine-4-carboxamide (81) 
 
Intermediate 81 was prepared via General Method C using 3,4-diaminobenzamide (80) (196 mg, 
1.3 mmol) and isonicotinic acid (23) (176 mg, 1.43 mmol).  The reaction mixture was filtered 
giving N-(2-amino-3-carbamoyl-phenyl)-pyridine-4-carboxamide (81) (299 mg, 96%) as an off-
white solid.  
Rf 0 (9:1 dichloromethane:methanol); m.p. degrades > 220 °C; νmax (thin film)/cm-1 3343 (N-H, 
br), 3190 (N-H, br), 1672 (C=O, s), 1606 (C-C aromatic, s), 1393 (C-C aromatic, s), 835 (N-H, m), 
690 (N-H, s), 675 (N-H, s); 1H NMR (500 MHz, DMSO-d6) δ 9.91 (s, 1H, H-10), 8.77 (d, J = 5.3 Hz, 
2H, H-2'and H-6'), 7.91 (d, J = 5.5 Hz, 2H, H-3'and H-5'), 7.87 (s, 1H, H-9), 7.53 (d, J = 7.9 Hz, 1H, 
H-6), 7.26 (d, J = 7.6 Hz, 1H, H-2), 7.23 (s, 1H, H-9), 6.57 (t, J = 7.8 Hz, 1H, H-5), 6.52 (s, 2H, H-13); 
13C NMR (151 MHz, DMSO-d6) δ 167.6 (C-11), 164.2 (C-7), 150.2 (C-2' and C-6'), 146.9 (C-1), 141.6 
(C-4'), 127.8 (C-3), 127.1 (C-4), 121.8 (C-3' and C-5'), 121.3 (C-5), 120.9 (C-6), 114.3 (C-2); HRMS 
m/z (ESI+) [Found: 257.1036, C13H13N4O2 requires (M+H)+ 257.1033]; LCMS (LCQ) Rt = 0.5 min (4 
min method), m/z (ESI+) 257.02 (M+H)+. 
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2-(4-Pyridyl)-1H-benzimidazole-5-carboxamide (78) 
 
Compound 78 was prepared via General Method D using N-(2-aminophenyl)-pyridine-4-
carboxamide  (81) (30 mg, 0.12 mmol).  The reaction mixture was concentrated under reduced 
pressure to give a pale yellow crude solid (27 mg). The crude was purified via flash column 
chromatography (11 g amino silica, ethyl acetate:methanol, 100:0 to 85:15) to give 2-(4-pyridyl)-
1H-benzimidazole-5-carboxamide (12) (4 mg, 13%) as a yellow solid.  
Rf 0.14 (9:1 dichloromethane:methanol); m.p. 210–213; νmax (thin film)/cm-1 3179 (N-H, br), 
1670 (C=O, s), 1606 (C-C aromatic, s), 1392 (C-C aromatic, s), 697 (N-H, s), 674 (N-H, s); 1H NMR 
(500 MHz, DMSO-d6) δ 9.19 (s, 2H, H-10), 8.80 (d, J = 4.3 Hz, 2H, H-2'and H-6'), 8.19 (d, J = 4.3 Hz, 
2H, H-3'and H-5'), 7.91 (d, J = 7.3 Hz, 1H, H-7), 7.84 (s, 1H, H-1), 7.81 (d, J = 7.9 Hz, 1H, H-5), 7.41 
(t, J = 7.7 Hz, 1H, H-6); 13C NMR insufficient quantities; HRMS m/z (ESI+) [Found: 
261.0741, C13H10N4NaO requires (M+H)+ 261.0747]; LCMS (LCQ) Rt = 0.46 min (4 min method), 
m/z (ESI+) 239.22 (M+H)+.  
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N-(2-Amino-3-nitro-phenyl)pyridine-4-carboxamide 
 
The intermediate was prepared via General Method C using 3-nitrobenzene-1,2-diamine 
(200 mg, 1.31 mmol) and isonicotinic acid (23) (177 mg, 1.44 mmol). The reaction mixture was 
filtered and N-(2-amino-3-nitro-phen-yl)pyridine-4-carboxamide (360 mg, 28%) was isolated as 
a brown solid. The product was taken forward without further purification. 
Rf 0.77 (9:1 ethyl acetate:methanol); m.p. 206–208 °C; νmax (thin film)/cm-1 3450 (N-H, w), 3323 
(N-H, br), 3256 (N-H, br), 1663 (C=O, m), 1525 (aromatic C-H, s), 738 (C-N, s); 1H NMR (500 MHz, 
DMSO-d6) δ 10.13 (s, 1H, H-11), 8.79 (s, 2H, H-2' and H-6'), 8.01 (d, J = 7.8 Hz, 1H, H-4), 7.94 (s, 
2H, H-3' and H-5'), 7.54–7.43 (m, 1H, H-6), 7.28 (s, 2H, H-10), 6.75–6.63 (m, 1H, H-5); 13C NMR 
(126 MHz, DMSO-d6) δ 164.7 (C-12), 150.0 (C-2' and C-6'), 142.6 (C-2), 141.2 (C-4'), 134.8 (C-6), 
131.7 (C-1), 125.8 (C-3), 124.3 (C-4), 121.9 (C-3' and C-5'), 114.3 (C-5); HRMS m/z (ESI+) [Found: 
259.0815, C12H11N4O3 requires (M+H)+ 259.0826]; LCMS (LCQ) Rt = 0.6 min (4 min method), m/z 
(ESI+) 259.09 (M+H)+. 
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4-Nitro-2-(4-pyridyl)-1H-benzimidazole (82) 
 
Compound 82 was prepared via General Method D using N-(2-amino-3-nitro-phenyl)pyridine-4-
carboxamide (150 mg, 0.55 mmol mg). The reaction mixture was concentrated under reduced 
pressure to give a pale yellow solid (114 mg). The crude was purified via flash column 
chromatography (4.7 g amino silica, ethyl acetate:methanol, 100:0 to 90:10) to give 4-nitro-2-
(4-pyridyl)-1H-benzimidazole (14) (46 mg, 33%) as an orange solid. 
Rf 0.43 (100% ethyl acetate); m.p. 257–259 °C; νmax (thin film)/cm-1 1613 (m, C=C), 1510 (m, ), 
1481 (m, aromatic C-H), 1342 (s, N-O), 1300 (s, N-O), 806 (m, C-H), 728 (s, C-H); 1H NMR 
(500 MHz, DMSO-d6) δ 8.79 (d, J = 4.1 Hz, 2H, H-2' and H-6'), 8.29 (d, J = 4.1 Hz, 2H, H-3' and H-
5'), 8.18 (m, 2H, H-4 and H-6), 7.47 (t, J = 7.0 Hz, 1H, H-5); 13C NMR insufficient resolution in 
10,000 scan experiment; HRMS m/z (ESI+) [Found: 263.0531, C12H8N4NaO2 requires (M+H)+ 
263.0539]; LCMS (LCQ) Rt = 0.8 min (4 min method), m/z (ESI+) 241.16 (M+H)+. 
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N-(2-Amino-5-cyano-phenyl)pyridine-4-carboxamide 
 
The intermediate was prepared via General Method C using 3,4-diaminobenzonitrile (100 mg, 
0.75 mmol) and isonicotinic acid (23) (102 mg, 0.83 mmol). The reaction mixture was filtered 
and N-(2-amino-5-cyano-phenyl)pyridine-4-carboxamide (114 mg, 57%) was isolated as a brown 
solid. 
1H NMR (500 MHz, DMSO-d6) δ 9.96 (s, 1H, H-7), 8.77 (d, J = 4.2 Hz, 2H, H-2' and H-6'), 7.90 (d, 
J = 4.4 Hz, 2H, H-3' and H-5'), 7.55 (s, 1H, H-3), 7.38 (d, J = 8.1 Hz, 1H, H-6), 6.81 (d, J = 8.4 Hz, 
1H, H-5), 6.15 (s, 2H, H-10); LCMS (LCQ) Rt = 0.5 min (4 min method); HRMS m/z (ESI+) [Found: 
499.1607, (C13H10N4O)2Na requires (dimer + Na)+ 499.4805; LCMS (LCQ) Rt = 0.5 min (4 min 
method), m/z (ESI+) 239.09 (M+H)+. 
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2-(4-Pyridyl)-1H-benzimidazole-5-carbonitrile (83) 
 
Compound 83 was prepared via General Method D using N-(2-amino-5-cyano-phenyl)pyridine-
4-carboxamide (90 mg, 0.38 mmol). The reaction mixture was concentrated under reduced 
pressure to give an off-white solid (103 mg). The crude was purified via flash column 
chromatography (4.7 g amino silica, ethyl acetate:methanol, 100:0 to 90:10) to give 2-(4-
pyridyl)-1H-benzimidazole-5-carbonitrile (83) (28 mg, 34%) as a pale pink solid. 
Rf 0.70 (9:1 ethyl acetate:methanol); m.p. sublimates > 260 °C; νmax (thin film)/cm-1 3352 (N-H, 
br), 2217 (C≡N, m), 1611 (C=C, s), 1536 (aromatic C-H, m), 798 (C-N, s); 1H NMR (500 MHz, DMSO-
d6) δ 8.79 (d, J = 4.1 Hz, 2H, H-2' and H-6'), 8.23 (s, 1H, H-4), 8.11 (d, J = 4.1 Hz, 2H, H-3' and H-
5'), 7.81 (d, J = 8.1 Hz, 1H, H-7), 7.65 (d, J = 8.1 Hz, 1H, H-6); 13C NMR (151 MHz, DMSO-d6) δ 
151.8 (C-2), 150.2 (C-2' and C-6'), 141.3 (C-3a), 139.4 (C-7a), 136.1 (C-4'), 125.7 (C-7), 120.9 (C-8), 
120.3 (C-3' and C-5'), 119.2 (C-6), 115.9 (C-5), 104.5 (C-4); HRMS m/z (ESI+) [Found: 221.0817, 
C13H9N4 requires (M+H)+ 221.0822]; LCMS (LCQ) Rt = 0.6 min (4 min method), m/z (ESI+) 221.35 
(M+H)+. 
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N-(2-Amino-5-nitro-phenyl)pyridine-4-carboxamide 
 
The intermediate was prepared via General Method C using 4-nitro-O-phenylene-diamine 
(150 mg, 0.98 mmol) and isonicotinic acid (23) (133 mg, 1.08 mmol). The reaction mixture was 
filtered and N-(2-amino-5-nitro-phenyl)-pyridine-4-carboxamide (146 mg, 52%) was isolated as 
a brown solid. The product was taken forward without further purification. 
Rf 0.74 (9:1 ethyl acetate:methanol); m.p. 209–211 °C; νmax (thin film)/cm-1 (bond, s) 3437 (N-H, 
w), 3342 (N-H, br), 3195 (N-H, br), 1626 (C=O, s), 1518 (aromatic C-H, s); 1H NMR (500 MHz, 
DMSO-d6) δ 10.03 (s, 1H, H-7), 8.88–8.70 (m, 2H, H-2' and H-6'), 8.12 (s, 1H, H-6), 8.00–7.86 (m, 
3H, H-4, H-3' and H-5'), 6.80 (d, J = 8.9 Hz, 1H, H-3), 6.70 (s, 2H, H-10); 13C NMR (126 MHz, 
DMSO-d6) δ 164.6 (C-8), 150.9 (C-2), 150.1(C-2' and C-6'), 141.3 (C-4'), 135.2 (C-5), 124.0 (C-4), 
124.0 (C-6), 121.9 (C-3' and C-5'), 120.5 (C-1), 113.8 (C-3); HRMS m/z (ESI+) [Found: 257.0670, 
C12H9N4O3 requires (M-H)+ 257.0680]; LCMS (LCQ) Rt = 0.5 min (4 min method), m/z (ESI+) 259.07 
(M+H)+. 
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5-Nitro-2-(4-pyridyl)-1H-benzimidazole (84) 
 
Compound 84 was prepared via General Method D using N-(2-amino-5-nitro-phenyl)-pyridine-
4-carboxamide (117 mg). The reaction mixture was concentrated under reduced pressure to give 
an off-white solid (130 mg). The crude was purified via flash column chromatography (4.7 g 
amino silica, ethyl acetate:methanol, 100:0 to 90:10) to give 5-nitro-2-(4-pyridyl)-1H-
benzimidazole (84) (63 mg, 0.24 mmol, 58%) as a pale orange solid. 
Rf 0.24 (100% ethyl acetate); sublimates > 265 °C; νmax (thin film)/cm-1 3109 (br, N-H), 1614 (m, 
C=C), 1519 (m, N-O), 1474 (m, aromatic C-H), 1339 (s, N-O), 1312 (s, N-O) 823 (m, N-H), 738 (s, 
N-H); 1H NMR (500 MHz, DMSO-d6) δ 8.81 (d, J = 4.9 Hz, 2H, H-2' and H-6'), 8.54 (s, 1H, H-4), 8.17 
(d, J = 8.9 Hz, 1H, H-6), 8.12 (d, J = 4.8 Hz, 2H, H-3' and H-5'), 7.83 (d, J = 8.8 Hz, 1H, H-7); 13C 
NMR insufficient resolution in 10,000 scan experiment; HRMS m/z (ESI+) [Found: 241.0721, 
C12H9N4O2 requires (M+H)+ 241.0720]; LCMS (LCQ) Rt = 0.6 min (4 min method), m/z 
(ESI+) 241.15 (M+H)+. 
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2-Amino-5-bromo-3-nitro-benzamide (89) 
 
Intermediate 89 was prepared via General Method A using 2-amino-5-bromo-3-nitrobenzoic 
acid (88) (900 mg, 3.45 mmol) and 13.4 M aqueous ammonia solution (2.6 mL, 34.48 mmol). The 
reaction mixture was filtered giving 2-amino-5-bromo-3-nitro-benzamide (89) (330 mg, 35%) as 
a fine orange solid. The filtrate was partially concentrated under reduced pressure, left 
overnight and a further batch of the product (89) (150 mg, 16%) was isolated by filtration. 
1H NMR (500 MHz, DMSO-d6) δ 8.49 (s, 2H, H-9), 8.29 (d, J = 2.3 Hz, 1H, H-4), 8.27 (s, 1H, H-10), 
8.08 (d, J = 2.3 Hz, 1H, H-6), 7.76 (s, 1H, H-10); LCMS (MDAP) Rt = 1.9 min (Ana 5-95 in 5 min), 
m/z (ESI+) 257.80 and 259.80 (M+H)+. 
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2,3-Diamino-5-bromo-benzamide (90) 
 
Intermediate 90 was prepared via General Method B using 2-amino-5-bromo-3-nitro-benzamide 
(89) (150 mg, 0.55 mmol). 2,3-Diamino-5-bromo-benzamide (90) (69 mg, 52%) was isolated as a 
pale-yellow solid. 
1H NMR (500 MHz, DMSO-d6) δ 7.74 (s, 1H, H-10), 7.11 (s, 1H, H-10), 7.03 (s, 1H, H-6), 6.73 (s, 
1H, H-4), 6.23 (s, 2H, H-9), 4.99 (s, 2H, H-11); HRMS m/z (ESI+) [Found: 251.9743 [Br-79] and 
253.9722 [Br-81], C7H8BrN3ONa (M+Na)+ requires 253.0516]; LCMS (MDAP) Rt = 25.1 min (Ana 
5–95 in 20 min), not ionisable by MDAP/LCQ LCMS. 
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N-(2-Amino-5-bromo-3-carbamoyl-phenyl)pyridine-4-carboxamide (91)126 
 
2,3-Diamino-5-bromo-benzamide (90) (750 mg, 3.26 mmol), isonicotinic acid (23) (401 mg, 
3.26 mmol), 1-hydroxybenzotriazole hydrate (HOBt) (582 mg, 3.8 mmol) and N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC·HCl) (750 mg, 3.91 mmol) in 
DMF (7 mL) were stirred overnight at 100 °C. The reaction was allowed to cool to room 
temperature and saturated aqueous Na2CO3 was added until effervescence ceased (ca. 10–
15 mL). A brown precipitate formed. The mixture was filtered, and the collected solids were 
dried in a vacuum oven overnight. The resulting brown solid (825 mg) was purified via flash 
column chromatography (40 g silica, ethyl acetate:methanol, 100:0 to 90:10) to give N-(2-amino-
5-bromo-3-carbamoyl-phenyl)pyridine-4-carboxamide (91) (825 mg, 52%) as a pale yellow solid.  
Rf 0.64 (9:1 dichloromethane:methanol); m.p. > 300 °C; νmax (thin film)/cm-1 3349 (br, N-H), 3156 
(br, N-H), 1649 (s, C=O), 1599 (aromatic C-H) 1533 (aromatic C-H), 1041 (m, C-N); 1H NMR 
(600 MHz, DMSO-d6) δ 9.95 (s, 1H, H-11), 8.78 (d, J = 4.6 Hz, 2H, H-2' and H-6'), 8.20 (s, 1H, H-
10), 8.00 (s, 1H, H-10), 7.90 (d, J = 4.0 Hz, 2H, H-3' and H-5'), 7.71 (s, 1H, H-6), 7.46 (s, 1H, H-4), 
6.66 (s, 2H, H-9); 13C NMR (151 MHz, DMSO-d6) δ 170.3 (C-7), 165.0 (C-12), 151.1 (C-1), 150.5 (C-
2' and C-6') , 145.3 (C-3), 141.7 (C-4'), 133.0 (C-4), 129.7 (C-6), 125.5 (C-2), 122.3 (C-3' and C-5'), 
104.3 (C-5); LCMS (LCQ) Rt = 0.6 min (4 min method); HRMS m/z (ESI+) [Found: 317.0038 
(product cyclised to 92 on column), C13H11BrN4O2 requires (M]) 335.1556]; LCMS (LCQ) 
Rt = 0.6 min (4 min method), m/z (ESI+) 317.16 [79Br], 318.15 [81Br] (product cyclised to 92 on 
column), 334.97 [79Br], 336.98 [81Br] (M+H)+. 
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6-Bromo-2-(4-pyridyl)-1H-benzimidazole-4-carboxamide (92) 
 
Compound 92 was prepared via General Method D using N-(2-amino-5-bromo-3-carbamoyl-
phenyl)pyridine-4-carboxamide (300 mg). The reaction mixture was neutralised to pH 8 with 
saturated aqueous sodium carbonate and the resulting suspension was filtered. The collected 
solids were dried in a vacuum oven overnight to yield 6-bromo-2-(4-pyridyl)-1H-benzimidazole-
4-carboxamide (92) (300 mg, 100%) as a pale brown solid. 
Rf 0.54 (9:1 ethyl acetate:methanol); m.p. > 300 °C; νmax (thin film)/cm-1 3344 (N-H, m), 3175 
(aromatic C-H, m), 1669 (C=O, s), 1603 (C=C, s), 1409 (aromatic C-C, m), 793 (N-H, s); 1H NMR 
(600 MHz, DMSO-d6) δ 10.09 (d, J = 4.2 Hz, 1H, H-10), 8.59–8.44 (m, 2H, H-2' and H-6'), 8.13 (d, 
J = 6.0 Hz, 2H, H-3' and H-5'), 7.69 (s, 1H, H-5), 7.57 (s, 1H, H-7), 7.45 (d, J = 3.6 Hz, 1H, H-10); 13C 
NMR (151 MHz, DMSO-d6) δ 175.1 (C-8), 167.5 (C-6), 159.5 (C-2), 150.1 (C-2' and C-6'), 149.9 
(C-4), 145.4 (C-3a), 143.5 (C-4'), 122.3 (C-5), 122.1 (C-7), 121.4 (C-3' and C-5'), 110.5 (C-7a); HRMS 
m/z (ESI+) [Found: 338.9859, C13H9BrN4O requires (M+H)+ 338.9826]; LCMS (MDAP) Rt = 2.9 min 
(Ana 5–95 over 5 minutes), m/z (ESI+) 316.850 [79Br], 318.8 [81Br] (M+H)+. 
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Methyl 2-[4-carbamoyl-2-(4-pyridyl)benzimidazol-1-yl]acetate (96)175 
 
To a solution of 2-(4-pyridyl)-1H-benzimidazole-4-carboxamide (10) (50 mg, 1 eq.) in N,N-
dimethylformamide (1 mL) was added methyl bromoacetate (95) (0.03 mL, 1.5 eq.) and sodium 
hydride (10 mg, 2 eq.). The reaction mixture was stirred at 80 °C for 2 h. The reaction mixture 
was concentrated under reduced pressure and chloroform (5 mL) was added. The mixture was 
extracted five times with water (5 × 2 mL). The organic phase was dried over MgSO4, filtered and 
concentrated under reduced pressure before being recrystallised from cyclohexane to 
give methyl 2-[4-carbamoyl-2-(4-pyridyl)-benzimidazol-1-yl]acetate (96) (22 mg, 34%) as an 
orange solid. 
1H NMR (600 MHz, DMSO-d6) δ 9.03 (s, 1H, H-15), 8.81 (d, J = 5.5 Hz, 2H, H-2' and H-6'), 7.98 (d, 
J = 7.5 Hz, 1H, H-5), 7.92 (d, J = 8.1 Hz, 1H, H-7), 7.85 (s, 1H, H-15), 7.80 (d, J = 5.6 Hz, 2H, H-3' 
and H-5'), 7.48 (t, J = 7.8 Hz, 1H, H-6), 5.45 (s, 2H, H-8), 3.67 (s, 3H, H-12); LCMS (MDAP) Rt = 0.7 
min (Ana 5–95 in 5 minutes); HRMS m/z (ESI+) 311.1011 (M+H)+, calculated MW for C16H14N4O3 
310.3068. 
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6.1.2 Preparation of compounds described in Chapter 3 
*indicates compounds synthesised by Mihaela Paula-Ficu 
2-(4-Pyridyl)-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one (11)105 
 
A mixture of 4-(bromoacetyl)pyridine hydrobromide (98) (2.00 g, 7.12mmol) ,piperidin-2,4-
dione (99) (1.21 g, 10.68 mmol)  and  ammonium acetate (2.19 g, 28.47 mmol)   in  ethanol 
(30 mL) was stirred at room temperature overnight. A red solution formed. LCMS analysis of the 
reaction mixture showed the desired product ion peak (m/z 214) was the major component of 
the reaction mixture. The reaction mixture was concentrated to under reduced pressure to give 
an orange/red residue (1.06 g). The crude was purified by flash column chromatography (70 g 
silica, dichloromethane:methanol 100:0 to 90:10) to give 2-(4-pyridyl)-1,5,6,7-
tetrahydropyrrolo-[3,2-c]pyridin-4-one (830 mg, 52%)  (11) as a pale orange solid. 
Rf 0.38 (9:1 dichloromethane:methanol); m.p. degrades > 190 °C; νmax (thin film)/cm-1 3242 (N-H, 
m), 2929 (C-H, w), 1634 (C=O, s), 1604 (C=N, s), 1520 (aromatic C=C, m), 1157 (C-N, m); 1H NMR 
(500 MHz, DMSO-d6) δ 11.94 (s, 1H, H-5), 8.47 (d, J = 4.9 Hz, 2H, H-2' and H-6'), 7.60 (d, J = 4.9 Hz, 
2H, H-3' and H-5'), 7.09 (s, 1H, H-1), 7.01 (s, 1H, H-3), 3.43–3.38 (m, 2H, H-6), 2.84 (t, J = 6.7 Hz, 
2H, H-7); 13C NMR (126 MHz, DMSO-d6) δ 164.8 (C-9), 150.0 (C-2' and C-6'), 139.0 (C-4), 138.8 
(C-4'), 128.4 (C-2), 117.5 (C-3' and C-5'), 115.7 (C-8), 106.3 (C-3), 40.1 (C-6), 21.9 (C-7); HRMS 
m/z (ESI+) [Found: 214.0977, C12H12N3O requires (M+H)+ 214.0975]; LCMS (LCQ) Rt = 0.4 min (4 
min method), m/z (ESI+) 214.26 (M+H)+. 
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2-(3-Pyridyl)-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one (109)  
 
A mixture of piperidin-2,4-dione (99) (339 mg, 3 mmol), ammonium acetate (617 mg, 8 
mmol) and 3-(bromoacetyl)pyridine hydrobromide (108) (400 mg, 2 mmol) in ethanol 
(5 mL) was stirred at room temperature overnight. A red solution formed. LCMS analysis of the 
reaction mixture showed the desired product ion peak (m/z 214) was the major component of 
the reaction mixture. The reaction mixture was concentrated to dryness under reduced pressure 
to give an orange/red residue (1.40 g). The crude was purified by flash column chromatography 
(11 g amino silica, ethyl acetate:methanol 100:0 to 90:10) to give a mixture of product and 
impurity (83 mg). The residue was purified a second time by flash column chromatography (5 g 
amino silica, ethyl acetate:methanol 100:0 to 9:1) to give 2-(3-pyridyl)-1,5,6,7-
tetrahydropyrrolo[3,2-c]pyridin-4-one (109) (41 mg, 9%) as a yellow foam. 
Rf 0.12 (9:1 ethyl acetate:methanol); m.p. degrades > 200 °C; νmax (thin film)/cm-1 3441 (N-H, w, 
br), 3202 (aromatic C-H, m, br), 1619 (C=O, s), 1509 (aromatic C-H, s), 1475 (aliphatic C-H, m), 
776 (N-H, s); 1H NMR (500 MHz, DMSO-d6) δ 11.79 (s, 1H, H-5), 8.89 (s, 1H, H-2'), 8.36 (d, J = 
3.6 Hz, 1H, H-6'/4'), 7.99 (d, J = 8.0 Hz, 1H, H-4'/6'), 7.37 (dd, J = 7.9, 4.8 Hz, 1H, H-5'), 7.02 (s, 
1H, H-1), 6.83 (s, 1H, H-3), 3.43–3.37 (m, 2H, H-6), 2.82 (t, J = 6.8 Hz, 2H, H-7); 13C NMR (126 MHz, 
DMSO-d6) δ 165.0 (C-9), 146.7 (C-6'), 144.9 (C-2'), 138.0 (C-4), 130.4 (C-4'), 128.1 (C-3'), 128.0 
(C-2), 123.7 (C-5'), 115.3 (C-8), 104.3 (C-3), 40.2 (C-6), 21.9 (C-7); HRMS m/z (ESI+) [Found: 
214.0979, C12H12N3O requires (M+H)+ 214.0975]; LCMS (LCQ) Rt = 0.5 min (7 min method), m/z 
(ESI+) 214.22 (M+H)+. 
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2-(2-Pyridyl)-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one (111)  
 
A mixture of piperidin-2,4-dione (99) (60 mg, 0.53 mmol), ammonium acetate (110 mg, 
1.42 mmol)  and  2-bromo-1-pyridin-2-ylethanone (110) (71 mg, 0.36 mmol)   in  ethanol 
(2 mL)   was stirred at room temperature for overnight. A red solution formed. LCMS analysis of 
the reaction mixture showed the desired product ion peak (m/z 214) was the major component 
of the reaction mixture. The reaction mixture was concentrated to dryness under reduced 
pressure to give an orange/red residue (435 mg). The crude was purified by flash column 
chromatography (12 g silica, dichloromethane:methanol 100:0 to 90:10) to give 2-(2-pyridyl)-
1,5,6,7-tetrahydropyrrolo-[3,2-c]pyridin-4-one (55 mg, 28%) as a pale pink solid. 
Rf 0.80 (9:1 dichloromethane:methanol); m.p. 271–273 °C; νmax (thin film)/cm-1 3248 (N-H, m, 
br), 3065 (aromatic C-H, m, br), 2842 (aliphatic C-H, w, br), 1642 (C=O, s), 1508 (aromatic C-H, 
s), 775 (N-H, s); 1H NMR (500 MHz, DMSO-d6) δ 11.85 (s, 1H, H-5), 8.48 (d, J = 4.4 Hz, 1H, H-6'), 
7.74 (s, 2H, H-4' and H-5'), 7.20–7.10 (m, 1H, H-3'), 7.03 (s, 1H, H-1), 6.99–6.91 (m, 1H, H-3), 
3.47–3.32 (m, 2H, H-6), 2.81 (t, J = 6.6 Hz, 3H, H-7); 13C NMR (126 MHz, DMSO-d6) δ 165.2 (C-9), 
150.3 (C-2'), 148.7 (C-6'), 138.3 (C-4), 136.8 (C-4'), 131.1 (C-2), 120.8 (C-3'), 118.1 (C-5'), 115.3 
(C-8), 105.3 (C-3), 40.2 (C-6), 22.0 (C-7); HRMS m/z (ESI+) [Found: 214.0978, C12H12N3O requires 
(M+H)+ 214.0975]; LCMS (LCQ) Rt  = 0.5 min (4 min method), m/z (ESI+) 214.23 (M+H)+. 
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2-Phenyl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one (113)105 
 
A mixture of piperidin-2,4-dione (99) (341 mg, 3.01 mmol), ammonium acetate (620 mg, 
8.04 mmol) and phenacyl bromide (112) (400 mg, 2.01 mmol) in ethanol (6mL) was stirred at 
room temperature overnight. A yellow solution formed. LCMS analysis confirmed product 
formation (m/z 213). The solution was concentrated under reduced pressure to give an orange 
residue (1.59 g). The crude was purified by flash column chromatography (30 g silica, 
dichloromethane:methanol, 1:0 to 9:1) and dried under vacuum to give  2-phenyl-1,5,6,7-
tetrahydropyrrolo[3,2-c]pyridin-4-one (113) (60 mg, 13%) as a yellow glass.  
Rf 0.64 (9:1 ethyl acetate:methanol); m.p. 109–111 °C; νmax (thin film)/cm-1 3204 (N-H, br), 1621 
(C=O, s), 1505 (aromatic C-H, s), 1448 (aliphatic C-H, m), 755 (N-H, s); 1H NMR (500 MHz, 
DMSO-d6) δ 11.62 (s, 1H, H-5), 7.63 (d, J = 7.6 Hz, 2H, H-2' and H-6'), 7.35 (t, J = 7.3 Hz, 2H, H-3' 
and H-5'), 7.17 (t, J = 7.1 Hz, 1H, H-4'), 6.97 (s, 1H, H-1), 6.67 (s, 1H, H-3), 3.39–3.35 (m, 2H, H-6), 
2.81 (t, J = 6.5 Hz, 2H, H-7); 13C NMR (126 MHz, DMSO-d6) δ 165.3 (C-9), 137.2 (C-8), 132.3 (C-1'), 
131.1 (C-2), 128.8 (C-3' and C-5'), 125.9 (C-4'), 123.4 (C-2' and C-6'), 115.0 (C-3), 103.0 (C-4), 40.3 
(C-6), 21.9 (C-7); HRMS m/z (ESI+) [Found: 213.1022, C13H13N2O requires (M+H)+ 213.1022]; LCMS 
(LCQ) Rt = 0.6 min (4 min method), m/z (ESI+) 213.16 (M+H)+. 
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2-(4-Pyridyl)-1,5,6,7-tetrahydroindol-4-one (114)* 
 
A mixture of 4-(bromoacetyl)pyridine hydrobromide (98) (200 mg, 0.71 mmol), 1,3-
cyclohexanedione (120 mg, 1.07 mmol) and ammonium acetate (220 mg, 2.85 mmol) in ethanol 
(3 mL) was stirred at room temperature for 18 hours. LCMS indicated product formation 
(m/z 213). The reaction mixture was concentrated under reduced pressure, and the resulting 
dark red residue (536 mg) was purified by flash column chromatography (12 g silica, 
dichloromethane:methanol, 1:0 to 9:1). The desired fractions were collected to yield 2-(4-
pyridyl)-1,5,6,7-tetrahydroindol-4-one (114) (35 mg, 22%) as a yellow solid.  
Rf 0.49 (dichloromethane:methanol, 9:1); m.p. sublimated at 200–203 °C; νmax (thin film)/cm-1 
3242 (N-H, m), 2929 (C-H, w), 1634 (C=O, s), 1604 (C=N, s), 1520 (aromatic C=C, m), 1157 (C-N, 
m); 1H NMR (500 MHz, DMSO-d6) δ 12.07 (1H, s, H-1), 8.51 (2H, d, J = 4.6 Hz, H-2’ and H-6’),3 
7.64 (2H, d, J = 5.1 Hz, H-3’ and H-5’),3 7.05 (1H, s, H-3), 2.85 (2H, t, J = 6.3 Hz, H-7), 2.36 (2H, t, 
J = 6.3 Hz, H-5), 2.06 (2H, q, J = 6.3 Hz, H-6); 13C NMR (126 MHz, DMSO-d6) δ 192.8 (C- 4), 150.0 
(C-2’ and C-6’), 146.5 (C-8), 138.5 (C-4’), 129.4 (C-2), 121.2 (C-9), 117.8 (C-3’ and C-5’), 105.0 
(C-3), 37.7 (C-5), 23.4 (C-6), 22.2 (C-7); HRMS m/z (ESI+) [Found: 213.1022, C13H13N2O requires 
(M+H)+ 213.1022]; LCMS (LCQ) Rt = 0.4 min (4 min method), m/z (ESI+) 213.28 (M+H)+. 
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Tert-Butyl 2-(4-pyridyl)-1,4,6,7-tetrahydropyrrolo[3,2-c]pyridine-5-carboxylate (115a)*  
 
A mixture of 4-(bromoacetyl)pyridine hydrobromide (98) (100 mg, 0.36 mmol), tert-butyl 4-oxo-
piperidine-1-carboxylate (106 mg, 0.53 mmol) and ammonium acetate (110 mg, 1.42 mmol) in 
ethanol (1.5 mL) was stirred at room temperature for 18 hours. The brown mixture was 
concentrated under reduced pressure and the residue (273 mg) was purified by flash column 
chromatography (20 g silica, dichloromethane:methanol, 1:0 to 9:1) to yield the tert-butyl 2-(4-
pyridyl)-1,4,6,7-tetrahydropyrrolo[3,2-c]pyridine-5-carboxylate (115a) (32 mg, 28%) as a yellow 
solid.  
Rf 0.58 (dichloromethane:methanol, 9:1); m.p. 145–175 °C; νmax (thin film)/cm-1 3088 (N-H, w), 
2979 (C-H, w), 1684 (C=O, s), 1632 (C=N, s), 1523 (aromatic C=C, s), 1234 (C-O, s), 1152 (C-N, s); 
1H NMR (600 MHz, DMSO-d6) δ 11.37 (1H, s, H-1), 8.41 (2H, d, J = 4.6 Hz, H-2’ and H-6’),5 7.48 
(2H, d, J = 5.1 Hz, H-3’ and H-5’),4 6.61 (1H, s, H-3), 4.32 (2H, s, H-4), 3.62 (2H, t, J = 5.2 Hz, H-6), 
2.66 (2H, t, J = 5.2 Hz, H-7), 1.42 (9H, s, H-14); 13C NMR (151 MHz, DMSO-d6) δ 172.0 (C-10), 
149.8 (C-2’ and C-6’), 139.4 (C-8), 129.0 (C-4’), 127.4 (C-2), 116.9 (C-3’ and C-5’), 105.4 (C-3), 90.2 
(C-9), 78.8 (C-12), 40.1 (C-4),6 39.9 (C-6),6 28.1 (C-13, C-14 and C-15), 21.0 (C-7); HRMS m/z (ESI+) 
[Found: 300.1698, C17H22N3O2 requires (M+H)+ 300.1707]; LCMS (LCQ) Rt = 0.4 min (4 min 
method), m/z (ESI+) 300.01 (M+H)+. 
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2-(4-Pyridyl)-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridine; 2,2,2-trifluoroacetic acid (115)* 
 
A solution of tert-butyl 2-(4-pyridyl)-1,4,6,7-tetrahydropyrrolo[3,2-c]pyridine-5-carboxylate 
(26 mg, 0.09 mmol) in dichloromethane (1.5 mL) was cooled to 0 °C and trifluoro acetic acid 
(0.3 mL, 3.92 mmol) was added dropwise. The resulting mixture was stirred at 0 °C for 3 hours 
and then was allowed to warm to room temperature. The yellow mixture was dissolved in 
methanol (3 mL), concentrated under reduced pressure, washed with diethyl ether and dried in 
a vacuum oven overnight to yield 2-(4-pyridyl)-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridine; 
2,2,2-trifluoroacetic acid (115) (10 mg, 34%) as a dark-yellow solid.  
Rf 0 (9:1 dichloromethane:methanol); m.p. 197–205 °C; νmax (thin film)/cm-1 3066 (N-H, w), 3009 
(C-H, w), 1670 (C=O, s), 1628 (C=N, s), 1519 (aromatic C=C, s), 1381 (C-F, m); 1182 (C-N, s); 1122 
(C-O, s); 1H NMR (600 MHz, DMSO-d6) δ 12.27 (1H, s, H-1), 9.11 (2H, s, H-5), 8.65 (2H, d, J = 
6.0 Hz, H-2’ and H-6’), 7.97 (2H, d, J = 6.0 Hz, H-3’ and H-5’), 7.13 (1H, s, H-3), 4.16 (2H, s, H-4), 
3.45–3.42 (2H, m, H-6), 2.97 (2H, t, J = 5.2 Hz, H-7); 13C NMR (151 MHz, DMSO-d6) δ 142.3 (C-2’ 
and C-6’), 131.9 (C-8), 126.6 (C-4’), 118.0 (C-3’ and C-5’), 113.9 (C-2), 111.6 (C-3), 109.5 (C-9), 
40.9 (C-4), 40.7 (C-6), 19.9 (C-7); HRMS m/z (ESI+) [Found: 200.1180, C12H14N3 requires (M+H)+ 
200.1182]; LCMS (LCQ) Rt = 0.4 min (4 min method), m/z (ESI+) 200.13 (M+H)+. 
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1-Methyl-2-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-4-one (120)105 
 
4-(Bromoacetyl)pyridine hydrobromide (98) (200 mg, 0.71 mmol), piperidin-2,4-dion (99) 
(121 mg, 1.07 mmol) and 8 M methylamine in ethanol (0.36 mL, 2.85 mmol) were stirred 
in ethanol (3 mL) at room temperature overnight. LCMS analysis indicated formation of the 
product (m/z 228). The reaction mixture was concentrated under reduced pressure. The crude 
was dissolved in saturated aqueous Sodium hydrogen carbonate (20 mL) and extracted three 
times with 2:1 chloroform:propan-2-ol (3 × 25 mL). The organic phases were combined, dried 
over MgSO4, filtered and concentrated under reduced pressure. The crude was purified by flash 
chromatography (5 g silica, dichloromethane:methanol, 100:0 to 90:10) to give 1-methyl-2-(4-
pyridyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-4-one (120) (39 mg, 23%) as a brown solid. 
Rf 0.71 (dichloromethane:methanol, 9:1); m.p. decomposed at 210–214 °C; νmax (thin film)/cm-1 
3197 (N-H, m), 3061 (C-H, w), 1644 (C=O, s), 1599 (C=N, s), 1497 (aromatic C=C, s), 1165 (C-N, 
m); 1H NMR (500 MHz, DMSO-d6) δ 8.60–8.52 (m, 2H, H-2' and H-6'), 7.52–7.45 (m, 2H, H-3' and 
H-5'), 7.09 (s, 1H, H-N-5), 6.64 (s, 1H, H-3), 3.42 (td, J = 6.9, 2.5 Hz, 2H, H-6), 3.34 (s, 3H, H-11), 
2.86 (t, J = 6.9 Hz, 2H, H-7); 13C NMR (126 MHz, DMSO-d6) δ 164.6 (C-4), 149.8 (C-2’ and C-6’), 
140.2 (C-8), 139.2 (C-4’), 131.5 (C-2), 121.8 (C-3’ and C-5’), 114.3 (C-9), 107.8 (C-3), 39.8 (C-6), 
32.5 (C-10), 21.2 (C-7); HRMS m/z (ESI+) [Found: 228.1126, C13H14N3O requires (M+H)+ 228.1131]; 
LCMS (LCQ) Rt = 0.4 min (4 min method), m/z (ESI+) 228.27 (M+H)+. 
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1-Ethyl-2-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-4-one (121)105 
 
4-(Bromoacetyl)pyridine hydrobromide (98) (3 g, 10.68 mmol), piperidin-2,4-dion (99) (1.81 g, 
16.02 mmol) and 70% ethylamine solution (2.8 mL, 42.71 mmol) in water were stirred in ethanol 
(45 mL) at room temperature overnight. LCMS (LCQ) indicated product formation (m/z 242). The 
reaction mixture was concentrated under reduced pressure and saturated aqueous Sodium 
hydrogen carbonate (240 mL) was added. The mixture was extracted six times with 
dichloromethane (6 × 240 mL). The combined organic phases were dried over MgSO4, filtered 
and concentrated under reduced pressure to give 1-ethyl-2-(4-pyridyl)-6,7-dihydro-5H-
pyrrolo[3,2-c]pyridin-4-one (121) (2.37 g, 87%) as an orange solid. 
Rf 0.42 (dichloromethane:methanol, 9:1); m.p. decomposed at 186–190 °C; νmax (thin film)/cm-1 
3189 (N-H, m), 2966 (C-H, m), 1654 (C=O, s), 1598 (C=N, s), 1496 (aromatic C=C, s), 1164 (C-N, 
m); 1H NMR (600 MHz, DMSO-d6) δ 8.59 (d, J = 4.3 Hz, 2H, H-2' and H-6'), 7.44 (d, J = 4.5 Hz, 2H, 
H-3' and H-5'), 7.08 (s, 1H, H-5), 6.59 (s, 1H, H-3), 4.05 (q, J = 6.2, 5.6 Hz, 2H, H-10), 3.48–3.38 
(m, 2H, H-6), 2.96–2.84 (m, 2H, H-7), 1.19 (t, J = 6.9 Hz, 3H, H-11); 13C NMR (151 MHz, DMSO-d6) 
δ 164.6 (C-4), 150.0 (C-2’ and C-6’), 139.5 (C-8), 139.4 (C-4’), 130.8 (C-2), 122.0 (C-3’ and C-5’), 
114.6 (C-9), 108.2 (C-3), 40.0 (C-6), 39.2 (C-10), 21.1 (C-7), 16.0 (C-11); HRMS m/z (ESI+) [Found: 
242.1289, C14H16N3O requires (M+H)+ 242.1288]; LCMS (LCQ) Rt = 0.4 min (4 min method), m/z 
(ESI+) 242.19 (M+H)+. 
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1-Propyl-2-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-4-one (122)* 
 
A mixture of 4-(bromoacetyl)pyridine hydrobromide (98) (200 mg, 0.71 mmol), piperidin-2,4-
dion (99) (121 mg, 1.07 mmol) and propylamine (0.23 mL, 2.85 mmol, 4.0 eq.) in ethanol (3 mL) 
was stirred at room temperature for 18 h. The reaction mixture was concentrated under reduced 
pressure. The residue (503 mg) was dissolved in saturated aqueous Sodium hydrogen carbonate 
(20 mL) and extracted with dichloromethane (5 x 25 mL). The organic components were 
combined, dried over MgSO4, filtered and concentrated under reduced pressure. The crude 
product (113 mg) was washed with ethyl acetate (2 mL) to give 1-propyl-2-(4-pyridyl)-6,7-
dihydro-5H-pyrrolo[3,2-c]pyridin-4-one (122) (33 mg, 17%). The remaining filtrate was 
concentrated under reduced pressure and purified by flash column chromatography (4 g silica, 
ethyl acetate:methanol, 1:0 to 8:2). The fractions containing the product were combined, 
concentrated under reduced pressure, washed with ethyl acetate (1 mL) and heated to 100 °C 
causing a solid to precipitate. The mixture was filtered to yield a second crop of 1-propyl-2-(4-
pyridyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-4-one (122) (5 mg, 3%).  
Rf 0.71 (ethyl acetate:methanol, 1:1); m.p. 171–175 °C; νmax (thin film)/cm-1 3207 (N-H, w), 2962 
(C-H, w), 1655 (C=O, s), 1598 (C=N, s), 1498 (aromatic C=C, s), 1163 (C-N, m); 1H NMR (600 MHz, 
DMSO-d6) δ 8.58 (2H, d, J = 5.2 Hz, H-2’ and H-6’), 7.44 (2H, d, J = 5.2 Hz, H-3’ and H-5’), 7.09 (1H, 
s, H-5), 6.58 (1H, s, H-3), 4.00 (2H, t, J = 7.4 Hz, H-10), 3.42 (2H, td, J = 7.0, 2.1 Hz, H-6), 2.87 (2H, 
t, J = 7.0 Hz, H-7), 1.49 (2H, h, J = 7.4 Hz, H-11), 0.70 (3H, t, J = 7.4 Hz, H-12); 13C NMR (151 MHz, 
DMSO-d6) δ 164.7 (C-4), 150.0 (C-2’ and C-6’), 139.9 (C-8), 139.8 (C-4’), 131.2 (C-2), 122.0 (C-3’ 
and C-5’), 114.4 (C-9), 108.3 (C-3), 45.8 (C-10), 40.0 (C-6), 23.6 (C-11), 21.4 (C-7), 10.7 (C-12); 
HRMS m/z (ESI+) [Found: 256.1446, C15H18N3O requires (M+H)+ 256.1444]; LCMS (LCQ) Rt = 
0.4 min (4 min method), m/z (ESI+) 256.26 (M+H)+. 
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1-Isopropyl-2-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-4-one (123) 
 
A mixture of 4-(bromoacetyl)pyridine hydrobromide (98) (200 mg, 0.71 mmol), piperidin-2,4-
dion (99) (121 mg, 1.07 mmol) and isopropylamine (0.23 mL, 2.85 mmol) in ethanol (3 mL) was 
stirred at room temperature for 18 h. LCMS (MDAP) confirmed product formation (m/z 258). 
The reaction mixture was concentrated under reduced pressure and saturated aqueous sodium 
bicarbonate (20 mL) was added. The mixture was extracted with 2:1 chloroform:propan-2-ol 
(3  × 25 mL). The combined organic phases were dried over MgSO4, filtered and concentrated 
under reduced pressure (339 mg). The crude was purified via flash column chromatography 
(50 g silica dichloromethane:methanol, 1:0 to 9:1) to give 1-isopropyl-2-(4-pyridyl)-6,7-dihydro-
5H-pyrrolo[3,2-c]pyridin-4-one (123) (36 mg, 19%) as a yellow solid.  
Rf 0.33 (ethyl acetate:methanol, 8:2); m.p. decomposed at 266–270 °C; νmax (thin film)/cm-1 3062 
(N-H, w), 2347 (C-H, w), 1657 (C=O, s), 1597 (C=N, s), 1500 (aromatic C=C, s), 1165 (C-N, m); 
1H NMR (600 MHz, DMSO-d6) δ 8.57 (d, J = 6.1 Hz, 2H, H-2' and H-6'), 7.51 (d, J = 6.1 Hz, 2H, H-3' 
and H-5'), 7.07 (s, 1H, H-5), 6.58 (s, 1H, H-3), 4.99 (t, J = 5.3 Hz, 1H, H-11), 4.09 (t, J = 5.9 Hz, 2H, 
H-6), 3.52 (q, J = 5.7 Hz, 2H, H-7), 3.41 (td, J = 6.8, 2.5 Hz, 3H, H-11), 2.89 (t, J = 6.9 Hz, 3H, H-12); 
13C NMR (151 MHz, DMSO-d6) δ 164.5 (C-4), 149.8 (C-2’ and C-6’), 140.0 (C-8), 137.8 (C-4’), 131.8 
(C-2), 123.2 (C-3’ and C-5’), 115.9 (C-9), 107.8 (C-3), 48.3 (C-10), 40.2 (C-6), 23.6 (C-7), 22.0 (C-11 
and C-12); HRMS m/z (ESI+) [Found: 278.1253, C15H17N3ONa requires (M+Na)+ 278.1264]; LCMS 
(LCQ) Rt = 0.4 min (4 min method), m/z (ESI+) 256.24 (M+H)+. 
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1-(2-Hydroxyethyl)-2-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-4-one (124)*  
 
A mixture of 4-(bromoacetyl)pyridine hydrobromide (98) (100 mg, 0.36 mmol), piperidin-2,4-
dion (99) (60 mg, 0.53 mmol) and ethanolamine (0.08 mL, 1.42 mmol) in ethanol (1.5 mL) was 
stirred at room temperature for 18 h. 12 M hydrochloric acid (3 drops) was added, and the 
reaction mixture was heated at 100 °C for 3.5 h. After cooling, the mixture was concentrated 
under reduced pressure. The residue (345 mg) was dissolved in saturated aqueous Sodium 
hydrogen carbonate (20 mL) and extracted with Dichloromethane (3 x 25 mL). The LCMS and 
TLC analysis of the aqueous layer indicated that a significant amount of the desired product was 
still present in the aqueous layer. Another extraction with a solution of 2:1 chloroform:propan-
2-ol (3 × 15 mL) was performed. The organic phases were combined, dried over MgSO4, filtered 
and concentrated under reduced pressure. The crude product (168 mg) was purified via flash 
column chromatography (12 g silica, dichloromethane:methanol, 1:0 to 9:1) to yield 1-(2-
hydroxyethyl)-2-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-4-one (124) (32 mg, 33%) as a 
pale yellow solid.  
Rf 0.43 (dichloromethane: methanol, 9:1); m.p. decomposed at 215–218 °C; νmax (thin film)/cm-1 
3204 (O-H, br), 3044 (N-H, w), 2927 (C-H, w), 1639 (C=O, s), 1600 (C=N, s), 1501 (aromatic C=C, 
s), 1162 (C-N, m); 1H NMR (400 MHz, DMSO-d6) δ 8.57 (2H, d, J = 4.3 Hz, H-2’ and H-6’), 7.53–
7.48 (2H, m, H-3’ and H-5’), 7.05 (1H, s, H-5), 6.58 (1H, s, H-3), 4.98 (1H, t, J = 5.4 Hz, H-12), 4.09 
(2H, t, J = 5.7 Hz, H-10), 3.52 (2H, q, J = 5.7, 5.4 Hz, H-11), 3.41 (2H, td, J = 6.8, 2.5 Hz, H-6), 2.89 
(2H, t, J = 6.8 Hz, H-7); 13C NMR (151 MHz, DMSO-d6) δ 164.7 (C-4), 149.9 (C-2’ and C-6’), 140.4 
(C-8), 139.7 (C-4’), 131.5 (C-2), 122.4 (C-3’ and C-5’), 114.5 (C-9), 108.2 (C-3), 60.3 (C-11), 46.9 
(C-10), 40.0 (C-6), 21.7 (C-7); HRMS m/z (ESI+) [Found: 258.1241, C14H16N3O2 requires (M+H)+ 
258.1237]; LCMS (LCQ) Rt = 0.4 min (4 min method), m/z (ESI+) 258.26 (M+H)+. 
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1-Benzyl-2-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-4-one (125) 
 
A mixture of 4-(bromoacetyl)pyridine hydrobromide (98) (500 mg, 1.78 mmol), piperidin-2,4-
dion (99) (302 mg, 2.67 mmol) and benzylamine (0.78 mL, 7.12 mmol) in ethanol (7.5 mL) was 
stirred at room temperature for 18 h. LCMS (MDAP) indicated product formation (m/z 304). The 
mixture was concentrated under reduced pressure. Saturated aqueous sodium hydrogen 
carbonate (20 mL) was added and the mixture was extracted with dichloromethane (3 × 25 mL). 
The combined organic phases were dried over MgSO4, filtered and concentrated under reduced 
pressure. The crude product (1.23 g) was purified via flash column chromatography (40 g silica, 
dichloromethane:methanol, 1:0 to 9:1) to give 1-benzyl-2-(4-pyridyl)-6,7-dihydro-5H-
pyrrolo[3,2-c]pyridin-4-one (125) (85 mg, 15%) as an off-white solid.  
Rf 0.78 (amino silica, dichloromethane:methanol, 1:0 to 95:5); m.p. decomposed at 180–184 °C; 
νmax (thin film)/cm-1 3081 (N-H, w), 1647 (C=O, w), 1407 (C=C, m), 1105 (C-N, s); 1H NMR 
(600 MHz, DMSO-d6) δ 8.50 (d, J = 5.9 Hz, 2H, H-2' and H-6'), 7.34 (d, J = 6.0 Hz, 2H, H-3' and 
H-5'), 7.31 (t, J = 7.6 Hz, 2H, H-13 and H-15), 7.24 (t, J = 7.3 Hz, 1H, H-14), 7.14 (s, 1H, H-5), 6.91 
(d, J = 7.4 Hz, 2H, H-12 and H-16), 6.71 (s, 1H, H-3), 5.34 (s, 2H, H-10), 3.44–3.35 (m, 2H, H-6), 
2.70 (t, J = 6.8 Hz, 2H, H-7); 13C NMR (151 MHz, CDCl3) δ 166.2 (C-4), 150.3 (C-2' and C-6'), 139.7 
(C-8), 139.6 (C-4'), 136.8 (C-11), 133.2 (C-2), 129.4 (C-13 and C-15), 128.1 (C-14), 125.6 (C-12 and 
C-16), 122.5 (C-3' and C-5'), 115.3 (C-9), 108.9 (C-3), 48.5 (C-10), 41.0 (C-6), 22.0 (C-7); HRMS 
m/z (ESI+) [Found: 303.3630, C19H17N3O requires (M)+ 303.3600]; LCMS (LCQ) Rt = 0.4 min (4 min 
method), m/z (ESI+) 304.19 (M+H)+.   
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1-Ethyl-5-methyl-2-(4-pyridyl)-6,7-dihydropyrrolo[3,2-c]pyridin-4-one (126)137 
 
1-Ethyl-2-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-4-one (121) (100 mg, 0.41 mmol) was 
dissolved in N,N-dimethylformamide (11.5 mL), flushed with nitrogen three times and cooled to 
0 °C. 60% sodium hydride (25 mg, 0.62 mmol) was added in portions at 0 °C and allowed to stir 
at room temperature for 15 minutes. The reaction was re-cooled to 0 °C and iodomethane 
(0.5 mL, 0.50 mmol) was added dropwise. The reaction mixture was stirred at room temperature 
overnight. LCMS indicated product formation (m/z 256). The reaction mixture was concentrated 
under reduced pressure and saturated aqueous sodium hydrogen carbonate (20 mL) was added. 
The mixture was extracted three times with 2:1 chloroform:propan-2-ol (3 × 25 mL). The 
combined organic phases were dried over MgSO4, filtered and concentrated under reduced 
pressure. The crude was purified via flash column chromatography (5 g silica, 
dichloromethane:methanol 1:0 to 85:15) to give 1-ethyl-5-methyl-2-(4-pyridyl)-6,7-dihydro-
pyrrolo[3,2-c]pyridin-4-one (126) (24 mg, 22%) as a brown solid. 
Rf 0.67 (9:1 dichloromethane:methanol); m.p. 211–213 °C; νmax (thin film)/cm-1 3258 (N-H, br), 
3039 (aromatic C-H, w), 2934 (aliphatic C-H, br), 2870 (C-H, br), 1632 (C=O, s), 1595 (aromatic C-
H, s), 1505 (aromatic C-H, s), 1478 (aliphatic, s), 764 (N-H, s); 1H NMR (500 MHz, DMSO-d6) δ 
8.58 (d, J = 5.2 Hz, 2H, H-2' and H-6'), 7.44 (d, J = 5.3 Hz, 2H, H-3' and H-5'), 6.60 (s, 1H, H-3), 4.04 
(q, J = 7.2 Hz, 2H, H-11), 3.57 (t, J = 6.9 Hz, 2H, H-6), 2.98 (t, J = 6.9 Hz, 2H, H-7), 2.91 (s, 3H, H-13), 
1.18 (t, J = 7.2 Hz, 3H, H-12); 13C NMR (151 MHz, DMSO-d6) δ 163.5 (C-9), 150.0 (C-2' and C-6'), 
139.5 (C-4'), 138.6 (C-8), 131.0 (C-2), 121.9 (C-3' and 5'), 114.6 (C-4), 108.3 (C-3), 48.1 (C-6), 39.3 
(C-11), 33.4 (C-13), 21.0 (C-7), 16.0 (C-12); HRMS m/z (ESI+) [Found: 256.1440, C15H18N3O 
requires (M+H)+ 256.1444]; LCMS (MDAP) Rt = 0.7 min (Ana 5-95 in 5 min), m/z (ESI+) 256.15 
(M+H)+. 
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1-Ethyl-5-propyl-2-(4-pyridyl)-6,7-dihydropyrrolo[3,2-c]pyridin-4-one (127) 
 
1-Ethyl-2-(4-pyridyl)-6,7-dihydro-5H-pyrrolo[3,2-c]pyridin-4-one (121) (100 mg, 0.41 mmol) was 
dissolved in N,N-dimethylformamide (11.5 mL), flushed with nitrogen three times and cooled to 
0 °C. 60% sodium hydride (33 mg, 0.83 mmol) was added portion wise and the reaction was 
allowed to stir for 15 min at room temperature before being cooled to 0 °C again. 1M 1-
iodopropane (0.5 mL, 0.50 mmol) in tetrahydrofuran was added dropwise and the reaction was 
left to stir at room temperature overnight. LCMS indicated formation of product (m/z 284). The 
reaction mixture was concentrated under reduced pressure and saturated aqueous sodium 
hydrogen carbonate (20 mL) was added. The mixture was extracted three times using 2:1 
chloroform:propan-2-ol (4 × 25 mL). The combined organic phases were dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude was purified via flash column 
chromatography (5 g silica, dichloromethane:methanol 1:0 to 9:1) to give 1-ethyl-5-propyl-2-(4-
pyridyl)-6,7-dihydropyrrolo[3,2-c]pyridin-4-one (127) (38 mg, 31%) as a yellow solid. 
Rf 0.03 (9:1 dichloromethane:methanol); m.p. 139–140 °C; νmax (thin film)/cm-1 2962 (m, 
aliphatic C-H), 1710 (s, C=O), 1688 (s, C=C), 1644 (s, C=C), 1593 (s, aromatic C-C), 1473 (s, 
aliphatic C-H), 1220 (s, aliphatic C-N); 1H NMR (600 MHz, DMSO-d6) δ 8.55 (dd, J = 5.9, 1.6 Hz, 
2H, H-2' and H-6'), 7.41 (dd, J = 6.0, 1.6 Hz, 2H, H-3' and H-5'), 6.56 (s, 1H, H-3), 4.01 (q, J = 7.2 
Hz, 2H, H-11), 3.55 (t, J = 6.9 Hz, 2H, H-6), 3.32 (t, J = 6.6 Hz, 2H, H-14), 2.93 (t, J = 6.9 Hz, 2H, 
H-7), 1.49 (t, J = 7.3 Hz, 2H, H-13), 1.16 (t, J = 7.2 Hz, 3H, H-12), 0.83 (t, J = 7.4 Hz, 3H, H-15); 
13C NMR (151 MHz, DMSO-d6) δ 162.8 (C-4), 150.0 (C-2' and C-6'), 139.5 (C-4'), 138.5 (C-8), 131.0 
(C-2), 121.9 (C-3' and C-5'), 114.9 (C-9), 108.4 (C-3), 46.8 (C-13), 46.1 (C-6), 39.2 (C-12), 21.2 (C-7), 
20.6 (C-14), 16.0 (C-11), 11.3 (C-15); HRMS m/z (ESI+) [Found: 284.1758, C17H22N3O requires 
(M+H)+ 284.1757]; LCMS (MDAP) Rt = 1.8 min (Ana 5-95 over 5 minutes), m/z (ESI+) 284.00 
(M+H)+.  
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6-Phenyl-2-(4-pyridyl)-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one (139) 
 
6-Phenylpiperidine-2,4-dione (138) (202 mg, 1.07 mmol), 2-bromo-1-(4-pyridyl)ethanone 
hydrobromide (98) (300 mg, 1.07 mmol) and ammonium acetate (329 mg, 4.27 mmol) were 
stirred in ethanol (4.5 mL) at room temperature overnight. LCMS (MDAP) indicated product 
formation (m/z 290). The reaction mixture was concentrated under reduced pressure and 
saturated aqueous sodium hydrogen carbonate (30 mL) was added. The mixture was extracted 
three times with 2:1 chloroform:propan-2-ol (3 × 40 mL). The combined organic phases were 
dried over MgSO4, filtered and concentrated under reduced pressure to give a red oil (320 mg). 
The crude was purified via flash column chromatography (20 g silica, 
dichloromethane:methanol, 1:0 to 9:1) to give an off-white solid (102 mg). This was purified via 
SCX cartridge by elution with methanol and 2 M ammonia in methanol to give 6-phenyl-2-(4-
pyridyl)-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one (139) (74 mg, 23%) as a pale yellow solid. 
Rf 0.02 (9:1 dichloromethane:methanol); m.p. 259–260 °C; νmax (thin film)/cm-1 3388 (N-H, br), 
3226 (N-H, br), 3014 (aromatic C-H, w), 2979 (aliphatic C-H, w), 1690 (C=O, s), 1524 (aromatic 
C-H, s), 766 (N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 11.87 (s, 1H, H-1), 8.50–8.44 (m, 2H, H-2' 
and H-6'), 7.60–7.55 (m, 2H, H-3' and H-5'), 7.42 (d, J = 1.8 Hz, 1H, H-5), 7.38 (d, J = 7.7 Hz, 2H, 
H-12 and H-16), 7.34 (t, J = 7.6 Hz, 2H, H-13 and H-15), 7.26 (t, J = 7.2 Hz, 1H, H-14), 7.05 (d, J = 
2.4 Hz, 1H, H-3), 4.86 (td, J = 7.1, 2.0 Hz, 1H, H-6), 3.26 (dd, J = 16.2, 6.1 Hz, 1H, H-7), 2.98 (dd, 
J = 16.2, 7.2 Hz, 1H, H-7); 13C NMR (151 MHz, DMSO-d6) δ 164.8 (C-9), 149.9 (C-2' and C-6'), 142.9 
(C-11), 138.8 (C-4'), 137.2 (C-8), 128.7 (C-4), 128.3 (C-13 and C-15), 127.3 (C-14), 126.4 (C-12 and 
C-16), 117.5 (C-3' and C-5'), 115.5 (C-2), 106.4 (C-3), 54.9 (C-6), 30.2 (C-7); HRMS m/z (ESI+) 
[Found: 290.1295, C18H16N3O requires (M+H)+ 290.1288]; LCMS (MDAP) Rt = 3.4 min (Ana 30–90 
in 20 min), m/z (ESI+) 290.1 (M+H)+.  
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6.1.3 Preparation of compounds described in Chapter 4 
N-Tert-Butylpyridine-4-carboxamide (152)106 
 
Isonicotinic acid (23) (5.00 g, 40.61 mmol) in dichloromethane (150 mL) was cooled to 0 °C. 
Triethylamine (9.06 mL, 64.98 mmol) was added dropwise maintaining the temperature 
between 0–5 ºC. Ethyl chloroformate (151) (4.60 mL, 48.74 mmol) was added dropwise 
maintaining the temperature between 0–5 ºC and then the reaction was stirred for 30 minutes 
at 0–5 ºC. Tert-butylamine (5.12 mL, 48.74 mmol) was added dropwise to the reaction 
maintaining the temperature between 0-5 ºC and then the reaction was allowed to warm up to 
room temperature and stirred for 3.5 hours. Water (50 mL) was added to the reaction mixture 
and the two resulting phases were separated. The organic phase was washed with 1 M aqueous 
hydrochloric acid (50 mL) and basified to pH 9 using 3.75 M aqueous sodium hydroxide (15 mL). 
The aqueous phase was washed twice with ethyl acetate (2 × 50 mL). The organic phases were 
combined, dried over MgSO4, filtered and concentrated under reduced pressure to give N-tert-
butylpyridine-4-carboxamide (152) (5.18 g, 68%) as an off-white solid. 
1H NMR (500 MHz, CDCl3) δ 8.70 (d, J = 5.4 Hz, 2H, H-3 and H-5), 7.55 (d, J = 5.7 Hz, 2H, H-2 and 
H-6), 6.09 (s, 1H, H-9), 1.47 (s, 9H, 9 × H-11); LCMS (LCQ) Rt = 0.8 min (7 min method), m/z (APCI+) 
179.1 (M+H)+. 
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N-Tert-Butyl-3-methyl-pyridine-4-carboxamide (156)106 
 
Tetrahydrofuran (250 mL) was added to N-tert-butylpyridine-4-carboxamide (152) (9.5 g, 
53.3 mmol). The suspension was cooled down to -75 °C. 2 M n-butyl lithium (47 mL, 117.26 
mmol) in hexanes was added maintaining temperature below -60 °C and the reaction was stirred 
for 30 min. Iodomethane (3.65 mL, 58.63 mmol) was added maintaining temperature below -
60 °C. The reaction was stirred at -75 °C for 1 h. It was then allowed to warm up to room 
temperature and stirred overnight. The reaction mixture was quenched by addition of aqueous 
saturated ammonium chloride (70 mL). The reaction mixture was diluted with water (130 mL) 
and ethyl acetate (130 mL). The organic layer was separated, and the aqueous layer was 
extracted with ethyl acetate (130 mL). The combined organic phases were washed with brine 
(130 mL), dried over MgSO4, filtered and concentrated under reduced pressure to give a pale 
orange crude solid (11.89 g). The residue was purified in two batches (ca. 5–6 g per column) 
using flash column chromatography (2 × 100 g silica, petroleum ether:ethyl acetate 20:80 to 
100:00) and combined to give a 1:10 mixture (by 1H NMR) of starting material and N-tert-butyl-
3-methyl-pyridine-4-carboxamide (156) (9.90 g, 87%) as a white solid. The product was taken 
forward without further purification. 
1H NMR (500 MHz, CDCl3) δ 8.38–8.30 (m, 2H, H-2 and H-6), 7.11 (d, J = 3.9 Hz, 1H, H-5), 5.97 (s, 
1H, H-9), 2.33 (s, 3H, 3 × H-12), 1.43 (s, 9H, 9 × H-11); LCMS (MDAP) Rt = 8.5 min (Ana 5-95, 
20 min method), m/z (ESI+) 193.1 (M+H)+. 
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N-Tert-Butyl-3-[2-oxo-2-(4-pyridyl)ethyl]pyridine-4-carboxamide (162)106 
 
2 M n-butyl lithium (16 mL, 38.78 mmol) in hexanes was added to N-tert-butyl-3-methyl-
pyridine-4-carboxamide (156) (3.55 g, 18.46 mmol) in THF (85 mL) at -45 °C (CO2/acetonitrile 
bath). The resulting red reaction mixture was stirred for 1 h at -45 °C. Ethyl isonicotinate (161) 
(3.10 mL, 20.31 mmol) was added in one portion. The reaction mixture was stirred at room 
temperature for 2 h, upon which a mustard yellow suspension formed. TLC showed consumption 
of starting material (100% ethyl acetate, UV). Saturated aqueous ammonium chloride solution 
(50 mL) was added to quench the reaction. Ethyl acetate (85 mL) was added and a white solid 
precipitated out (thought to be ammonium chloride) into the separation funnel. Water (40 mL) 
was added which dissolved this solid. The organic and aqueous phases were separated, and the 
aqueous layer was washed three times with ethyl acetate (3 × 85 mL). The combined organic 
phases were dried over MgSO4, filtered and concentrated under reduced pressure to give a 
yellow crude oil (7.05 g). The crude was purified by flash column chromatography (100 g silica, 
ethyl acetate:methanol, 100:0 to 90:10) to give N-tert-butyl-3-[2-oxo-2-(4-pyridyl)ethyl]pyr-
idine-4-carboxamide (162) (2.12g, 37%) as a pale yellow foam. 
1H NMR (500 MHz, DMSO-d6) δ 8.84 (m, 2H, H-2'and H-6'), 8.59–8.48 (m, 2H, H-5 and H-2), 8.14 
(s, 1H, H-9), 7.91–7.83 (m, 2H, H-3'and H-5'), 7.39 (d, J = 4.8 Hz, 1H, H-6), 4.64 (s, 2H, H-12), 1.21 
(s, 9H, 9 × H-11); LCMS (LCQ) Rt = 0.8 min (4 min method), m/z (APCI+) 298.1 (M+H)+. 
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3-(4-Pyridyl)pyrano[4,3-c]pyridin-1-one (166)106 
 
N-Tert-Butyl-3-[2-oxo-2-(4-pyridyl)ethyl]pyridine-4-carboxamide (162) (1.82 g, 6.12 mmol) 
in N,N-dimethylformamide (3.5 mL) was heated in a microwave at  220 °C for 2 × 10 minutes. 
Upon cooling, a solid precipitated out of the clear brown solution. 3-(4-Pyridyl)pyrano[4,3-
c]pyridin-1-one (166) (695 mg, 48%) was isolated by filtration as a pale pink crystalline solid. 
1H NMR (500 MHz, DMSO-d6) δ 9.09 (s, 1H, H-10), 8.83 (d, J = 5.1 Hz, 1H, H-2), 8.78–8.70 (m, 2H, 
H-2' and H-6'), 8.03 (d, J = 5.1 Hz, 1H, H-3), 7.91–7.74 (m, 3H, H-8, H-3'and H-5'); LCMS (LCQ) 
Rt = 0.7 min (4 min method), m/z (APCI+) 225.3 (M+H)+.  
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3-Hydroxy-3-(4-pyridyl)-2,4-dihydro-2,6-naphthyridin-1-one (167)106 
 
3-(4-Pyridyl)pyrano[4,3-c]pyridin-1-one (166) (666 mg, 2.97 mmol) in 2 M ammonia (20 mL, 40 
mmol) isopropanol solution was stirred for 2 h at room temperature during which a pale yellow 
suspension formed. The reaction mixture was concentrated under reduced pressure to give 3-
hydroxy-3-(4-pyridyl)-2,4-dihydro-2,6-naphthyridin-1-one (167) (626 mg, 83%) as a white solid. 
1H NMR (500 MHz, DMSO-d6) δ 9.16 (s, 1H, H-6), 8.66 (d, J = 4.9 Hz, 1H, H-2), 8.64–8.58 (m, 3H, 
H-2', H-6' and H-10), 7.79 (d, J = 4.9 Hz, 1H, H-3), 7.60 (d, J = 5.9 Hz, 2H, H-3'and H-5'), 6.77 (s, 
1H, H-12), 3.37, 3.13 (ABq, J = 12.5Hz, 2H, 2 × H-8); LCMS (LCQ) Rt = 0.6 min (4 min method), m/z 
(APCI+) 242.2 (M+H)+.  
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1-Bromo-3-(4-pyridyl)-2,6-naphthyridine (173)106 
 
3-(4-Pyridyl)-dihydro-2,6-naphthyridin-1-one (167) (57 mg, 0.26 mmol) and phosphorus(V) 
oxybromide (183.0 mg, 0.64 mmol) were mixed and heated to 130 °C for 6 h. A yellow solid 
formed. The reaction mixture was cooled to room temperature and ice was added to quench 
the reaction. An orange solid formed. The pH was adjusted to pH 8–9 with saturated aqueous 
Na2CO3. The resulting precipitate was filtered, washed with water and dried in a vacuum oven 
to give 1-bromo-3-(4-pyridyl)-2,6-naphthyridine (173) (56 mg, 61%) as a brown solid. As per 
procedure, the crude was not further purified before the next reaction step. 
1H NMR (500 MHz, DMSO-d6) δ 9.55 (s, 1H, H-10), 8.95 (s, 1H, H-8), 8.90 (d, J = 5.8 Hz, 1H, H-2), 
8.79 (d, J = 5.9Hz, 2H, H-2'and H-6'), 8.16–8.13 (m, 2H, H-3'and H-5'), 8.06 (d, J = 5.8 Hz, 1H, H-3); 
LCMS (LCQ) Rt = 0.6 min (4 min method), m/z (APCI+) 286.3 [79Br] and 288.2 [81Br] (M+H)+. 
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1-Chloro-3-(4-pyridyl)-2,6-naphthyridine (174)106 
 
3-Hydroxy-3-(4-pyridyl)-2,4-dihydro-2,6-naphthyridin-1-one (167) (1.55 g, 6.42 mmol) and 
phosphorus(V) oxychloride (14 mL, 149.8 mmol) were mixed and heated to 80 °C for 24 h. A 
green-blue suspension formed. LCMS showed a mixture of mass ions corresponding to the 
product and the hydrolysed by-product. The reaction was heated for a further 24 h at 80 °C. The 
reaction mixture was concentrated under reduced pressure and warm water (50 mL at 30 °C) 
was added. A green/blue solution formed. NaHCO3 was added which caused an effervescent 
reaction and a blue-grey gum formed. Water (100 mL) and dichloromethane (150 mL) were 
added and the resulting mixture was filtered. The two phases of the filtrate were separated, and 
the aqueous phase was extracted with more dichloromethane (50 mL). The gum that was 
isolated by filtration was stirred in dichloromethane (50 mL) for 10 minutes and then filtered. 
The combined organic phases were dried over MgSO4, filtered and concentrated under reduced 
pressure to give an off-white solid crude (548 mg). The crude product was purified by flash 
column chromatography (12 g silica, 100:0 to 95:5) to give 1-chloro-3-(4-pyridyl)-2,6-
naphthyridine (174) (484 mg, 30%) as an off-white solid. 
1H NMR (500 MHz, DMSO-d6) δ 9.54 (s, 1H, H-6), 8.89–8.83 (m, 2H, H-4 and H-8), 8.78–8.71 (m, 
2H, H-2’ and H-6’), 8.13–8.05 (m, 3H, H-9, H-3’ and H-5’). LCMS (LCQ) Rt = 0.6 min (4 min 
method), m/z (ESI+) 242.4 [35Cl]  and 244.6 [37Cl] (M+H)+.  
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Tert-Butyl-N-[2-[[3-(4-pyridyl)-2,6-naphthyridin-1-yl]amino]ethyl]carbamate (183)106 
 
1-Bromo-3-(4-pyridyl)-2,6-naphthyridine (173) (45 mg, 0.16 mmol), tert-butyl-N-(2-aminoethyl)-
carbamate (182) (37.8 mg, 0.24 mmol) and 2 M sodium hydroxide aqueous solution (1.1 mL, 
2.25 mmol) in 1,4-dioxane (7 mL) was heated to 110 °C for 16 h. The reaction mixture was 
diluted with water (10 mL) and extracted with ethyl acetate (2 × 10 mL). The combined organic 
phases were dried over MgSO4, filtered and concentrated under reduced pressure to give a 
yellow oil crude (198 mg). The crude was purified by flash column chromatography (4 g silica, 
ethyl acetate:methanol, 100:0 to 90:10) to give tert-butyl-N-[2-[[3-(4-pyridyl)-2,6-naphthyridin-
1-yl]amino]ethyl]carbamate (183) (11 mg, 18%) as a pale yellow solid. 
1H NMR (500 MHz, DMSO-d6) δ 9.22 (s, 1H, H-8), 8.69–8.64 (d, 2H, H-3' and H-5'), 8.62 (d, 
J  = 5.7 Hz, 1H, H-3), 8.17 (d, J = 4.9 Hz, 2H, H-2'and H-6'), 8.10 (d, J = 5.8 Hz, 1H, H-2), 7.97 (t, J = 
4.9 Hz, 1H, H-14), 7.87 (s, 1H, H-10), 7.06 (t, J = 5.9 Hz, 1H, H-12), 3.66 (q, J = 5.8 Hz, 4H, 2 × H-12 
and 2 × H-13), 1.37 (s, 9H, 9 × H-19); LCMS (LCQ) Rt = 0.8 min (4 min method), m/z (APCI+) 365.8 
(M+H)+ and 310.2 (M+H-t-Bu)+. 
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2-[[3-(4-Pyridyl)-2,6-naphthyridin-1-yl]amino]ethylammonium;2,2,2-trifluoroacetate 
(12)106,161,176  
 
Tert-Butyl-N-[2-[[3-(4-pyridyl)-2,6-naphthyridin-1-yl]amino]ethyl]carbamate (183) (11 mg, 
0.03 mmol) was stirred in trifluoroacetic acid (0.1 mL, 1.31 mmol) and dichloromethane 
(2.75 mL) for 10 min at 0 °C then at room temperature for 4 h. The reaction mixture was 
concentrated under reduced pressure to give 2-[[3-(4-pyridyl)-2,6-naphthyridin-1-
yl]amino]ethylammonium;2,2,2-trifluoroacetate (12) (12 mg, 95%) as a yellow solid. 
Rf 0.55 (1:9 methanol:dichloromethane); 180–m.p. 183 °C; νmax (thin film)/cm-1 2922 (C-H alkane, 
m), 2852 (C-H alkane, m), 1673 (C=C, s), 1634 (N-H, s), 1585 (N-H, m), 1540 (C-C, m), 1499 (C-H, 
m), 1178 (C-N, s), 1123 (C-N, s), 796 (N-H, s); 1H NMR (500 MHz, DMSO-d6) δ 9.30 (s, 1H, H-10), 
8.85 (s, 2H, H-2'and H-6'), 8.73 (d, J = 5.8Hz, 1H, H-2), 8.47 (d, J = 3.6Hz, 2H, H-3'and H-5'), 8.19–
8.09 (m, 2H, H-3 and H-8), 7.89 (s, 2H, H-14), 3.93–3.85 (m, 2H, H-12), 3.26–3.17 (m, 2H, 2 × 
H-13); 13C NMR (151 MHz, DMSO-d6) δ 154.4 (C-1), 151.7 (C-6), 150.2 (C-2' and C-6'), 146.7 (C-3), 
145.9 (C-4'), 144.6 (C-9), 131.9 (C-10), 121.3 (C-5), 120.5 (C-3' and C-5'), 116.1 (C-8), 105.3 (C-4), 
38.9 (C-12), 38.0 (C-13); HRMS m/z (ESI+) [Found: 266.1397, C15H15N5 requires (M+H)+ 266.1400]; 
LCMS (LCQ) Rt = 0.6 min (4 method), m/z (APCI+) 266.2 (M+H)+. 
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Tert-Butyl 4-[3-(4-pyridyl)-2,6-naphthyridin-1-yl]piperazine-1-carboxylate (186)106 
 
1-Boc-Piperazine (185) (154 mg, 0.83 mmol) and potassium carbonate (109 mg, 0.79 mmol) 
were added to a solution of 1-chloro-3-(4-pyridyl)-2,6-naphthyridine (174) (100 mg, 0.39 mmol) 
in N,N-dimethylformamide (1 mL) at room temperature. The reaction mixture was heated 
to 90 °C and stirred for 5 h. LCQ (LCMS) confirmed formation of the product  (m/z 392). The 
reaction mixture was cooled to room temperature. Ethyl acetate (5 mL) and water (5 mL) were 
added and the two resulting phases were separated. The aqueous layer was extracted three 
times with ethyl acetate (3 × 5 mL) and the combined organic phases were dried over MgSO4, 
filtered and concentrated under reduced pressure to give a solid crude residue (136 mg). The 
crude was purified by flash column chromatography (11 g silica, petroleum ether:ethyl acetate, 
1:0 to 0:1) to give tert-butyl 4-[3-(4-pyridyl)-2,6-naphthyridin-1-yl]piperazine-1-carboxylate 
(186) (97 mg, 60%) as an off-white solid. 
1H NMR (500 MHz, DMSO-d6) δ 9.40 (s, 1H, H-6), 8.72 (d, J = 5.1 Hz, 2H, H-2' and H-6'), 8.67 (d, 
J = 5.7 Hz, 1H, H-8), 8.35 (s, 1H, H-4), 8.16 (d, J = 5.1 Hz, 2H, H-3'and H-5'), 7.95 (d, J = 5.8 Hz, 1H, 
H-9), 3.63 (s, 4H, H-13 and H-15), 3.50 (s, 4H, H-12 and H-16), 1.44 (s, 9H, H-21).); LCMS (LCQ) 
Rt = 0.8 min (4 min method), m/z (APCI)+ 392.1 (M+H)+, 336.1 (M+H-t-Bu)+, 292.2 (M+H-Boc)+. 
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1-Piperazin-4-ium-1-yl-3-(4-pyridyl)-2,6-naphthyridine; 2,2,2-trifluoroacetate (187)106,161 
 
tert-Butyl 4-[3-(4-pyridyl)-2,6-naphthyridin-1-yl]piperazine-1-carboxylate (186) (102 mg, 0.26 
mmol) was dissolved in TFA (1.0 mL, 13.06 mmol) and dichloromethane (1 mL) and stirred for 1 
h at room temperature. The reaction mixture was concentrated under reduced pressure to give 
a crude yellow oil (239 mg).  On addition of methanol (1 mL), a precipitate formed which was 
found to be 1-piperazin-4-ium-1-yl-3-(4-pyridyl)-2,6-naphthyridine; 2,2,2-trifluoroacetate (187) 
(17 mg, 15%) as a yellow solid. 
Rf 0.73 (9:1 ethyl acetate:methanol); m.p. 253–254 °C (from methanol); vmax (thin 
film)/cm-1 3009 (N-H, br), 2491 (C=C, w), 1634 (C=O, s), 1505 (C-H, m), 1175 (C-N, s), 1120 (C-N, 
s); 1H NMR (500 MHz, DMSO-d6) δ 9.46 (s, 1H, H-6), 9.09 (s, 1H, H-14), 8.88 (d, J = 5.4 Hz, 2H, H-
2’ and H-6’), 8.74 (d, J = 5.7 Hz, 1H, H-9), 8.58 (s, 1H, H-4), 8.43 (d, J = 5.0 Hz, 2H, H-3’ and H-5’), 
8.06 (d, J = 5.7 Hz, 1H, H-8), 3.75 (s, 4H, H-12), 3.43 (s, 4H, H-13); 13C NMR (126 MHz, DMSO-d6) 
δ 159.0 (C-1), 153.4 (C-6), 147.7 (C-2'and C-6'), 145.9 (C-9), 145.1 (C-4'), 133.3 (C-10), 124.0 (C-
5), 122.0 (C-3'and C-5'), 118.2 (C-8), 113.4 (C-4), 47.7 (C-12 and 16), 43.2 (C-13 and 15).; HRMS 
m/z (ESI+) [Found: 292.1548, C17H17N5 requires (M+H)+ 292.1557]; LCMS (MDAP) Rt = 4.5 min (30 
min method), m/z (ESI+) 292.2 (M+H)+. 
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1-(1-Piperidyl)-3-(4-pyridyl)-2,6-naphthyridine (189) 
 
Triethylamine (0.09 mL, 0.63 mmol) was added to 1-chloro-3-(4-pyridyl)-2,6-naphthyridine (174) 
(50 mg, 0.20 mmol) in ethanol (0.60 mL) at room temperature. The reaction vessel was flushed 
with nitrogen gas, sealed and then piperidine (0.02 mL, 0.25 mmol) was added at room 
temperature. The reaction was heated to 80 °C and stirred overnight. LCMS (LCQ) confirmed 
formation of the product (m/z 291). The resulting red solution was concentrated under reduced 
pressure to give an orange solid (86 mg). Dichloromethane (10 mL) and water (10 mL) were 
added and the phases separated. The aqueous layer was extracted three times with 
dichloromethane (3 × 10 mL). The organic phases were combined, dried over MgSO4, filtered 
and concentrated under reduced pressure to give a dark red heterogeneous solid (53 mg). 1H 
NMR showed a mixture of product and unreacted piperidine so the solid was dissolved in 
methanol (10 mL) and concentrated under reduced pressure. Toluene (10 mL) was added and 
the solution was concentrated under reduced pressure. The co-evaporation with toluene (10 
mL) was repeated resulting in an orange solid (43 mg). Dichloromethane (5 mL) and saturated 
aqueous NaHCO3 solution (5 mL) were added and the resulting phases separated. The organic 
phase was dried over MgSO4, filtered and concentrated under reduced pressure. The crude was 
purified by flash column chromatography (12 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) 
to give  1-(1-piperidyl)-3-(4-pyridyl)-2,6-naphthyridine (189) (12 mg, 20%) as an off-white solid. 
Rf 0.70 (9:1 ethyl acetate:methanol); m.p. 150–151 °C; νmax (thin film)/cm-1 3029 (aromatic C-H, 
w), 2936 (aliphatic C-H, m), 2853 (aliphatic C-H, w), 2820 (aliphatic C-H, w), 1600 (aromatic C-C, 
m), 1558 (aromatic C-C, m), 1484 (aliphatic C-H, m), 1416 (aliphatic C-H, s), 1255 (aliphatic C-N, 
m), 680 (alkene C-H, s); 1H NMR (500 MHz, DMSO-d6) δ 9.35 (s, 1H, H-6), 8.70 (d, J = 4.6 Hz, 2H, 
H-2' and H-6'), 8.64 (d, J = 5.4 Hz, 1H, H-8), 8.24 (s, 1H, H-4), 8.12 (d, J = 4.7 Hz, 2H, H-3' and H-5'), 
7.83 (d, J = 5.6 Hz, 1H, H-9), 3.48 (s, 4H, H-12 and H-16), 1.78 (s, 4H, H-13 and 15), 1.72–1.61 (m, 
2H, H-14); 13C NMR (126 MHz, DMSO-d6) δ 159. (C-1), 152.6 (C-6), 150.3 (C-2' and C-6'), 146.0 
(C-3), 145.5 (C-4'), 144.5 (C-8), 133.1 (C-5), 123.3 (C-10), 120.4 (C-3' and C-5'), 117.8 (C-9), 109.8 
(C-4), 51.5 (C-12), 25.5 (C-13), 24.2 (C-14); HRMS m/z (ESI+) [Found: 291.1614, C18H19N4 requires 
(M+H)+ 291.1604]; LCMS (LCQ) Rt = 1.2 min (4 min method), m/z (ESI+) 291.3 (M+H)+. 
190 
 
N',N'-Dimethyl-N-[3-(4-pyridyl)-2,6-naphthyridin-1-yl]ethane-1,2-diamine (191) 
 
Triethylamine (0.28 mL, 2.01 mmol) and N,N-dimethylethylenediamine (190) (0.09 mL, 
0.79 mmol) were added to 1-chloro-3-(4-pyridyl)-2,6-naphthyridine (174) (160 mg, 0.63 mmol) 
in ethanol (1 mL) at room temperature. The reaction was heated to 120 °C and left to stir 
overnight. TLC and LCMS (LCQ) showed full consumption of starting material. The reaction 
mixture was concentrated under reduced pressure and toluene (10 mL) was added before the 
reaction mixture was again concentrated under reduced pressure. This was repeated with a 
second portion of toluene (10 mL) to aid removal of excess N,N-dimethylethylenediamine 
(190). Dichloromethane (10 mL) and water (10 mL) were added to the residue and the phases 
separated. The aqueous phase was washed three times with dichloromethane (3 × 10 mL). The 
combined organic phases were dried over MgSO4, filtered and concentrated under reduced 
pressure to give a crude residue (204 mg). 1H NMR of the crude showed the product still 
contained excess amine. 1 M aqueous hydrochloric acid (5 mL) and ethyl acetate (5 mL) were 
added to the crude and the resulting phases separated. The pH was adjusted to pH 10 using 
saturated NaCO3 aqueous solution (ca. 35 mL). Ethyl acetate (40 mL) was added and the resulting 
phases were separated. The organic phase was dried over MgSO4, filtered and concentrated 
under reduced pressure to give N',N'-dimethyl-N-[3-(4-pyridyl)-2,6-naphthyridin-1-yl]ethane-
1,2-diamine (191) (119 mg, 61%) as an off-white solid. 
Rf 0.72 (9:1 ethyl acetate:methanol); m.p. 244–246 °C; νmax (thin film)/cm-1 3256 (N-H, m), 3066 
(aromatic C-H, w), 2977 (aliphatic C-H, w), 2766 (C-H, m), 1603 (N-H, m), 1543 (aromatic C-C, s), 
684 (N-H, s); 1H NMR (500 MHz, DMSO-d6) δ 9.21 (s, 1H, H-6), 8.68 (d, J = 5.9 Hz, 2H, H-2' and 
H-6'), 8.61 (d, J = 5.7 Hz, 1H, H-8), 8.15–8.07 (m, 3H, H-9, H-3' and H-5'), 7.87 (t, J = 5.2 Hz, 1H, 
H-11), 7.84 (s, 1H, H-4), 3.73 (q, J = 6.5 Hz, 2H, H-12), 2.60 (t, J = 6.9 Hz, 2H, H-13), 2.24 (s, 6H, 
H-15); 13C NMR (126 MHz, DMSO-d6) δ 154.3 (C-1), 151.7 (C-6), 150.2 (C-2' ad C-6'), 146.9 (C-5), 
146.2 (C-4'), 144.5 (C-8), 132.0 (C-3), 121.1 (C-10), 120.4 (C-3' and C-5'), 115.8 (C-9), 104.5 (C-4), 
57.7 (C-13), 45.5 (C-15). C-12 peak under DMSO peak. HRMS m/z (ESI+) [Found: 294.1722, 
C17H20N5 requires (M+H)+ 294.1713]; LCMS (LCQ) Rt = 0.4 min (4 min method), m/z (ESI+) 294.1 
(M+H)+.  
191 
 
N-Methyl-3-(4-pyridyl)-2,6-naphthyridin-1-amine (193) 
 
Methylamine (0.16 mL, 0.31 mmol) and triethylamine (0.14 mL, 1.01 mmol) were added to 1-
chloro-3-(4-pyridyl)-2,6-naphthyridine (174) (80 mg, 0.31 mmol) in ethanol (1 mL) at room 
temperature. The reaction was heated to 120 °C and left to stir overnight. After 24 h TLC and 
LCMS (LCQ) showed a mixture of starting material and product so additional portions of 
methylamine (0.16 mL, 0.31 mmol) and triethylamine (0.14 mL, 1.01 mmol) were added. The 
reaction was left to stir for an additional 24 h at 120 °C, after which TLC and LCMS (LCQ) 
(m/z 237) confirmed complete conversion. The reaction mixture was concentrated under 
reduced pressure and dichloromethane (10 mL) and water (10 mL) were added. A yellow 
suspension formed. The mixture was concentrated under reduced pressure to remove the 
dichloromethane and ethyl acetate (10 mL) was added but again, the solid did not fully dissolve. 
The mixture was filtered, and the isolated yellow solid was found to be N-methyl-3-(4-pyridyl)-
2,6-naphthyridin-1-amine (193) (30 mg, 38%). 
Rf 0.65 (9:1 ethyl acetate:methanol); m.p. 260–261 °C; νmax (thin film)/cm-1 3316 (N-H, b), 2937 
(aliphatic C-H, m), 1588 (N-H, s), 683 (C-H, s); 1H NMR (500 MHz, DMSO-d6) δ 9.21 (s, 1H, H-6), 
8.68 (d, J = 4.5 Hz, 2H, H-2' and H-6'), 8.61 (d, J = 5.5 Hz, 1H, H-6), 8.14 (d, J = 4.6 Hz, 2H, H-3' and 
H-5'), 8.08 (d, J = 5.6 Hz, 1H, H-8), 8.00–7.93 (m, 1H, H-11), 7.84 (s, 1H, H-4), 3.11 (d, J = 3.5 Hz, 
3H, H-12); 13C NMR (126 MHz, DMSO-d6) δ 155.3 (C-1), 152.0 (C-6), 150.5 (C-2' and C-6'), 147.4 
(C-4'), 146.7 (C-3), 145.0 (C-8), 132.3 (C-5), 121.7 (C-10), 120.9 (C-3' and C-5'), 116.1 (C-9), 104.8 
(C-4), 28.4 (C-12); HRMS m/z (ESI+) [Found: 237.1141, C14H13N4 requires (M+H)+ 237.1135]; LCMS 
(LCQ) Rt = 0.5 min (4 min method), m/z (ESI+) 237.3 (M+H)+.177 
  
192 
 
Tert-Butyl N-[2-[(2-chloroquinazolin-4-yl)amino]ethyl]carbamate (198)  
 
2,4-Dichloroquinazoline (194) (1 g, 5.02 mmol), triethylamine (1.1 mL, 7.54 mmol) and neat tert-
butyl N-(2-aminoethyl)carbamate (2.4 mL, 15.07 mmol) were stirred in tetrahydrofuran (10 mL) 
at 0 °C for 1 h in a water/ice bath. LCMS confirmed starting material consumption and formation 
of product (m/z 323, 325, 267 and 269). The reaction mixture was concentrated to give a yellow 
oil (3.99 g). The residue was purified via flash chromatography (80 g silica, petroleum ether:ethyl 
acetate, 1:0 to 0:1) to give tert-butyl N-[2-[(2-chloroquinazolin-4-yl)amino]ethyl]carbamate 
(198) (1.50 g, 88%) as a clear colourless oil. 
1H NMR (600 MHz, DMSO-d6) δ 8.77–8.68 (m, 1H, H-14), 8.23 (d, J = 8.5 Hz, 1H, H-9), 7.79 (t, J = 
7.9 Hz, 1H, H-7), 7.61 (d, J = 8.6 Hz, 1H, H-6), 7.53 (t, J = 7.5 Hz, 1H, H-8), 7.03–6.94 (m, 1H, H-11), 
3.58–3.51 (m, 2H, H-13), 3.24 (q, J = 6.0 Hz, 2H, H-12), 1.35 (s, 9H, H-19); LCMS (LCQ) Rt = 2.5 min 
(4 min method), m/z (ESI+) 322.96 [35Cl], 324.96 [37Cl] (M+H)+, 267.1 [35Cl] and 269.1 [37Cl] (M-t-
Bu+H)+. 
  
193 
 
4-(2-Chloroquinazolin-4-yl)piperazine-1-carboxylate (199)178–180  
 
2,4-Dichloroquinazoline (194) (400 mg, 2.01 mmol), triethylamine (0.42 mL, 3.01 mmol) 
and neat 1-boc-piperazine (185) (1.12 g, 6.03 mmol) were stirred in tetrahydrofuran (4 mL) 
at 0 °C for 1 h in a water/ice bath. LCMS confirmed starting material consumption and formation 
of product (m/z 348, 350). The reaction mixture was concentrated to give a white solid (1.77 g). 
The residue was purified via flash chromatography (40 g silica, petroleum ether:ethyl acetate 
1:0 to 0:1) to give tert-butyl 4-(2-chloroquinazolin-4-yl)piperazine-1-carboxylate (199) (637 mg, 
86%) as a clear colourless oil which crystallised upon standing to form a white solid. 
1H NMR (600 MHz, DMSO-d6) δ 8.07 (d, J = 8.3 Hz, 1H, H-9), 7.84 (t, J = 7.6 Hz, 1H, H-7), 7.72 (d, 
J = 8.4 Hz, 1H, H-6), 7.54 (t, J = 7.7 Hz, 1H, H-8), 3.87–3.81 (m, 4H, H-13 and H-15), 3.57 (s, 4H, 
H-12 and H-16), 1.44 (s, 9H, H-21); LCMS (LCQ) Rt = 2.47 min (4 min method), m/z (ESI+) 349.0 
(M+H)+, 293.1 (M+H-t-Bu)+ and 249.2 (M+H-Boc)+. 
  
194 
 
2-Chloro-4-(1-piperidyl)quinazoline (200)181–185  
 
2,4-Dichloroquinazoline (194) (400 mg, 2.01 mmol), triethylamine (0.42 mL, 3.01 mmol) 
and neat piperidine (188) (0.6 mL, 6.03 mmol) were stirred in tetrahydrofuran (4 mL) at 0 °C for 
1 h in a water/ice bath. LCMS confirmed starting material consumption and formation of product 
(m/z 248, 250). The reaction mixture was concentrated to give a yellow oil (775 mg). The residue 
was purified via flash chromatography (40 g silica, petroleum ether:ethyl acetate 1:0 to 0:1) to 
give a mixture of the product and the bis-substituted product. The mixed fractions containing 
the product were combined, concentrated and re-purified by flash column chromatography 
(12 g silica, petroleum ether:ethyl acetate 1:0 to 0:1) to give 2-chloro-4-(1-piperidyl)quinazoline 
(200) (247 mg, 47%) as a white solid. 
1H NMR (600 MHz, DMSO-d6) δ 7.97 (d, J = 8.3 Hz, 1H, H-9), 7.81 (t, J = 7.5 Hz, 1H, H-7), 7.69 (d, 
J = 8.3 Hz, 1H, H-6), 7.52 (t, J = 7.9 Hz, 1H, H-8), 3.78 (s, 4H, H-12 and H-16), 1.71 (s, 6H, H-13, 
H-14 and H-15); LCMS (LCQ) Rt = 3.2 min (4 min method), m/z (ESI+) 248.3 [35Cl] and 250.3 [37Cl] 
(M+H)+. 
  
195 
 
N-(2-Chloroquinazolin-4-yl)-N',N'-dimethyl-ethane-1,2-diamine (201)186–188 
 
2,4-Dichloroquinazoline (194) (100 mg, 0.50 mmol), 2M THF N,N-dimethylethylenediamine 
(190) (0.06 mL, 0.55 mmol) and  triethylamine (0.07 mL, 0.50 mmol) in ethanol (3.6 mL) were 
stirred at 0 °C for 1 h. LCMS confirmed formation of the product (m/z 250 and 252). The reaction 
mixture was diluted with water (5 mL) and extracted twice with ethyl acetate (2 × 5 mL). The 
combined organic phases were dried over MgSO4, filtered and concentrated under reduced 
pressure to give N-(2-chloroquinazolin-4-yl)-N',N'-dimethyl-ethane-1,2-diamine (201) (74 mg, 
56%) as an off-white solid. 
1H NMR (600 MHz, DMSO-d6) δ 8.67 (app. s, 1H, H-11), 8.24 (d, J = 8.2 Hz, 1H, H-9), 7.79 (t, J = 
7.7 Hz, 1H, H-7), 7.61 (d, J = 8.3 Hz, 1H, H-6), 7.53 (t, J = 7.5 Hz, 1H, H-8), 3.62 (q, J = 6.0 Hz, 2H, 
H-12), 2.54 (t, J = 6.5 Hz, 2H, H-13), 2.22 (s, 6H, H-15); LCMS (LCQ) Rt = 0.5 min (4 min method), 
m/z (ESI+) 251.1 [35Cl] and 253.0 [37Cl] (M+H)+. 
  
196 
 
2-Chloro-N-methyl-quinazolin-4-amine (202)189–197  
 
2,4-Dichloroquinazoline (194) (500 mg, 2.51 mmol), triethylamine (0.53 mL, 3.77 mmol) and 2 M 
methylamine in THF (0.71 mL, 7.54 mmol) were stirred in THF (25 mL) at 0 °C for 1 h in a 
water/ice bath. TLC and LCMS (LCQ) indicated product formation (m/z 194 and 196). The 
reaction mixture was concentrated under reduced pressure and purified via flash 
chromatography (5 g silica, petroleum ether:ethyl acetate 1:0 to 0:1) to give 2-chloro-N-methyl-
quinazolin-4-amine (202) (390 mg, 76%) as a white solid. 
1H NMR (600 MHz, DMSO-d6) δ 8.78 (s, 1H, H-11), 8.19 (d, J = 8.1 Hz, 1H, H-9), 7.78 (t, J = 8.2 Hz, 
1H, H-7), 7.61 (d, J = 8.4 Hz, 1H, H-6), 7.53 (t, J = 8.0 Hz, 1H, H-8), 3.00 (d, J = 4.5 Hz, 3H, H-12);  
LCMS (LCQ)  Rt = 1.25 min (4 min method), m/z (ESI+) 194.2 [35Cl] and 196.2 [37Cl] (M+H)+. 
  
197 
 
Tert-Butyl N-[2-[[2-(4-pyridyl)quinazolin-4-yl]amino]ethyl]carbamate (219)  
 
Pyridine-4-boronic acid hydrate (196) (36 mg, 0.29 mmol), tert-butyl N-[2-[(2-chloroquinazolin-
4-yl)amino]ethyl]carbamate (198) (100 mg, 0.29 mmol),  bis(triphenylphosphine)palladium(II) 
dichloride (10 mg, 0.01 mmol) and potassium carbonate (94 mg, 0.88 mmol) in 4:1 
acetonitrile:water (8 mL) were degassed under a flow of nitrogen and heated in a microwave 
reactor at 140 °C for 15 minutes. LCMS (LCQ) confirmed reaction completion (m/z 365, 332 and 
265). The reaction mixture was diluted with water (12.5 ml) and extracted twice with ethyl 
acetate (2 × 15 mL). The combined organic phases were dried over MgSO4, filtered and 
concentrated under reduced pressure to give a green oil (85 mg). The crude was purified via 
flash column chromatography (4 g silica, petroleum ether:ethyl acetate 1:0 to 0:1) to give tert-
butyl N-[2-[[2-(4-pyridyl)quinazolin-4-yl]amino]ethyl]-carbamate (219) (64 mg, 57%) as a 
colourless glass. 
Rf 0.25 (100% ethyl acetate); m.p. 152–154 °C; νmax (thin film)/cm-1 3217 (N-H, br), 2936 
(aliphatic C-H, m), 1708 (C=O, s), 1676 (C=C, s), 1607 (C=C, s), 764 (N-H, s); 1H NMR (600 M Hz, 
DMSO-d6) δ 8.72 (d, J = 5.3 Hz, 2H, H-2' and H-6'), 8.52–8.46 (m, 1H, H-14), 8.39 (d, J = 5.5 Hz, 
2H, H-3' and H-5'), 8.24 (d, J = 8.1 Hz, 1H, H-9), 7.82 (d, J = 3.4 Hz, 2H, H-8/7/6), 7.55 (dt, J = 7.2, 
3.8 Hz, 2H, H-6/7/8 and O=PPh3 impurity), 7.09–6.97 (m, 1H, H-11), 3.72 (q, J = 6.7, 6.0 Hz, 2H, 
H-13), 3.34 (d, J = 4.9 Hz, 2H, H-12), 1.35 (s, 9H, H-19). Triphenylphosphine impurity present; 
13C NMR (151 MHz, DMSO-d6) δ 160.1 (C-15), 157.5 (C-4'), 155.8 (C-1), 150.0 (C-2' and C-6'), 
149.6 (C-10), 145.9 (C-3), 133.0 (C-7), 128.0 (C-6), 126.1 (C-8), 122.8 (C-9), 121.9 (C-3' and C-5'), 
114.3 (C-5), 77.7 (C-18), 40.9 (C-13), 39.0 (C-12), 28.2 (C-19).; HRMS m/z (ESI+) [Found: 366.1932, 
C20H24N5O2 requires (M+H)+ 366.1925]; LCMS (LCQ) Rt = 0.83 min (4 min method), m/z (ESI+) 
365.96 (M+H)+, 310.10 (M+H-t-Bu)+ and 266.21 (M+H-Boc)+. 
  
198 
 
N'-[2-(4-pyridyl)quinazolin-4-yl]ethane-1,2-diamine (220)198 
 
Tert-Butyl N-[2-[[2-(4-pyridyl) quinazolin-4-yl]amino]ethyl]carbamate (219) (50 mg, 0.14 mmol) 
was stirred in trifluoro acetic acid (0.45 mL, 5.94 mmol) and dichloromethane (2.6 mL) for 10 min 
at 0 °C the at room temperature for 4 h. The reaction mixture was concentrated under reduced 
pressure then purified via SCX cartridge by elution of methanol then 2 M NH3 in methanol to 
give N'-[2-(4-pyridyl)quinazolin-4-yl]ethane-1,2-diamine (220) (30 mg, 77%) as a yellow solid. 
Rf 0 (9:1 dichloromethane:methanol); m.p. 197–200 °C; νmax (thin film)/cm-1 3284 (N-H, br), 2923 
(C-H aliphatic, br), 1683 (C=O, m), 1636 (C=C, m), 1560 (N-H, m), 1525 (C-C aromatic, m), 1126 
(C-N, s), 722 (N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.88 (d, J = 5.8 Hz, 2H, H-2' and H-6'), 8.75 
(s, 1H, H-11), 8.59 (d, J = 5.3 Hz, 2H, H-3' and H-5'), 8.28 (d, J = 8.6 Hz, 1H, H-9), 7.90 (d, J = 3.8 Hz, 
2H, H-6/7/8), 7.87 (s, 2H, H-14), 7.68–7.64 (m, 1H, H-8/7/6), 3.96 (app. q, J = 6.1 Hz, 2H, H-12), 
3.22 (app. q, J = 6.3 Hz, 2H, H-13); 13C NMR (151 MHz, DMSO-d6) δ 160.4 (C-1), 156.3 (C-3), 148.6 
(C-5), 148.1 (C-4'), 147.4 (C-2' and C-6'), 133.6 (C-7/6/8), 127.6 (C-8/7/6), 123.1 (C-3' and C-5'), 
123.0 (C-9), 114.4 (C-6/7/8), 38.4 (C-12), 38.1 (C-13); HRMS m/z (ESI+) [Found: 266.1385, 
C15H16N5 requires (M+H)+ 266.1400]; LCMS (LCQ) Rt = 0.38 min (4 min method), m/z (ESI+) 266.2 
(M+H)+. 
  
199 
 
Tert-Butyl 4-[2-(4-pyridyl)quinazolin-4-yl]piperazine-1-carboxylate (221)199  
 
Pyridine-4-boronic acid hydrate (196) (35 mg, 0.29 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (10 mg, 0.01 mmol),  sodium carbonate (91 mg, 0.86 mmol) and tert-butyl 4-(3-
chloro-1-isoquinolyl)piperazine-1-carboxylate (199) (100 mg, 0.29 mmol) in 4:1 
acetonitrile:water (8 mL) were degassed under a flow of nitrogen and heated in a microwave 
reactor at 140 °C for 15 minutes. LCMS confirmed reaction completion (m/z 365, 332 and 265). 
The reaction mixture was diluted with water (12.5 ml) and extracted twice with ethyl acetate 
(2 × 15 mL). The combined organic phases were dried over MgSO4, filtered and concentrated 
under reduced pressure to give a pale yellow solid (107 mg). The crude was purified via flash 
column chromatography (4 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl 
4-[2-(4-pyridyl)quinazolin-4-yl]piperazine-1-carboxylate (221) (27 mg, 23%) as an off-white solid. 
1H NMR (600 MHz, DMSO-d6) δ 8.76 (d, J = 4.4 Hz, 2H, H-2' and H-6'), 8.35 (d, J = 4.5 Hz, 2H, H-3' 
and H-5'), 8.10 (d, J = 8.1 Hz, 1H, H-9), 7.95 (d, J = 8.7 Hz, 1H, H-6), 7.88 (t, J = 7.7 Hz, 1H, H-7), 
7.60 (d, J = 7.7 Hz, 2H, H-8), 3.88 (s, 4H, H-13 and H-15), 3.62 (s, 4H, H-12 and H-16), 1.44 (s, 9H, 
H-21); LCMS (LCQ) Rt = 0.92 min (4 min method), m/z (ESI+) 392.1 (M+H)+, 336.1 (M+H-t-Bu)+ 
and 292.3 (M+H-Boc)+. 
  
200 
 
4-Piperazin-1-yl-2-(4-pyridyl)quinazoline (222)199  
 
Tert-Butyl 4-[2-(4-pyridyl)quinazolin-4-yl]piperazine-1-carboxylate (221) (15 mg, 0.04 mmol) 
was dissolved in dichloromethane (1.00 mL) and trifluoro acetic acid (0.3 mL, 3.92 mmol) at 0 °C. 
The reaction mixture was allowed to stir for 4 h at room temperature. LCMS confirmed removal 
of the Boc protecting group (m/z 292). The reaction mixture was concentrated under reduced 
pressure to give 4-piperazin-1-yl-2-(4-pyridyl)quinazoline (222) (16 mg, 99%) as a brown oil. 
Rf 0.08 (9:1 dichloromethane:methanol); m.p. 168–170 °C; νmax (thin film)/cm-1 3004 (C-H 
aromatic, br), 1673 (C=C, s), 1634 (C=C, m), 1567 (C-C aromatic, m), 1508 (C-C aromatic, m), 1431 
(C-H aliphatic, m), 1180 (C-N, s), 1117 (C-N, s), 720 (N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.92 
(s, 2H, H-14), 8.89 (d, J = 5.6 Hz, 2H, H-2' and H-6'), 8.59 (d, J = 5.1 Hz, 2H, H-3' and H-5'), 8.15 (d, 
J = 8.3 Hz, 1H, H-6), 8.01 (d, J = 8.6 Hz, 1H, H-9), 7.94 (t, J = 7.6 Hz, 1H, H-8), 7.66 (t, J = 7.5 Hz, 
1H, H-7), 4.08–3.99 (m, 4H, H-12 and H-16), 3.43–3.31 (m, 4H, H-13 and H-15); 13C NMR 
(151 MHz, DMSO-d6) δ 164.2 (C-1), 155.6 (C-3), 151.6 (C-10), 148.4 (C-2' and C-6'), 147.0 (C-3), 
133.7 (C-8), 128.7 (C-9), 127.0 (C-7), 125.4 (C-6), 122.6 (C-3' and C-5'), 115.2 (C-5), 46.2 (C-12 
and C-16), 42.6 (C-13 and C-15); HRMS m/z (ESI+) [Found: 292.1550, C17H18N5 requires (M+H)+ 
292.1557]; LCMS (LCQ) Rt = 0.4 min (4 min method), m/z (ESI+) 292.3 (M+H)+. 
  
201 
 
4-(1-Piperidyl)-2-(4-pyridyl)quinazoline (223) 
 
Pyridine-4-boronic acid hydrate (196) (47 mg, 0.38 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (13 mg, 0.02 mmol),  potassium carbonate (121 mg, 1.14 mmol) and (3E)-6-chloro-3-
[(2Z)-penta-2,4-dienylidene]-2-(1-piperidyl)-4H-pyridine (200)  (100 mg, 0.38 mmol) in 4:1 
acetonitrile:water (8 mL) were degassed under a flow of nitrogen and heated in a microwave 
reactor at 140 °C for 15 minutes. LCMS confirmed reaction completion (m/z 365, 332 and 265). 
The reaction mixture was diluted with water (12.5 ml) and extracted twice with ethyl acetate 
(2 × 15 mL). The combined organic phases were dried over MgSO4, filtered and concentrated 
under reduced pressure to give a green oil (108 mg). The crude was purified via flash column 
chromatography (4 g silica, petroleum ether:ethyl acetate 1:0 to 0:1) to give 4-(1-piperidyl)-2-
(4-pyridyl)quinazoline (223) (40 mg, 34%) as an off-white solid. 
Rf 0.47 (100% ethyl acetate); m.p. 150–151 °C; νmax (thin film)/cm-1 3009 (C-H aromatic, w), 2942 
(C-H aliphatic, m), 1612 (C=C, m), 1570 (C-C aromatic, m), 1504 (C-C aromatic, m), 1112 (C-N, m), 
764 (N-H, s);  1H NMR (600 MHz, DMSO-d6) δ 8.75 (d, J = 5.8 Hz, 2H, H-2' and H-6'), 8.33 (d, J = 
5.8 Hz, 2H, H-3' and H-5'), 8.01 (d, J = 8.3 Hz, 1H, H-9), 7.91 (d, J = 8.2 Hz, 1H, H-6), 7.85 (t, J = 
7.6 Hz, 1H, H-7), 7.57 (t, J = 7.5 Hz, 1H, 8), 3.88–3.81 (m, 4H, H-12 and H-16), 1.81–1.70 (m, 6H, 
H-13, H-14, H-15); 13C NMR (151 MHz,  DMSO-d6) δ 164.1 (C-1), 156.3 (C-3), 151.9 (C-5), 150.2 
(C-2' and C-6'), 145.4 (C-4'), 133.0 (C-7), 128.4 (C-6), 125.9 (C-8), 125.4 (C-9), 121.8 (C-3' and 
C-5'), 115.0 (C-10), 50.2 (C-12 and C-16), 25.5 (C-13 and C-15), 24.2 (C-14); HRMS m/z (ESI+) 
[Found: 291.1592, C18H19N4 requires (M+H)+ 291.1604]; LCMS (LCQ)  Rt = 0.7 min (4 min 
method), m/z (ESI+) 291.3 (M+H)+. 
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N',N'-Dimethyl-N-[3-(4-pyridyl)-2,6-naphthyridin-1-yl]ethane-1,2-diamine (224)199 
 
Pyridine-4-boronic acid hydrate (196) (74 mg, 0.60 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (21 mg, 0.03 mmol),  sodium carbonate (190 mg, 1.79 mmol) and N-(2-
chloroquinazolin-4-yl)-N',N'-dimethyl-ethane-1,2-diamine (201) (150 mg, 0.60 mmol) in 4:1 
acetonitrile:water (12 mL) were degassed under a flow of nitrogen and heated in a microwave 
reactor at 140 °C for 15 minutes. LCMS confirmed reaction completion (m/z 294). The reaction 
mixture was diluted with water (15 mL) and extracted twice with ethyl acetate (2 × 20 mL). The 
combined organic phases were dried over MgSO4, filtered and concentrated under reduced 
pressure to give N',N'-dimethyl-N-[3-(4-pyridyl)-2,6-naphthyridin-1-yl]ethane-1,2-diamine (224) 
as a yellow solid (37 mg).  
Rf 0.59 (100% ethyl acetate); m.p. 121-123 °C; νmax (thin film)/cm-1 3256 (N-H, br), 3128 
(aromatic C-H, w), 3064 (aromatic C-H, w), 2972 (aliphatic C-H, w), 1583 (aromatic C-H, s), 1560 
(aromatic C-H, s), 1529 (aromatic C-H, s), 1489 (aliphatic C-H, m), 758 (N-H, s), 694 (C-H, s); 
1H NMR (600 MHz, DMSO-d6) δ 8.74 (d, J = 5.3 Hz, 2H, H-2' and H-6'), 8.42 (t, J = 5.4 Hz, 1H, H-11), 
8.33 (d, J = 4.4 Hz, 2H, H-3' and H-5'), 8.27 (d, J = 8.2 Hz, 1H, H-9), 7.81 (d, J = 3.2 Hz, 2H, H-7 and 
H-6), 7.56 (d, J = 4.7 Hz, 1H, H-8), 3.80 (q, J = 6.5 Hz, 2H, H-12), 2.61 (t, J = 6.8 Hz, 2H, H-13), 2.25 
(s, 6H, H-15); 13C NMR pending; HRMS pending; LCMS (LCQ) Rt = 0.4 min (4 min method), m/z 
(ESI+) 294.2 (M+H)+. 
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N-Methyl-2-(4-pyridyl)quinazolin-4-amine (225)  
 
Pyridine-4-boronic acid hydrate (196) (95 mg, 0.77 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (27 mg, 0.04 mmol),  potassium carbonate (246 mg, 2.32 mmol) and 2-chloro-N-
methyl-quinazolin-4-amine (202) (150 mg, 0.77 mmol) in 4:1 acetonitrile:water (12 mL) were 
degassed under a flow of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. 
LCMS confirmed reaction completion (m/z 237). The reaction mixture was diluted with water 
(20 ml) and extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were 
dried over MgSO4, filtered and concentrated under reduced pressure to give a pale yellow solid 
(135 mg). The crude was purified via flash column chromatography (5 g silica, petroleum 
ether:ethyl acetate 1:0 to 0:1) to give N-methyl-2-(4-pyridyl)quinazolin-4-amine (225) (39 mg, 
9%) as a white solid. 
Rf 0.27 (100% ethyl acetate); m.p. 237–239 °C; νmax (thin film)/cm-1 3265 (N-H, br), 3132 (C-H 
aromatic, br), 2993 (C-H alkane, w), 1586 (C-C aromatic, s), 1562 (C-C aromatic, s), 1532 (C-C 
aromatic, m), 720 (N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.73 (d, J = 5.4 Hz, 2H, H-2' and H-6'), 
8.50 (m, 1H, H-11), 8.36 (d, J = 5.3 Hz, 2H, H-3' and H-5'), 8.24 (d, J = 8.1 Hz, 1H, H-9), 7.84–7.78 
(m, 2H, H-6/7/8), 7.65–7.59 (m, 2H, H-7/8/6), 7.58–7.52 (m, 1H, H-8/7/6), 3.17 (d, J = 4.4 Hz, 3H, 
H-12); 13C NMR (151 MHz, DMSO-d6) δ 160.3 (C-1), 157.5 (C-3), 150.0 (C-2' and C-6'), 149.3 (C-5), 
145.9 (C-4'), 132.8 (C-10), 131.4 (C-7/6/8), 128.0 (C-6/7/8), 126.2 (C-8/7/6), 122.6 (C-9), 121.8 
(C-3' and C-5'), 27.6 (C-12); HRMS m/z (ESI+) [Found: 237.1136, C14H13N4 requires (M+H)+ 
237.1135]; LCMS (LCQ) Rt = 0.5 min (4 min method), m/z (ESI+) 237.4 (M+H)+. 
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Tert-Butyl N-[2-[(3-chloro-1-isoquinolyl)amino]ethyl]carbamate (228)  
 
1,3-Dichloroisoquinoline (225) (500 mg, 2.52 mmol), 2 M N,N-diisopropylethylamine in THF 
(1.78 mL, 10.2 mmol) and  tert-butyl N-(2-aminoethyl)carbamate (182) (2.37 mL, 15 mmol) 
in ethanol (18 mL) were stirred at 100 °C for 3 days. LCMS confirmed product formation 
(m/z 322). The reaction mixture was concentrated under reduced pressure, diluted with water 
(10 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic extracts were 
washed with water (100 mL) and brine (100 mL), dried over MgSO4, filtered and concentrated 
under reduced pressure to give a yellow solid (1.95 g). The crude was purified via flash column 
chromatography (80 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl N-[2-
[(3-chloro-1-isoquinolyl)amino]ethyl]carbamate (228) (703 mg, 82%) as a white solid. 
1H NMR (600 MHz, DMSO-d6) δ 8.19 (d, J = 8.3 Hz, 1H, H-9), 7.83–7.76 (m, 1H, H-14), 7.67 (d, 
J = 7.9 Hz, 1H, H-6), 7.63 (t, J = 7.4 Hz, 1H, H-7), 6.97 (app. s, 2H, H-11 and H-8), 3.49 (q, J = 5.6 Hz, 
2H, H-13), 3.23 (q, J = 6.0 Hz, 2H, H-12), 1.37 (s, 9H, H-19); LCMS (LCQ) Rt = 2.99 min (4 min 
method), m/z (ESI+) 321.87 [35Cl], 323.87 [37Cl] (M+H)+, 265.94 [35Cl], 267.94 [37Cl]  (M+H-t-Bu)+, 
222.0 [35Cl] and 224.0 [37Cl] (M+H-Boc)+. 
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Tert-Butyl 4-(3-chloro-1-isoquinolyl)piperazine-1-carboxylate (229)198 
 
1,3-Dichloroisoquinoline (225) (500 mg, 2.52 mmol), N,N-diisopropylethylamine (1.78 mL, 
10.2 mmol) and  1-Boc-piperazine (185) (2.82 g, 15.2 mmol) in ethanol (18 mL) were stirred 
at 100 °C for 3 days. TLC and LCMS showed product formation (m/z 247 and 249). The reaction 
mixture was concentrated under reduced pressure, diluted with water (10 mL) and extracted 
with ethyl acetate (3 × 100 mL). The combined organic extracts were washed with water 
(100 mL) and brine (100 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure to give a yellow solid (900 mg). The crude was purified via flash column 
chromatography (40 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give  tert-butyl 4-(3-
chloro-1-isoquinolyl)piperazine-1-carboxylate (229) (867 mg, 89%) as an off-white solid. 
1H NMR (600 MHz, DMSO-d6) δ 8.09 (d, J = 8.4 Hz, 1H, H-9), 7.87 (d, J = 8.0 Hz, 1H, H-6), 7.74 (t, 
J = 7.5 Hz, 1H, H-7), 7.60 (t, J = 7.8 Hz, 1H, H-8), 7.53 (s, 1H, H-4), 3.59 (s, 4H, H-12 and H-16), 
3.36–3.32 (m, 4H, H-13 and H-15), 1.44 (s, 9H, H-21); LCMS (LCQ) Rt = 0.64 min (4 min method), 
m/z (ESI+) 247.2 [35Cl] and 249.3 [37Cl] (M+H-Boc)+. 
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3-Chloro-1-(1-piperidyl)isoquinoline (230) 
 
1,3-Dichloroisoquinoline (225) (500 mg, 2.52 mmol), N,N-diisopropylethylamine (1.78 mL, 
10.2 mmol) and  piperidine (188) (1.5 mL, 15.2 mmol) in ethanol (18 mL) were stirred 
at 100 °C for 3 days. TLC and LCMS confirmed reaction had gone to completion (m/z 245). The 
reaction mixture was concentrated under reduced pressure, diluted with water (10 mL) and 
extracted with ethyl acetate (3 × 100 mL). The combined organic extracts were washed with 
water (100 mL) and brine (100 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure to give 3-chloro-1-(1-piperidyl)isoquinoline (230) (640 mg, 98%) as a pale orange solid. 
1H NMR (600 MHz, DMSO-d6) δ 8.01 (d, J = 8.4 Hz, 1H, H-9), 7.85–7.81 (d, 1H, H-6), 7.71 (t, J = 
7.4 Hz, 1H, H-7), 7.58 (t, J = 7.6 Hz, 1H, H-8), 7.44 (s, 1H, H-4), 3.36–3.33 (m, 4H, H-12 and H-16), 
1.76 (m, H-13 and H-15), 1.65 (m, 2H, H-14); LCMS (LCQ) Rt = 0.5 min (4 min method), m/z (ESI+) 
245.3 (M-H)+. 
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N-(3-Chloro-1-isoquinolyl)-N’,N’-dimethyl-ethane-1,2-diamine (231) 
 
1,3-Dichloroisoquinoline (225) (500 mg, 2.52 mmol), N,N-diisopropylethylamine (1.8 mL, 
10.2 mmol) and  N,N-dimethylethylenediamine (190) (1.6 mL, 15 mmol) in ethanol (18 mL) were 
stirred at 100 °C for 3 days. LCMS confirmed product formation (m/z 250). The reaction mixture 
was concentrated under reduced pressure, diluted with water (10 mL) and extracted three times 
with ethyl acetate (3 × 100 mL). The combined organic extracts were washed with water 
(100 mL) and brine (100 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure to give a yellow solid (1.95 g). The crude was purified via flash column chromatography 
(24 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1 then ethyl acetate:methanol, 100:0 to 
90:10) to give  N-(3-chloro-1-isoquinolyl)-N’,N’-dimethyl-ethane-1,2-diamine (231) (200mg, 
30%) as a yellow oil. 
1H NMR (600 MHz, DMSO-d6) δ 8.19 (dd, J = 8.5, 1.0 Hz, 1H, H-9), 7.71 (t, J = 5.5 Hz, 1H, H-11), 
7.67 (dd, J = 8.3, 1.4 Hz, 1H, H-6), 7.63 (ddd, J = 8.0, 6.7, 1.1 Hz, 1H, H-7), 7.48 (ddd, J = 8.3, 6.7, 
1.5 Hz, 1H, H-8), 6.94 (d, J = 0.8 Hz, 1H, H-4), 3.56 (td, J = 6.8, 5.4 Hz, 2H, H-12), 2.54–2.51 (m, 
2H, H-13), 2.21 (s, 6H, H-15); LCMS (MDAP) Rt = 2.2 min (Ana 5-95 over 5 minutes), m/z (ESI+) 
251.0 (M+H)+.  
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3-Chloro-N-methyl-isoquinolin-1-amine (232)155 
 
1,3-Dichloroisoquinoline (225) (500 mg, 2.52 mmol), 2 M methylamine in THF (1.88 mL, 
15 mmol) and  N,N-diisopropylethylamine (0.7 mL, 4.04 mmol) in ethanol (20 mL) were stirred 
at 100 °C overnight. LCMS showed consumption of the starting material (m/z 193 and 195). The 
reaction mixture was concentrated under reduced pressure, diluted with water (10 mL) and 
extracted with ethyl acetate (3 × 100 mL). The combined organic extracts were washed with 
water (100 mL) and brine (100 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure to give 3-chloro-N-methyl-isoquinolin-1-amine (232) (470 mg, 92%) as a pale yellow 
solid. 
1H NMR (600 MHz, DMSO-d6) δ 8.17 (d, J = 8.3 Hz, 1H, H-9), 7.87 (d, J = 4.3 Hz, 1H, H-11), 7.67 
(d, J = 8.1 Hz, 1H, H-6), 7.63 (t, J = 7.4 Hz, 1H, H-7), 7.47 (t, J = 7.5 Hz, 1H, H-8), 6.95 (s, 1H, H-4), 
2.95 (d, J = 4.4 Hz, 3H, H-12); LCMS (LCQ) Rt = 1.4 min (4 min method), m/z (ESI+) 193.2 [35Cl] and 
195.21 [37Cl] (M+H+Na)+. 
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Tert-Butyl N-[2-[[3-(4-pyridyl)-1-isoquinolyl]amino]ethyl]carbamate (234) 
 
Pyridine-4-boronic acid hydrate (196) (54 mg, 0.44 mmol), potassium carbonate (141 mg, 
1.33 mmol),  bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(14 mg, 0.02 mmol) and tert-butyl N-[2-[(3-chloro-1-isoquinolyl)amino]ethyl]carbamate (228) 
(150 mg, 0.44 mmol) in 4:1 acetonitrile: water (12 mL) were degassed under a flow of nitrogen 
and heated in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed reaction 
completion (m/z 365, 332 and 265). The reaction mixture was diluted with water (3 ml) and 
extracted twice with ethyl acetate (2 × 4 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated under reduced pressure to give a brown oil (142 mg). The 
crude was purified via flash column chromatography (5 g silica, petroleum ether:ethyl acetate 
1:0 to 0:1) to give tert-butyl N-[2-[[3-(4-pyridyl)-1-isoquinolyl]amino]ethyl]carbamate (234) 
(99 mg, 58%) as a pale orange solid. 
Rf 0.73 (100% ethyl acetate); m.p. 158–160 °C; νmax (thin film)/cm-1 3386 (N-H, m), 3312 (N-H, 
m), 2932 (C-H aliphatic, w), 1681 (C=O, s), 1542 (C-C aromatic, s), 1520 (C-C, aromatic, s), 1172 
(C-N, s), 671 (N-H, m); 1H NMR (600 MHz, DMSO-d6) δ 8.64 (d, J = 4.2 Hz, 2H, H-2' and H-6'), 8.22 
(d, J = 8.2 Hz, 1H, H-9), 8.16 (d, J = 3.6 Hz, 2H, H-3' and H-5'), 7.84 (d, J = 7.6 Hz, 1H, H-6), 7.75 (s, 
1H, H-4), 7.71–7.61 (m, 2H, H-7 and H-14), 7.55 (t, J = 7.8 Hz, 1H, H-8), 7.04 (s, 1H, H-11), 3.69–
3.63 (m, 2H, H-13), 3.37–3.31 (m, 2H, H-12), 1.38 (s, 9H, H-19); 13C NMR (151 MHz, DMSO-d6) δ 
155.9 (C-15), 155.1 (C-10), 149.9 (C-2' and C-6'), 146.6 (C-4'), 145.1 (C-2), 137.2 (C-4), 130.1 (C-6), 
127.5 (C-5), 126.5 (C-7), 123.0 (C-8), 120.5 (C-9), 118.1 (C-3' and C-5'), 107.0 (C-9), 77.6 (C-3), 
41.3 (C-18), 39.7 (C-13), 28.2 (C-12); HRMS m/z (ESI+) [Found: 365.1965, C21H25N4O2 requires 
(M+H)+ 365.1972]; LCMS (LCQ) Rt = 0.5 min (4 min method), m/z (ESI+) 365.03 (M+H)+, 309.1 
(M+H-t-Bu)+ and 265.2 (M+H-Boc)+. 
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N'-[3-(4-Pyridyl)-1-isoquinolyl]ethane-1,2-diamine (233)161 
 
Tert-Butyl N-[2-[[3-(4-pyridyl)-1-isoquinolyl]amino]ethyl]carbamate (234) (47 mg, 0.12 mmol) 
was stirred in trifluoro acetic acid (0.5 mL, 6.0 mmol) and dichloromethane (1 mL) for 10 min 
at 0 °C then at room temperature overnight. LCMS confirmed product formation (m/z 265). The 
reaction mixture was concentrated under reduced pressure, purified by SCX cartridge and the 
product was eluted using 2 M NH3 in methanol and concentrated under reduced pressure to 
give N'-[3-(4-pyridyl)-1-isoquinolyl]ethane-1,2-diamine (233) (34 mg, 100%) as a yellow solid. 
Rf 0.33 (1:1 petroleum ether:ethyl acetate); m.p. 137–139 °C; νmax (thin film)/cm-1 3133 (N-H, br), 
1594 (aromatic C-H, m) 1534 (aromatic C-H, s), 813 (N-H, s), 677 (C-H, s); 1H NMR (600 MHz, 
DMSO-d6) δ 8.65 (d, 2H, J = 5.6, H-2' and H-6'), 8.29 (d, J = 8.3 Hz, 1H, H-9), 8.12 (d, J = 5.3 Hz, 
2H, H-3' and H-5'), 7.83 (d, J = 8.0 Hz, 1H, H-6), 7.73 (s, 1H, H-4), 7.67 (t, J = 7.4 Hz, 1H, H-7), 7.60 
(m, 1H, H-11), 7.55 (t, J = 7.4 Hz, 1H, H-8), 3.68 (app. q, J = 6.1 Hz, 2H, H-12), 2.96 (t, J = 6.5 Hz, 
2H, H-13), -NH2 peak likely under water peak; 13C NMR (151 MHz, DMSO-d6) δ 155.2 (C-1), 150.0 
(C-2' and C-6'), 146.7 (C-4'), 145.0 (C-3), 137.1 (C-5), 130.2 (C-7), 127.5 (C-6), 126.5 (C-8), 123.3 
(C-9), 120.4 (C-3' and C-5', 118.3 (C-10), 107.1 (C-4), 42.5 (C-13), 39.7 (C-12); HRMS m/z (ESI+) 
[Found: 265.1440, C16H17N4 requires (M+H)+ 265.1448]; LCMS (LCQ) Rt = 0.4 min (4 min method), 
m/z (ESI+) 265.1 (M+H)+. 
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Tert-Butyl 4-[3-(4-pyridyl)-1-isoquinolyl]piperazine-1-carboxylate (236)  
 
Pyridine-4-boronic acid hydrate (196) (53 mg, 0.43 mmol), potassium carbonate (138 mg, 
1.3 mmol),  bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(14 mg, 0.02 mmol) and tert-butyl 4-(3-chloro-1-naphthyl)piperazine-1-carboxylate (229) 
(150 mg, 0.43 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow of nitrogen 
and heated in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed reaction 
completion (m/z 391, 335, 291). The reaction mixture was diluted with water (20 ml) and 
extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated under reduced pressure to give a brown solid (174 mg). The 
crude was purified via flash column chromatography (5 g silica, PE:EA, 1:0 to 0:1) to give tert-
butyl 4-[3-(4-pyridyl)-1-isoquinolyl]piperazine-1-carboxylate (236) (82 mg, 46%) as a pale brown 
solid.  
Rf 0.33 (100% ethyl acetate); m.p. 185–187 °C; νmax (thin film)/cm-1 2979 (C-H aliphatic, w), 
2839 (C-H aliphatic, w), 1699 (C=O, s), 1560 (C-C aromatic, m), 1411 (C-H aliphatic, s), 1248 (C-N, 
s), 827 (C-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.69 (d, J = 4.6 Hz, 2H, H-2' and H-6'), 8.24 (s, 1H, 
H-4), 8.18–8.12 (m, 3H, H-3', H-5' and H-9), 8.01 (d, J = 8.2 Hz, 1H, H-6), 7.77 (t, J = 7.8 Hz, 1H, 
H-7), 7.66 (t, J = 7.5 Hz, 1H, H-8), 3.64 (s, 4H, H-13 and H-15), 3.48–3.37 (m, 4H, H-12 and H-16), 
1.45 (s, 9H, H-21); 13C NMR (151 MHz, DMSO-d6) δ 160.3 (C-17), 154.0 (C-1), 150.2 (C-2' and C-6'), 
146.0 (C-4'), 144.3 (C-3), 138.4 (C-5), 130.6 (C-7), 128.2 (C-6), 127.5 (C-8), 125.4 (C-9), 120.8 
(C-10), 120.5 (C-3' and C-5'), 113.0 (C-4), 79.1 (C-20), 50.8 (C-12 and C-16), 28.1 (C-21). C-13 and 
C-15 under solvent peak; HRMS m/z (ESI+) [Found: 391.2110, C23H27N4O2 requires (M+H)+ 
391.2129]; LCMS (LCQ) Rt = 0.7 min (4 min method), m/z (ESI+) 391.10 (M+H)+, 335.2 (M+H-t-
Bu)+ and 291.3 (M+H-Boc)+.  
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1-Piperazin-1-yl-3-(4-pyridyl)isoquinoline (237) 
 
Tert-Butyl 4-[3-(4-pyridyl)-1-isoquinolyl]piperazine-1-carboxylate (236) (41 mg, 0.10 mmol) was 
stirred in trifluoro acetic acid (0.42 mL, 5.47 mmol) and dichloromethane (2.8 mL) for 10 min 
at 0 °C then at room temperature overnight. LCMS confirmed product formation (m/z 291). The 
reaction mixture was concentrated under reduced pressure, purified by SCX cartridge and the 
product was eluted using 2 M NH3 in methanol then concentrated under reduced pressure to 
give 1-piperazin-1-yl-3-(4-pyridyl)isoquinoline (237) (32 mg, 62% yield) as an off-white powder.  
Rf 0.07 (9:1 dichloromethane:methanol); m.p. 156-158 °C; νmax (thin film)/cm-1 3247 (N-H, br), 
2820 (aliphatic C-H, w), 1603 (C=C, m), 1558 (aromatic C-H, m), 1412 (aliphatic C-H, s), 827 (N-H, 
s), 677 (C-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.69 (d, J = 4.7 Hz, 2H, H-2' and H-6'), 8.19 (s, 1H, 
H-4), 8.14 (d, J = 4.7 Hz, 2H, H-3' and H-5'), 8.12 (d, J = 8.3 Hz, 1H, H-9), 7.99 (d, J = 8.1 Hz, 1H, 
H-6), 7.75 (t, J = 7.5 Hz, 1H, H-7), 7.64 (t, J = 7.5 Hz, 1H, H-8), 3.42 (s, 4H, H-12 and H-16), 3.06 (s, 
4H, H-13 and H-15); 13C NMR (151 MHz, DMSO-d6) δ 160.6 (C-1), 150.2 (C-2' and C-6'), 146.0 
(C-4'), 144.3 (C-5), 138.3 (C-10), 130.4 (C-7), 128.1 (C-6), 127.3 (C-8), 125.4 (C-9), 120.7 (C-3), 
120.4 (C-3' and C-5'), 112.7 (C-4), 51.1 (C-12 and C-16), 44.9 (C-13 and C-15); HRMS m/z (ESI+) 
[Found: 291.1591, C18H19N4 requires (M+H)+ 291.1604]; LCMS (LCQ) Rt = 0.4 min (4 min method), 
m/z (ESI+) 291.3 (M+H)+. 
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1-(1-Piperidyl)-3-(4-pyridyl)isoquinoline (238) 
 
Pyridine-4-boronic acid hydrate (196) (75 mg, 0.61 mmol), potassium carbonate (193 mg, 
1.82 mmol),  bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(20 mg, 0.03 mmol) and 3-chloro-1-(1-piperidyl)isoquinoline (230) (150 mg, 0.61 mmol) in 4:1 
acetonitrile:water (12 mL) were degassed under a flow of nitrogen and heated in a microwave 
reactor at 140 °C for 15 minutes. LCMS confirmed reaction completion (m/z 290). The reaction 
mixture was diluted with water (20 ml) and extracted twice with ethyl acetate (2 × 25 mL). The 
combined organic phases were dried over MgSO4, filtered and concentrated under reduced 
pressure (150 mg). The crude was purified via flash column chromatography (5 g silica, 
petroleum ether:ethyl acetate 1:0 to 0:1) to give 1-(1-piperidyl)-3-(4-pyridyl)isoquinoline (238) 
(67 mg, 36%) as pale yellow needle crystals.  
Rf 0.38 (100% ethyl acetate); m.p. 129–131 °C; νmax (thin film)/cm-1 2949 (C-H aliphatic, m), 
2918(C-H aliphatic, m), 2819 (C-H aliphatic, m), 1557 (C-C aromatic, s), 1413 (C-H aliphatic, s), 
825 (N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.68 (d, J = 5.5 Hz, 2H, H-2' and H-6'), 8.16 (s, 1H, 
H-4), 8.14 (d, J = 5.6 Hz, 2H, H-3' and H-5'), 8.07 (d, J = 8.3 Hz, 1H, H-9), 7.98 (d, J = 8.3 Hz, 1H, 
H-6), 7.74 (t, J = 7.4 Hz, 1H, H-7), 7.64 (t, J = 7.6 Hz, 1H, H-8), 3.47–3.40 (m, 4H, H-12 and H-16), 
1.89–1.76 (m, 4H, H-13 and H-15), 1.68 (d, J = 5.3 Hz, 2H, H-14); 13C NMR (151 MHz, DMSO-d6) δ 
161.2 (C-10), 150.1 (C-2' and C-6'), 146.1 (C-4'), 144.3 (C-2), 138.3 (C-4), 130.3 (C-6), 128.0 (C-5), 
127.1 (C-7), 125.4 (C-8), 120.9 (C-9), 120.4 (C-3' and C-5'), 112.2 (C-3), 52.1 (C-12 and C-16), 25.6 
(C-13 and C-15), 24.4 (C-14); HRMS m/z (ESI+) [Found: 290.1639, C19H20N3 requires (M+H)+ 
290.1652]; LCMS (LCQ) Rt = 1.9 min (4 min method), m/z (ESI+) 290.4 (M+H)+. 
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N’,N’-Dimethyl-N-[3-(4-pyridyl)-1-isoquinolyl]ethane-1,2-diamine (239) 
 
Pyridine-4-boronic acid hydrate (196) (74 mg, 0.60 mmol), sodium carbonate (191 mg, 
1.8 mmol) and N-(3-chloro-1-isoquinolyl)-N’,N’-dimethyl-ethane-1,2-diamine (231) (150 mg, 
0.60 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow of nitrogen. bis[2-(Di-
tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium (20 mg, 0.03 mmol) was 
added and the reaction was heated in a sealed microwave reactor vial at 140 °C in a microwave 
for 15 minutes. LCMS showed formation of the product (m/z 293). The reaction mixture was 
diluted with water (15 ml) and extracted twice with ethyl acetate (2 × 20 mL). The combined 
organic phases were dried over MgSO4, filtered and concentrated under reduced pressure to 
give a brown solid (121 mg). The crude was purified via flash column chromatography (12 g silica, 
petroleum ether:ethyl acetate 1:0 to 0:1) to give N’,N’-dimethyl-N-[3-(4-pyridyl)-1-
isoquinolyl]ethane-1,2-diamine (239) (110 mg, 60%) as a pale orange solid. 
Rf 0.66 (9:1 dichloromethane:methanol); m.p. 118–120 °C; νmax (thin film)/cm-1 2962 (m, 
aliphatic C-H), 1710 (s, C=C), 1687 (s, C=C), 1645 (s, N-H), 1594 (s, aromatic C-C), 1475 (s, aliphatic 
C-H), 1305 (s, aliphatic C-H), 1220 (s, aliphatic C-N), 1067 (s, aliphatic C-N); 1H NMR (600 MHz, 
DMSO-d6) δ 8.65 (d, J = 6.0 Hz, 2H, H-2' and H-6'), 8.23 (d, J = 8.4 Hz, 1H, H-9), 8.11 (d, J = 6.0 Hz, 
2H, H-3' and H-5'), 7.83 (d, J = 8.0 Hz, 1H, H-6), 7.73 (s, 1H, H-4), 7.67 (t, J = 7.5 Hz, 1H, H-7), 7.54 
(t, J = 7.2 Hz, 2H, H-8 and H-11), 3.74 (q, J = 6.5 Hz, 2H, H-12), 2.61 (t, J = 7.0 Hz, 2H, H-13), 2.25 
(s, 6H, H-15); 13C NMR (151 MHz, DMSO-d6) δ 155.1 (C-1), 150.0 (C-2' and C-6'), 146.7 (C-4'), 
145.1 (C-3), 137.2 (C-5), 130.1 (C-7), 127.5 (C-6), 126.5 (C-8), 123.0 (C-9), 120.3 (C-3' and C-5'), 
118.2 (C-10), 106.8 (C-4), 57.9 (C-13), 45.4 (C-15), 39.0 (C-12); HRMS m/z (ESI+) [Found: 
293.1760, C18H21N4 requires (M+H)+ 293.1761]; LCMS (MDAP) Rt = 0.7 min (Ana 5-95 over 5 min), 
m/z (ESI+) 293.1 (M+H)+.  
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N-Methyl-3-(4-pyridyl)isoquinolin-1-amine (240) 
 
Pyridine-4-boronic acid hydrate (196) (91 mg, 0.74 mmol), potassium carbonate (235 mg, 
2.22 mmol) and 3-chloro-N-methyl-isoquinolin-1-amine (232) (150 mg, 0.74 mmol) in 4:1 
acetonitrile:water (12 mL) were degassed under a flow of nitrogen. Bis[2-(di-tert-
butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium (24 mg, 0.04 mmol) was 
added and the reaction was heated in a sealed microwave reactor at 140 °C for 15 minutes. 
LCMS showed formation of the product (m/z 236). The reaction mixture was diluted with water 
(15 ml) and extracted twice with ethyl acetate (2 × 20 mL). The combined organic phases were 
dried over MgSO4, filtered and concentrated under reduced pressure to give a brown solid 
(185 mg). The crude was purified via flash column chromatography (12 g silica, petroleum ether: 
ethyl acetate, 1:0 to 0:1) to give N-methyl-3-(4-pyridyl)isoquinolin-1-amine (240) (123 mg,  67%) 
as a pale orange solid. 
Rf 0.78 (100% ethyl acetate); m.p. 168–170 °C; νmax (thin film)/cm-1 3306 (N-H, br), 1595 
(aromatic C-H, m), 1548 (aromatic C-H, s), 1390 (aliphatic C-H, m), 804 (N-H, s), 732 (C-H, s); 1H 
NMR (600 MHz, DMSO-d6) δ 8.65 (d, J = 4.6 Hz, 2H, H-2' and H-6'), 8.22 (d, J = 8.2 Hz, 1H, H-9), 
8.14 (d, J = 4.6 Hz, 2H, H-3' and H-5'), 7.83 (d, J = 8.0 Hz, 1H, H-6), 7.73 (s, 1H, H-4), 7.70–7.62 
(m, 2H, H-7 and H-11), 7.54 (t, J = 7.5 Hz, 1H, H-8), 3.11 (d, J = 4.3 Hz, 3H, H-12); 13C NMR 
(151 MHz, DMSO-d6) δ 156.2 (C-1), 150.4 (C-2' and C-'6), 147.2 (C-4'), 145.6 (C-3), 137.5 (C-5), 
130.6 (C-7), 128.0 (C-6), 127.0 (C-8), 123.4 (C-9), 120.8 (C-3' and C-5'), 118.8 (C-10), 107.2 (C-4), 
28.6 (C-12); HRMS m/z (ESI+) [Found: 236.1174, C15H14N3 requires (M+H)+ 236.1182]; LCMS 
Rt = 0.5 min (4 min method), m/z (ESI+) 236.3 (M+H)+.  
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4-Chloro-2-(4-pyridyl)quinoline (246)198  
 
Pyridine-4-boronic acid hydrate (196) (124 mg, 1.01 mmol), sodium carbonate (321 mg, 
3.03 mmol),  2,4-dichloroquinoline (225) (200 mg, 1.01 mmol) and bis(triphenylphosphine)-
palladium(II) dichloride (35 mg, 0.0500 mmol) in 4:1 acetonitrile:water (16 mL) were de-gassed 
under a flow of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS 
indicated product formation (m/z 241 and 243). The reaction mixture was diluted with water 
(40 ml) and extracted twice with ethyl acetate (2 × 50 mL). The combined organic phases were 
dried over MgSO4, filtered and concentrated under reduced pressure to give 4-chloro-2-(4-
pyridyl)quinoline (246) (310 mg, 100%) as an off-white solid. The intermediate was carried 
forward without further purification. 
1H NMR (600 MHz, DMSO-d6) δ 8.77 (d, J = 4.2 Hz, 2H, H-2' and H-6'), 8.52 (s, 1H, H-2), 8.28–8.22 
(m, 3H, H-3', H-5' and H-9), 8.20 (d, J = 8.0 Hz, 1H, H-6), 7.94 (t, J = 7.5 Hz, 1H, H-7), 7.81 (t, J = 
7.4 Hz, 1H, H-8); LCMS (MDAP) Rt = 2.5 min (Ana 5-95 5 min), m/z (ESI+) 241.0 [35Cl] and 243.0 
[37Cl] (M+H)+. 
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Tert-Butyl N-[2-[[2-(4-pyridyl)-4-quinolyl]amino]ethyl]carbamate (244) 
 
4-Chloro-2-(4-pyridyl)quinoline (246) (100 mg, 0.42 mmol) , Potassium carbonate (1.15 g, 
8.31 mmol), tert-butyl N-(2-aminoethyl)carbamate (0.13 mL, 0.83 mmol), benzyl(1-{2-
[benzyl(phenyl)phosphanyl]-naphthalen-1-yl}naphthalen-2-yl)phenylphosphane (14 mg, 0.02 
mmol) and palladium(II) acetate (5 mg, 0.02 mmol) in dry 1,4-dioxane (5 mL) were refluxed for 
12 h under nitrogen. The reaction mixture was concentrated under reduced pressure and water 
(10 mL) was added. The aqueous phase was extracted three times with ethyl acetate (3 × 10 mL). 
The combined organic layers were dried over MgSO4, filtered and concentrated under reduced 
pressure to give a brown mixture (287 mg). The crude was purified by flash column 
chromatography (10 g silica, petroleum ether:ethyl acetate 1:0 to 0:1) to give tert-butyl N-[2-
[[2-(4-pyridyl)-4-quinolyl]amino]ethyl]carbamate (244) (103 mg, 65%) as a yellow foam. 
Rf 0.34 (100% ethyl acetate); m.p.186–187 °C; νmax (thin film)/cm-1 3322 (br, N-H), 3144 (m, 
aromatic C-H), 2948 (w, aliphatic C-H), 1586 (s, aromatic C-H), 1431 (s, aliphatic C-H), 1401 (s, 
aliphatic C-H), 754 (s, N-H); 1H NMR (600 MHz, DMSO-d6) δ 8.70 (d, J = 5.3 Hz, 2H, H-2' and H-6'), 
8.21 (d, J = 5.1 Hz, 2H, H-3' and H-5'), 8.17 (d, J = 8.9 Hz, 1H, H-9), 7.90 (d, J = 8.6 Hz, 1H, H-6), 
7.67 (t, J = 7.3 Hz, 1H, H-7), 7.47 (t, J = 7.5 Hz, 1H, H-8), 7.39–7.33 (m, 1H, H-14), 7.24 (s, 1H, H-2), 
7.13–7.06 (m, 1H, H-11), 3.54–3.41 (m, 2H, H-13), 3.30–3.21 (m, 2H, H-12), 1.38 (s, 9H, H-19); 
13C NMR (151 MHz, DMSO-d6) δ 156.1 (C-15), 154.1 (C-3), 151.2 (C-1), 150.0 (C-2' and C-6'), 148.2 
(C-5), 147.0 (C-4'), 129.6 (C-7), 129.5 (C-6), 124.5 (C-8), 121.5 (C-9), 121.4 (C-3' and C-5'), 118.5 
(C-10), 95.2 (C-2), 78.0 (C-18), 42.7 (C-13), 38.5 (C-12), 28.2 (C-19); HRMS m/z (ESI+) [Found: 
365.1956, C21H24N4O2 requires (M+H)+ 365.1972]; LCMS (LCQ) Rt = 2.3 min (Ana 5-95 in 5 min), 
m/z (ESI+) 365.15 (M+H)+. 
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N'-[2-(4-pyridyl)-4-quinolyl]ethane-1,2-diamine (245) 
 
Trifluoro acetic acid (1.4 mL, 18.06 mmol) was added to tert-butyl N-[2-[[2-(4-pyridyl)-4-
quinolyl]amino]ethyl]carbamate (244) (70 mg, 0.19 mmol) in dichloromethane (2 mL) over 
10 min at 0 °C then at room temperature for 4 h. The reaction mixture was concentrated under 
reduced pressure, purified by SCX cartridge and the product eluted using 2 M NH3 in 
methanol to give N'-[2-(4-pyridyl)-4-quinolyl]ethane-1,2-diamine (245) (36 mg, 67%) as a yellow 
oil. 
Rf 0 (9:1 dichloromethane:methanol); m.p. 175–177 °C ; νmax (thin film)/cm-1 3400 (N-H, br), 
3277 (N-H, br), 3071 (aromatic C-H, br), 1586 (aromatic C-H, s), 1531 (aromatic C-H, s), 1474 
(aliphatic C-H, s), 1140 (C-N, m), 770 (N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.71 (d, J = 5.3 Hz, 
2H, H-2' and H-6'), 8.27 (d, J = 8.5 Hz, 1H, H-9), 8.16 (d, J = 4.9 Hz, 2H, H-3' and H-5'), 7.89 (d, J = 
8.4 Hz, 1H, H-6), 7.66 (t, J = 7.6 Hz, 1H, H-7), 7.57 (s, 1H, H-14), 7.46 (t, J = 7.7 Hz, 1H, H-8), 7.35–
7.25 (m, 1H, H-11), 7.10 (s, 1H, H-2), 6.90 (s, 1H, H-14), 3.44 (q, J = 6.2 Hz, 2H, H-12), 2.89 (t, J = 
6.5 Hz, 2H, H-13); 13C NMR (151 MHz, DMSO-d6) δ 154.1 (C-3), 151.4 (C-1), 150.1 (C-2' and C-6'), 
148.2 (C-5), 147.0 (C-4'), 129.5 (C-6), 129.5 (C-7), 124.5 (C-8), 121.8 (C-9), 121.4 (C-3' and C-5'), 
118.6 (C-10), 95.2 (C-2), 43.5 (C-13), 39.4 (C-12); HRMS m/z (ESI+) [Found: 265.1437, C16H17N4 
requires (M+H)+ 265.1448]; LCMS (MDAP) Rt = 0.7 min (Ana 5-95 in 5 minutes method), m/z 
(ESI+) 265.15 (M+H)+. 
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Tert-Butyl N-[2-[[2-(3-pyridyl)quinazolin-4-yl]amino]ethyl]carbamate 
 
Sodium carbonate (140 mg, 1.32 mmol), bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-
yl]iron; dichloropalladium (14 mg, 0.02 mmol), tert-butyl N-[2-[(2-chloroquinazolin-4-
yl)amino]ethyl]-carbamate (198) (150 mg, 0.44 mmol) and pyridine-3-boronic acid (54 mg, 
0.44 mmol) in 4:1 acetonitrile: water (12 mL) were degassed under a flow of nitrogen and 
heated in a microwave reactor at 140 °C for 15 minutes. LCMS indicated product formation (m/z 
366, 290, 265). Water (15 mL) was added and the mixture was extracted twice with ethyl acetate 
(2 × 20 mL). The combined organic phases were dried over MgSO4, filtered and concentrated 
under reduced pressure to give a brown oil (263 mg). The crude was purified using flash column 
chromatography (10 g silica, petroleum ether: ethyl acetate 1:0 to 0:1) to give tert-butyl N-[2-
[[2-(3-pyridyl)quinazolin-4-yl]amino]ethyl]carbamate (46 mg, 27%) as a yellow gum. 
Rf 0 (9:1 dichloromethane:methanol); m.p. 142–144 °C; νmax (thin film)/cm-1 3296 (N-H, br), 1574 
(aromatic C-H. m), 1534 (aromatic C-H, m), 1492 (aliphatic C-H, m), 765 (N-H, s); 1H NMR 
(600 MHz, DMSO-d6) δ 9.61 (s, 1H, H-2'), 8.75 (d, J = 7.9 Hz, 1H, H-4'/6'), 8.68 (d, J = 4.6 Hz, 1H, 
H-6'/4'), 8.41 (s, 1H, H-11), 8.30 (d, J = 8.3 Hz, 1H, H-9), 7.78 (d, J = 2.7 Hz, 2H, H-7/6), 7.58 – 7.45 
(m, 2H, H-8 and H-5'), 3.75 – 3.67 (m, 2H, H-12), 2.93 (t, J = 6.5 Hz, 2H, H-13), NH2 peak not 
observed; 13C NMR (151 MHz, DMSO-d6) δ 160.0 (C-1), 157.7 (C-3), 150.7 (C-6'/4'), 149.6 (C-10), 
149.3 (C-2'), 135.1 (C-4'/6'), 133.9 (C-6), 132.8 (C-5), 127.8 (C-7), 125.6 (C-8), 123.4 (C-5'), 123.0 
(C-9), 114.1 (C-3'), 42.4 (C-12), 39.8 (C-13); HRMS m/z (ESI+) [Found: 266.1393, C15H16N5 requires 
[M+H]+ 266.1400]; LCMS (LCQ) Rt = 0.4 min (4 min method), m/z (ESI+) 266.20 (M+H)+. 
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N'-[2-(3-Pyridyl)quinazolin-4-yl]ethane-1,2-diamine (260) 
 
Tert-Butyl N-[2-[[2-(3-pyridyl)quinazolin-4-yl]amino]ethyl]carbamate (35 mg, 0.10 mmol) was 
stirred in dichloromethane (1 mL) and cooled to 0 °C. Trifluoro acetic acid (0.29 mL, 3.83 mmol) 
was added and the reaction was stirred at 0 °C for ten minutes then allowed to warm up to room 
temperature and stir overnight. LCMS formed (m/z 266). The reaction mixture was concentrated 
under reduced pressure and purified by SCX cartridge and eluted with 2 M NH3 in methanol then 
concentrated under reduced pressure to give N'-[2-(3-pyridyl)quinazolin-4-yl]ethane-1,2-
diamine (260) (23 mg, 86%) as a yellow solid. 
Rf 0 (9:1 dichloromethane:methanol); m.p. 142–144 °C; νmax (thin film)/cm-1 3296 (N-H, br), 1574 
(aromatic C-H. m), 1534 (aromatic C-H, m), 1492 (aliphatic C-H, m), 765 (N-H, s); 1H NMR (600 
MHz, DMSO-d6) δ 9.61 (s, 1H, H-2'), 8.75 (d, J = 7.9 Hz, 1H, H-4'/6'), 8.68 (d, J = 4.6 Hz, 1H, H-6'/4'), 
8.41 (s, 1H, H-11), 8.30 (d, J = 8.3 Hz, 1H, H-9), 7.78 (d, J = 2.7 Hz, 2H, H-7/6), 7.58–7.45 (m, 2H, 
H-8 and H-5'), 3.75–3.67 (m, 2H, H-12), 2.93 (t, J = 6.5 Hz, 2H, H-13), NH2 peak not observed; 13C 
NMR (151 MHz, DMSO-d6) δ 160.0 (C-1), 157.7 (C-3), 150.7 (C-6'/4'), 149.6 (C-10), 149.3 (C-2'), 
135.1 (C-4'/6'), 133.9 (C-6), 132.8 (C-5), 127.8 (C-7), 125.6 (C-8), 123.4 (C-5'), 123.0 (C-9), 114.1 
(C-3'), 42.4 (C-12), 39.8 (C-13); HRMS m/z (ESI+) [Found: 266.1393, C15H16N5 requires (M+H)+ 
266.1400]; LCMS (LCQ) Rt = 0.4 min (4 min method), m/z (ESI+) 266.20 (M+H)+. 
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Tert-butyl 4-[2-(3-pyridyl)quinazolin-4-yl]piperazine-1-carboxylate198 
 
Bis(Triphenylphosphine)palladium(II) dichloride (15 mg, 0.02 mmol), sodium carbonate 
(137 mg, 1.29 mmol),  tert-butyl 4-(2-chloroquinazolin-4-yl)piperazine-1-carboxylate (198) 
(150 mg, 0.43 mmol) and pyridine-3-boronic acid (53 mg, 0.43 mmol) in 4:1 acetonitrile:water 
(12 mL) were degassed under a flow of nitrogen and heated in a microwave reactor at 140 °C 
for 15 minutes. LCMS confirmed reaction completion (m/z 392, 336, 292). The reaction mixture 
was diluted with water (20 ml) and extracted twice with ethyl acetate (2 × 25 mL). The combined 
organic phases were dried over MgSO4, filtered and concentrated under reduced pressure to 
give a yellow oil (167 mg). The crude was purified via flash column chromatography  (5 g 
petroleum ether:ethyl acetate 1:0 to 0:1) to give a yellow solid (76 mg) which was further 
purified via SCX cartridge by eluting with methanol then 2 M ammonia in methanol to give tert-
butyl 4-[2-(3-pyridyl)quinazolin-4-yl]piperazine-1-carboxylate (66 mg, 37%) as an off-white solid. 
1H NMR (600 MHz, DMSO-d6) δ 9.61 (d, J = 1.5 Hz, 1H, H-2'), 8.76 (dt, J = 7.9, 1.9 Hz, 1H, H-4'), 
8.70 (dd, J = 4.7, 1.7 Hz, 1H, H-6'), 8.08 (d, J = 8.0 Hz, 1H, H-9), 7.92 (d, J = 8.3 Hz, 1H, H-6), 7.86 
(t, J = 7.6 Hz, 1H, H-7), 7.60–7.50 (m, 2H, H-8 and H-5'), 3.89–3.82 (m, 4H, H-13 and H-15), 3.61 
(s, 4H, H-12 and H-16), 1.44 (s, 9H, H-20); LCMS (LCQ) Rt = 0.8 min (4 min method), m/z (ESI+) 
392.07 (M+H)+, 336.2 (M+H-t-Bu)+, 292.1 (M+H-Boc)+.  
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4-Piperazin-1-yl-2-(3-pyridyl)quinazoline (261) 
 
Tert-Butyl 4-[2-(3-pyridyl)quinazolin-4-yl]piperazine-1-carboxylate (50 mg, 0.13 mmol) was 
dissolved in dichloromethane (1 mL) and cooled to 0 °C. Trifluoro acetic acid (0.5 mL, 5.17 mmol) 
was added dropwise and the reaction mixture was allowed to stir at room temperature 
overnight. LCMS (LCQ) indicated product formation (m/z 292). The reaction mixture was 
concentrated under reduced pressure to give a yellow solid. The crude was purified via SCX 
cartridge by elution with methanol then 2 M ammonia in methanol to give 4-piperazin-1-yl-2-
(3-pyridyl)quinazoline (261) (38 mg, 97%) as a yellow solid.106 
Rf 0.18 (9:1 dichloromethane:methanol); m.p. 182-185 °C; νmax (thin film)/cm-1 3024 (aromatic 
C-H, w), 2851 (aliphatic C-H, w), 1683 (aromatic C=C, m), 1562 (aromatic C-C, m), 1539 (aromatic 
C-C, m), 1499 (aliphatic C-H, s), 1114 (C-N, s), 768 (N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 9.66–
9.54 (m, 1H, H-2'), 8.76 (dt, J = 7.9 Hz, 1H, H-4'), 8.70 (td, J = 4.7 Hz, 1H, H-6'), 8.08 (d, J = 8.2 Hz, 
1H, H-9), 7.93 (d, J = 8.3 Hz, 1H, H-6), 7.87 (t, J = 7.6 Hz, 1H, H-7), 7.62–7.50 (m, 2H, H-8 and H-5'), 
3.94 (t, J = 5.0 Hz, 4H, H-12 and H-16), 3.23 (t, J = 5.1 Hz, 4H, H-13 and H-15); 13C NMR (151 MHz, 
DMSO-d6) δ 164.5 (C-1), 156.9 (C-3), 152.3 (C-5), 151.4 (C-6'), 149.7 (C-2'), 149.7 (C-3'), 135.6 
(C-4'), 133.7 (C-7), 128.8 (C-6), 126.4 (C-8), 125.8 (C-9), 124.0 (C-5'), 115.2 (C-10), 48.2 (C-12 and 
C-16), 44.0 (C-13 and C-15); HRMS m/z (ESI+) [Found: 292.1560, C17H18N5 requires (M+H)+ 
292.1557]; LCMS (LCQ) Rt = 0.6 min (4 min method), m/z (ESI+) 292.4 (M+H)+. 
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4-(2-Chloroquinazolin-4-yl)morpholine181,184,185,191,200–202 
 
2,4-Dichloroquinazoline (194) (250 mg, 1.26 mmol), triethylamine (0.26 mL, 1.88 mmol) 
and morpholine (0.12 mL, 1.38 mmol) were stirred in THF (2.5 mL) at 0 °C for 1 h in a water/ice 
bath. TLC and LCMS (LCQ) indicated product formation (m/z 250 and 252). The reaction mixture 
was concentrated under reduced pressure and water (20 mL) was added followed by extraction 
twice by ethyl acetate (2 × 25 mL). The combined organic phases were dried over MgSO4 and 
concentrated under reduced pressure to give a white solid (190 mg). The crude was purified by 
flash column chromatography (10 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give 4-
(2-chloroquinazolin-4-yl)morpholine (114 mg, 33%) as a white solid. 
1H NMR (600 MHz, DMSO-d6) δ 8.04 (d, J = 8.4 Hz, 1H, H-9), 7.82 (t, J = 7.7 Hz, 1H, H-7), 7.71 (d, 
J = 8.4 Hz, 1H, H-6), 7.52 (t, J = 7.6 Hz, 1H, H-8), 3.86–3.78 (m, 4H, H-13 and H-15), 3.79–3.72 (m, 
4H, H-12 and H-16); LCMS (LCQ) Rt = 1.6 min (4 min method), m/z (ESI+) 250.3 [35Cl] and 252.3 
[37Cl] (M+H)+. 
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4-[2-(4-Pyridyl)quinazolin-4-yl]morpholine (262) 
 
Pyridine-4-boronic acid hydrate (196) (69 mg,  0.56 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (20 mg, 0.03 mmol),  potassium carbonate (178 mg, 1.68 mmol) and 4-(2-
chloroquinazolin-4-yl)morpholine (140 mg, 0.56 mmol) in 4:1 acetonitrile:water (12 mL) were 
degassed under a flow of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. 
LCMS confirmed reaction completion (m/z 293 and 295). The reaction mixture was diluted with 
water (20 ml) and extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases 
were dried over MgSO4, filtered and concentrated under reduced pressure to give a pale yellow 
solid (135 mg). The crude was purified via flash column chromatography (5 g silica, petroleum 
ether: ethyl acetate, 1:0 to 0:1) to give 4-[2-(4-pyridyl)quinazolin-4-yl]morpholine (262) (116 mg, 
67%). 
Rf 0.38 (100% ethyl acetate); m.p. 157–160 °C; νmax (thin film)/cm-1 3345 (N-H, br), 2951 (aliphatic 
C-H, w), 1688 (C=C, m), 1557 (aromatic C-H, m), 1528 (aromatic C-H, s), 1501 (aromatic C-H, s), 
1492 (aliphatic C-H, s), 1114 (C-N, s), 768 (N-H, s), 674 (C-H, s); 1H NMR (600 MHz, DMSO-d6) 
δ 8.66 (m, 2H, H-2' and H-6'), 8.34 (m, 2H, H-3' and H-5'), 8.10 (d, J= 8.4 Hz, 1H, H-9), 7.95 (d, J = 
8.3 Hz, 1H, H-6), 7.88 (t, J = 7.5 Hz, 1H, H-7), 7.59 (t, J = 7.5 Hz, 1H, H-8), 3.86 (dd, J = 20.4, 4.5 Hz, 
8H, H-12, H-13, H-14 and H-15); 13C NMR (151 MHz, DMSO-d6) δ 164.0 (C-1), 156.2 (C-3), 151.8 
(C-5), 150.2 (C-3' and C-5'), 145.2 (C-4'), 133.1 (C-7), 128.6 (C-6), 126.1 (C-8), 125.4 (C-9), 121.8 
(C-2' and C-6'), 115.0 (C-10), 66.0 (C-12 and C-16), 49.6 (C-13 and C-15); HRMS m/z (ESI+) [Found: 
293.1392, C17H17N4O requires (M+H)+ 293.1397]; LCMS Rt = 0.56 min (4 min method), m/z (ESI+) 
293.4 (M+H)+. 
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2-Chloro-N-[2-(1-piperidyl)ethyl]quinazolin-4-amine 
 
2,4-Dichloroquinazoline (194) (500 mg, 2.51 mmol), triethylamine (0.53 mL, 3.77 mmol) and 2-
(1-piperidinyl)ethanamine (1.1 mL, 7.54 mmol) were stirred in tetrahydrofuran (5 mL) at 0 °C for 
1 h in a water/ice bath. TLC and LCMS (LCQ) indicated product formation (m/z 323 and 325, 269 
and 267). The reaction mixture was concentrated under reduced pressure to give a colourless 
oil (422 mg, excess thought to be due to unreacted amine). The crude was purified by flash 
column chromatography (12 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give 2-chloro-
N-[2-(1-piperidyl)ethyl]quinazolin-4-amine (564 mg, 73%) as a clear colourless glass. 
1H NMR (600 MHz, DMSO-d6) δ 8.67 (t, J = 5.6 Hz, 1H, H-11), 8.22 (d, J = 8.3 Hz, 1H, H-9), 7.79 (t, 
J = 7.7 Hz, 1H, H-7), 7.61 (d, J = 8.4 Hz, 1H, H-6), 7.53 (t, J = 7.5 Hz, 1H, H-8), 3.62 (q, J= 6.5 Hz, 
2H, H-12), 2.62–2.52 (m, 2H, H-13), 2.43 (s, 4H, H-15 and H-19), 1.49 (p, J = 5.3 Hz, 4H, H-16 and 
H-18), 1.41–1.33 (m, 2H, H-17); LCMS (LCQ) Rt = 0.4 min (4 min method), m/z (ESI+) 291.2 [35Cl] 
and 293.1 [37Cl] (M+H)+. 
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N-[2-(1-Piperidyl)ethyl]-2-(4-pyridyl)quinazolin-4-amine (263) 
 
Pyridine-4-boronic acid hydrate (196) (60 mg, 0.49 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (17 mg, 0.02 mmol),  sodium carbonate (156 mg, 1.47 mmol) and 2-chloro-N-[2-(1-
piperidyl)ethyl]-quinazolin-4-amine (150 mg, 0.49 mmol) in 4:1 acetonitrile:water (12 mL) were 
degassed under a flow of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. 
LCMS confirmed reaction completion (m/z 334). The reaction mixture was diluted with water 
(15 ml) and extracted twice with ethyl acetate (2 × 20 mL). The combined organic phases were 
dried over MgSO4, filtered and concentrated under reduced pressure to give a heterogeneous 
mixture (215 mg). The crude was purified via flash column chromatography (10 g silica, 
petroleum ether: ethyl acetate 1:0 to 0:1) to give N-[2-(1-piperidyl)ethyl]-2-(4-
pyridyl)quinazolin-4-amine (263) (105 mg, 61%) as an orange solid. 
Rf 0.08 (9:1 ethyl acetate:methanol); m.p. 151-153 °C; νmax (thin film)/cm-1 3261 (N-H, br), 2932 
(aliphatic C-H, m), 1588 (aromatic C-H, s), 1574 (aromatic C-H, s), 1460 (aliphatic C-H, s), 761 
(N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.74 (d, J = 4.8 Hz, 2H, H-2' and H-6'), 8.43 (s, 1H, H-11), 
8.33 (d, J = 5.0 Hz, 2H, H-3' and H-5'), 8.26 (d, J = 8.3 Hz, 1H, H-9), 7.82 (app. d, J = 3.2 Hz, 2H, 
H-6 and H-7), 7.60–7.52 (m, 1H, H-8), 3.82 (app. s, 2H, H-12), 2.65 (app. s, 2H, H-13), 2.48 (app. 
s, 4H, H-15 and H-19), 1.50 (app. s, 4H, H-16 and H-18), 1.38 (app. s, 2H, H-17); 13C NMR 
(151 MHz, DMSO-d6) δ 159.9 (C-1), 157.5 (C-3), 150.1 (C-2' and C-6'), 149.5 (C-5/10), 145.9 (C-4'), 
132.9 (C-7), 128.1 (C-6), 126.2 (C-8), 122.7 (C-9), 121.7 (C-3' and C-5'), 114.3 (C-10/5), 57.1 (C-13), 
54.1 (C-15 and C-19), 38.1 (C-12), 25.4 (C-16 and C-18), 23.8 (C-17); HRMS m/z (ESI+) [Found: 
334.2018, C20H24N5 requires (M+H)+ 334.2026]; LCMS (LCQ) Rt = 0.4 min (4 min method), m/z 
(ESI+) 334.2 (M+H)+. 
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Tert-Butyl 4-[2-[(2-chloroquinazolin-4-yl)amino]ethyl]piperazine-1-carboxylate 
 
2,4-Dichloroquinazoline (194) (300 mg, 1.51 mmol), triethylamine (0.32 mL, 2.26 mmol) and 2-
methyl-2-propanyl 4-(2-aminoethyl)-1-piperazinecarboxylate (1.04 g, 4.52 mmol) were stirred 
in THF (3 mL) at 0 °C for 1 h in a water/ice bath. LCMS (LCQ) indicated product formation 
(m/z 392 and 394). The reaction mixture was concentrated under reduced pressure and diluted 
with water (15 mL) and extracted twice with ethyl acetate (2 × 15 mL). The combined organic 
phases were dried over MgSO4, filtered and concentrated under reduced pressure to give a 
yellow oil (372 mg). The crude was purified via flash column chromatography (10 g silica, 
petroleum ether:ethyl acetate 1:0 to 0:1) to give tert-butyl 4-[2-[(2-chloroquinazolin-4-
yl)amino]ethyl]piperazine-1-carboxylate (147 mg, 24%) as a white solid. 
1H NMR (600 MHz, DMSO-d6) δ 8.69 (t, J = 5.1 Hz, 1H, H-11), 8.23 (d, J = 8.4 Hz, 1H, H-9), 7.79 (t, 
J = 7.6 Hz, 1H, H-7), 7.61 (d, J = 8.2 Hz, 1H, H-6), 7.53 (t, J = 7.7 Hz, 1H, H-8), 3.64 (app. q, J = 
6.7 Hz, 2H, H-12), 3.29 (app. s, 4H, H-16 and H-18), 2.60 (t, J = 6.6 Hz, 2H, H-13), 2.40 (m, 4H, 
H-15 and H-19), 1.39 (s, 9H, H-24); LCMS (LCQ) Rt = 0.5 min (4 min method), m/z (ESI+) 392.0 
[35Cl] and 394.2 [37Cl] (M+H)+. 
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Tert-Butyl 4-[2-[[2-(4-pyridyl)quinazolin-4-yl]amino]ethyl]piperazine-1-carboxylate 
 
Pyridine-4-boronic acid hydrate (196) (38 mg, 0.31 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (11 mg, 0.02 mmol),  potassium carbonate (97 mg, 0.92 mmol) and tert-butyl 4-[2-[(2-
chloroquina-zolin-4-yl)amino]ethyl]piperazine-1-carboxylate (120 mg, 0.31 mmol) in 4:1 
acetonitrile:water (12 mL) were degassed under a flow of nitrogen and heated in a microwave 
reactor at 140 °C for 15 minutes. LCMS confirmed reaction completion (m/z 435, 335). The 
reaction mixture was diluted with water (12 ml) and extracted twice with ethyl acetate (2 × 
16 mL). The combined organic phases were dried over MgSO4, filtered and concentrated under 
reduced pressure to give tert-butyl 4-[2-[[2-(4-pyridyl)quinazolin-4-yl]amino]ethyl]piperazine-1-
carboxylate (115 mg, 82%) as a pale yellow solid. 
Rf 0.11 (100% ethyl acetate); m.p. 118–120 °C; νmax (thin film)/cm-1 3251 (N-H, br), 2939 
(aliphatic C-H, w), 1691 (C=O, m), 1586 (aromatic C-H, s), 1561 (aromatic C-H, s), 1526 (aromatic 
C-H, s), 1117 (C-N, s), 762 (N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.74 (d, J = 5.2 Hz, 2H, H-2' 
and H-6'), 8.44 (t, J = 5.3 Hz, 1H, H-11), 8.33 (d, J = 5.2 Hz, 2H, H-3' and H-5'), 8.26 (d, J = 8.4 Hz, 
1H, H-9), 7.82 (d, J = 3.5 Hz, 2H, H-6 and H-7), 7.56 (dd, J= 8.0, 3.9 Hz, 2H, H-8/7), 3.83 (q, J= 
6.5 Hz, 2H, H-12), 3.29 (app. s, 4H, H-16 and H-18), 2.70 (t , J = 6.7 Hz, 2H, H-13), 2.47 (app. s, 
4H, H-15 and H-19), 1.38 (s, 9H, H-23); 13C NMR (151 MHz, DMSO-d6) δ 159.9 (C-1), 157.5 (C-3), 
153.8 (C-21), 150.1 (C-2' and C-6'), 149.5 (C-5), 145.9 (C-4'), 133.0 (C-7), 131.4 (TPP/C-8), 128.8 
(TPP/C-8), 128.1 (TPP/C-6), 126.2 (TPP/C-8), 122.7(C-9), 121.7 (C-3' and C-5'), 114.3 (C-10), 78.7 
(C-23), 56.4 (C-13), 52.6 (C-15 and C-19), 43.9 (C-16/18), 42.6 (C-18/16), 38.1 (C-12), 28.0 (C-24), 
TPP = triphenylphosphine oxide impurity; HRMS m/z (ESI+) [Found: 435.2507, C24H31N6O2 
requires (M+H)+ 435.2503]; LCMS (LCQ) Rt = 0.45 min (4 min method), m/z (ESI+) 335.15 (M+H)+, 
379.2 (M+H-t-Bu)+, 435.1 (M+H-Boc)+. 
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N-(2-Piperazin-1-ylethyl)-2-(4-pyridyl)quinazolin-4-amine (264)199 
 
Tert-Butyl 4-[2-[[2-(4-pyridyl)quinazolin-4-yl]amino]ethyl]piperazine-1-carboxylate (90 mg, 
0.21 mmol) was stirred in trifluoro acetic acid (1.49 mL, 19.47 mmol) and dichloromethane 
(2 mL) for 10 min at 0 °C the at room temperature for 4 h. LCMS confirmed product formation 
(m/z 335). The reaction mixture was concentrated under reduced pressure, purified by SCX 
cartridge and the product eluted using 2M NH3 in methanol to give N-(2-piperazin-1-ylethyl)-2-
(4-pyridyl)quinazolin-4-amine (264) (63 mg, 86%) as a yellow oil. 
Rf 0 (9:1 dichloromethane:methanol); m.p. N/A; νmax (thin film)/cm-1 3290 (N-H, br), 2940 
(aliphatic C-H, br), 2826 (aliphatic C-H, br), 1579 (N-H, s), 1559 (C=C, s), 1527 (aromatic C-H), 
1411 (aliphatic C-H, s), 764 (N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.74 (d, J = 5.3 Hz, 2H, H-2' 
and H-6'), 8.47–8.37 (m, 1H, H-11), 8.33 (d, J = 5.3 Hz, 2H, H-3' and H-5'), 8.26 (d, J = 8.1 Hz, 2H, 
H-9/8/7/6), 7.81 (d, J = 3.7 Hz, 2H, H-8/7/6/9), 7.61–7.51 (m, 1H, H-7/6/9/8), 3.81 (q, J = 6.5 Hz, 
2H, H-12), 2.75 (s, 4H, H-16 and H-18), 2.66 (t, J = 6.7 Hz, 2H, H-13), 2.48 (s, 4H, H-15 and H-19); 
13C NMR (151 MHz, DMSO-d6) δ 159.9 (C-1), 157.5 (C-3), 150.1 (C-2' and C-6'), 149.5 (C-5), 146.0 
(C-4'), 133.0 (C-7), 128.1 (C-6), 126.2 (C-8), 122.8 (C-9), 121.8 (C-3' and C-5'), 114.3 (C-10), 57.0 
(C-13), 53.2 (C-15 and C-19), 45.0 (C-16 and C-18), 38.0 (C-12); HRMS m/z (ESI+) [Found: 
335.1965, C19H23N6 requires (M+H)+ 335.1979]; LCMS (MDAP) Rt = 3.0 min (Ana 30-95 in 20 min), 
m/z (ESI+) 335.0 (M+H)+. 
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2-Chloro-N-(2-morpholinoethyl)quinazolin-4-amine186 
 
2,4-Dichloroquinazoline (194) (250 mg, 1.26 mmol), triethylamine (0.26 mL, 1.88 mmol) and 4-
(2-amino-ethyl)morpholine (0.20 mL, 1.38mmol) were stirred in THF (2.5 mL) at 0 °C for 1 h in a 
water/ice bath. TLC and LCMS indicated product formation (m/z 293 and 295). The reaction 
mixture was concentrated under reduced pressure and water (25 mL) was added. The mixture 
was extracted four times with ethyl acetate (4 x 25 mL). The combined organic phases were 
dried over MgSO4, filtered and concentrated under reduced pressure to give an orange oil 
(278 mg). The crude was purified via flash column chromatography (10 g silica, petroleum 
ether:ethyl acetate, 1:0 to 0:1) to give 2-chloro-N-(2-morpholinoethyl)quinazolin-4-amine 
(199 mg, 51%) as a pale orange solid. 
1H NMR (600 MHz, DMSO-d6) δ 8.69 (t, J = 5.3 Hz, 1H, H-11), 8.23 (d, J = 8.2 Hz, 1H, H-9), 7.79 (t, 
J = 7.6 Hz, 1H, H-7), 7.61 (d, J = 8.3 Hz, 1H, H-6), 7.54 (t, J = 7.6 Hz, 1H, H-8), 3.64 (q, J = 6.4 Hz, 
2H, H-12), 3.56 (t, J = 4.2 Hz, 4H, H-16 and H-18), 2.58 (t, J = 6.7 Hz, 2H, H-13), 2.46 (s, 4H, H-15 
and H-19); LCMS (LCQ)  Rt = 0.44 min (4 min method), m/z (ESI+) 293.1 [35Cl] and 295.1 [37Cl] 
(M+H)+. 
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N-(2-Morpholinoethyl)-2-(4-pyridyl)quinazolin-4-amine (265) 
 
Pyridine-4-boronic acid hydrate (196) (63 mg, 0.51 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (18 mg, 0.03 mmol),  potassium carbonate (163 mg, 1.54 mmol) and 2-chloro-N-(2-
morpholinoethyl)-quinazolin-4-amine (150 mg, 0.51 mmol) in 4:1 acetonitrile:water 
(12 mL) were degassed under a flow of nitrogen and heated in a microwave reactor at 140 °C 
for 15 minutes. LCMS confirmed reaction completion (m/z 336). The reaction mixture was 
diluted with water (15 ml) and extracted twice with ethyl acetate (2 × 20 mL). The combined 
organic phases were dried over MgSO4, filtered and concentrated under reduced pressure to 
give N-(2-morpholinoethyl)-2-(4-pyridyl)quinazolin-4-amine (265) (121 mg, 66%) as a pale 
yellow solid. 
Rf 0.25 (9:1 ethyl acetate:methanol); m.p. 102–103 °C; νmax (thin film)/cm-1 3289 (N-H, br), 3053 
(aromatic C-H, w), 2948 (aliphatic C-H, w), 2854 (aliphatic C-H. w), 1583 (C=C, s), 1113 (aliphatic 
C-N, s), 721 (N-H, s), 694 (C-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.74 (d, J = 5.8 Hz, 2H, H-2' and 
H-6'), 8.46–8.40 (m, 1H, H-11), 8.33 (d, J = 5.7 Hz, 2H, H-3' and H-5'), 8.27 (d, J = 8.1 Hz, 1H, H-9), 
7.82 (d, J = 4.0 Hz, 2H, H-8/7/6), 7.65–7.58 (m, 1H, H-8/7/6), 7.58–7.54 (m, 2H, H-7/6/8), 3.83 
(q, J = 6.5 Hz, 2H, H-12), 3.58 (t, J = 4.6 Hz, 4H, H-16 and H-18), 2.68 (t, J = 6.9 Hz, 2H, H-13). H-15 
and H-19 under solvent peak according to COSY NMR; 13C NMR (151 MHz, DMSO-d6) δ 159.9 
(C-1), 157.5 (C-3), 150.1 (C-2' and C-6'), 149.5 (C-5), 145.9 (C-4'), 132.9 (C-8/7/6), 128.1 (C-8/7/6), 
126.2 (C-8/7/6), 122.7 (C-9), 121.7 (C-3' and C-5'), 114.3 (C-10), 66.2 (C-16 and C-18), 56.9 (C-13), 
53.4 (C-15 and C-19), 37.9 (C-12); HRMS m/z (ESI+) [Found: 336.1810, C19H22N5O requires (M+H)+ 
336.1819]; LCMS (LCQ) Rt = 0.4 min (4 min method), m/z (ESI+) 336.3 (M+H)+. 
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2-Chloro-4-pyrrolidin-1-yl-quinazoline185,203–205 
 
2,4-Dichloroquinazoline (194) (250 mg, 1.26 mmol), triethylamine (0.26 mL, 1.88 mmol) 
and pyrrolidine (0.11 mL, 1.38 mmol) were stirred in tetrahydrofuran (2.5 mL) at 0 °C for 1 h in 
a water/ice bath. TLC and LCMS (MDAP) indicated product formation (m/z 234 and 236). The 
reaction mixture was concentrated under reduced pressure and water (25 mL) was added. The 
mixture was extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were 
dried over MgSO4, filtered and concentrated under reduced pressure (227 mg). The crude was 
purified via flash column chromatography (10 g silica, petroleum ether:ethyl acetate 1:0 to 0:1) 
to give 2-chloro-4-pyrrolidin-1-yl-quinazoline (80 mg, 26%) as a white solid. 
1H NMR (500 MHz, DMSO-d6) δ 8.31 (d, J = 8.4 Hz, 1H, H-9), 7.78 (t, J = 7.6 Hz, 1H, H-7), 7.62 (d, 
J = 8.3 Hz, 1H, H-6), 7.48 (t, J = 7.8 Hz, 1H, H-8), 3.88 (s, 4H, H-12 and H-15), 1.97 (s, 4H, H-13 and 
H-14); LCMS (MDAP) Rt = 2.1 min (Ana 5-95 in 5 min), m/z (ESI+) 234.05 [35Cl] and 236.00 [37Cl] 
(M+H)+. 
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2-(4-Pyridyl)-4-pyrrolidin-1-yl-quinazoline (266) 
 
Pyridine-4-boronic acid hydrate (196) (42 mg, 0.34 mmol), bis(triphenylphosphine)-palladium(II) 
dichloride (12 mg, 0.02 mmol),  potassium carbonate (142 mg, 1.03 mmol) and 2-chloro-4-
pyrrolidin-1-yl-quinazoline (80 mg, 0.34 mmol) in 4:1 acetonitrile:water (6.4 mL) was degassed 
under a flow of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS 
confirmed product formation (m/z 277). Water (8 mL) was added and the reaction mixture was 
extracted twice with ethyl acetate (2 × 10 mL). The organic phases were combined, dried over 
MgSO4, filtered and concentrated under reduced pressure to give a white solid (62 mg). The 
crude was purified via flash column chromatography (4 g silica, petroleum ether:ethyl acetate 
1:0 to 0:1) to give 2-(4-pyridyl)-4-pyrrolidin-1-yl-quinazoline (266) (42 mg, 38%) as a white solid. 
Rf 0.72 (100% ethyl acetate); m.p. 154–156 °C; νmax (thin film)/cm-1 2971 (aromatic C-H, br), 
2866 (aromatic C-H, br), 1558 (aliphatic C-H, s), 1501 (aliphatic C-H, s), 1459 (aromatic C-H, s), 
677 (aromatic C-H, s); 1H NMR (500 MHz, DMSO-d6) δ 8.73 (d, J = 6.0 Hz, 2H, H-2' and H-6'), 8.37–
8.29 (m, 3H, H-3', H-5' and H-9), 7.88–7.75 (m, 2H, H-6 and H-7), 7.51 (t, J = 6.8 Hz, 1H, H-8), 4.00 
(s, 4H, H-12 and H-15), 2.08–1.93 (m, 4H, H-13 and H-14); 13C NMR (151 MHz, DMSO-d6) δ 159.3 
(C-3/1), 156.5 (C-1/3), 151.6 (C-5), 150.1 (C-2' and C-6'), 145.8 (C-4'), 132.5 (C-7), 128.0 (C-6), 
125.9 (C-9), 125.2 (C-8), 121.8 (C-3' and C-5'), 115.2 (C-10), 50.6 (C-12 and C-15), 39.1 (C-13 and 
C-14); HRMS m/z (ESI+) [Found: 277.1442, C17H17N4 requires (M+H)+ 277.1448]; LCMS (MDAP) 
Rt = 3.6 min (Ana 30-95 in 8 min), m/z (ESI+) 277.00 (M+H)+. 
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2-Chloro-N,N-dimethyl-quinazolin-4-amine195,196,212,213,197,204,206–211 
 
2,4-Dichloroquinazoline (200 mg, 1 mmol), triethylamine (0.21 mL, 1.51 mmol) 
and dimethylamine (0.55 mL, 1.11 mmol) were stirred in tetrahydrofuran (2 mL) at 0 °C for 1 h 
in a water/ice bath. LCMS (MDAP) indicated product formation (m/z 208 and 210). The reaction 
mixture was concentrated under reduced pressure and water (25 mL) was added. The mixture 
was extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were dried 
over MgSO4, filtered and concentrated under reduced pressure (227 mg). The crude was purified 
via flash column chromatography (10 g silica, petroleum ether:ethyl acetate 1:0 to 0:1) to give a 
3:1 mixture (by 1H NMR) of 2-chloro-N,N-dimethyl-quinazolin-4-amine (76 mg, 27%) and excess 
starting material as a white solid. The intermediate was carried forward without further 
purification.  
1H NMR (600 MHz, DMSO-d6) δ 8.23 (d, J = 8.5 Hz, 1H, H-9), 7.79 (t, J = 8.2 Hz, 1H, H-7), 7.65 (d, 
J = 8.9 Hz, 1H, H-6), 7.48 (t, J = 8.3 Hz, 1H, H-8), 3.37 (s, 6H, H-12); LCMS (LCQ) Rt = 1.8 min (4 min 
method), m/z (ESI+) 208.3 [35Cl] and 210.3 [37Cl] (M+H)+.  
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N,N-Dimethyl-2-(4-pyridyl)quinazolin-4-amine (267)214 
 
Pyridine-4-boronic acid hydrate (196) (36 mg, 0.29 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (10 mg, 0.01 mmol),  potassium carbonate (120 mg, 0.87 mmol) and 2-chloro-N,N-
dimethyl-quinazolin-4-amine (60 mg, 0.29 mmol) in 4:1 acetonitrile:water (4 mL) were degassed 
under a flow of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS 
(MDAP) indicated product formation (m/z 251). Water (6 mL) was added and the mixture was 
extracted twice with ethyl acetate (2 × 8 mL). The organic phases were combined, dried over 
MgSO4 and concentrated under reduced pressure to give a yellow oil (68 mg). The crude was 
purified via flash column chromatography (5 g silica, petroleum ether:ethyl acetate 1:0 to 0:1) 
to give the product contaminated with O=PPh3 (52 mg). The product was purified via a SCX 
cartridge eluted with methanol and then 2 M ammonia in methanol to give N,N-dimethyl-2-(4-
pyridyl)quinazolin-4-amine (267) (43 mg, 56%) as a brown solid. 
Rf 0.36 (100% ethyl acetate); m.p. 109-111 °C; νmax (thin film)/cm-1 3033 (w, aromatic C-H), 2938 
(aliphatic C-H), 1680 (w, C=C), 1574 (s, aromatic C-C), 1522 (s, aromatic C-C), 1484 (aliphatic, 
C-H), 1029 (s, aliphatic C-N); 1H NMR (600 MHz, DMSO-d6) δ 8.74 (d, J = 6.0 Hz, 2H, H-2' and H-6'), 
8.34 (d, J = 6.0 Hz, 2H, H-3' and H-5'), 8.24 (d, J = 8.4 Hz, 1H, H-9), 7.87 (d, J = 8.3 Hz, 1H, H-6), 
7.82 (t, J = 8.1 Hz, 1H, H-7), 7.52 (t, J = 8.2 Hz, 1H, H-8), 3.46 (s, 6H, H-12); 13C NMR (151 MHz, 
DMSO-d6) δ 162.7 (C-1), 156.0 (C-3), 152.0 (C-5), 150.1 (C-2' and C-6'), 145.6 (C-4'), 132.6 (C-7), 
128.1 (C-6), 126.2 (C-9), 125.1 (C-8), 121.8 (C-3' and C-5'), 114.7 (C-10), 41.5 (C-12); HRMS m/z 
(ESI+) [Found: 251.1285, C15H15N requires (M+H)+ 251.1291]; LCMS (MDAP) Rt = 0.8 min (Ana 5–
95 over 5 minutes), m/z (ESI+) 251.0 (M+H)+.  
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Tert-Butyl N-[3-[(2-chloroquinazolin-4-yl)amino]propyl]carbamate (270) 
 
2,4-Dichloroquinazoline (194) (500 mg, 2.51 mmol), triethylamine (0.53 mL, 3.77 mmol) and N-
Boc-1,3-propanediamine (268) (0.49 mL, 2.76 mmol) were stirred in tetrahydrofuran (5 mL) 
at 0 °C for 1 h in a water/ice bath.  LCMS confirmed product formation (m/z 337 an 379). The 
reaction mixture was concentrated under reduced pressure. Water (40 mL) was added and the 
mixture was extracted twice with dichloromethane (2 × 50 mL). The organic phases were 
combined, dried over MgSO4, filtered and concentrated under reduced pressure to give an off-
white heterogeneous mixture (280 mg). The crude was purified via flash column 
chromatography (12 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl N-[3-
[(2-chloroquinazolin-4-yl)amino]propyl]carbamate (270) (262 mg, 26%) as an off-white foam. 
1H NMR (600 MHz, DMSO-d6) δ 8.66 (t, J = 5.3 Hz, 1H, H-15), 8.24 (d, J = 8.0 Hz, 1H, H-9), 7.79 (t, 
J = 8.2 Hz, 1H, H-7), 7.61 (d, J = 8.3 Hz, 1H, H-6), 7.53 (t, J = 7.6 Hz, 1H, H-8), 6.85 (t, J = 5.4 Hz, 
1H, H-11), 3.50 (q, J = 6.6 Hz, 2H, H-14), 3.02 (q, J = 6.6 Hz, 2H, H-12), 1.76 (q, J = 6.9 Hz, 2H, 
H-13), 1.36 (s, 9H, H-20); LCMS (LCQ) Rt = 0.5 min (4 min method), m/z (ESI+) 337.02 [35Cl], 339.03 
[37Cl] (M+H)+, 281.13 [35Cl], 283.14 [37Cl] (M+H-t-Bu)+, 237.1 [35Cl] and 239.1 [37Cl] (M+H-Boc)+.  
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Tert-Butyl N-[3-[[2-(4-pyridyl)quinazolin-4-yl]amino]propyl]carbamate (271) 
 
Pyridine-4-boronic acid hydrate (196) (55 mg, 0.45 mmol), bis(triphenylphosphine)palladium(II) 
dichloride (16 mg, 0.02 mmol),  potassium carbonate (185 mg, 1.34 mmol) and tert-butyl N-[3-
[(2-chloroquinazolin-4-yl)amino]propyl]carbamate (270) (150 mg, 0.45 mmol) in 4:1 
acetonitrile:water (12 mL) were degassed under a flow of nitrogen and heated in a microwave 
reactor at 140 °C for 15 minutes. LCMS confirmed product formation (m/z 380). Water (20 mL) 
was added to the reaction and the mixture was extracted twice with ethyl acetate (2 × 
25 mL). The combined organic phases were dried over MgSO4, filtered and concentrated under 
reduced pressure to give a yellow gum (94 mg). The crude was purified via flash column 
chromatography (5 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl N-[3-[[2-
(4-pyridyl)quinazolin-4-yl]amino]propyl]carbamate (271) (55 mg, 31%) as a yellow solid.  
Rf 0.48 (100% ethyl acetate); m.p. 142-144 °C, νmax (thin film)/cm-1 3388 (N-H, br), 3226 (N-H br), 
3014 (aromatic C-H, w), 2979 (aliphatic C-H, w), 1690 (C=O, s), 1524 (aromatic C-H, s), 766 (N-H, 
s); 1H NMR (600 MHz, DMSO-d6) δ 8.75–8.66 (d, J = 6.0 Hz, 2H, H-2' and H-6'), 8.42 (t, J = 5.6 Hz, 
1H, H-15), 8.37–8.32 (d, J = 5.3 Hz, 1H, H-3' and H-5'), 8.26 (d, J = 8.2 Hz, 1H, H-9), 7.81 (d, J = 
3.9 Hz, 2H, H-6 and H-7), 7.58–7.51 (m, 1H, H-8), 6.88 (t, J = 5.9 Hz, 1H, H-11), 3.69 (q, J = 6.6 Hz, 
2H, H-14), 3.07 (q, J = 6.6 Hz, 2H, H-12), 1.85 (q, J = 7.0 Hz, 2H, H-13), 1.35 (s, 9H, H-20); 13C NMR 
(151 MHz, DMSO-d6) δ 160.3 (C-16), 157.9 (C-3), 156.1 (C-1), 150.5 (C-2' and C-6'), 150.0 (C-5), 
146.4 (C-4'), 133.4 (C-7), 128.5 (C-6), 126.6 (C-8), 123.1 (C-9), 122.2 (C-3' and C-5'), 114.7 (C-10), 
77.9 (C-19), 38.9 (C-14), 38.3 (C-12), 29.5 (C-13), 28.7 (C-20); HRMS m/z (ESI+) [Found: 380.2094, 
C21H26N5O2 requires (M+H)+ 380.2081]; LCMS (MDAP) Rt = 7.5 min (Ana 30–90 in 20 min), m/z 
(ESI+) 380.2 (M+H)+.  
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Tert-Butyl N-[5-[(2-chloroquinazolin-4-yl)amino]pentyl]carbamate (273) 
 
2,4-Dichloroquinazoline (194) (500 mg, 2.51 mmol), triethylamine (0.53 mL, 3.77 mmol) and 2-
methyl-2-propanyl (5-aminopentyl)carbamate (269) (0.58 mL, 2.76 mmol) were stirred 
in tetrahydrofuran (5 mL) at 0 °C for 1 h in a water/ice bath. TLC and LCMS indicated product 
formation (m/z 365, 309, 265). The reaction mixture was concentrated under reduced pressure, 
diluted with water (25 mL) and extracted three times with 2:1 chloroform:propan-2-ol (2 × 
20  mL). The combined organic phases were dried over MgSO4, filtered and concentrated under 
reduced pressure to give an off-white oil (521 mg). The crude was purified via flash column 
chromatography (12 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give   tert-butyl N-[5-
[(2-chloroquinazolin-4-yl)amino]pentyl]carbamate (273) (351 mg, 36%) as a colourless gum.150 
1H NMR (600 MHz, DMSO-d6) δ 8.70 (t, J = 5.6 Hz, 1H, H-17), 8.26 (d, J = 8.3 Hz, 1H, H-9), 7.78 
(m, 1H, H-7), 7.60 (d, J = 7.2 Hz, 1H, H-6), 7.52 (m, 1H, H-8), 6.79 (t, J = 5.6 Hz, 1H, H-11), 3.48 (q, 
J = 6.6 Hz, 2H, H-16), 2.91 (q, J = 6.6 Hz, 2H, H-12), 1.63 (q, J = 7.4 Hz, 2H, H-15), 1.42 (p, J = 
7.1 Hz, 2H, H-13), 1.35 (s, 9H, H-22), 1.34–1.28 (m, 2H, H-14); LCMS (MDAP) Rt = 19.0 min 
(30 min method), m/z (ESI+) 365.0 [35Cl] and 366.9 [37Cl] and  (M+H)+. 
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Tert-Butyl N-[5-[[2-(4-pyridyl)quinazolin-4-yl]amino]pentyl]carbamate (274) 
 
Pyridine-4-boronic acid hydrate (196) (51 mg, 0.41 mmol),  bis(triphenylphosphine)palladium(II) 
dichloride (14 mg, 0.02 mmol),  potassium carbonate (170 mg, 1.23 mmol) and tert-butyl N-[5-
[(2-chloroquinazolin-4-yl)amino]pentyl]carbamate (273) (150 mg, 0.41 mmol) in 4:1 
acetonitrile:water (12 mL) were degassed under a flow of nitrogen and heated in a microwave 
reactor at 140 °C for 15 minutes. LCMS indicated product formation (m/z 408). Water (15 mL) 
was added and the reaction mixture was extracted twice with ethyl acetate (2 × 20 mL). The 
combined organic phases were dried over MgSO4, filtered and concentrated under reduced 
pressure to give a yellow oil (190 mg). The crude was purified via flash column chromatography 
(5 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl N-[5-[[2-(4-
pyridyl)quinazolin-4-yl]amino]pentyl]carbamate (274) (82 mg, 46%) as a yellow solid.  
Rf 0.47 (100% ethyl acetate); m.p. 110–111 °C; νmax (thin film)/cm-1 3308 (N-H, br), 1932 
(aromatic C-H, w), 1682 (C=O, m), 1581 (C=C, s), 1529 (aromatic C-C, s), 1449 (aliphatic C-H, m), 
1120 (C-N, s), 766 (N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.73 (d, J = 6.1 Hz, 2H, H-2' and H-6'), 
8.47 (t, J = 5.6 Hz, 1H, H-17), 8.33 (d, J = 6.0 Hz, 2H, H-3' and H-5'), 8.29 (d, J = 8.3 Hz, 1H, H-9), 
7.81 (d, J = 3.8 Hz, 2H, H-6 and H-7), 7.58–7.51 (m, 1H, H-8), 6.81 (t, J = 5.6 Hz, 1H, H-11), 3.68 
(q, J = 6.6 Hz, 2H, H-16), 2.93 (q, J = 6.6 Hz, 2H, H-12), 1.77–1.69 (m, 2H, H-15), 1.46 (q, J = 7.0 Hz, 
2H, H-13), 1.42–1.36 (m, 2H, H-14), 1.34 (s, 9H, H-22); 13C NMR (151 MHz, DMSO-d6) δ 159.9 
(C-1), 157.5 (C-5), 155.6 (C-18), 150.1 (C-2' and H-6'), 149.5 (C-3), 146.0 (C-4'), 132.9 (C-7/6), 
128.1 (C-6/7), 126.1 (C-8), 122.8 (C-9), 121.8 (C-3' and C-5'), 114.3 (C-10), 77.3 (C-21), 40.6 (C-16), 
39.8 (C-12), 29.3 (C-13), 28.3 (C-22), 28.2 (C-15), 23.9 (C-14); HRMS m/z (ESI+) [Found: 408.2378, 
C23H30N5O2 requires (M+H)+ 408.2394]; LCMS (MDAP) Rt = 9.5 min (Ana 30–95 over 20 min), m/z 
(ESI+) 408.1 (M+H)+. 
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N’-[2-(4-Pyridyl)quinazolin-4-yl]pentane-1,5-diamine (275) 
 
Tert-Butyl N-[5-[[2-(4-pyridyl)quinazolin-4-yl]amino]pentyl]carbamate (274) (40 mg, 0.10 mmol) 
was dissolved in dichloromethane (1 mL) and cooled to 0 °C. Trifluoro acetic acid (0.5 mL, 6.53 
mmol) was added dropwise and the reaction mixture was allowed to stir at room temperature 
overnight. LCMS (MDAP) confirmed product formation (m/z 308). The reaction mixture was 
concentrated under reduced pressure and purified via SCX cartridge, eluting first with methanol 
then 2 M ammonia in methanol to give N’-[2-(4-pyridyl)quinazolin-4-yl]pentane-1,5-diamine 
(275) (23 mg, 77%) as an off-white solid. 
Rf 0.05 (9:1 dichloromethane:methanol); m.p. 118–120 °C; νmax (thin film)/cm-1 3283 (br, N-H), 
2937 (m, aliphatic C-H), 1579 (s, aromatic C-C/C-N), 1557 (s, aromatic C-C/C-N), 1527 (s, aromatic 
C-C/C-N), 1413 (s, aliphatic C-H), 1037 (s, aliphatic C-N), 763 (s, N-H);1H NMR (600 MHz, 
DMSO-d6) δ 8.73 (d, J = 5.7 Hz, 2H, H-2' and H-6'), 8.51 – 8.45 (m, 1H, H-11), 8.37 – 8.26 (m, 3H, 
H-3', H-5' and H-9), 7.83 – 7.76 (m, 2H, H-6 and H-7), 7.57 – 7.50 (m, 1H, H-8), 5.70 (s, 2H, H-17), 
3.68 (q, J = 6.6 Hz, 2H, H-12), 2.66 (t, J = 7.2 Hz, 2H, H-16), 1.74 (p, J = 7.3 Hz, 2H, H-13), 1.53 (p, 
J = 7.3 Hz, 2H, H-15), 1.44 (q, J = 8.0 Hz, 2H, H-14); 13C NMR (151 MHz, DMSO-d6) δ 159.9 (C-1), 
157.4 (C-3), 150.1 (C-2' and C-6'), 149.5 (C-5/10), 146.0 (C-4'), 132.8 (C-7), 128.0 (C-6), 126.1 
(C-8), 122.9 (C-9), 121.7 (C-3' and C-5'), 114.3 (C-10/5), 40.5 (C-16), 40.1 (C-12), 29.8 (C-15), 28.1 
(C-13), 23.7 (C-14); HRMS m/z (ESI+) [Found: 308.1863, C18H22N5 requires (M+H)+ 308.1870]; 
LCMS (MDAP) Rt = 1.9 min (Ana 5–95 over 5 minutes), m/z (ESI+) 308.10 (M+H)+.106 
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2-(4-Pyridyl)-4-pyrrolidin-1-yl-pyrimidine (281) 
 
Pyridine-4-boronic acid hydrate (196) (100 mg, 0.82 mmol), bis(triphenylphosphine)-
palladium(II) dichloride (29 mg, 0.04 mmol),  potassium carbonate (339 mg, 2.45 mmol) and 2-
chloro-4-(1-pyrrolidinyl)pyrimidine (280) (150 mg, 0.82 mmol) in 4:1 acetonitrile:water 
(12 mL) were degassed under a flow of nitrogen and heated in a microwave reactor at 140 °C 
for 15 minutes. LCMS indicated formation of the product (m/z 227). Water (15 mL) was added 
to the reaction mixture and extracted twice with ethyl acetate (2 × 20 mL). The combined organic 
phases were dried over MgSO4, filtered and concentrated under reduced pressure. The crude 
was purified via flash column chromatography (5 g silica, petroleum ether:ethyl acetate 1:0 to 
0:1) to give 2-(4-pyridyl)-4-pyrrolidin-1-yl-pyrimidine (281) (52 mg, 27%) as an off-white solid. 
Rf 0.48 (100% ethyl acetate); m.p. 100–103 °C; νmax (thin film)/cm-1 3039 (aromatic C-H, br), 2966 
(aliphatic C-H, w), 2866 (aliphatic C-H, w), 1587 (aromatic C-H, s), 1541 (aromatic C-H, s), 1494 
(aliphatic C-H, s) 1482 (aliphatic C-H, s), 1125 (C-N, m), 833 (aromatic C-H, s); 1H NMR (600 MHz, 
DMSO-d6) δ 8.70 (d, J = 4.7 Hz, 2H, H-2' and H-6'), 8.31 (d, J = 6.0 Hz, 1H, H-6), 8.21 (d, J = 4.7 Hz, 
2H, H-3' and H-5'), 6.53 (d, J = 6.0 Hz, 1H, H-5), 3.66 (s, 2H, H-11/8), 3.39 (s, 2H, H-8/11), 1.98 
(app. d, J = 28.6 Hz, 4H, H-9 and H-10); 13C NMR (151 MHz, DMSO-d6) δ 284.1 (C-3), 283.0 (C-1), 
278.6 (C-6), 273.7 (C-2' and C-6'), 269.1 (C-4'), 245.1 (C-3' and C-5'), 227.1 (C-5), 169.6 (C-11 and 
C-8), 148.7 (C-9/10), 148.0 (C-10/9); HRMS m/z (ESI+) [Found: 227.1284, C13H15N4 requires 
(M+H)+ 227.1291]; LCMS (LCQ) Rt = 0.7 min (Ana 5-95 in 5 min method), m/z (ESI+) 227.10 
(M+H)+. 
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4-[2-(4-Pyridyl)pyrimidin-4-yl]morpholine (283) 
 
Pyridine-4-boronic acid hydrate (196) (92 mg, 0.75 mmol), bis(triphenylphosphine)-palladium(II) 
dichloride (26 mg, 0.04 mmol),  potassium carbonate (312 mg, 2.25 mmol) and 4-(2-chloro-4-
pyrimidinyl)morpholine (282) (150 mg, 0.75 mmol) in 4:1 acetonitrile:water (12 mL) were 
degassed under a flow of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. 
LCMS indicated product formation (m/z 243). Water (15 mL) was added and the reaction 
mixture was extracted twice with ethyl acetate (2 × 20 mL). The combined organic phases were 
dried over MgSO4, filtered and concentrated under reduced pressure to give an off-white solid 
(163 mg). The crude was purified via flash column chromatography (5 g silica, petroleum 
ether:ethyl acetate 1:0 to 0:1) to give 4-[2-(4-pyridyl)pyrimidin-4-yl]morpholine (283) (67 mg, 
35%) as a pale yellow solid. 
Rf 0.28 (100% ethyl acetate); m.p. 71–73 °C; νmax (thin film)/cm-1 3391 (N-H, br), 2975 (aliphatic 
C-H, br), 2870 (aliphatic C-H, w), 1596 (aromatic C-H, s), 1542 (aromatic C-H, s), 1478 (aliphatic 
C-H, s), 963 (aliphatic C-H, m), 774 (N-H, s); 1H NMR (500 MHz, DMSO-d6) δ 8.71 (d, J = 5.3 Hz, 
2H, H-2' and H-6'), 8.40 (d, J = 6.2 Hz, 1H, H-5), 8.20 (d, J = 5.4 Hz, 2H, H-3' and H-5'), 6.90 (d, J = 
6.2 Hz, 1H, H-6), 3.72 (s, 8H, H-8, H-9, H-11 and H-12); 13C NMR (151 MHz, DMSO-d6) δ 161.6 
(C-1), 160.5 (C-3), 156.2 (C-5), 150.2 (C-2' and C-6'), 145.1 (C-4'), 121.5 (C-3' and C-5'), 103.1 
(C-6), 65.8 (C-8/9/11/12), 43.7(C-8/9/11/12); HRMS m/z (ESI+) [Found: 243.1235, C13H15N4O 
requires (M+H)+ 243.1240]; LCMS (MDAP) Rt = 0.7 min (Ana 5-95 in 5 min method), m/z (ESI+) 
243.10 (M+H)+. 
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Tert-Butyl N-[2-[(7-chloro-1,6-naphthyridin-5-yl)amino]ethyl]carbamate (285) 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol), tert-butyl N-(2-aminoethyl)carbamate (182) 
(0.94 mL, 5.97 mmol) and  5,7-dichloro-1,6-naphthyridine (284) (200 mg, 1 mmol) in ethanol 
(7 mL) were stirred at 100 °C overnight. LCMS confirmed product formation (m/z 323, 267, 223). 
The reaction mixture was concentrated under reduced pressure, diluted with water (4 mL) and 
extracted with ethyl acetate (3 × 40 mL). The combined organic extracts were washed with 
water (40 mL) and brine (40 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure to give a white solid (791 mg). The crude was purified via flash column chromatography 
(20 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give  tert-butyl N-[2-[(7-chloro-1,6-
naphthyridin-5-yl)amino]ethyl]carbamate (285) (292 mg, 86%) as a white solid.  
Rf 0.61 (100% ethyl acetate); m.p. 110–113 °C; νmax (thin film)/cm-1 3387 (N-H, br), 3215 (N-H, 
br), 3039 (aromatic C-H, w), 2979 (aliphatic C-H), 1684 (C=O, m), 1526 (aromatic C-H), 765 (N-H, 
s); 1H NMR (600 MHz, DMSO-d6) δ 8.90 (dd, J = 4.4, 1.6 Hz, 1H, H-7), 8.63 (d, J = 8.4 Hz, 1H, H-9), 
8.11 (t, J = 5.5 Hz, 1H, H-14), 7.49 (dd, J = 8.4, 4.3 Hz, 1H, H-8), 6.97 (s, 1H, H-4), 6.95 (t, J = 6.3 Hz, 
1H, H-11), 3.50 (q, J = 6.1 Hz, 2H, H-13), 3.23 (q, J = 6.2 Hz, 2H, H-12), 1.36 (s, 9H, H-19); 13C NMR 
(151 MHz, DMSO-d6) δ 156.6 (C-15), 156.3 (C-1), 154.7 (C-7), 153.5 (C-3), 148.0 (C-10), 132.5 
(C-9), 121.2 (C-8), 112.4 (C-10), 108.3 (C-4), 78.1 (C-18), 41.8 (C-13), 39.4 (C-12), 28.6 (C-19); 
HRMS m/z (ESI+) [Found: 345.1098, C15H19ClN4NaO2 requires (M+H)+ 345.1089]; LCMS (LCQ) 
Rt = 0.6 min (4 min method), m/z (ESI+) 323.1 (M+H)+, 267.2 (M-tBu+H)+. 
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Tert-Butyl N-[2-[[7-(4-pyridyl)-1,6-naphthyridin-5-yl]amino]ethyl]carbamate (286) 
 
Pyridine-4-boronic acid hydrate (196) (57 mg, 0.46 mmol), potassium carbonate (193 mg, 
1.39 mmol) and tert-butyl N-[2-[(7-chloro-1,6-naphthyridin-5-yl)amino]ethyl]carbamate (285) 
(150 mg, 0.46 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow of nitrogen.  
bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium (15 mg, 
0.02 mmol) was added and the reaction was heated in a sealed microwave reactor at 140 °C for 
15 minutes. LCMS indicated formation of the product (m/z 293). The reaction mixture was 
diluted with water (15 ml) and extracted twice with ethyl acetate (2 × 20 mL). The combined 
organic phases were dried over MgSO4, filtered and concentrated under reduced pressure to 
give a brown gum (163 mg). The crude was purified via flash column chromatography (5 g silica, 
petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl N-[2-[[7-(4-pyridyl)-1,6-
naphthyridin-5-yl]amino]ethyl]carbamate (286) (59 mg, 31%) as a yellow solid.  
Rf 0.57 (9:1 dichloromethane:methanol); m.p. 180–181 °C; νmax (thin film)/cm-1 3396 (N-H, br), 
3222 (N-H, br), 1977 (aliphatic C-H, m), 1688 (C=O, s), 1556 (aromatic C-H, s), 765 (N-H, s); 1H 
NMR (600 MHz, DMSO-d6) δ 8.96 (dd, J = 4.3, 1.6 Hz, 1H, H-9), 8.67 (d, J = 6.1 Hz, 2H, H-2' and 
H-6'), 8.65 (d, J = 8.7 Hz, 1H, H-7), 8.21 (d, J = 6.2 Hz, 2H, H-3' and h-5'), 7.94 (t, J = 5.5 Hz, 1H, 
H-14), 7.75 (s, 1H, H-4), 7.55 (dd, J = 8.3, 4.3 Hz, 1H, H-8), 7.05 (t, J = 5.9 Hz, 1H, H-11), 3.66 (q, 
J = 6.3 Hz, 2H, H-13), 3.35 – 3.29 (m, 2H, H-12), 1.37 (s, 9H, H-19); 13C NMR (151 MHz, DMSO-d6) 
δ 155.8 (C-15), 155.8 (C-1), 154.0 (C-7), 152.7 (C-7), 150.1 (C-2' and C-6'), 149.2 (C-3), 146.1 
(C-4'), 131.6 (C-9), 121.4 (C-8), 120.8 (C-3' and C-5'), 113.5 (C-10), 107.7 (C-4), 77.6 (C-18), 41.3 
(C-13), 39.1 (C-12), 28.3 (C-19); HRMS m/z (ESI+) [Found: 366.1912, C20H24N5O2 requires [M+H]+ 
366.1925]; LCMS (MDAP) Rt = 7.2 min (Ana 30–95 over 20 min), m/z (ESI+) 366.9 [M+H]+. 
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N'-[7-(4-Pyridyl)-1,6-naphthyridin-5-yl]ethane-1,2-diamine (287)161 
 
Tert-Butyl N-[2-[[7-(4-pyridyl)-1,6-naphthyridin-5-yl]amino]ethyl]carbamate (286) (50 mg, 
0.14 mmol) was dissolved in dichloromethane (1 mL) and cooled to 0 °C. Trifluoro acetic acid 
(0.5 mL, 5.53 mmol) was added dropwise and the reaction mixture was allowed to stir at room 
temperature overnight. LCMS (LCQ) indicated product formation (m/z 266). The reaction 
mixture was concentrated under reduced pressure to give a yellow solid. The crude was purified 
via SCX cartridge by elution with methanol then 2 M ammonia in methanol. The resulting yellow 
solid (34 mg) was triturated in methanol to give N'-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]ethane-
1,2-diamine (287) (6 mg, 15%) as a pale yellow solid.  
1H NMR (600 MHz, DMSO-d6) δ 8.99 (d, J = 4.0 Hz, 1H, H-7), 8.80 (d, J = 8.4 Hz, 1H, H-9), 8.69 (d, 
J = 5.9 Hz, 2H, H-2' and H-6'), 8.19 (d, J = 6.0 Hz, 2H, H-3' and H-5'), 7.98 (s, 3H, H-11 and H-14), 
7.81 (s, 1H, H-4), 7.57 (dd, J = 8.2, 4.3 Hz, 1H, H-8), 3.90 (q, J = 5.7 Hz, 2H, H-12), 3.22 (t, J = 6.1 Hz, 
2H, H-13); LCMS (MDAP) Rt = 0.8 min (Ana 5–95 over 5 minutes), m/z (ESI+) 266.0 (M+H)+. 
Insufficient quantities isolated for further characterisation. 
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Tert-Butyl 4-(7-chloro-1,6-naphthyridin-5-yl)piperazine-1-carboxylate (288) 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol) 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1  mmol) and  1-Boc-piperazine (185) (1.11 g, 5.97 mmol) in ethanol (7 mL) were stirred 
at 100 °C overnight. LCMS confirmed product formation (m/z 349). The reaction mixture was 
concentrated under reduced pressure, diluted with water (4 mL) and extracted with ethyl 
acetate (3 × 40 mL). The combined organic extracts were washed with water (40 mL) and brine 
(40 mL), dried over MgSO4, filtered and concentrated under reduced pressure to give a yellow 
solid (884 mg). The crude was purified via flash column chromatography (25 g silica, petroleum 
ether:ethyl acetate, 1:0 to 0:1) to give  tert-butyl 4-(7-chloro-1,6-naphthyridin-5-yl)piperazine-
1-carboxylate (288) (188 mg, 51%) as a white solid.  
1H NMR (600 MHz, DMSO-d6) δ 9.01 (dd, J = 4.2, 1.5 Hz, 1H, H-7), 8.48 (d, J = 8.4 Hz, 1H, H-9), 
7.57 (dd, J = 8.5, 4.2 Hz, 1H, H-8), 7.45 (s, 1H, H-4), 3.58 (s, 4H, H-13 and H-15), 3.47–3.41 (m, 
4H, H-12 and H-16), 1.44 (s, 9H, H-21); LCMS (LCQ) Rt = 4.8 min (5 min method), m/z (ESI+) 349.1 
(M+H)+, 293.2 (M+H-t-Bu)+, 249.2 (M+H-Boc)+. 
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Tert-Butyl 4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate (289) 
 
Sodium carbonate (137 mg, 1.29 mmol), tert-butyl 4-(7-chloro-1,6-naphthyridin-5-yl)piperazine-
1-carboxylate (288) (150 mg, 0.43 mmol),  pyridine-4-boronic acid hydrate (196) (53 mg, 
0.43 mmol) and bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron;dichloropalladium 
(14 mg, 0.02 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow of nitrogen 
and heated in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed reaction 
completion (m/z 392, 336, 292). The reaction mixture was diluted with water (20 ml) and 
extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated under reduced pressure to give a brown solid (160 mg). The 
crude was purified via flash column chromatography  (5 g silica,  petroleum ether:ethyl acetate, 
1:0 to 0:1) to give tert-butyl 4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate 
(289) (103 mg, 58%) as a pale brown solid.151 
Rf 0.59 (9:1 dichloromethane:methanol); m.p. 209–210 °C; νmax (thin film)/cm-1 3050 (aromatic 
C-H, br), 2972 (aliphatic C-H, br), 1699 (C=O, s), 1569 (aromatic C-H, s), 834 (alkene C-H, s), 767 
(alkene C-H, s); 1H NMR (600 MHz, DMSO-d6) δ 9.07 (dd, J = 4.3, 1.6 Hz, 1H, H-9), 8.70 (d, J = 
5.8 Hz, 2H, H-2' and H-6'), 8.52 (d, J = 8.3 Hz, 1H, H-7), 8.26–8.12 (m, 3H, H-3', H-5' and H-4), 7.62 
(dd, J = 8.4, 4.2 Hz, 1H, H-8), 3.63 (s, 4H, H-13 and H-15), 3.51–3.46 (m, 4H, H-12 and H-16), 1.44 
(s, 9H, H-21); 13C NMR (151 MHz, DMSO-d6) δ 161.1 (C-17), 155.0 (C-9), 154.4 (C-1), 153.8 (C-5), 
150.7 (C-2' and C-6'), 148.5 (C-3), 145.9 (C-4'), 134.4 (C-7), 122.6 (C-8), 121.2 (C-3' and C-5'), 
116.4 (C-10), 113.7 (C-4), 79.5 (C-20), 55.3 (C-13 and C-15), 51.1 (C-12 and C-16), 28.5 (C-21); 
HRMS m/z (ESI+) [Found: 392.2098, C22H26N5O2 requires (M+H)+ 392.2081]; LCMS (LCQ) Rt = 
0.7 min (4 min method), m/z (ESI+) 392.2 (M+H)+, 336.2 (M+H-t-Bu)+, 292.4 (M+H-Boc)+. 
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5-Piperazin-1-yl-7-(4-pyridyl)-1,6-naphthyridine (290) 
 
Tert-Butyl 4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate (289) (80 mg, 
0.20 mmol) was dissolved in dichloromethane (1.5 mL) and cooled to 0 °C. Trifluoro acetic acid 
(0.80 mL, 8.26 mmol) was added dropwise and the reaction mixture was allowed to stir at room 
temperature overnight. LCMS (LCQ) indicated product formation (m/z 292). The reaction 
mixture was concentrated under reduced pressure to give a yellow solid. The crude was purified 
via SCX cartridge by elution with methanol then 2 M ammonia in methanol to give 5-piperazin-
1-yl-7-(4-pyridyl)-1,6-naphthyridine (290) (45 mg, 72%) as a pale brown solid.106  
Rf 0.59 (9:1 dichloromethane: methanol); m.p. 147–149 °C; νmax (thin film)/cm-1 3399 (N-H, br), 
1669 (C=C, m), 1597 (aromatic C-H, s), 1565 (aromatic C-H, s), 1496 (aliphatic C-H), 826 (N-H, s); 
1H NMR (600 MHz, DMSO-d6) δ 9.05 (d, J = 4.3 Hz, 1H, H-9), 8.71 (d, J = 5.0 Hz, 2H, H-2' and H-6'), 
8.50 (d, J = 8.4 Hz, 1H, H-7), 8.19 (d, J = 5.2 Hz, 2H, H-3' and H-5'), 8.17 (s, 1H, H-4), 7.61 (dd, J = 
8.4, 4.2 Hz, 1H, H-8), 3.51 (t, J = 4.9 Hz, 4H, H-12 and H-16), 3.10 (t, J = 4.9 Hz, 4H, H-13 and H-15). 
N-H peak not observed; 13C NMR (151 MHz, DMSO-d6) δ 161.2 (C-1), 154.9 (C-9), 153.7 (C-5), 
150.7 (C-2' and C-6'), 148.4 (C-3), 145.9 (C-4'), 134.4 (C-7), 122.5 (C-8), 121.1 (C-3' and C-5'), 
116.4 (C-10), 113.6 (C-4), 51.1 (C-12 and C-16), 45.0 (C-13 and C-15); HRMS m/z (ESI+) [Found: 
292.1560, C17H18N5 requires (M+H)+ 292.1557]; LCMS (MDAP) Rt = 2.9 min (Ana 30–90 in 20min), 
m/z (ESI+) 292.1 (M+H)+. 
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N-[2-[(7-Chloro-1,6-naphthyridin-5-yl)amino]ethyl]acetamide 
 
N,N-Diisopropylethylamine (1.77 mL, 10.2 mmol), 5,7-dichloro-1,6-naphthyridine (284) (500 mg, 
2.51 mmol), and N-(2-aminoethyl)acetamide (1.52 g, 14.9 mmol) in ethanol (17.5mL) were 
degassed under a flow of nitrogen and heated to 100 °C overnight. LCMS confirmed reaction 
completion (m/z 265.0 and 266.9). The reaction mixture was diluted with water (20 ml) and 
extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated under reduced pressure to give a yellow oil (631 mg). The 
crude was purified via flash column chromatography (5 g silica, petroleum ether:ethyl acetate, 
1:0 to 0:1) to give N-[2-[(7-chloro-1,6-naphthyridin-5-yl)amino]ethyl]acetamide (502 mg, 72%) 
as an off-white solid. 
Rf 0.32 (9:1 ethyl acetate:methanol); m.p. 238–240 °C; νmax (thin film)/cm-1 3270 (N-H, br), 3223 
(N-H, br), 1651 (C=O, m), 1588 (aromatic C-C, s), 1332 (aliphatic C-H, s), 805 (N-H, s); 1H NMR 
(600 MHz, DMSO-d6) δ 8.90 (dd, J = 4.4, 1.6 Hz, 1H, H-9), 8.61 (dt, J = 8.2, 1H, H-7), 8.20 (t, J = 
5.4 Hz, 1H, H-14), 8.04 (t, J = 5.7 Hz, 1H, H-11), 7.50 (dd, J = 8.4, 4.3 Hz, 1H, H-8), 6.97 (s, 1H, 
H-4), 3.51 (q, J = 6.3 Hz, 2H, H-13), 3.36–3.31 (m, 2H, H-12), 1.81 (s, 3H, H-17); 13C NMR (151 MHz, 
DMSO-d6) δ 170.1 (C-15), 156.6 (C-1), 154.8 (C-7), 153.5 (C-5), 148.0 (C-3), 132.4 (C-9), 121.3 
(C-8), 112.4 (C-10), 108.3 (C-4), 41.4 (C-13), 38.0 (C-12), 23.1 (C-17); HRMS m/z (ESI+) [Found: 
287.0663, C12H13ClN4NaO requires (M+H)+ 287.0670]; LCMS (MDAP) Rt = 7.8 min (Ana 30–95 
over 20 min), m/z (ESI+) 264.9 [35Cl] and 266.9 [37Cl] (M+H)+. 
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N-[2-[[7-(4-Pyridyl)-1,6-naphthyridin-5-yl]amino]ethyl]acetamide (291) 
 
Potassium carbonate (203 mg, 1.47 mmol), pyridine-4-boronic acid hydrate (196) (60 mg, 
0.49 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(16 mg, 0.02 mmol) and N-[2-[(7-chloro-1,6-naphthyridin-5-yl)amino]ethyl]acetamide (150 mg, 
0.54 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow of nitrogen and heated 
in a microwave reactor at 140 oC for 15 minutes. LCMS confirmed reaction completion 
(m/z 308). The reaction mixture was diluted with water (15 ml) and extracted three times with 
ethyl acetate (3 × 20 mL). The combined organic phases were dried over MgSO4, filtered and 
concentrated under reduced pressure to give a yellow oil (71 mg). The crude was purified via 
flash column chromatography  (4 g silica dichloromethane:methanol, 1:0 to 9:1) to give N-[2-[[7-
(4-pyridyl)-1,6-naphthyridin-5-yl]amino]ethyl]acetamide (291) (26 mg, 15%) as a light brown 
solid.  
Rf 0.28 (9:1 dichloromethane:methanol); m.p. 273–275 °C; νmax (thin film)/cm-1 3338 (N-H, m), 
3200 (aromatic C-H, br), 2997 (aliphatic C-H, br), 1671 (C=O, s), 1539 (aromatic C-C, s), 792 (N-H, 
m); 1H NMR (600 MHz, DMSO-d6) δ 8.96 (d, J = 4.0 Hz, 1H, H-7), 8.67 (d, J = 5.7 Hz, 2H, H-2' and 
H-6'), 8.65 (d, J = 8.5 Hz, 1H, H-9), 8.19 (d, J = 5.8 Hz, 2H, H-3' and H-5'), 8.06 (t, J = 5.3 Hz, 1H, H-
14), 7.98 (t, J = 5.1 Hz, 1H, H-11), 7.75 (s, 1H, H-4), 7.54 (dd, J = 8.3, 4.2 Hz, 1H, H-8), 3.67 (q, 
J = 6.3 Hz, 2H, H-13), 3.42 (q, J = 6.4 Hz, 2H, H-12), 1.82 (s, 3H, H-17); 13C NMR (151 MHz, 
DMSO-d6) δ 170.0 (C-15), 156.2 (C-1), 154.4 (C-7), 153.1 (C-5), 150.5 (C-2' and C-6'), 149.6 (C-3), 
146.5 (C-4'), 132.0 (C-9), 121.8 (C-8), 121.1 (C-3' and C-5'), 113.9 (C-10), 108.1 (C-4), 41.4 (C-13), 
38.3 (C-12), 23.2 (C-17); HRMS m/z (ESI+) [Found: 308.1499, C17H18N5O requires (M+H)+ 
308.1506]; LCMS (MDAP) Rt = 10.2 min (Ana 5–95 over 20 min), m/z (ESI+) 308.1 (M+H)+. 
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1-[4-(7-Chloro-1,6-naphthyridin-5-yl)piperazin-1-yl]ethanone 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol) and 1-(1-piperazinyl)ethanone (765 mg, 5.97 mmol) in ethanol (7 mL) were stirred 
at 100 oC overnight. LCMS indicated product formation (m/z 293). The reaction mixture was 
concentrated under reduced pressure and water (4 mL) was added. The reaction mixture was 
extracted three times with ethyl acetate (3 × 40 mL) and the combined organic phases were 
washed with water (40 mL) and brine (40 mL) before being dried over MgSO4, filtered and 
concentrated under reduced pressure (321 mg). The crude was purified via flash column 
chromatography (12 g silica, dichloromethane:methanol, 1:0 to 9:1) to give 1-[4-(7-chloro-1,6-
naphthyridin-5-yl)piperazin-1-yl]ethanone (256 mg, 83%) as a white solid.  
Rf 0.28 (9:1 ethyl acetate:methanol); m.p. 144–146 °C; νmax (thin film)/cm-1 2998 (aliphatic C-H, 
w), 2850 (aldehyde C-H, m), 1630 (C=O, s), 1596 (C=C, s), 1556 (aliphatic C-C, s), 1366 (aliphatic 
C-H, s), 977 (aliphatic C-H, s), 874 (N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 9.01 (dd, J = 4.2, 
1.6 Hz, 1H, H-9), 8.50 (dt, J = 8.5, 1.2 Hz, 1H, H-7), 7.57 (dd, J = 8.5, 4.2 Hz, 1H, H-8), 7.45 (s, 1H, 
H-4), 3.68 (t, J = 4.6 Hz, 4H, H-12 and H-16), 3.54–3.46 (m, 2H, H-13/15), 3.43 (dd, J = 6.5, 3.9 Hz, 
2H, H-15/13), 2.06 (s, 3H, H-19); 13C NMR (151 MHz, DMSO-d6) δ 168.5 (C-17), 160.5 (C-1), 154.9 
(C-7), 153.8 (C-5), 145.6 (C-3), 134.4 (C-9), 121.4 (C-8), 114.3 (C-10), 113.9 (C-4), 50.7 
(C-13/C-15), 50.4 (C-15/C-13), 45.2 (C-12/16), 40.6 (C-16/12), 21.3 (C-19); HRMS m/z (ESI+) 
[Found: 313.0822, C14H15ClN4NaO requires (M+H)+ 313.0827]; LCMS (MDAP) Rt = 11.6 min, (Ana 
30–95 over 20 min); m/z (ESI+) 291.0 [35Cl] and 292.9 [37Cl] [M-H]+. 
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1-[4-[7-(4-Pyridyl)-1,6-naphthyridin-5-yl]piperazin-1-yl]ethanone (292) 
 
Potassium carbonate (214 mg, 1.55 mmol), pyridine-4-boronic acid hydrate (196) (63 mg, 
0.52 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(17 mg, 0.03 mmol) and 1-[4-(7-chloro-1,6-naphthyridin-5-yl)piperazin-1-yl]ethanone (150 mg, 
0.52 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow of nitrogen and heated 
in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed reaction completion (m/z 334). 
The reaction mixture was diluted with water (20 ml) and extracted twice with ethyl acetate (2 × 
25 mL). The combined organic phases were dried over MgSO4, filtered and concentrated under 
reduced pressure (158 mg). The crude was purified via flash column chromatography  (5 g 
petroleum ether:ethyl acetate, 1:0 to 0:1) to give 1-[4-[7-(4-pyridyl)-1,6-naphthyridin-5-
yl]piperazin-1-yl]ethanone (292) (71 mg, 39%) as an off-white solid.151  
Rf 0.23 (9:1 dichloromethane:methanol); m.p. 201–202 °C; νmax (thin film)/cm-1 2923 (aliphatic 
C-H, w), 2853 (aliphatic C-H, m), 1647 (C=O, m), 1600 (aromatic C-C, s), 1567 (aromatic C-C, s), 
818 (alkene C-H, m); 1H NMR (600 MHz, DMSO-d6) δ 9.07 (dd, J = 4.2, 1.3 Hz, 1H, H-7), 8.71 (d, 
J = 5.9 Hz, 2H, H-2' and H-6'), 8.54 (d, J = 8.4 Hz, 1H, H-9), 8.24–8.17 (m, 3H, H-3', H-5' and H-4), 
7.63 (dd, J = 8.4, 4.2 Hz, 1H, H-8), 3.79–3.68 (m, 4H, H-12 and H-16), 3.59–3.51 (m, 2H, H-13/15), 
3.50–3.41 (m, 2H, H-15/13), 2.08 (s, 3H, H-19); 13C NMR (151 MHz, DMSO-d6) δ 168.6 (C-17), 
160.6 (C-1), 154.6 (C-7), 153.3 (C-5), 150.3 (C-2' and C-6'), 148.0 (C-1'), 145.5 (C-3), 134.0 (C-9), 
122.2 (C-8), 120.8 (C-3' and C-5'), 116.0 (C-10), 113.3 (C-4), 51.0 (C-13/15), 50.7 (C-15/13), 45.5 
(C-12/16), 40.8 (C-16/12), 21.4 (C-19); HRMS m/z (ESI+) [Found: 334.1662, C19H20N5O requires 
(M+H)+ 334.1662]; LCMS (LCQ/MDAP) Rt = 6.9 min (Ana 30–95 over 20 min) m/z (ESI+) 334.1 
(M+H)+. 
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4-(7-Chloro-1,6-naphthyridin-5-yl)piperazin-2-one 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol), piperazin-2-one (598 mg, 5.97 mmol) and in ethanol (7 mL) were heated 
at 100 °C overnight. LCMS  indicated product formation (m/z 263). The reaction mixture was 
concentrated under reduced pressure and water (4 mL) was added. The mixture was extracted 
three times with ethyl acetate (3 × 40 mL) but the product was not soluble in ethyl acetate. The 
organic and aqueous phases were re-concentrated under reduced pressure and the remaining 
aqueous layer extracted with dichloromethane (3 × 40 mL). The combined organic phases were 
washed with water (40 mL), brine (40 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure to give 4-(7-chloro-1,6-naphthyridin-5-yl)piperazin-2-one (123 mg, 44%) as an 
off-white solid.215  
Rf 0.23 (9:1 ethyl acetate:methanol); m.p. 210–212 °C; νmax (thin film)/cm-1 3228 (N-H, br), 3052 
(aromatic C-H, w), 1673 (C=O, s), 1571 (aromatic C-C, s), 1049 (C-N, s), 870 (N-H, s); 1H NMR 
(600 MHz, DMSO-d6) δ 9.01 (dd, J = 4.2, 1.6 Hz, 1H, H-9), 8.49 (d, J = 8.5 Hz, 1H, H-7), 8.09 (s, 1H, 
H-14), 7.56 (dd, J = 8.5, 4.2 Hz, 1H, H-8), 7.49–7.39 (m, 1H, H-4), 4.04 (s, 2H, H-16), 3.74 (d, J = 
5.0 Hz, 2H, H-12), 3.44–3.38 (m, 2H, H-13); 13C NMR (151 MHz, DMSO-d6) δ 166.7 (C-15), 159.2 
(C-1), 155.0 (C-7), 153.9 (C-5), 145.5 (C-3), 134.4 (C-9), 121.5 (C-10), 114.3 (C-4), 113.8 (C-8), 52.9 
(C-16), 48.2 (C-12), 39.9 (C-13); HRMS m/z (ESI+) [Found: 285.0508, C12H11ClN4NaO requires 
(M+H)+ 285.0514]; LCMS (MDAP) Rt = 9.4 min (Ana 30–95 over 20 min), m/z (ESI+) 263.0 [35Cl] 
and 264.7 [37Cl] (M+H)+. 
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4-[7-(4-Pyridyl)-1,6-naphthyridin-5-yl]piperazin-2-one (293) 
 
Potassium carbonate (150 mg, 1.08 mmol), pyridine-4-boronic acid hydrate (196) (44 mg, 
0.36 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(12 mg, 0.02 mmol) and 4-(7-chloro-1,6-naphthyridin-5-yl)piperazin-2-one (100 mg, 
0.36 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow of nitrogen and heated 
in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed reaction completion 
(m/z 306). The reaction mixture was diluted with water (10 ml) and extracted twice with ethyl 
acetate (2 × 15 mL). The combined organic phases were dried over MgSO4, filtered and 
concentrated under reduced pressure (55 mg). The crude was purified via flash column 
chromatography  (4 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give  4-[7-(4-pyridyl)-
1,6-naphthyridin-5-yl]piperazin-2-one (293) (31 mg, 27%) as a brown solid.151 
Rf 0.70  (9:1 dichloromethane:methanol); m.p. 241–242 °C; νmax (thin film)/cm-1 3383 (N-H, br), 
3196 (aromatic C-H, m), 3072 (aromatic C-H, m), 1662 (C=O, s), 1599 (aromatic C-C, m), 1358 
(aliphatic C-H, s), 837 (N-H, s), 772 (C-H, s); 1H NMR (600 MHz, DMSO-d6) δ 9.07 (dd, J = 4.3, 
1.6 Hz, 1H, H-7), 8.71 (d, 6.1 Hz, 2H, H-2' and H-6'), 8.54 (d, J = 8.3 Hz, 1H, H-9), 8.22–8.19 (m, 
3H, H-13, H-14 and H-15), 8.01 (s, 1H, H-4), 7.62 (dd, J = 8.4, 4.2 Hz, 1H, H-8), 4.12 (s, 2H, H-16), 
3.77 (t, J = 5.4 Hz, 2H, H-12), 3.47–3.32 (m, 2H, H-13); 13C NMR (151 MHz, DMSO-d6) δ 167.4 
(C-15), 159.2 (C-1), 154.7 (C-7), 153.4 (C-5), 150.3 (C-2' and C-6'), 147.9 (C-3), 145.3 (C-4'), 133.8 
(C-9), 122.2 (C-8), 120.8 (C-3' and C-5'), 115.9 (C-10), 113.3 (C-4), 53.0 (C-16), 48.6 (C-12), 40.0 
(C-13); HRMS m/z (ESI+) [Found: 328.1161 C17H15N5NaO requires (M+Na)+ 328.1169]; LCMS 
(MDAP) Rt = 7.2 min (Ana 30–95 over 20 min), m/z (ESI+) 306.0 (M+H)+. 
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4-(7-Chloro-1,6-naphthyridin-5-yl)-1-methyl-piperazin-2-one 
 
N,N-Diisopropylethylamine (0.71  mL, 4.06mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol),  and 1-methylpiperazin-2-one (684 mg, 5.99 mmol) in ethanol (7mL) were stirred 
at 100 °C overnight. LCMS indicated product formation (m/z 276, 278). The mixture was 
concentrated under reduced pressure and water (4 mL) was added. The mixture was extracted 
four time with ethyl acetate (4 × 40 mL). The combined organic phases were washed with water 
(40 mL) and brine (40 mL) then dried over MgSO4, filtered and concentrated under reduced 
pressure to give an orange oil (553 mg). The crude was purified via flash column chromatography 
(12 g silica, dichloromethane:methanol, 1:0 to 9:1) to give 4-(7-chloro-1,6-naphthyridin-5-yl)-1-
methyl-piperazin-2-one (212 mg, 72%) as a pale yellow solid.  
Rf 0.53 (9:1 dichloromethane:methanol); m.p. 162–164 °C; νmax (thin film)/cm-1 2939 (aliphatic 
C-H, w), 1657 (C=O, s), 1578 (aromatic C-C, s), 1346 (aliphatic C-H, s), 1071 (C-N, s), 873 (C-H, 
m); 1H NMR (600 MHz, DMSO-d6) δ 9.01 (dd, J = 4.2, 1.6 Hz, 1H, H-7), 8.51–8.47 (m, 1H, H-9), 
7.57 (dd, J = 8.5, 4.2 Hz, 1H, H-8), 7.45 (d, J = 0.7 Hz, 1H, H-4), 4.10 (s, 2H, H-16), 3.81 (t, J = 5.4 Hz, 
2H, H-12), 3.61–3.47 (m, 2H, H-13), 2.91 (s, 3H, H-17); 13C NMR (151 MHz, DMSO-d6) δ 165.4 
(C-15), 159.3 (C-1), 155.4 (C-7), 154.2 (C-5), 145.9 (C-3), 134.6 (C-9), 121.9 (C-8), 114.5 (C-10), 
114.3 (C-4), 53.5 (C-16), 48.4 (C-12), 47.6 (C-13), 33.9 (C-17); HRMS m/z (ESI+) [Found: 299.0665, 
C13H13ClN4NaO requires (M+H)+ 299.0670]; LCMS (MDAP) Rt = 15.6 min (Ana 5–95 over 20 min), 
m/z (ESI+) 276.900 [35Cl] and 278.850 [37Cl] (M+H)+. 
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1-Methyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazin-2-one (294) 
 
Potassium carbonate (225 mg, 1.63 mmol), pyridine-4-boronic acid hydrate (196) (67 mg, 
0.54 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(18 mg, 0.03 mmol) and 4-(7-chloro-1,6-naphthyridin-5-yl)-1-methyl-piperazin-2-one (150 mg, 
0.54 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow of nitrogen and heated 
in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed reaction completion 
(m/z 320). The reaction mixture was diluted with water (20 ml) and extracted twice with ethyl 
acetate (2 × 25 mL). The combined organic phases were dried over MgSO4, filtered and 
concentrated under reduced pressure to give a yellow oil (52 mg). The crude was purified via 
flash column chromatography  (4 g dichloromethane:methanol, 1:0 to 9:1) to give 1-methyl-4-
[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazin-2-one (294) (36 mg, 20%) as a pale brown solid.  
Rf 0.62 (9:1 dichloromethane:methanol); m.p. 200–202 °C; νmax (thin film)/cm-1 3029 (aromatic 
C-H, w), 2918 (aliphatic C-H, w), 1635 (C=O, s), 1598 (C=C, s), 1567 (aromatic C-C, s), 1076 (C-N, 
s); 1H NMR (600 MHz, DMSO-d6) δ 9.08 (dd, J = 4.2, 1.6 Hz, 1H, H-7), 8.71 (d, J = 5.9 Hz, 2H, H-2' 
and H-6'), 8.54 (d, J = 8.4 Hz, 1H, H-9), 8.22 (s, 1H, H-4), 8.20 (d, J = 6.0 Hz, 2H, H-3' and H-5'), 
7.63 (dd, J = 8.4, 4.2 Hz, 1H, H-8), 4.17 (s, 2H, H-16), 3.84 (t, J = 5.5 Hz, 2H, H-13), 3.55 (t, J = 
5.5 Hz, 2H, H-12), 2.91 (s, 3H, H-17); 13C NMR (151 MHz, DMSO-d6) δ 165.7 (C-15), 159.0 (C-1), 
154.7 (C-7), 153.3 (C-5), 150.3 (C-2' and C-6'), 147.9 (C-3), 145.3 (C-4'), 133.8 (C-9), 122.3 (C-8), 
120.8 (C-3' and C-5'), 115.8 (C-10), 113.4 (C-4), 53.2 (C-16), 48.6 (C-13), 47.4 (C-12), 33.4 (C-17); 
HRMS m/z (ESI+) [Found: 342.1320, C18H17N5NaO requires (M+H)+ 342.1325]; LCMS (MDAP) 
Rt = 9.9 min (Ana 5–95 over 20 min), m/z (ESI+) 320.1 (M+H)+. 
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7-Chloro-5-(4-methylpiperazin-1-yl)-1,6-naphthyridine 
 
5,7-Dichloro-1,6-naphthyridine (284) (200 mg, 1 mmol), 1-methylpiperazine (0.66 mL, 
5.97 mmol) and N,N-diisopropylethylamine (0.71 mL, 4.06 mmol) were stirred in ethanol (7 mL) 
at 100 °C overnight. LCMS confirmed formation of product (m/z 263). The reaction mixture was 
concentrated under reduced pressure and water was added (4 mL). The mixture was extracted 
three times with ethyl acetate (3 × 40 mL). The combined organic phases were washed with 
water (40 mL) and brine (40 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure to give a brown solid (252 mg). The crude was purified via flash column 
chromatography (10 g silica, dichloromethane:methanol, 1:0 to 9:1) to give 7-chloro-5-(4-
methylpiperazin-1-yl)-1,6-naphthyridine (206 mg, 74%) as an off-white solid.  
Rf 0.38 (9:1 dichloromethane:methanol); m.p. 125–127 °C; νmax (thin film)/cm-1 2929 (aromatic 
C-H, w), 2831 (aliphatic C-H, w), 2795 (aliphatic C-H, m), 1598 (aromatic C=C, m), 1557 (aromatic 
C-C, s), 1417 (C-H, s), 1004 (C-N, s); 1H NMR (600 MHz, DMSO-d6) δ 8.99 (dd, J = 4.2, 1.5 Hz, 1H, 
H-7), 8.42 (d, J = 8.5 Hz, 1H, H-9), 7.55 (dd, J = 8.5, 4.2 Hz, 1H, H-8), 7.40 (s, 1H, H-4), 3.46 (t, J = 
4.9 Hz, 4H, H-12 and H-16), 2.55 (t, J = 4.9 Hz, 4H, H-13 and H-15), 2.26 (s, 3H, H-17); 13C NMR 
(151 MHz, DMSO-d6) δ 106.6 (C-1), 154.8 (C-7), 153.7 (C-5), 145.7 (C-3), 134.3 (C-9), 121.3 (C-8), 
114.2 (C-10), 113.5 (C-4), 54.3 (C-13 and C-15), 50.6 (C-12 and C-16), 45.7 (C-17); HRMS m/z 
(ESI+) [Found: 263.0512, C13H16ClN4 requires (M+H)+ 263.1058]; LCMS (LCQ) Rt = 2.4 min, (4 min 
method); m/z (ESI+) 263.18 (M+H)+. 
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5-(4-Methylpiperazin-1-yl)-7-(4-pyridyl)-1,6-naphthyridine (295) 
 
Potassium carbonate (225 mg, 1.63 mmol), pyridine-4-boronic acid hydrate (196) (67 mg, 
0.54 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(18 mg, 0.03 mmol) and 7-chloro-5-(4-methylpiperazin-1-yl)-1,6-naphthyridine (150 mg, 
0.54 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow of nitrogen and heated 
in a microwave reactor at 140 °C for 15 minutes. LCMS indicated product formation (m/z 306). 
The reaction mixture was diluted with water (20 ml) and extracted twice with ethyl acetate (2 × 
25 mL). The combined organic phases were dried over MgSO4, filtered and concentrated under 
reduced pressure to give a yellow oil (191 mg). The crude was purified twice via flash column 
chromatography  (5 g petroleum ether:ethyl acetate, 1:0 to 0:1; then ethyl acetate:methanol, 
1:0 to 9:1) to give 5-(4-methylpiperazin-1-yl)-7-(4-pyridyl)-1,6-naphthyridine (295) (116 mg, 
67%) as a pale brown solid.  
Rf 0.68 (100% ethyl acetate); m.p. 174–175 °C; νmax (thin film)/cm-1 2922 (aliphatic C-H, m), 2836 
(aliphatic C-H, m), 1599 (aromatic C-C, s), 1569 (aromatic C-H, s), 1443 (aliphatic C-H, s), 1007 
(C-N, s); 1H NMR (600 MHz, DMSO-d6) δ 9.05 (dd, J = 4.3, 1.6 Hz, 1H, H-7), 8.70 (d, J = 6.1 Hz, 2H, 
H-2' and H-6'), 8.46 (d, J = 8.3 Hz, 1H, H-9), 8.19 (d, J = 6.2 Hz, 2H, H-3' and H-5'), 8.15 (s, 1H, 
H-4), 7.60 (dd, J = 8.4, 4.2 Hz, 1H, H-8), 3.52 (t, J = 4.6 Hz, 4H, H-12 and H-165), 2.61 (t, J = 4.8 Hz, 
4H, H-13 and H-15), 2.29 (s, 3H, H-17); 13C NMR (151 MHz, DMSO-d6) δ 160.7 (C-1), 154.4 (C-7), 
153.3 (C-5), 150.3 (C2' and C-6'), 148.0 (C-1'), 145.5 (C-3), 133.9 (C-9), 122.0 (C-8), 120.7 (C-3' 
and C-5'), 115.9 (C-10), 112.9 (C-4), 54.5 (C-13 and C-15), 50.6 (C-12 and C-16), 45.7 (C-17); HRMS 
m/z (ESI+) [Found: 306.1711, C18H20N5 requires (M+H)+ 306.1713]; LCMS (LCQ) Rt = 7.9 min (Ana 
5–95 over 20 min), m/z (ESI+) 306.1 (M+H)+. 
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7-Chloro-5-(4-isopropylpiperazin-1-yl)-1,6-naphthyridine 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol) and 1-isopropylpiperazine (765 mg, 5.97 mmol) in ethanol (7 mL) were stirred at 100 °C 
overnight. LCMS indicated product formation (m/z 291, 293). The mixture was concentrated 
under reduced pressure and water (4 mL) was added. The mixture was extracted four time with 
ethyl acetate (4 × 40 mL). The combined organic phases were washed with water (40 mL) and 
brine (40 mL) then dried over MgSO4, filtered and concentrated under reduced pressure 
(313 mg). The crude was purified via flash column chromatography (12 g silica, 
dichloromethane:methanol, 1:0 to 9:1) to give 7-chloro-5-(4-isopropylpiperazin-1-yl)-1,6-
naphthyridine (271 mg, 88%) as a yellow oil.  
Rf 0.28 (9:1 ethyl acetate:methanol); m.p. N/A; νmax (thin film)/cm-1 2966 (aliphatic C-H, m), 1675 
(C=C, m), 1596 (aromatic C-C, s), 1555 (aromatic C-C, s), 1441 (aliphatic C-H, s), 1015 (C-N, s), 
769 (C-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.98 (dd, J = 4.2, 1.6 Hz, 1H, H-7), 8.43 (d, J = 8.5 Hz, 
1H, H-9), 7.54 (dd, J = 8.5, 4.2 Hz, 1H, H-8), 7.39 (s, 1H, H-4), 3.45 (t, J = 4.8 Hz, 4H, H-12 and 
H-16), 2.72 (p, J = 6.6 Hz, 1H, H-17), 2.67 (t, J = 4.8 Hz, 4H, H-13 and H-15), 1.02 (d, J = 6.5 Hz, 6H, 
H-18); 13C NMR (151 MHz, DMSO-d6) δ 161.1 (C-1), 155.2 (C-7), 154.3 (C-5), 146.2 (C-3), 134.8 
(C-9), 121.7 (C-8), 114.6 (C-10), 113.8 (C-4), 54.2 (C-17), 51.5 (C-12 and C-16), 48.3 (C-13 and 
C-15), 18.6 (C-18); HRMS m/z (ESI+) [Found: 291.1362, C15H20ClN4 requires (M+H)+ 291.1371]; 
LCMS (MDAP) Rt = 7.1 min, (Ana 30–95 over 20 min); m/z (ESI+) 291.0 [35Cl] and 293.0 [37Cl] 
(M+H)+.  
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5-(4-Isopropylpiperazin-1-yl)-7-(4-pyridyl)-1,6-naphthyridine (296) 
 
Potassium carbonate (203 mg, 1.47 mmol), pyridine-4-boronic acid hydrate (196) (60 mg, 
0.49 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(16 mg, 0.02 mmol) and 7-chloro-5-(4-isopropylpiperazin-1-yl)-1,6-naphthyridine (150 mg, 
0.49 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow of nitrogen and heated 
in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed reaction completion 
(m/z 334). The reaction mixture was diluted with water (15 ml) and extracted twice with ethyl 
acetate (2 × 20 mL). The combined organic phases were dried over MgSO4, filtered and 
concentrated under reduced pressure to give a yellow oil (167 mg). The crude was purified via 
flash column chromatography  (4 g silica, dichloromethane:methanol, 1:0 to 9:1) to give 5-(4-
isopropylpiperazin-1-yl)-7-(4-pyridyl)-1,6-naphthyridine (296) (87 mg, 51%) as an off-white solid.  
Rf 0.28 (9:1 dichloromethane:methanol); m.p. 145–146 °C; νmax (thin film)/cm-1 2962 (aliphatic 
C-H, m), 1599 (C=C, s), 1569 (aromatic C-C, s), 1328 (aliphatic C-H, s), 1118 (C-N, m), 774 (C-H, 
s); 1H NMR (600 MHz, DMSO-d6) δ 9.04 (dd, J = 4.3, 1.6 Hz, 1H, H-7), 8.70 (d, J = 6.1 Hz, 2H, H-2' 
and H-6'), 8.47 (dd, J = 8.2, 1.5 Hz, 1H, H-9), 8.19 (d, J = 6.1 Hz, 2H, H-3' and H-5'), 8.14 (s, 1H, 
H-4), 7.60 (dd, J = 8.3, 4.2 Hz, 1H, H-8), 3.51 (app. s, 4H, H-12 and H-15), 2.73 (app. s, 2H, H-13 
and H-15), 1.05 (d, J = 6.5 Hz, 7H, H-17 and H-18); 13C NMR (151 MHz, DMSO-d6) δ 160.7 (C-1), 
154.5 (C-7), 153.3 (C-5), 150.3 (C-2' and C-6'), 148.0 (C-3), 145.5 (C-4'), 134.0 (C-9), 122.0 (C-8), 
120.8 (C-3' and C-5'), 115.9 (C-10), 112.9 (C-4), 54.0 (C-17), 51.1 (C-12 and C-16), 48.0 (C-13 and 
C-15), 18.2 (C-18); HRMS m/z (ESI+) [Found: 334.2019, C20H24N5 requires (M+H)+ 334.2026]; LCMS 
(MDAP) Rt = 5.5 min (Ana 5–95 over 20 min), m/z (ESI+) 334.1 (M+H)+. 
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7-Chloro-5-(4-phenylpiperazin-1-yl)-1,6-naphthyridine 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol), and phenyl piperazine (972 mg, 5.99 mmol) in ethanol (7 mL) were heated 
at 100 °C overnight. LCMS indicated product formation (m/z 325). The reaction mixture was 
concentrated under reduced pressure and water (4 mL) was added. The mixture was extracted 
three times with ethyl acetate (3 × 40 mL). The combined organic phases were washed with 
water (40 mL), brine (40 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure (976 mg). The crude was purified via flash column chromatography (30 g silica, 
petroleum ether:ethyl acetate, 1:0 to 0:1) to give 7-chloro-5-(4-phenylpiperazin-1-yl)-1,6-
naphthyridine (322 mg, 94%) as an orange solid.  
Rf 0.78 (100% ethyl acetate); m.p. 154-155 °C; νmax (thin film)/cm-1 3044 (aromatic C-H, w), 2954 
(aliphatic C-H, w), 1597 (C=C, s), 1558 (aromatic C-C, s), 1077 (C-N, s), 697 (C-H, s); 1H NMR 
(600 MHz, DMSO-d6) δ 9.02 (dd, J = 4.2, 1.4 Hz, 1H, H-7), 8.52 (d, J = 8.4 Hz, 1H, H-9), 7.58 (dd, 
J = 8.5, 4.2 Hz, 1H, H-8), 7.46 (s, 1H, H-4), 7.25 (t, J = 7.9 Hz, 1H, H-19 and H-21), 7.01 (d, J = 
8.2 Hz, 2H, H-18 and H-22), 6.82 (t, J = 7.2 Hz, 1H, H-20), 3.65–3.55 (m, 4H, H-12 and H-16/H-13 
and H-15), 3.44–3.36 (m, 4H, H-13 and H-15/H-12 and H-16); 13C NMR (151 MHz, DMSO-d6) δ 
160.7 (C-1), 155.0 (C-7), 153.8 (C-5), 150.9 (C-17), 145.8 (C-3), 134.5 (C-9), 129.1 (C-19 and C-21), 
121.6 (C-8), 119.2 (C-20), 115.6 (C-18 and C-22), 114.4 (C-4), 113.9 (C-10), 50.7 (C-12 and C-16), 
48.1 (C-13 and C-15); HRMS m/z (ESI+) [Found: 347.1032, C18H17ClN4Na requires (M+H)+ 
347.1034]; LCMS (MDAP) Rt = 25.1 min (Ana 30–95 over 30 min), m/z (ESI+) 326.0 [35Cl] and 
327.9 [37Cl] (M+H)+. 
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5-(4-Phenylpiperazin-1-yl)-7-(4-pyridyl)-1,6-naphthyridine (297) 
 
Potassium carbonate (191 mg, 1.39 mmol), pyridine-4-boronic acid hydrate (196) (57 mg, 
0.46  mol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(15 mg, 0.02 mmol) and 7-chloro-5-(4-phenylpiperazin-1-yl)-1,6-naphthyridine (150 mg, 
0.46 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow of nitrogen and heated 
in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed reaction completion 
(m/z 368). The reaction mixture was diluted with water (20 ml) and extracted twice with ethyl 
acetate (2 × 25 mL). The combined organic phases were dried over MgSO4, filtered and 
concentrated under reduced pressure (135 mg). The crude was purified via flash column 
chromatography  (4 g petroleum ether:ethyl acetate, 1:0 to 0:1) to give 5-(4-phenylpiperazin-1-
yl)-7-(4-pyridyl)-1,6-naphthyridine (297) (108 mg, 60%) as a yellow solid.  
Rf 0.15 (100% ethyl acetate); m.p. 167–168 °C; νmax (thin film)/cm-1 3030 (aromatic C-H, w), 1960 
(aliphatic C-H, w), 1598 (C=C, s), 1570 (aromatic C-C, s), 1111 (C-N, m), 757 (C-H, s); 1H NMR 
(600 MHz, DMSO-d6) δ 9.08 (dd, J = 4.2, 1.7 Hz, 1H, H-7), 8.72 (d, J = 6.2 Hz, 1H, H-2' and H-6'), 
8.57 (d, J = 8.3 Hz, 1H, H-9), 8.23 (d, J = 6.2 Hz, 1H, H-3' and H-5'), 8.21 (s, 1H, H-4), 7.64 (dd, J = 
8.4, 4.2 Hz, 1H, H-8), 7.27 (t, J = 8.5, 7.2 Hz, 1H, H-19 and H-21), 7.04 (d, J = 7.8 Hz, 1H, H-18 and 
H-22), 6.83 (t, J = 7.3 Hz, 1H, H-20), 3.68 (t, J = 5.1, 4.7 Hz, 4H, H-12 and H-16), 3.46 (t, J = 5.0 Hz, 
4H, H-13 and H-15); 13C NMR (151 MHz, DMSO-d6) δ 160.7 (C-1), 154.6 (C-7), 153.3 (C-5), 151.0 
(C-17), 150.3 (C-2' and C-6'), 148.1 (C-3), 145.5 (C-4'), 134.0 (C-9), 129.0 (C-19 and C-21), 122.1 
(C-8), 120.8 (C-3' and C-5'), 119.1 (C-20), 116.0 (C-10), 115.6 (C-18 and C-22), 113.2 (C-4), 50.8 
(C-12 and C-16), 48.2 (C-13 and C-15); HRMS m/z (ESI+) [Found: 368.1862, C23H22N5 requires 
(M+H)+ 368.1870]; LCMS (MDAP) Rt = 9.9 min (Ana 30–95 over 20 min), m/z (ESI+) 368.0 (M+H)+. 
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Tert-Butyl (3R)-4-(7-chloro-1,6-naphthyridin-5-yl)-3-methyl-piperazine-1-carboxylate 
 
N,N-diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol) and tert-butyl (3R)-3-methylpiperazine-1-carboxylate (1.20 g, 5.99 mmol) in ethanol 
(7 mL) were heated at 100 °C overnight. LCMS indicated product formation (m/z/ 363). The 
reaction mixture was concentrated under reduced pressure and water (4 mL) was added. The 
mixture was extracted three times with ethyl acetate (3 × 40 mL). The combined organic phases 
were washed with water (40 mL), brine (40 mL), dried over MgSO4, filtered and concentrated 
under reduced pressure to give a yellow oil (1.03 g). The crude was purified via flash column 
chromatography (30 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl (3R)-4-
(7-chloro-1,6-naphthyridin-5-yl)-3-methyl-piperazine-1-carboxylate (345 mg, 85%) as a yellow 
solid.  
Rf 0.70 (100% ethyl acetate); m.p. 101–102 °C; νmax (thin film)/cm-1 3051 (aromatic C-H, w), 2934 
(aliphatic C-H, m), 1688 (C=O, s), 1597 (C=C, m), 1557 (aromatic C-C, s), 1056 (C-N, s), 771 (C-H, 
s); 1H NMR (600 MHz, DMSO-d6) δ 9.01 (dd, J = 4.2, 1.2 Hz, 1H, H-7), 8.48 (d, J = 8.5 Hz, 1H, H-9), 
7.58 (dd, J = 8.5, 4.2 Hz, 1H, H-8), 7.45 (s, 1H, H-4), 4.27 (s, 1H, H-16), 3.84 (t, J = 15.0 Hz, 1H, 
H-12), 3.71 (d, J = 12.9 Hz, 1H, H-15), 3.41 (t, J = 12.4 Hz, 1H, H-13), 3.21 (dd, J = 13.0, 3.8 Hz, 1H, 
H-15), 3.06–2.91 (m, 1H, H-13), 1.42 (s, 9H, H-21), 1.28 (d, J = 6.7 Hz, 3H, H-22); 13C NMR 
(151 MHz, DMSO-d6) δ 161.1 (C-1), 154.9 (C-7), 153.8 (C-17), 153.8 (C-5), 145.7 (C-3), 134.1 (C-9), 
121.5 (C-8), 114.3 (C-10), 113.9 (C-4), 79.0 (C-20), 54.2 (C-15), 50.8 (C-12), 46.9 (C-16), 38.6 
(C-13), 28.1 (C-21), 15.8 (C-22); HRMS m/z (ESI+) [Found: 385.1391, C18H23ClN4NaO2 requires 
(M+H)+ 385.1402]; LCMS (MDAP) Rt = 25.3 min (Ana 30–95 over 20 min), m/z (ESI+) 363.1 [35Cl] 
and 365.0 [37Cl] (M+H)+. 
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Tert-Butyl (3R)-3-methyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxyl-ate 
 
Potassium carbonate (171 mg, 1.24 mmol), pyridine-4-boronic acid hydrate (196) (51 mg, 
0.41 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(13 mg, 0.02 mmol) and tert-butyl (3R)-4-(7-chloro-1,6-naphthyridin-5-yl)-3-methyl-piperazine-
1-carboxylate (150 mg, 0.41 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow 
of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed 
reaction completion (m/z 406). The reaction mixture was diluted with water (20 ml) and 
extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated under reduced pressure (107 mg). The crude was purified via 
flash column chromatography (4 g petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl 
(3R)-3-methyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate (77 mg, 44%) as a 
pale orange solid.  
Rf 0.15 (100% ethyl acetate); m.p. 170–172 °C; νmax (thin film)/cm-1 2972 (aliphatic C-H, w), 1690 
(C=O, s), 1598 (C=C, m), 1568 (aromatic C-C, m), 1025 (C-N, s), 769 (C-H, s); 1H NMR (600 MHz, 
DMSO-d6) δ 9.08 (dd, J = 4.3, 1.6 Hz, 1H, H-7), 8.71 (d, J = 1.6 Hz, 2H, H-2' and H-6'), 8.52 (d, J = 
7.9 Hz, 1H, H-9), 8.23–8.19 (m, 2H, H-3' and H-5'), 8.20 (s, 1H, H-4), 7.64 (dd, J = 8.4, 4.2 Hz, 1H, 
H-8), 4.33 (s, 1H, H-16), 3.98–3.86 (m, 2H, H-12), 3.81 (d, J = 13.0 Hz, 1H, H-15), 3.46 (t, J = 
12.5 Hz, 1H, H-13), 3.23 (dd, J = 12.9, 3.7 Hz, 1H, H-15), 3.03 (td, J = 12.4, 3.3 Hz, 1H, H-13), 1.44 
(s, 9H, H-21), 1.34 (d, J = 6.7 Hz, 3H, H-22); 13C NMR (151 MHz, DMSO-d6) δ 161.1 (C-1), 154.6 
(C-7), 153.9 (C-17), 153.4 (C-5), 150.3 (C-2' and C-6'), 148.0 (C-3), 145.4 (C-4'), 133.7 (C-9), 122.1 
(C-8), 120.8 (C-3' and C-5'), 116.0 (C-10), 113.2 (C-9), 79.0 (C-20), 54.7 (C-15), 50.9 (C-12), 47.0 
(C-13), 28.1 (C-21), 15.8 (C-22); HRMS m/z (ESI+) [Found: 406.2230, C23H28N5O2 requires (M+H)+ 
406.2238]; LCMS (MDAP) Rt = 11.0 min (Ana 30–95 over 20 min), m/z (ESI+) 406.1 (M+H)+. 
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5-[(2R)-2-Methylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (298) 
 
Tert-Butyl(3R)-3-methyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate (35 mg, 
0.08 mmol) was stirred in dichloromethane (1 mL) to 0 °C. Trifluoro acetic acid (0.35 mL, 4.57 
mmol) was added dropwise and the reaction was stirred at room temperature for 4 h. The 
reaction mixture was concentrated under reduced pressure and purified via SCX cartridge by 
elution with methanol then 2 M ammonia in methanol to give 5-[(2R)-2-methylpiperazin-1-yl]-
7-(4-pyridyl)-1,6-naphthyridine (298) (24 mg, 91%) as a yellow solid.  
Rf 0.10 (9:1 dichloromethane:methanol); m.p. sublimates above 220 °C; νmax (thin film)/cm-1 
2983 (aromatic C-H, w), 1669 (C=C, s), 1598 (aromatic C-C, s), 1464 (aliphatic C-H, m), 1058 (C-
N, s), 713 (N-H, s); 1HNMR(600 MHz, DMSO-d6) δ 9.10–9.08 (m, 1H, H-7), 8.72 (d, J = 5.9 Hz, 2H, 
H-2' and H-6'), 8.59 (d, J = 8.4 Hz, 1H, H-9), 8.27 (s, 1H, H-4), 8.21 (d, J = 6.0 Hz, 2H, H-3' and H-5'), 
7.65 (dd, J = 8.5, 4.3 Hz, 1H, H-8), 7.15 (s, 1H, H-14), 4.06–3.89 (m, 2H, H-13), 3.64 (s, 1H, 
H-16),3.52–3.36(m, 3H, H-12 and H-15), 3.23–3.10 (m, 1H, H-15), 1.32 (d, J = 6.5 Hz, 3H, H-17); 
13C NMR (151 MHz, DMSO-d6) δ 159.9 (C-1), 154.8 (C-7), 153.2 (C-5), 149.9 (C-2' and C-6'), 147.8 
(C-3), 145.8 (C-4'), 133.5 (C-9), 122.5 (C-8), 120.9 (C-3' and C-5'), 116.2 (C-10), 114.3 (C-4), 53.6 
(C-13), 50.3 (C-16), 47.5 (C-12), 42.5 (C-15), 15.8 (C-17); HRMS m/z (ESI+) [Found: 306.1700, 
C18H20N5 requires (M+H)+ 306.1713]; LCMS (MDAP) Rt = 6.8 min (Ana 30–95 over 20 min), m/z 
(ESI+) 305.900 (M+H)+. 
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Tert-Butyl (2S)-4-(7-chloro-1,6-naphthyridin-5-yl)-2-methyl-piperazine-1-carboxylate 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol) and (S)-1-N-Boc-2-methylpiperazine (1.20 g, 5.99 mmol) in ethanol (7 mL) were heated 
at 100 °C overnight. LCMS  indicated product formation (m/z 363). The reaction mixture was 
concentrated under reduced pressure and water (4 mL) was added. The mixture was extracted 
three times with ethyl acetate (3 × 40 mL). The combined organic phases were washed with 
water (40 mL), brine (40 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure to give an orange oil (920 mg). The crude was purified via flash column chromatography 
(30 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl (2S)-4-(7-chloro-1,6-
naphthyridin-5-yl)-2-methyl-piperazine-1-carboxylate (365 mg, 80%) as a yellow solid.  
Rf 0.70 (100% ethyl acetate); m.p. 104–106 °C; νmax (thin film)/cm-1 3052 (aromatic C-H, w), 2972 
(aliphatic C-H, m), 1688 (C=O, s), 1598 (C=C, m), 1577 (aromatic C-C, s), 1118 (C-N, s); 1H NMR 
(600 MHz, DMSO-d6) δ 9.01 (dd, J = 4.2, 1.3 Hz, 1H, H-7)), 8.48 (d, J = 8.5 Hz, 1H, H-9), 7.58 (dd, 
J = 8.5, 4.2 Hz, 1H, H-8), 7.45 (s, 1H, H-4), 4.27 (s, 1H, H-15), 3.84 (t, J = 15.4 Hz, 2H, H-12), 3.71 
(d, J = 13.1 Hz, 1H, H-16), 3.48–3.36 (t, J = 11.4 Hz, 1H, H-13), 3.20 (dd, J = 12.9, 3.6 Hz, 1H, H--16), 
3.00 (td, J = 11.9 , 2.8 Hz, 1H, H-13), 1.42 (s, 9H, H-21), 1.28 (d, J = 6.7 Hz, 3H, H-22); 13C NMR 
(151 MHz, DMSO-d6) δ 161.1 (C-1), 154.9 (C-7), 153.8 (H-17), 153.8 (H-5), 145.7 9 (C-3), 134.1 
(C-9), 121.5 (C-8), 114.3 (C-4), 113.9 (C-10), 79.0 9 (C-20), 54.2 (C-16), 50.8 (C-12), 46.9 (C-15), 
38.6 (C-13), 28.1 (C-21), 15.8 (C-22); HRMS m/z (ESI+) [Found: 385.1390, C18H23ClN4NaO2 requires 
(M+H)+ 385.1402]; LCMS (MDAP) Rt = 25.3 min (Ana 5–95 over 20 min), m/z (ESI+) 363.1 [35Cl] 
and 365.0 [37Cl] (M+H)+. 
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Tert-Butyl (2S)-2-methyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate 
 
Potassium carbonate (171 mg, 1.24 mmol), Pyridine-4-boronic acid hydrate (196) (51 mg, 
0.41 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(13 mg, 0.02 mmol) and tert-butyl (2S)-4-(7-chloro-1,6-naphthyridin-5-yl)-2-methyl-piperazine-
1-carboxylate (150 mg, 0.41 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow 
of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed 
reaction completion (m/z 406). The reaction mixture was diluted with water (20 ml) and 
extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated under reduced pressure (139 mg). The crude was purified via 
flash column chromatography  (4 g petroleum ether:ethyl acetate, 1:0 to 0:1) give tert-butyl 
(2S)-2-methyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxy-late (79 mg, 45%) as a 
pale pink solid.  
Rf 0.49 (9:1 ethyl acetate:methanol); m.p. 180–181 °C; νmax (thin film)/cm-1 3030 (aromatic C-H, 
w), 2978 (aromatic C-H, w), 1692 (C=O, m), 1598 (C=C, s), 1569 (aromatic C-C, s); 1H NMR 
(600 MHz, DMSO-d6) δ 9.07 (d, J = 4.3 Hz, 1H, H-7), 8.71 (d, J = 6.2 Hz, 2H, H-2' and H-6'), 8.52 
(d, J = 7.0 Hz, 1H, H-9), 8.21 (d, J = 6.3 Hz, 2H, H-3' and H-5'), 8.20 (s, 1H, H-4), 7.64 (dd, J = 8.4, 
4.2 Hz, 1H, H-8), 4.33 (s, 1H, H-15), 3.96–3.87 (m, 1H, H-12), 3.81 (d, J = 12.6 Hz, 1H, H-16), 3.46 
(t, J = 11.4 Hz, 1H, H-13), 3.23 (dd, J = 13.1, 4.2 Hz, 1H, H-16), 3.03 (td, J = 12.4, 3.4 Hz, 1H, H-13), 
1.44 (s, 9H, H-21), 1.34 (d, J = 6.7 Hz, 3H, H-22); 13C NMR (151 MHz, DMSO-d6) δ 161.1 (C-1), 
154.6 (C-7), 153.9 (C-17), 153.4 (C-5), 150.3 (C-2' and C-6'), 148.0 (C-3), 145.4 (C-4'), 133.7 (C-9), 
122.1 (C-8), 120.8 (C-3' and C-5'), 116.0 (C-10), 113.2 (C-4), 79.0 (C-20), 54.7 (C-16), 50.9 (C-13), 
47.0 (C-12), 28.1 (C-21), 15.8 (C-22); HRMS m/z (ESI+) [Found: 406.2232, C23H28N5O2 requires 
(M+H)+ 406.2238]; LCMS (MDAP) Rt = 11.0 min (Ana 30–95 over 20 min), m/z (ESI+) 406.1 (M+H)+. 
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5-[(3S)-3-Methylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (299) 
 
Tert-Butyl (2S)-2-methyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate (30 mg, 
0.07 mmol) was stirred in dichloromethane (1 mL) for 10 min at 0 °C. Trifluoro acetic acid 
(0.3 mL, 3.92 mmol) was added dropwise and then the reaction was stirred at room temperature 
for 4 h. The reaction mixture was concentrated under reduced pressure and purified via SCX 
cartridge by elution with methanol then 2 M ammonia in methanol to give 5-[(3S)-3-
methylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (299) (22 mg, 97%) as a yellow solid.  
Rf 0.10 (9:1 dichloromethane:methanol); m.p. 156–158 °C; νmax (thin film)/cm-1 3352 (N-H, br), 
2971 (aliphatic C-H, w), 1597 (C=C, m), 1569 (aromatic C-C, s), 1029 (C-N, s), 827 (N-H, s); 1H NMR 
(600 MHz, DMSO-d6) δ 9.05 (dd, J = 4.1, 1.3 Hz, 1H, H-7), 8.70 (d, J = 6.0 Hz, 2H, H-2' and H-6'), 
8.51 (d, J = 8.3 Hz, 1H, H-9), 8.18 (s, 1H, H-4), 8.17 (d, J = 3.1 Hz, 2H, H-3' and H-5'), 7.61 (dd, J = 
8.4, 4.2 Hz, 1H, H-8), 3.85-3.87 (m, 2H, H-12 and H-16), 3.29 (s, 1H, H-15), 3.19 (d, J = 10.1 Hz, 
3H, H-12 and H-13), 2.91 (t, J = 11.7 Hz, 1H, H-16), 1.17 (d, J= 6.3 Hz, 3H, H-17); 13C NMR 
(151 MHz, DMSO-d6) δ 160.4 (C-1), 154.5 (C-7), 153.3 (C-5), 150.3 (C-2' and C-6'), 147.9 (C-3), 
145.4 (C-4'), 134.0 (C-9), 122.2 (C-8), 120.7 (C-3' and C-5'), 116.0 (C-10), 113.2 (C-4), 56.0 (C-16), 
50.2 (C-15), 49.7 (C-12), 44.1 (C-13), 17.7 (C-17); HRMS m/z (ESI+) [Found: 306.1700, C18H20N5 
requires (M+H)+ 306.1713]; LCMS (MDAP) Rt = 7.0 min (Ana 30–95 over 20 min), m/z (ESI+) 305.9 
(M+H)+. 
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Tert-Butyl (2S,5R)-4-(7-chloro-1,6-naphthyridin-5-yl)-2,5-dimethyl-piperazine-1-carboxylate 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol), and (2S,5R)-1-Boc-2,5-dimethylpiperazine (1 g, 4.67 mmol) in ethanol (7 mL) 
and  heated to 100 °C overnight. LCMS confirmed reaction completion (m/z 377). The reaction 
mixture was diluted with water (4 ml) and extracted three times with ethyl acetate (3 × 40 mL). 
The combined organic phases were washed with water (40 mL), brine (40 mL), dried over MgSO4, 
filtered and concentrated under reduced pressure to give a brown oil (813 mg). The crude was 
purified via flash column chromatography  (24 g petroleum ether:ethyl acetate, 1:0 to 0:1) to 
give tert-butyl (2S,5R)-4-(7-chloro-1,6-naphthyridin-5-yl)-2,5-dimethyl-piperazine-1-carboxyl-
ate (369 mg, 93%) as an orange solid.  
Rf 0.73 (100% ethyl acetate); m.p. 92–94 °C; νmax (thin film)/cm-1 2972 (aliphatic C-H, w), 1679 
(C=O, s), 1552 (aromatic C-C, s), 1364 (aliphatic C-H, s), 1130 (C-N, s), 779 (aliphatic C-H, s); 
1H NMR (600 MHz, DMSO-d6) δ 8.99 (dd, J = 4.2, 1.5 Hz, 1H, H-7), 8.47 (d, J = 8.3 Hz, 1H, H-9), 
7.55 (dd, J = 8.5, 4.2 Hz, 1H, H-8), 7.40 (s, 1H, H-4), 4.39–4.20 (m, 2H, H-16 and H-13), 3.71–3.59 
(m, 3H, H-12 and H-15), 3.50–3.38 (m, 1H, H-12), 1.43 (s, 9H, H-22), 1.17 (d, J = 6.8 Hz, 3H, H-17), 
1.05 (d, J = 6.6 Hz, 3H, H-23); 13C NMR (151 MHz, DMSO-d6) δ 161.0 (C-1), 155.3 (C-7), 154.7 
(C-18), 154.3 (C-5), 146.1 (C-3), 134.8 (C-9), 121.7 (C-8), 114.9 (C-4), 113.8 (C-10), 79.3 (C-21), 
53.2 (C-13 and C-16), 48.3 (C-12 and C-15), 16.4 (C-17), 14.2 (C-23); HRMS m/z (ESI+) [Found: 
399.1548, C19H25ClN4NaO2 requires (M+H)+ 399.1558]; LCMS (MDAP) Rt = 25.7 min (Ana 5–95 
over 20 min); m/z (ESI+) 377.1 (M+H)+. 
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Tert-Butyl (2S,5R)-2,5-dimethyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxyl-
ate 
 
Potassium carbonate (165 mg, 1.19 mmol), pyridine-4-boronic acid hydrate (196) (49 mg, 
0.40 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(13 mg, 0.02 mmol) and tert-butyl (2S,5R)-4-(7-chloro-1,6-naphthyridin-5-yl)-2,5-dimethyl-
piperazine-1-carboxylate (150 mg, 0.40 mmol) in 4:1 acetonitrile:water (12 mL) were degassed 
under a flow of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS 
confirmed reaction completion (m/z 420). The reaction mixture was diluted with water (20 ml) 
and extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were dried 
over MgSO4, filtered and concentrated under reduced pressure to give a yellow oil (167 mg). The 
crude was purified via flash column chromatography  (5 g petroleum ether:ethyl acetate, 1:0 to 
0:1) to give tert-butyl (2S,5R)-2,5-dimethyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-
carboxylate (103 mg, 59%) as an off-white solid.  
Rf 0.18 (100% ethyl acetate); m.p. 182–184 °C; νmax (thin film)/cm-1 2972 (aliphatic C-H, w), 1682 
(C=O, s), 1594 (C=C, s), 1478 (aromatic C-C, m), 1031 (C-N, m), 829 (N-H, s); 1H NMR (600 MHz, 
DMSO-d6) δ 9.05 (dd, J = 4.1, 1.3 Hz, 1H, H-9), 8.70 (d, J = 6.0 Hz, 2, H-2' and H-6'), 8.51 (d, J = 
8.3 Hz, 1H, H-7), 8.19 (d, J = 6.1 Hz, 2H, H-3' and H-5'), 8.13 (s, 1H, H-4), 7.60 (dd, J = 8.4, 4.2 Hz, 
1H, H-8), 4.46–4.40 (m, 1H, H-16), 4.34 (s, 1H, H-13), 3.78 (dd, J = 13.7, 3.9 Hz, 1H, H-12), 3.70 
(s, 2H, H-15), 3.54 (d, J = 13.4 Hz, 1H, H-12), 1.44 (s, 9H, H-22), 1.22 (d, J = 6.7 Hz, 3H, H-17), 1.08 
(d, J = 6.3 Hz, 3H, H-23); 13C NMR (151 MHz, DMSO-d6) δ 160.5 (C-1), 154.4 (C-7), 153.5 (C-5), 
150.6 (C-18), 150.3 (C-2' and C-6'), 148.0 (C-3), 145.5 (C-4'), 134.0 (C-9), 121.9 (C-8), 121.3, 120.8 
(C-3' and C-5'), 116.0 (C-10), 112.6 (C-4), 78.9 (C-21), 52.4 (C-13 and C-16), 47.9 (C-12 and C-15), 
28.1 (C-22), 16.0 (C-17/23), 13.5 (C-23/17); HRMS m/z (ESI+) [Found: 420.2387, C24H30N5O2 
requires (M+H)+ 420.2394]; LCMS (MDAP) Rt = 2.8 min (Ana 5–95 over 5 min), m/z (ESI+) 420.3 
(M+H)+. 
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5-[(2R,5S)-2,5-Dimethylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (300) 
 
Tert-Butyl (2S,5R)-2,5-dimethyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate 
(25 mg, 0.06 mmol) was stirred in dichloromethane (1 mL) and cooled to 0 °C. Trifluoro acetic 
acid (0.25 mL, 3.26 mmol) was added dropwise and the reaction was allowed to stir at room 
temperature for 4 h. The reaction mixture was concentrated under reduced pressure 
and purified via SCX cartridge by elution with methanol then 2 M ammonia in methanol to give 
5-[(2R,5S)-2,5-dimethylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (300) (18 mg, 95%) as a 
yellow solid.  
Rf 0.10 (9:1 dichloromethane:methanol); m.p. 124–125 °C; νmax (thin film)/cm-1 3288 (N-H, br), 
1965 (aliphatic C-H, w), 1599 (C=C, m), 1570 (aromatic C-C, m), 1032 (C-N, s), 691 (N-H, 
m); 1H NMR (600 MHz, DMSO-d6) δ 9.11 (dd, J = 4.1, 1.5 Hz, 1H, H-7), 8.74–8.71 (m, 2H, H-2' and 
H-6'), 8.66 (d, J = 8.2 Hz, 1H, H-9), 8.38 (s, 1H, H-4), 8.22–8.16 (m, 2H, H-3' and H-5'), 7.68 (dd, 
J = 8.4, 4.2 Hz, 1H, H-8), 3.75 (s, 1H, H-13), 3.36 (s, 2H, H-16), 3.26 (d, J = 14.1 Hz, 2H, H-12 and 
H-15), 2.85 (t, J = 12.4 Hz, 1H, H-12), 2.61 (t, J = 10.4 Hz, 1H, H-15), 1.06 (d, J = 6.2 Hz, 3H, H-18), 
1.03 (d, J = 6.0 Hz, 3H, H-17); 13C NMR (151 MHz, DMSO-d6) δ 161.5 (C-1), 155.5 (C-7), 153.0 
(C-5), 150.6 (C-17), 150.4 (C-2' and C-6'), 148.3 (C-3), 145.3 (C-4'), 133.5 (C-9), 123.2 (C-8), 120.7 
(C-3' and C-5'), 119.3 (C-10), 115.3 (C-4), 58.9 (C-12), 56.0 (C-15), 51.1 (C-16/13), 49.8 (C-13/16), 
17.5 (C-18), 15.7 (C-17); HRMS m/z (ESI+) [Found: 320.1857, C19H22N5 requires (M+H)+ 320.1870]; 
LCMS (MDAP) Rt = 7.1 min (Ana 30–95 over 20 min), m/z (ESI+) 320.9 (M+H)+. 
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Tert-Butyl (2R,5S)-4-(7-chloro-1,6-naphthyridin-5-yl)-2,5-dimethyl-piperazine-1-carboxylate 
 
5,7-Dichloro-1,6-naphthyridine (284) (200 mg, 1 mmol), (2R,5S)-1-Boc-2,5-dimethylpiperazine 
hydrochloride (1.50 g, 5.97 mmol) and N,N-diisopropylethylamine (0.71 mL, 4.06 mmol) were 
stirred in ethanol (7 mL) at 100 °C overnight. LCMS indicated product formation (m/z 377). The 
reaction mixture was concentrated under reduced pressure and water (4 mL) was added. The 
mixture was extracted three times with ethyl acetate (3 × 40 mL). The combined organic phases 
were washed with water (40 mL) and brine (40 mL) and then dried over MgSO4, filtered and 
concentrated under reduced pressure to give a brown mixture (569 mg). The crude was purified 
via flash column chromatography (20 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to 
give tert-butyl (2R,5S)-4-(7-chloro-1,6-naphthyridin-5-yl)-2,5-dimethyl-piperazine-1-carboxyl-
ate (328 mg, 82%) as a yellow glass.  
Rf 0.73 (100% ethyl acetate); m.p. 95–97 °C; νmax (thin film)/cm-1 2975 (aliphatic C-H, w), 1679 
(C=O, s), 1553 (aromatic C-C, s), 1488 (aliphatic C-H, m), 1031 (C-N, s), 859 (C-H, s); 1H NMR 
(600 MHz, DMSO-d6) δ 8.99 (dd, J = 4.1, 1.4 Hz, 1H, H-7), 8.47 (d, J = 8.3 Hz, 1H, H-9), 7.55 (dd, 
J = 8.5, 4.2 Hz, 1H, H-8), 7.40 (s, 1H, H-4), 4.32 (m, 2H, H-13 and H-16), 3.77–3.61 (m, 3H, H-12 
and H-15), 3.54–3.38 (m, 1H, H-12/15), 1.43 (s, 9H, H-22), 1.17 (d, J = 6.8 Hz, 3H, H-17/23), 1.05 
(d, J = 6.5 Hz, 3H, H-23/17); 13C NMR (151 MHz, DMSO-d6) δ 160.6 (C-1), 154.8 (C-5), 154.3 
(C-18), 153.9 (C-7), 145.7 (C-3), 134.4 (C-9), 121.3 (C-8), 114.5 (C-10), 113.4 (C-4), 78.9 (C-21), 
52.8 (C-13 and C-16), 47.9 (C-15 and C-12), 28.1 (C-22), 16.0 (C-17/23), 13.8 (C-17/23); HRMS 
m/z (ESI+) [Found: 399.1546, C19H25ClN4NaO2 requires (M+H)+ 399.1558]; LCMS (MDAP) Rt = 
22.9 min (Ana 30–95 over 30 min), m/z (ESI+) 377.1 [35Cl] and 379.1 [37Cl] (M+H)+. 
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Tert-Butyl (2R,5S)-2,5-dimethyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxyla-
te 
 
Potassium carbonate (157 mg, 1.13 mmol), pyridine-4-boronic acid hydrate (196) (46 mg, 
0.38 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(12 mg, 0.02 mmol) and tert-butyl (2R,5S)-4-(7-chloro-1,6-naphthyridin-5-yl)-2,5-dimethyl-
piperazine-1-carboxylate (150 mg, 0.38 mmol) in 4:1 acetonitrile:water (12 mL) were degassed 
under a flow of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS 
confirmed reaction completion (m/z 420). The reaction mixture was diluted with water (20 ml) 
and extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were dried 
over MgSO4, filtered and concentrated under reduced pressure (163 mg). The crude was purified 
via flash column chromatography  (5 g silica petroleum ether:ethyl acetate, 1:0 to 0:1) to 
give tert-butyl (2R,5S)-2,5-dimethyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-
carboxylate (104 mg, 0.24 mmol, 62%) as an orange foam.151 
Rf 0.18 (100% ethyl acetate); m.p. 135–137 °C; νmax (thin film)/cm-1 2974 (aliphatic C-H, w), 1682 
(C=O, s), 1595 (C=C, m), 1563 (aromatic C-C, s), 1055 (C-N, s), 731 (C-H, m); 1H NMR (600 MHz, 
DMSO-d6) δ 9.05 (dd, J = 4.2, 1.4 Hz, 1H, H-7), 8.70 (d, J = 6.0 Hz, 2H, H-2' and H-6'), 8.51 (d, J = 
8.4 Hz, 1H, H-9), 8.19 (d, J = 6.1 Hz, 2H, H-3' and H-5'), 8.13 (s, 1H, H-4), 7.60 (dd, J = 8.4, 4.2 Hz, 
1H, H-8), 4.47–4.38 (m, 1H, H-16), 4.34 (s, 1H, H-13), 3.78 (dd, J = 13.5, 4.1 Hz, 1H, H-12), 3.70 
(s, 2H, H-15), 3.54 (dd, J = 13.1, 1.8 Hz, 1H, H-12), 1.44 (s, 9H, H-22), 1.21 (d, J = 6.8 Hz, 3H, H-17), 
1.08 (d, J = 6.4 Hz, 3H, H-23); 13C NMR (151 MHz, DMSO-d6) δ 160.5 (C-1), 154.4 (C-7), 153.5 
(C-5), 150.6 (C-18), 150.3 (C-2' and C-6'), 148.0 (C-3), 145.5 (C-4'), 133.9 (C-9), 121.8 (C-8), 120.7 
(C-3' and C-5'), 116.0 (C-10), 112.6 (C-4), 78.9 (C-21), 52.4 (C-13 and C-16), 47.9 (C-12 and C-15), 
28.1 (C-22), 16.2 (C-17), 13.5 (C-23); HRMS m/z (ESI+) [Found: 420.2384, C24H30N5O2 requires 
(M+H)+ 420.2394]; LCMS (MDAP) Rt = 15.8 min (Ana 5–95 over 20 min), m/z (ESI+) 420.2 (M+H)+. 
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5-[(2S,5R)-2,5-Dimethylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (301) 
 
Tert-Butyl (2R,5S)-2,5-dimethyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate 
(50 mg, 0.12 mmol) was dissolved in dichloromethane (1 mL) and cooled to 0 °C. Trifluoro acetic 
acid (0.5 mL, 6.68mmol) was added dropwise and the reaction mixture was allowed to stir at 
room temperature overnight. LCMS (LCQ) indicated product formation (m/z 320). The reaction 
mixture was concentrated under reduced pressure to give a yellow solid. The crude was purified 
via SCX cartridge by elution with methanol then 2 M ammonia in methanol to give 5-[(2S,5R)-
2,5-dimethylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (301) (40 mg, 100%) as a yellow 
glass.  
Rf 0.1 (9:1 dichloromethane:methanol); m.p. 185–186 °C; νmax (thin film)/cm-1 2983 (aliphatic 
C-H br), 1671 (C=O, m), 1600 (C=C, m), 1570 (aromatic C-C, m), 1126 (C-N, s), 829 (N-H, s); 1H 
NMR (600 MHz, DMSO-d6) δ 9.17–9.08 (m, 1H, H-7), 8.74 (d, J = 5.6 Hz, 2H, H-2' and H-6'), 8.72 
(d, J = 8.2 Hz, 1H, H-9), 8.44 (s, 1H, H-4), 8.20 (d, J = 5.7 Hz, 2H, H-3' and H-5'), 7.71 (dd, J = 8.4, 
4.3 Hz, 1H, H-8), 3.95–3.83 (m, 1H, H-13), 3.68–3.53 (m, 1H, H-16), 3.47 (td, J = 13.8, 13.2, 3.0 Hz, 
1H, H-12 and H-15), 3.07 (t, J = 11.6 Hz, 1H, H-12), 2.86 (t, J = 11.7 Hz, 1H, H-15), 1.18 (d, J = 
6.5 Hz, 3H, H-18), 1.07 (d, J = 6.1 Hz, 3H, H-17); 13C NMR (151 MHz, DMSO-d6) δ 161.0 (C-1), 155.3 
(C-7), 153.0 (C-5), 150.5 (C-2' and C-6'), 148.4 (C-3), 145.2 (C-4'), 133.9 (C-9), 123.3 (C-8), 120.7 
(C-3' and C-5'), 119.4 (C-10), 115.9 (C-4), 57.4 (C-15), 50.4 (C-16), 50.2 (C-13), 48.6 (C-12), 16.5 
(C-17), 16.2 (C-18); HRMS m/z (ESI+) [Found: 320.1863, C19H22N5 requires (M+H)+ 320.1870]; 
LCMS (MDAP) Rt = 5.5 min (Ana 5–95 over 20 min), m/z (ESI+) 320.1 (M+H)+. 
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Tert-Butyl (2R)-4-(7-chloro-1,6-naphthyridin-5-yl)-2-methyl-piperazine-1-carboxylate 
 
N,N-diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol) and (R)-N-Boc-2-methylpiperazine (1.20 g, 5.99 mmol) in ethanol (7 mL) were heated 
at 100 °C overnight. LCMS  indicated product formation (m/z 263 and 365). The reaction mixture 
was concentrated under reduced pressure and water (4 mL) was added. The mixture was 
extracted three times with ethyl acetate (3 × 40 mL). The combined organic phases were washed 
with water (40 mL), brine (40 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure (1.03 g). The crude was purified via flash column chromatography (4 g silica, petroleum 
ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl (2R)-4-(7-chloro-1,6-naphthyridin-5-yl)-2-
methyl-piperazine-1-carboxylate  (328 mg, 81%) as an off-white solid.  
Rf 0.67 (100% ethyl acetate); m.p. 106–108 °C; νmax (thin film)/cm-1 2972 (aliphatic C-H, w), 1690 
(C=O, s), 1598 (C=C, m), 1558 (aromatic C-C, s), 1471 (aliphatic C-H, m), 1024 (C-N, s), 772 (C-H, 
s); 1H NMR (600 MHz, DMSO-d6) δ 9.01 (dd, J = 4.1, 1.3 Hz, 1H, H-7), 8.48 (d, J = 8.5 Hz, 1H, H-9), 
7.58 (dd, J = 8.5, 4.2 Hz, 1H, H-8), 7.45 (s, 1H, H-4), 4.27 (s, 1H, H-15), 3.84 (t, J = 14.8 Hz, 2H, 
H-12), 3.71 (d, J = 13.0 Hz, 1H, H-16), 3.41 (t, J = 12.3 Hz, 1H, H-13), 3.20 (dd, J = 13.1, 3.8 Hz, 1H, 
H-16), 3.00 (td, J = 12.5, 3.4 Hz, 1H, H-13), 1.42 (s, 9H, H-21), 1.28 (d, J = 6.7 Hz, 3H, H-22); 
13C NMR (151 MHz, DMSO-d6) δ 161.1 (C-1), 154.9 (C-7), 154.9 (C-17), 153.8 (C-5), 145.7 (C-3), 
134.1 (C-9), 121.5 (C-8), 114.3 (C-4), 113.9 (C-10), 79.0 (C-20), 54.2 (C-16), 50.8 (C-12), 46.9 
(C-15), 38.5 (C-13), 28.1 (C-21), 15.8 (C-22); HRMS m/z (ESI+) [Found: 385.1391, C18H23ClN4NaO2 
requires (M+H)+ 385.1402]; LCMS (MDAP) Rt = 22.6 min (Ana 30–95 over 20 min), m/z (ESI+) 
363.9 [35Cl] and 365.800 [37Cl] (M+H)+. 
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Tert-Butyl (2R)-2-methyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate  
 
Potassium carbonate (171.4 mg, 1.24 mmol), pyridine-4-boronic acid hydrate (196) (51 mg, 
0.41 mmol), bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(13 mg, 0.02 mmol) and tert-butyl (2R)-4-(7-chloro-1,6-naphthyridin-5-yl)-2-methyl-piperazine-
1-carboxylate (150 mg, 0.41 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow 
of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed 
reaction completion (m/z 406). The reaction mixture was diluted with water (20 ml) and 
extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated under reduced pressure to give a brown foam (126 mg). The 
crude was purified via flash column chromatography  (4 g petroleum ether:ethyl acetate, 1:0 to 
0:1) to give tert-butyl (2R)-2-methyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-
carboxylate (90 mg, 51%) as a pale pink solid.  
Rf 0.48 (9:1 ethyl acetate:methanol); m.p. 181–183 °C; νmax (thin film)/cm-1 2975 (aliphatic C-H, 
w), 1689 (C=O, s), 1598 (C=C, m), 1569 (aromatic C-C, s), 1053 (C-N, s), 769 (C-H, s); 1H NMR 
(600 MHz, DMSO-d6) δ 9.08–9.06 (m, 1H, H-7), 8.70 (d, J = 6.0 Hz, 2H, H-2' and H-6'), 8.52 (d, J = 
8.5 Hz, 1H, H-9), 8.21 (d, J = 6.0 Hz, 2H, H-3' and H-5'), 8.20 (s, 1H, H-4), 7.64 (dd, J = 8.4, 4.2 Hz, 
1H, H-8), 4.33 (s, 1H, H-15), 3.99–3.85 (m, 2H, H-12), 3.81 (d, J = 12.9 Hz, 1H, H-16), 3.46 (t, J = 
12.5 Hz, 1H, H-13), 3.23 (dd, J = 13.0, 3.7 Hz, 1H, H-16), 3.03 (td, J = 12.4, 3.3 Hz, 1H, H-13), 1.43 
(s, 9H, H-21), 1.34 (d, J = 6.7 Hz, 3H, H-22); 13C NMR (151 MHz, DMSO-d6) δ 161.1 (C-1), 154.5 
(C-7), 153.9 (C-17), 153.4 (C-5), 150.3 (C-2' and C-6'), 148.0 (C-3), 145.4 (C-4'), 133.7 (C-9), 122.1 
(C-8), 120.8 (C-3' and C-5'), 116.0 (C-10), 113.2 (C-4), 79.0 (C-20), 54.7 (C-16), 50.8 (C-12), 46.9 
(C-15), 38.7 (C-13), 28.1 (C-21), 15.7 (C-22); HRMS m/z (ESI+) [Found: 406.2234, C23H28N5O2 
requires (M+H)+ 406.2238];  LCMS (MDAP) Rt = 10.9 min (Ana 30–95 over 20 min), m/z (ESI+) 
406.1 (M+H)+. 
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5-[(3R)-3-Methylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (302) 
 
Tert-Butyl (2R)-2-methyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate 
(40 mg, 0.09 mmol) was stirred in dichloromethane (1 mL) for 10 min at 0 °C. Trifluoro acetic 
acid (0.40 mL, 6.2 mmol) was added dropwise and the reaction mixture was stirred at room 
temperature for 4 h. The reaction mixture was concentrated under reduced pressure and 
purified via SCX cartridge by elution with methanol then 2 M ammonia in methanol to give 5-
[(3R)-3-methylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (302) (30 mg, 100%) as a yellow 
solid.  
Rf 0 (9:1 dichloromethane:methanol); m.p. degrades above 200 °C; νmax (thin film)/cm-1 2988 
(aliphatic C-H, w), 1598 (C=C, m), 1568 (aromatic C-C, m), 1465 (aliphatic C-H, m), 1130 (C-N, s), 
722 (N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 9.08 (d, J = 3.0 Hz, 1H, H-7), 8.89 (s, 1H, H-14), 8.72 
(d, J = 5.2 Hz, 2H, H-2' and H-6'), 8.58 (d, J = 8.5 Hz, 1H, H-9), 8.25 (s, 1H, H-4), 8.19 (d, J = 5.1 Hz, 
1H, H-3' and H-5'), 7.64 (dd, J = 7.9, 3.7 Hz, 1H, H-8), 3.98 (d, J = 9.5 Hz, 2H, H-12 and H-16), 3.63 
(s, 1H, H-15), 3.52–3.36 (m, 3H, H-12 and H-13), 3.17 (t, J = 13.6 Hz, 1H, H-16), 1.31 (d, J = 5.4 Hz, 
3H, H-17); 13C NMR (151 MHz, DMSO-d6) δ 159.9 (C-1), 154.8 (C-7), 153.3 (C-5), 150.4 (C-2' and 
C-6'), 147.9 (C-3), 145.3 (C-4'), 134.0 (C-9), 122.5 (C-8), 120.8 (C-3' and C-5'), 116.1 (C-10), 114.1 
(C-4), 53.6 (C-16), 50.3 (C-15), 47.5 (C-12), 42.5 (C-13), 15.8 (C-17); HRMS m/z (ESI+) [Found: 
306.1702, C18H20N5 requires (M+H)+ 306.1713]; LCMS (MDAP) Rt = 5.5 min (Ana 30–95 over 
20 min), m/z (ESI+) 305.9 (M+H)+. 
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Tert-Butyl (2R)-4-(7-chloro-1,6-naphthyridin-5-yl)-2-isopropyl-piperazine-1-carboxylate 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol) and  (S)-1-Boc-2-isopropylpiperazine (1.37 g, 5.98 mmol) in ethanol (7mL) were heated 
to 100 °C overnight. LCMS  indicated product formation (m/z 391). The reaction mixture was 
concentrated under reduced pressure and water (4 mL) was added. The mixture was extracted 
three times with ethyl acetate (3 × 40 mL). The combined organic phases were washed with 
water (40 mL), brine (40 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure to give an orange oil (805 mg). The crude was purified via flash column chromatography 
(24 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl (2R)-4-(7-chloro-1,6-
naphthyridin-5-yl)-2-isopropyl-piperazine-1-carboxylate (380 mg, 92%) as a yellow solid.  
Rf 0.72 (100% ethyl acetate); m.p. 129–130 °C; νmax (thin film)/cm-1 2970 (aliphatic C-H, m), 1686 
(C=O, s), 1601 (C=C, m), 1561 (aromatic C-C, s), 1016 (C-N, s), 761 (C-Cl, m); 1H NMR (600 MHz, 
DMSO-d6) δ 8.99 (dd, J = 4.2, 1.5 Hz, 1H, H-7), 8.47 (d, J = 8.7 Hz, 1H, H-9), 7.55 (dd, J = 8.5, 4.2 Hz, 
1H, H-8), 7.40 (s, 1H, H-4), 3.99 (d, J = 12.7 Hz, 1H, H-12), 3.92 (d, J = 11.9 Hz, 1H, H-13), 3.88 
(d, J = 12.6 Hz, 1H, H-16), 3.79 (s, 1H, H-15), 3.26 (s, 1H, H-13), 3.14 (dd, J = 13.6, 3.5 Hz, 1H, 
H-12), 3.07 (td, J = 12.4, 3.6 Hz, 1H, H-16), 2.23–2.15 (m, 1H, H-22), 1.41 (s, 9H, H-21), 0.88 (d, J = 
6.6 Hz, 3H, H-23), 0.83 (d, J = 5.5 Hz, 3H, H-23); 13C NMR (151 MHz, DMSO-d6) δ 160.8 (C-1), 154.9 
(C-7), 154.1 (C-17), 153.9 (C-5), 145.7 (C-3), 134.3 (C-9), 121.3 (C-8), 114.1 (C-10), 113.5 (C-4), 
78.9 (C-20), 57.6 (C-13), 56.3 (C-15), 51.5 (C-16), 49.7 (C-12), 28.0 (C-21), 26.3 (C-22), 20.1 (C-23), 
18.8 (C-23); HRMS m/z (ESI+) [Found: 413.1704, C20H27ClN4NaO2 requires (M+H)+ 413.1715]; 
LCMS (MDAP) Rt = 27.3 min (Ana 5–95 over 20 min); m/z (ESI+) 391.1 [35Cl] and 393.1 
[37Cl] (M+H)+. 
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Tert-Butyl (2R)-2-isopropyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate 
 
Potassium carbonate (154 g, 1.11 mmol), pyridine-4-boronic acid hydrate (196) (46 mg, 
0.37 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(12 mg, 0.02 mmol) and tert-butyl (2R)-4-(7-chloro-1,6-naphthyridin-5-yl)-2-isopropyl-
piperazine-1-carboxylate (145 mg, 0.37 mmol) in 4:1 acetonitrile:water (12 mL) were degassed 
under a flow of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS 
confirmed reaction completion (m/z 434). The reaction mixture was diluted with water (20 ml) 
and extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were dried 
over MgSO4, filtered and concentrated under reduced pressure to give a brown oil (116 mg). The 
crude was purified via flash column chromatography (4 g petroleum ether:ethyl acetate, 1:0 to 
0:1) to give tert-butyl (2R)-2-isopropyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-
carboxylate (71 mg, 42%) as an off-white foam. 
  
Rf 0.22 (100% ethyl acetate); m.p. 78–79 °C; νmax (thin film)/cm-1 2957 (aliphatic C-H, br), 1686 
(C=O, s), 1598 (C=C, m), 1569 (aromatic C-C, s), 1103 (C-N, m), 826 (C-H, s); 1H NMR (600 MHz, 
DMSO-d6) δ 9.07 (dd, J = 4.2, 1.7 Hz, 1H, H-9), 8.71 (d, J = 6.2 Hz, 2H, H-2' and H-6'), 8.52 (d, J = 
8.4 Hz, 1H, H-9), 8.20 (d, J = 6.2 Hz, 2H, H-3' and H-5'), 8.18 (s, 1H, H-4), 7.62 (dd, J = 8.4, 4.2 Hz, 
1H, H-8), 4.06–3.93 (m, 2H, H-12 and H-13), 3.92 (d, J = 12.5 Hz, 1H, H-16), 3.86 (d, J = 10.4 Hz, 
1H, H-15), 3.36 (s, 1H, H-13), 3.22 (d, J = 13.2 Hz, 1H, H-12), 3.06–2.98 (m, 1H, H-16), 2.42–2.25 
(m, 1H, H-22), 1.41 (s, 9H, H-21), 0.93–0.75 (m, 6H, H-23); 13C NMR (151 MHz, DMSO-d6) δ 161.1 
(C-1), 154.6 (C-17), 153.9 (C-17), 153.4 (C-5), 150.3 (C-2' and C-6'), 148.1 (C-3), 145.4 (C-4'), 133.6 
(C-9), 122.1 (C-8), 120.8 (C-3' and C-5'), 115.9 (C-10), 113.1 (C-4), 79.0 (C-20), 53.0 (C-13), 51.3 
(C-15), 49.5 (C-16), 38.6 (C-12), 28.1 (C-21), 24.4 (C-22), 22.9 (C-23), 22.6 (C-23); HRMS m/z (ESI+) 
[Found: 456.2360, C25H31N5NaO2 requires (M+H)+ 456.2370]; LCMS (MDAP) Rt = 12.4 min (Ana 
30–95 over 20 min), m/z (ESI+) 434.1 (M+H)+.  
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5-[(3R)-3-Isobutylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (303) 
 
Tert-Butyl (2R)-2-isobutyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate 
(50 mg, 0.11 mmol) was stirred in dichloromethane (1 mL) for 10 min at 0 °C. Trifluoro acetic 
acid (0.5 mL, 6.53 mmol) was added dropwise and the reaction was allowed to stir at room 
temperature for 4 h. The reaction mixture was concentrated under reduced pressure and 
purified via SCX cartridge by elution with methanol then 2 M ammonia in methanol to give 5-
[(3R)-3-isobutylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (303) (37 mg, 92%) as a yellow 
solid.  
Rf 0.21 (9:1 dichloromethane:methanol); m.p. 245–247 °C; νmax (thin film)/cm-1 2960 (aliphatic 
C-H, w), 1597 (C=C, m), 1567 (aromatic C-C, s), 1478 (aliphatic C-H, m), 1176 (C-N, s), 723 (N-H, 
s); 1H NMR (600 MHz, DMSO-d6) δ 9.08 (d, J = 4.4 Hz, 1H, H-7), 8.71 (d, J = 6.2 Hz, 2H, H-2' and 
H-6'), 8.54 (d, J = 8.5 Hz, 2H, H-9), 8.22 (s, 1H, H-4), 8.18 (d, J = 6.2 Hz, 2H, H-3' and H-5'), 7.64 
(dd, J = 8.5, 4.1 Hz, 1H, H-8), 4.06 (d, J = 14.2 Hz, 1H, H-16), 3.98 (d, J = 12.5 Hz, 1H, H-12/13), 
3.57–3.54 (m, 1H, H-15), 3.49–3.37 (m, 1H, H-12/13), 3.33–3.26 (m, 2H, H-13/12) 3.13 (t, 
J = 12.1 Hz, 1H, H-16), 1.88–1.74 (m, 1H, H-15), 1.50 (t, J = 7.1 Hz, 1H, H-17), 0.94 (d, J = 6.5 Hz, 
6H, H-18); 13C NMR (151 MHz, DMSO-d6) δ 159.8 (C-1), 154.7 (C-7), 153.2 (C-5), 150.3 (C-2' and 
C-6'), 148.0 (C-3), 145.3 (C-4'), 133.8 (C-9), 122.3 (C-8), 120.8 (C-3' and C-5'), 116.0 (C-10), 113.8 
(C-4), 52.3 (C-15 and C-16), 52.1 (C-13/12), 48.4 (C-12/13), 43.0 (C-12), 23.5 (C-17), 22.7 (C-18), 
22.4 (C-19); HRMS m/z (ESI+) [Found: 348.2169, C21H26N5 requires (M+H)+ 348.2183]; LCMS 
(MDAP) Rt = 10.7 min (method), m/z (ESI+) 348.2  (M+H)+. 
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Tert-Butyl (2R)-4-(7-chloro-1,6-naphthyridin-5-yl)-2-isobutyl-piperazine-1-carboxylate 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1  mmol) and  (R)-1-Boc-2-isobutylpiperazine (1.44 g, 5.95 mmol) in ethanol (7 mL) were stirred 
at 100 °C overnight. LCMS  indicated product formation (m/z 405). The reaction mixture was 
concentrated under reduced pressure and water (4 mL) was added. The mixture was extracted 
three times with ethyl acetate (3 × 40 mL). The combined organic phases were washed with 
water (40 mL), brine (40 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure to give an orange oil (773 mg). The crude was purified via flash column chromatography 
(24 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl (2R)-4-(7-chloro-1,6-
naphthyridin-5-yl)-2-isobutyl-piperazine-1-carboxylate (373 mg, 83%) as a yellow glass.  
Rf 0.76 (100% ethyl acetate); m.p. 60–61 °C; νmax (thin film)/cm-1 2957 (aliphatic C-H, w), 1687 
(C=O, s), 1598 (C=C, m), 1559 (aromatic C-C, s), 1410 (aliphatic C-H, s), 1059 (C-N, s); 1H NMR 
(600 MHz, DMSO-d6) δ 8.96 (s, 1H, H-7), 8.39 (d, J = 8.5 Hz, 1H, H-9), 7.52 (ddd, J = 8.4, 4.1, 1.8 Hz, 
1H, H-8), 7.37 (s, 1H, H-4), 4.20 (s, 1H, H-15), 3.83 (dd, J = 34.5, 13.1 Hz, 2H, H-12), 3.71 (d, J = 
13.2 Hz, 1H, H-16), 3.28 (s, 1H, H-13), 3.13 (d, J = 12.9 Hz, 1H, H-16), 2.97 (t, J = 12.2 Hz, 1H, H-
13), 1.74–1.56 (m, 2H, H-22), 1.48 (s, 1H, H-23), 1.38 (s, 9H, H-21), 0.98–0.69 (m, 6H, H-
24); 13C NMR (151 MHz, DMSO-d6) δ 161.4 (C-1), 155.3 (C-7), 155.3 (C-17), 154.2 (C-5), 146.1 
(C-3), 134.5 (C-9), 121.7 (C-8), 114.6 (C-4), 114.1 (C-10), 79.4 (C-20), 55.3 (C-13), 53.0 (C-16), 51.5 
(C-12), 50.0 (C-15), 38.9 (C-22), 28.4 (C-21), 24.8 (C-23), 23.1 (C-24); HRMS m/z (ESI+) [Found: 
427.1867, C21H29ClNaO2 requires (M+H)+ 427.1871]; LCMS (MDAP) Rt = 27.13 min (Ana 30–95 
over 20 min), m/z (ESI+) 262.950 [35Cl] and 264.700 [37Cl] (M+H)+. 
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Tert-Butyl (2R)-2-isobutyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate 
 
Potassium carbonate (154 mg, 1.11 mmol), pyridine-4-boronic acid hydrate (196) (46 mg, 
0.37 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(12 mg, 0.02 mmol) and tert-butyl (2R)-4-(7-chloro-1,6-naphthyridin-5-yl)-2-isobutyl-piperazine-
1-carboxylate (150 mg, 0.37 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow 
of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed 
reaction completion (m/z 448); The reaction mixture was diluted with water (20 ml) and 
extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated under reduced pressure to give a brown oil (116 mg). The 
crude was purified via flash column chromatography  (5 g petroleum ether:ethyl acetate, 1:0 to 
0:1) to give tert-butyl (2R)-2-isobutyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-
carboxylate (71 mg, 41%) as an off-white solid.  
Rf 0.22 (100% ethyl acetate); m.p. 93–95 °C; νmax (thin film)/cm-1 2970 (aliphatic C-H, br), 1685 
(C=O, s), 1604 (C=C, m), 1570 (aromatic C-C, s), 1110 (C-N, s), 825 (C-H, s); 1H NMR (600 MHz, 
DMSO-d6) δ 9.07 (dd, J = 4.2, 1.4 Hz, 1H, H-7), 8.70 (d, J = 6.0 Hz, 2H, H-2' and H-6'), 8.50 (d, J = 
8.3 Hz, 1H, H-9), 8.20 (d, J = 6.0 Hz, 2H, H-3' and H-5'), 8.18 (s, 1H, H-4), 7.63 (dd, J = 8.4, 4.2 Hz, 
1H, H-8), 4.31 (s, 1H, H-15), 3.96 (d, J = 13.4 Hz, 1H, H-16), 3.93–3.85 (m, 1H, H-12/13), 3.81 (d, 
J = 13.1 Hz, 1H, H-12/13), 3.40 (s, 1H, H-16), 3.24 (d, J = 12.8 Hz, 1H, H-13/12), 3.02 (td, J = 12.4, 
3.4 Hz, 1H, H-13/12), 1.78 (s, 1H, H-22), 1.60–1.50 (m, 1H, H-22), 1.50–1.43 (m, 1H, H-23), 1.42 
(s, 9H, H-21), 0.93 (d, J = 6.6 Hz, 3H, H-24) 0.91 (d, J = 6.5 Hz, 3H, H-24); 13C NMR (151 MHz, 
DMSO-d6) δ 161.1 (C-1), 154.6 (C-7), 154.1 (C-17), 153.4 (C-5), 150.3 (C-2' and C-6'), 148.1 (C-3), 
145.4 (C-4'), 133.7 (C-9), 122.1 (C-8), 120.8 (C-3' and C-5'), 116.0 (C-10), 113.1 (C-4), 78.9 (C-20), 
57.6 (C-13), 56.4 (C-16), 52.3 (C-12), 49.1 (C-15), 38.2 (C-22), 28.5 (C-21), 26.3 (C-23), 20.2 (C-24), 
18.7 (C-24); HRMS m/z (ESI+) [Found: 448.2707, C26H34N5O2 requires (M+H)+ 448.2707]; LCMS 
(MDAP) Rt = 14.2 min (Ana 30–95 over 20 min), m/z (ESI+) 448.2 (M+H)+. 
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5-[(3R)-3-Isopropylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (304) 
 
Tert-Butyl (2R)-2-isopropyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate 
(46 mg, 0.11 mmol) was stirred in dichloromethane (1 mL) for 10 min at 0 °C. Trifluoro acetic 
acid (0.46 mL, 6.53 mmol) was added dropwise and the reaction was stirred at room 
temperature for 4 h. The reaction mixture was concentrated under reduced pressure and 
purified via SCX cartridge by elution with methanol then 2 M ammonia in methanol to give 5-
[(3R)-3-isopropylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (304) (36 mg, 97%) as a yellow 
solid.  
Rf 0.21 (9:1 dichloromethane:methanol); m.p. 241–243 °C; νmax (thin film)/cm-1 2971 (aliphatic 
C-H, w), 1598 (C=C, s), 1567 (aromatic C-C, s), 1467 (aliphatic C-H, m), 1125 (C-N, s), 722 (N-H, 
s); 1H NMR (600 MHz, DMSO-d6) δ 9.08 (dd, J = 4.2, 1.7 Hz, 1H, H-7), 8.72 (d, J = 6.3 Hz, 1H, H-2' 
and H-6'), 8.54 (d, J = 8.4 Hz, 1H, H-9), 8.24 (s, 1H, H-4), 8.19 (d, J = 6.2 Hz, 1H, H-3' and H-5'), 
7.65 (dd, J = 8.5, 4.3 Hz, 1H, H-8), 4.11 (d, J = 13.5 Hz, 1H, H-12), 4.03 (d, J = 12.9 Hz, 1H, H-12) 
3.43 (t, J = 12.5 Hz, 1H, H-13), 3.38–3.35 (m, 3H, H-15 and H-16), 3.14 (t, J = 12.4 Hz, 1H, H-13), 
1.97–1.89 (m, 1H, H-18), 1.07 (d, J = 6.8 Hz, 3H, H-19), 1.03 (d, J = 6.8 Hz, 3H, H-19); 13C NMR 
(151 MHz, DMSO-d6) δ 159.8 (C-1), 154.7 (C-7), 153.3 (C-5), 150.3 (C-2' and C-6'), 147.9 (C-3), 
145.3 (C-4'), 133.8 (C-9), 122.4 (C-8), 120.7 (C-3' and C-5'), 116.0 (C-10), 113.9 (C-4), 59.2 (C-15), 
50.3 (C-12), 47.8 (C-13), 43.6 (C-16), 28.9 (C-17), 18.7 (C-18), 18.1 (C-18); HRMS m/z (ESI+) 
[Found: 334.2016, C20C24N5 requires (M+H)+ 334.2026]; LCMS (MDAP)  Rt = 9.1 min (Ana 5–95 
over 20 min), m/z (ESI+) 334.1 (M+H)+. 
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Tert-Butyl (2R)-2-benzyl-4-(7-chloro-1,6-naphthyridin-5-yl)piperazine-1-carboxylate 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol),  (R)-1-Boc-2-benzylpiperazine (1.65 g, 5.98 mmol) in ethanol (7 mL) were heated 
at 100 °C overnight. LCMS  indicated product formation (m/z 263). The reaction mixture was 
concentrated under reduced pressure and water (4 mL) was added. The mixture was extracted 
three times with ethyl acetate (3 × 40 mL). The combined organic phases were washed with 
water (40 mL), brine (40 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure to give a yellow oil. The crude was purified via flash column chromatography to give 
tert-butyl (2R)-2-benzyl-4-(7-chloro-1,6-naphthyridin-5-yl)piperazine-1-carboxylate (338 mg, 
73%) as an off-white solid.  
Rf 0.76 (100% ethyl acetate); m.p. 63–65 °C; νmax (thin film)/cm-1 2975 (aliphatic C-H, w), 1686 
(C=O, s), 1597 (C=C, m), 1559 (aromatic C-C, m), 1057 (C-N, s), 697 (C-H, s); 1H NMR (600 MHz, 
DMSO-d6) δ 9.02 (dd, J = 4.1, 1.2 Hz, 1H, H-7), 8.55 (d, J = 8.9 Hz, 1H, H-9), 7.56 (dd, J = 8.9, 3.2 Hz, 
1H, H-8), 7.46 (s, 1H, H-4), 7.26–7.18 (m, 2H, H-24 and H-28), 7.20–7.12 (m, 1H, H-26), 7.14–7.05 
(m, 2H, H-25 and H-27), 4.41 (s, 1H, H-15), 3.94 (d, J = 12.1 Hz, 2H, H-12 and H-13), 3.75 (m, 1H, 
H-22), 3.66–3.54 (m, 1H, H-15), 3.19 (dd, J = 13.4, 3.2 Hz, 1H, H-22), 3.10 (s, 1H, H-16), 3.04 
(td, J = 12.9, 3.6 Hz, 1H, H-13), 2.94–2.92 (m, 1H, H-16), 1.22 (s, 9H, H-21); 13C NMR (151 MHz, 
DMSO-d6) δ 161.0 (C-1), 155.0 (C-7), 153.8 (C-5), 153.5 (C-17), 145.7 (C-3), 138.6 (C-23), 134.3 
(C-9), 129.2 (C-25 and C-27), 128.2 (C-24 and C-28), 126.1 (C-26), 121.4 (C-8), 114.4 (C-4), 113.9 
(C-10), 78.8 (C-20), 53.3 (C-15), 52.1 (C-22), 51.3 (C-12), 37.9 (C-13), 35.6 (C-16), 27.8 (C-21); 
HRMS m/z (ESI+) [Found: 461.1718, C24H27ClN4NaO2 requires (M+H)+ 461.1715]; LCMS (MDAP) 
Rt = 27.3 min (Ana 5–95 over 30 min), m/z (ESI+) 439.150 [35Cl] 441.100 [37Cl] (M+H)+.  
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Tert-Butyl (2R)-2-benzyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate 
 
Potassium carbonate (142 g, 1.03 mmol), pyridine-4-boronic acid hydrate (196) (42 mg, 
0.34 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(11 mg, 0.02 mmol) and tert-butyl (2R)-2-benzyl-4-(7-chloro-1,6-naphthyridin-5-yl)piperazine-1-
carboxylate (150 mg, 0.34 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow 
of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed 
reaction completion (m/z 482). The reaction mixture was diluted with water (20 ml) and 
extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated under reduced pressure to give a brown oil (118 mg). The 
crude was purified via flash column chromatography  (4 g petroleum ether:ethyl acetate, 1:0 to 
0:1) to give tert-butyl (2R)-2-benzyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-
carboxylate (74 mg, 43%) as a yellow glass.  
Rf 0.20 (100% ethyl acetate); m.p. 92–94 °C; νmax (thin film)/cm-1 2973 (aliphatic C-H, w), 1685 
(C=O, s), 1597 (C=C, m), 1568 (aromatic C-C, s), 1111 (C-N, s), 699 (C-H, s); 1H NMR (600 MHz, 
DMSO-d6) δ 9.08 (d, J = 3.9 Hz, 1H, H-7), 8.70 (d, J = 5.7 Hz, 2H, H-2' and H-6'), 8.63–8.55 (m, 1H, 
H-9), 8.21 (s, 1H, H-4), 8.19 (d, J = 5.4 Hz, 2H, H-3' and H-5'), 7.66–7.52 (m, 1H, H-8), 7.29–7.19 
(m, 2H, H-28 and H-24), 7.19–7.14 (m, 1H, H-26), 7.15–7.08 (m, 2H, H-25 and H-27), 4.48 (s, 1H, 
H-15), 4.06–3.92 (m, 3H, H-12 and H-13), 3.84 (d, J = 12.9 Hz, 1H, H-22), 3.68 (t, J = 12.3 Hz, 1H, 
H-15), 3.27 (s, 1H, H-22), 3.19 (s, 1H, H-16), 3.05 (t, J = 11.6 Hz, 1H, H-13), 2.99 (s, 1H, H-16), 1.22 
(s, 9H, H-21); 13C NMR (151 MHz, DMSO-d6) δ 161.5 (C-17), 155.0 (C-7), 154.0 (C-5), 153.8 (C-1), 
150.7 (C-2' and C-6'), 148.5 (C-3), 145.8 (C-4'), 138.3 (C-23) 134.3 (C-9), 129.6 (C-25 and C-27), 
128.6 (C-28 and C-24), 126.5 (C-26), 122.5 (C-8), 121.2 (C-3' and C-5'), 116.4 (C-10), 113.6 (C-4), 
79.1 (C-20), 53.8 (C-15), 52.9 (C-22), 51.9 (C-12), 38.1 (C-13), 36.0 (C-16), 28.2 (C-21); HRMS m/z 
(ESI+) [Found: 482.2551, C29H32N5O2 requires (M+H)+ 482.2551]; LCMS (MDAP) Rt = 13.7 min (Ana 
30–95 over 20 min), m/z (ESI+) 482.1 (M+H)+. 
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5-[(3R)-3-Benzylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (305) 
 
Tert-Butyl (2R)-2-benzyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate (50 mg, 
0.10 mmol) was stirred in dichloromethane (1 mL) for 10 min at 0 °C. Trifluoro acetic acid 
(0.5 mL, 6.53 mmol) was added dropwise and the reaction was stirred at room temperature for 
4 h. The reaction mixture was concentrated under reduced pressure and purified via SCX 
cartridge by elution of methanol then 2 M ammonia in methanol to give 5-[(3R)-3-
benzylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (39 mg, 98%) as a yellow solid.  
Rf 0.43 (9:1 dichloromethane:methanol); m.p. 130–132 °C; νmax (thin film)/cm-1 3034 (aromatic 
C-H, br), 2823 (aliphatic C-H, br), 1599 (C=C, s), 1569 (aromatic C-C, s), 1123 (C-N, s), 700 (N-H, 
s); 1H NMR (600 MHz, DMSO-d6) δ 9.02 (m, 1H, H-7), 8.66 (d, J = 5.7 Hz, 2H, H-2' and H-6'), 8.39 
(m, 1H, H-9), 8.16 (s, 1H, H-4), 8.01 (m, 2H, H-3' and H-5'), 7.53 (s, 1H, H-8), 7.37 (t, J = 7.5, 6.3 
Hz, 2H, H-20 and H-22), 7.35–7.26 (m, 3H, H-19, H-23 and H-21), 7.20 (s, 1H, H-14), 3.96 (s, 2H, 
H-16), 3.64 (s, 1H, H-17), 3.40 (s, 1H, H-15), 3.19 (s, 1H, H-13), 3.13 (s, 1H, H-17) 2.99 (s, 1H, 
H-12), 2.85 (s, 1H, H-12). Second H-13 peak under water peak; 13C NMR (151 MHz, DMSO-d6) δ 
160.0 (C-1), 154.5 (C-7), 153.4 (C-5), 150.3 (C-2' and C-6'), 147.8 (C-3), 145.3 (C-4'), 137.4 (C-18), 
133.8 (C-9), 129.3 (C-19 and C-23), 128.6 (C-20 and C-22), 126.6 (C-21), 121.8 (C-8), 120.6 (C-3' 
and C-5'), 115.7 (C-10), 112.9 (C-4), 55.5 (C-17), 53.5 (C-16), 50.1 (C-15), 44.3 (C-13), 38.3 (C-12); 
HRMS m/z (ESI+) [Found: 382.2007, C24H24N5 requires (M+H)+ 382.2026]; LCMS (MDAP) Rt = 10.5 
min (Ana 5–95 over 20 min), m/z (ESI+) 382.1 (M+H)+. 
  
287 
 
Tert-Butyl (2R,6S)-4-(7-chloro-1,6-naphthyridin-5-yl)-2,6-dimethyl-piperazine-1-carboxylate 
 
N,N-diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol) and  (2R,6S)-tert-butyl 2,6-dimethylpiperazine-1-carboxylate (1.28 g, 
5.97 mmol) in ethanol (7 mL) were stirred overnight at 100 °C. LCMS indicated product 
formation (m/z 377). The reaction mixture was concentrated under reduced pressure and water 
(4 mL) was added. The mixture was extracted three times with ethyl acetate (3 × 40 mL) then 
washed with water (40 mL) and brine (40 mL). The organic phase was dried over MgSO4, filtered 
and concentrated under reduced pressure (1.04 g). The crude was purified by flash column 
chromatography (30 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl (2R,6S)-
4-(7-chloro-1,6-naphthyridin-5-yl)-2,6-dimethyl-piperazine-1-carboxylate (393 mg, 99%) as a 
yellow crystalline solid.  
Rf 0.73 (100% ethyl acetate); m.p. 131–132 °C; νmax (thin film)/cm-1 2976 (aliphatic C-H, w), 1684 
(C=O, s), 1598 (C=C, m), 1560 (aromatic C-C, s), 1404 (aliphatic C0H, s), 1036 (C-N, s), 819 (N-H, 
s); 1H NMR (600 MHz, DMSO-d6) δ 9.04 (dd, J = 4.2, 1.2 Hz, 1H, H-7), 8.51 (d, J = 8.5 Hz, 1H, H-9), 
7.64 (dd, J = 8.5, 4.2 Hz, 1H, H-8), 7.52 (s, 1H, H-4), 4.21 (q, J = 6.6 Hz, 2H, H-13 and H-15), 3.75 
(d, J = 12.8 Hz, 2H, H-12 and 16), 3.07 (dd, J = 12.8, 4.3 Hz, 2H, H-12 and 16), 1.44 (s, 9H, H-23), 
1.42 (d, J = 6.8 Hz, 6H, H-17 and H-18); 13C NMR (151 MHz, DMSO-d6) δ 162.1 (C-1), 155.5 (C-7), 
154.1 (C-5), 146.0 (C-10), 134.0 (C-89 122.1 (C-8), 115.1 (C-4), 79.4 (C-22), 55.5 (C-12 and C-16), 
47.0 (C-13 and C-15), 28.5 (C-23), 20.8 (C-17 and C-18); HRMS m/z (ESI+) [Found: 399.1548, 
C19H25ClN4NaO2 requires (M+H)+ 399.1558]; LCMS (MDAP) Rt = 24.2 min (Ana 30–95 over 
20 min), m/z (ESI+) 377.1 [35Cl] and 379.0 [37Cl] (M+H)+. 
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Tert-Butyl (2R,6S)-2,6-dimethyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxyl-
ate 
 
Potassium carbonate (157 mg, 1.13 mmol), pyridine-4-boronic acid hydrate (196) (46 mg, 
0.38 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(12 mg, 0.02 mmol) and tert-butyl (2R,6S)-4-(7-chloro-1,6-naphthyridin-5-yl)-2,6-dimethyl-
piperazine-1-carboxylate (150 mg, 0.38 mmol) in 4:1 acetonitrile:water (12 mL) were degassed 
under a flow of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. 
LCMS indicated product formation (m/z 420). Water (15 mL) was added and the mixture was 
extracted twice with ethyl acetate (2 × 20 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated under reduced pressure (148 mg). The crude was purified via 
flash column chromatography (5 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-
butyl (2R,6S)-2,6-dimethyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate 
(99 mg, 59%) as a light brown solid.  
Rf 0.18 (100% ethyl acetate); m.p. 219–220 °C; νmax (thin film)/cm-1 2969 (aliphatic C-H, w), 1686 
(C=O, s), 1601 (aromatic C=C, m), 1573 (aromatic C-C, m), 1364 (aliphatic C-H, s), 829 (N-H, s); 
1H NMR (600 MHz, DMSO-d6) δ 9.09 (dd, J = 4.3, 1.5 Hz, 1H, H-7), 8.71 (d, J = 6.2 Hz, 2H, H-2' and 
H-6'), 8.56 (d, J = 9.0 Hz, 1H, H-9), 8.24 (s, 1H, H-4), 8.22 (d, J = 6.1 Hz, 2H, H-3' and H-5'), 7.68 
(dd, J = 8.4, 4.2 Hz, 1H, H-8), 4.26 (p, J = 6.8 Hz, 2H, H-12 and H-16), 3.84 (d, J = 12.7 Hz, 2H, H-13 
and H-15), 3.13 (dd, J = 12.8, 4.4 Hz, 2H, H-12 and H-16), 1.48 (d, J = 6.8 Hz, 6H, H-17 and H-23), 
1.45 (s, 9H, H-22); 13C NMR (151 MHz, DMSO-d6) δ 161.6 (C-18), 154.6 (C-7), 153.8 (C-1), 153.3 
(C-5), 150.3 (C-2' and C-6'), 148.0 (C-3), 145.4 (C-4'), 133.2 (C-9), 122.3 (C-8), 120.8 (C-3' and 
C-5'), 116.3 (C-10), 113.7 (C-4), 78.9 (C-21), 55.3 (C-12 and C-16), 46.7 (C-13 and C-15), 28.2 
(C-22), 20.5 (C-17 and C-23); HRMS m/z (ESI+) [Found: 420.2385, C24H30N5O2 requires (M+H)+ 
420.2394]; LCMS (MDAP) Rt = 12.3 min (Ana 30–95 over 20 min), m/z (ESI+) 420.2 (M+H)+. 
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5-[(3R,5S)-3,5-Dimethylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (306) 
 
Tert-Butyl (2R,6S)-2,6-dimethyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate 
(40 mg, 0.09 mmol) was dissolved in dichloromethane (1 mL) and cooled to 0 °C. Trifluoro acetic 
acid (0.4 mL, 5.17 mmol) was added dropwise and the reaction mixture was allowed to stir at 
room temperature overnight. LCMS indicated product formation (m/z 320). The reaction 
mixture was concentrated under reduced pressure to give a yellow solid. The crude was purified 
via SCX cartridge by elution with methanol then 2 M ammonia in methanol to give 5-[(3R,5S)-
3,5-dimethylpiperazin-1-yl]-7-(4-pyridyl)-1,6-naphthyridine (306) (29 mg, 92%) as a yellow solid.  
Rf 0.1 (9:1 dichloromethane:methanol); m.p. 168–170 °C; νmax (thin film)/cm-1 3200 (N-H, br), 
2970 (aliphatic C-H, w), 1599 (C=C, s), 1570 (aromatic C-C, s), 1035 (C-N, s), 765 (N-H, s); 1H NMR 
(600 MHz, CDCl3) δ 9.02 (d, J = 4.1 Hz, 1H, H-7), 8.75 (d, J = 5.5 Hz, 2H, H-2' and H-6'), 8.37 (d, J = 
8.4 Hz, 1H, H-9), 8.06 (d, J = 5.5 Hz, 2H, H-3' and H-5'), 8.04 (s, 1H, H-4), 7.46 (dd, J = 8.4, 4.3 Hz, 
1H, H-8), 3.89 (d, J = 12.8 Hz, 2H, H-13 and H-15), 3.38–3.25 (m, 2H, H-12/16), 2.88 (t, J = 12.5 Hz, 
2H, H-16/12), 1.23 (d, J = 6.3 Hz, 6H, H-17 and H-18); 13C NMR (151 MHz, DMSO-d6) δ 160.7 
(C-1), 154.8 (C-7), 153.7 (C-10'), 150.7 (C-2' and C-6'), 148.3 (C-3), 145.8 (C-4'), 134.5 (C-9), 122.5 
(C-8), 121.1 (C-3' and C-5'), 116.4 (C-10), 113.5 (C-4), 56.4 (C-13 and C-15), 50.8 (C-12 and C-16), 
18.4 (C-17 and C-18); HRMS m/z (ESI+) [Found: 320.1857, C19H22N5 requires (M+H)+ 320.1870]; 
LCMS (MDAP) Rt = 8.8 min (Ana 5–95 over 20 min), m/z (ESI+) 320.1 (M+H)+. 
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Tert-Butyl 4-(7-chloro-1,6-naphthyridin-5-yl)-2,2-dimethyl-piperazine-1-carboxylate 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol) and  tert-butyl 2,2-dimethylpiperazine-1-carboxylate (1.28 g, 5.97 mmol) were stirred 
in ethanol (7mL) at 100 °C overnight. LCMS indicated product formation (m/z 377, 379). The 
reaction mixture was concentrated and water (4 mL) was added. The mixture was extracted 
three times with ethyl acetate (3 × 40 mL). The combined organic phases were washed with 
water (40 mL) and brine (40 mL) then dried over MgSO4, filtered and concentrated under 
reduced pressure to give a brown heterogeneous mixture (885 mg). The crude was purified via 
flash column chromatography (30 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-
butyl 4-(7-chloro-1,6-naphthyridin-5-yl)-2,2-dimethyl-piperazine-1-carboxylate (342 mg, 80%) 
as a yellow foam.  
Rf 0.75 (100% ethyl acetate); m.p. 153–155 °C; νmax (thin film)/cm-1 2976 (aliphatic C-H, w), 1675 
(C=O, s), 1555 (aromatic C-H, s), 1401 (aliphatic C-H, s), 1068 (C-N, s), 769 (N-H, s); 1H NMR 
(600 MHz, DMSO-d6) δ 8.94 (dd, J = 4.2, 1.4 Hz, 1H, H-7), 8.58 (d, J = 8.6 Hz, 1H, H-9), 7.49 (dd, 
J = 8.5, 4.2 Hz, 1H, H-8), 7.27 (s, 1H, H-4), 3.88–3.77 (m, 2H, H-13), 3.79–3.69 (m, 2H, H-12), 3.67 
(s, 2H, H-16) 1.44 (s, 9H, H-21), 1.42 (s, 6H, H-22); 13C NMR (151 MHz, DMSO-d6) δ 159.7 (C-17), 
154.4 (C-7), 154.2 (C-1), 145.7 (C-5), 134.9 (C-9), 120.5 (C-8), 113.2 (C-10), 111.5 (C-4), 79.0 
(C-20), 57.5 (C-16), 55.6 (C-15), 50.1 (C-13), 40.9 (C-12), 28.2 (C-21), 25.2 (C-22); HRMS m/z (ESI+) 
[Found: 399.1555, C19H25ClN4NaO2 requires (M+H)+ 399.1558]; LCMS (MDAP) Rt = 22.7 min, (Ana 
30–95 over 20 min); m/z (ESI+) 377.1 [35Cl] and 379.050 [37Cl] (M+H)+. 
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Tert-butyl 2,2-dimethyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate 
 
Potassium carbonate (165 mg, 1.19 mmol), pyridine-4-boronic acid hydrate (196) (49 mg, 
0.40 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(13 mg, 0.02 mmol) and tert-butyl 4-(7-chloro-1,6-naphthyridin-5-yl)-2,2-dimethyl-piperazine-1-
carboxylate (150 mg, 0.40 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow 
of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed 
reaction completion (m/z 420). The reaction mixture was diluted with water (15 mL) and 
extracted twice with ethyl acetate (2 × 20 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated under reduced pressure to give a yellow oil (147 mg). The 
crude was purified via flash column chromatography  (5 g petroleum ether:ethyl acetate, 1:0 to 
0:1) to give tert-butyl 2,2-dimethyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-
carboxylate (101 mg, 57%) as an off-white solid.  
Rf 0.38 (9:1 ethyl acetate:methanol); m.p. 194–195 °C; νmax (thin film)/cm-1 2967 (aliphatic C-H, 
w), 2880 (aliphatic C-H, w), 1694 (C=O, s), 1597 (aromatic C=C, m), 1563 (aromatic C-C, s), 832 
(alkene C-H, s); 1H NMR (600 MHz, DMSO-d6) δ 9.02 (dd, J = 4.2, 1.6 Hz, 1H, H-7), 8.70 (d, J = 
6.2 Hz, 1H, H-2' and H-6'), 8.59 (d, J = 8.4 Hz, 1H, H-9), 8.19 (d, J = 6.2 Hz, 2H, H-3' and H-5'), 8.05 
(s, 1H, H-4), 7.56 (dd, J = 8.2, 4.0 Hz, 1H, H-8), 3.89 – 3.80 (m, 2H, H-12), 3.77 (t, J = 5.3 Hz, 2H, 
H-13), 3.74 (s, 2H, H-16), 1.53 – 1.35 (m, 15H, H-21 and H-22). 13C NMR (151 MHz, CDCl3) δ 160.5 
(C-1), 155.6 (C-17), 154.3 (C-7), 154.0 (C-5), 150.5 (C-2' and C-6'), 149.2 (C-1'), 146.4 (C-3), 134.0 
(C-9), 121.1 (C-3' and C-5'), 120.9 (C-8), 115.9 (C-10), 112.6 (C-4), 80.3 (C-20), 60.7 (C-16), 56.0 
(C-15), 50.5 (C-12), 41.8 (C-13), 28.7 (C-21), 25.8 (C-22); HRMS m/z (ESI+) [Found: 420.2386, 
C24H30N5O2 requires (M+H)+ 420.2394]; LCMS (MDAP) Rt = 15.8 min (Ana 5–95 over 20 min), m/z 
(ESI+) 420.2 (M+H)+. 
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5-(3,3-Dimethylpiperazin-1-yl)-7-(4-pyridyl)-1,6-naphthyridine (307) 
 
Tert-Butyl 2,2-dimethyl-4-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]piperazine-1-carboxylate (50 mg, 
0.12 mmol) was dissolved in dichloromethane (1 mL) and cooled to 0 °C. Trifluoro acetic acid 
(0.50 mL, 4.82 Mmol) was added dropwise and the reaction mixture was allowed to stir at room 
temperature overnight. LCMS (LCQ) indicated product formation (m/z 320). The reaction 
mixture was concentrated under reduced pressure to give a yellow solid. The crude was purified 
via SCX cartridge by elution with methanol then 2 M ammonia in methanol to give 5-(3,3-
dimethylpiperazin-1-yl)-7-(4-pyridyl)-1,6-naphthyridine (307) (36 mg, 90%) as a yellow solid.  
Rf 0.55 (100% ethyl acetate); m.p. 138–141 °C; νmax (thin film)/cm-1 3247 (N-H, w), 2970 (aliphatic 
C-H, w), 1596 (C=C, m), 1572 (aromatic C-C, s), 1020 (C-N, m), 827 (N-H, s); 1H NMR (600 MHz, 
DMSO-d6) δ 9.04 (dd, J = 4.1, 1.3 Hz, 1H, H-7), 8.70 (d, J = 5.9 Hz, 2H, H-2' and H-6'), 8.47 (d, J = 
8.4 Hz, 1H, H-9), 8.18 (d, J = 6.0 Hz, 2H, H-3' and H-5'), 8.14 (s, 1H, H-4), 7.61 (dd, J = 8.4, 4.2 Hz, 
1H, H-8), 3.44–3.37 (m, 2H, H-12), 3.25 (s, 2H, H-16), 3.14–3.04 (m, 2H, H-13), 1.22 (s, 6H, H-17); 
13C NMR (151 MHz, DMSO-d6) δ 161.7 (C-1), 154.8 (C-7), 153.8 (C-5), 150.7 (C-2' and C-6'), 148.5 
(C-3), 145.9 (C-4'), 134.2 (C-9), 122.4 (C-8), 121.1 (C-3' and C-5'), 116.4 (C-10), 113.3 (C-4), 61.4 
(C-16), 51.8 (C-12), 51.0 (C-15), 40.7 (C-13), 25.7 (C-17); HRMS m/z (ESI+) [Found: 320.1862, 
C19H22N5 requires (M+H)+ 320.1870]; LCMS (MDAP) Rt = 8.9 min (Ana 5–95 over 20 minutes), m/z 
(ESI+) 320.050 (M+H)+. 
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Tert-butyl (1R,4R)-5-(7-chloro-1,6-naphthyridin-5-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carbo-
xylate 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (200 mg, 
1 mmol), and tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (1.19 mg, 5.99 mmol) 
in ethanol (7 mL) were heated at 100 °C overnight. LCMS indicated product formation (m/z 263). 
The reaction mixture was concentrated under reduced pressure and water (4 mL) was added. 
The mixture was extracted three times with ethyl acetate (3 × 40 mL). The combined organic 
phases were washed with water (40 mL), brine (40 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure (123 mg) to give tert-butyl (1R,4R)-5-(7-chloro-1,6-
naphthyridin-5-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (302 mg, 79%) as an off-white 
solid.215  
Rf 0.52 (100% ethyl acetate); m.p. 179–181 °C; νmax (thin film)/cm-1 2980 (aliphatic C-H, w), 1686 
(C=O, s), 1594 (C=C, m), 1571 (aromatic C-C, m), 1127 (C-N, m), 758 (C-H, m); 1H NMR (600 MHz, 
DMSO-d6) δ 8.90 (d, J = 3.9 Hz, 1H, H-7), 8.53 (d, J = 8.8 Hz, 1H, H-9), 7.44 (dd, J = 8.3, 3.6 Hz, 1H, 
H-8), 7.14 (s, 1H, H-4), 4.98 (d, J = 18.5 Hz, 1H, H-12/15), 4.50 (d, J = 35.1 Hz, 1H, H-15/12), 4.22 
(t, J = 7.7, 0.6 Hz, 1H, H-13/16), 3.59 (t, J = 8.9 Hz, 1H, H-13/16), 3.54–3.40 (m, 2H, H-16/13), 1.95 
(q, J = 11.4, 10.0 Hz, 2H, H-17), 1.36 (s, 6H, H-22), 1.34 (3, 3H, H-22); 13C NMR (151 MHz, 
DMSO-d6) δ 156.3 (C-1/18), 154.2 (C-7), 153.0 (C-3), 147.2 (C-4'), 134.5 (C-9), 120.9 (C-8), 113.1 
(C-10), 109.9 (C-4), 78.8 (C-21), 61.6 (C-12/15), 60.0 (C-13/16), 59.9 (C-13/16), 58.6 (C-12/15), 
57.3 (C-15/12), 55.9 (C-15/12), 53.2 (C-16/13), 51.2 (C-16/13), 36.3 (C-17), 34.9 (C-17), 28.8 
(C-22), C-1/18 peak missing, double peaks due to rotamers; HRMS m/z (ESI+) [Found: 383.1236, 
C18H21ClN4NaO2 requires (M+H)+ 383.1245]; LCMS (MDAP) Rt = 22.1 min (Ana 5–95 over 30 min), 
m/z (ESI+) 361.1 [35Cl] and 363.0 [37Cl] (M+H)+. 
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Tert-butyl (1R,4R)-5-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]-2,5-diazabicyclo[2.2.1]heptane-2-
carboxylate 
 
Potassium carbonate (172 mg, 1.25 mmol), pyridine-4-boronic acid hydrate (196) (51 mg, 
0.42 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(14 mg, 0.02 mmol) and tert-butyl (1R,4R)-5-(7-chloro-1,6-naphthyridin-5-yl)-2,5-
diazabicyclo[2.2.1]heptane-2-carboxy-late (150 mg, 0.42 mmol) in 4:1 acetonitrile:water (12 mL) 
were degassed under a flow of nitrogen and heated in a microwave reactor at 140 °C for 
15 minutes. LCMS confirmed reaction completion (m/z 404). The reaction mixture was diluted 
with water (20 ml) and extracted twice with ethyl acetate (2 × 25 mL). The combined organic 
phases were dried over MgSO4, filtered and concentrated under reduced pressure (162 mg). The 
crude was purified via flash column chromatography  (4 g petroleum ether:ethyl acetate, 1:0 to 
0:1) to give tert-butyl (1R,4R)-5-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]-2,5-diazabicyclo[2.2.1]-
heptane-2-carboxylate (130 mg, 74%) as a pale brown solid.  
Rf 0.39 (9:1 ethyl acetate:methanol); m.p. 220–222 °C; νmax (thin film)/cm-1 2972 (aliphatic C-H, 
w), 1682 (C=O, s), 1594 (C=C, m), 1558 (aromatic C-C, s), 1098 (C-N, s), 771 (C-H, m); 1H NMR 
(600 MHz, DMSO-d6) δ 8.98 (d, J = 4.4 Hz, 1H, H-7), 8.70 (d, J = 6.2 Hz, 2H, H-2' and H-6'), 8.56 
(d, J = 7.9 Hz, 1H, H-9), 8.16 (d, J = 6.3 Hz, 2H, H-3' and H-5'), 7.94 (s, 1H, H-4), 7.54–7.48 (m, 1H, 
H-8), 5.27–5.07 (m, 1H, H-12/15), 4.67–4.42 (m, 1H, H-15/12), 4.39–4.21 (m, 1H, H-13/16), 3.73–
3.55 (m, 2H, H-16/13 and H-13/16), 3.55–3.43 (m, 1H, H16/13), 2.05–1.96 (m, 2H, H-17), 1.37 (s, 
6H, H-22), 1.32 (s, 3H, H-22); 13C NMR (151 MHz, DMSO-d6) δ 156.7 (C-1), 156.0 (C-1), 153.9 
(C-7), 153.4 (C-18), 150.6 (C-5), 149.6 (C-2' and C-6'), 147.1 (C-3), 145.7 (C-4'), 134.1 (C-9), 122.4 
(C-8), 120.7 (C-3' and C-5'), 114.8 (C-10), 114.7 (C-10), 109.8 (C-4), 109.6 (C-4), 78.8 (C-21), 78.7 
(C-21), 60.3 (C-12/15), 59.8 (C-13/16), 59.4 (C-12/15), 57.4 (C-15/12), 56.4 (C-15/12), 52.0 (C-
16/13), 51.5 (C-16/13), 36.3 (C-17), 35.7 (C-17), 28.2 (C-22), 28.1 (C-22), double peaks due to 
rotamers; HRMS m/z (ESI+) [Found: 404.2079, C23H26N5O2 requires (M+H)+ 404.2081]; LCMS 
(MDAP) Rt = 8.4 min (Ana 30–95 over 20 min), m/z (ESI+) 404.1 (M+H)+. 
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5-[(1R,4R)-2,5-Diazabicyclo[2.2.1]heptan-2-yl]-7-(4-pyridyl)-1,6-naphthyridine (308) 
 
Tert-butyl (1R,4R)-5-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]-2,5-diazabicyclo[2.2.1]heptane-2-car-
boxylate (90 mg, 0.21 mmol) was stirred in dichloromethane (1 mL) and cooled to 0 °C . Trifluoro 
acetic acid (0.93 mL, 12.25 mmol) was added dropwise and the reaction was allowed to stir at 
room temperature for 4 h. The reaction mixture was concentrated under reduced pressure and 
purified via SCX cartridge by elution with methanol then 2 M ammonia in methanol to give 5-
[(1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(4-pyridyl)-1,6-naphthyridine (308) (60 mg, 89%) 
as a yellow solid.  
Rf 0.10 (9:1 dichloromethane:methanol); m.p. 140–141 °C; νmax (thin film)/cm-1 3279 (N-H, br), 
2943 (aliphatic C-H, w), 1672 (C=C, m), 1597 (aromatic C-C, s), 1025 (C-N, s), 776 (N-H, m); 1H 
NMR (600 MHz, DMSO-d6) δ 8.99 (d, J = 4.2 Hz, 1H, H-7), 8.69 (d, J = 6.0 Hz, 2H, H-2' and H-6'), 
8.54 (d, J = 8.5 Hz, 1H, H-9), 8.16 (d, J = 6.0 Hz, 2H, H-3' and H-5'), 7.96 (s, 1H, H-4), 7.53 (dd, J = 
8.5, 4.2 Hz, 1H, H-8), 5.12 (s, 1H, H-12), 4.32 (dd, J = 9.8, 1.9 Hz, 1H, H-16), 4.17 (s, 1H, H-15), 
3.70 (d, J = 9.7 Hz, 1H, H-16), 3.50 (d, J = 10.3 Hz, 1H, H-13), 3.27 (d, J = 11.3 Hz, 1H, H-13), 2.12 
(d, J = 10.4 Hz, 1H, H-17), 1.89 (d, J = 10.3 Hz, 1H, H-17); 13C NMR (151 MHz, DMSO-d6) δ 156.6 
(C-1), 154.0 (C-7), 153.8 (C-5), 150.3 (C-2' and C-6'), 148.2 (C-3), 145.8 (C-4'), 133.9 (C-9), 121.1 
(C-8), 120.8 (C-3' and C-5'), 114.8 (C-10), 110.0 (C-4), 58.9 (C-12), 57.9 (C-16), 57.2 (C-15), 49.8 
(C-13), 35.2 (C-17); HRMS m/z (ESI+) [Found: 304.1539, C18H18N5 requires (M+H)+ 304.1557]; 
LCMS (MDAP) Rt = 6.9 min (Ana 30–95 over 20 min), m/z (ESI+) 304.850 (M+H)+. 
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Tert-Butyl N-[(3R)-1-(7-chloro-1,6-naphthyridin-5-yl)pyrrolidin-3-yl]carbamate 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol) and tert-butyl N-[(3R)-pyrrolidin-3-yl]carbamate (1.11 g, 5.97mmol) in ethanol 
(7mL) were stirred at 100 °C overnight. LCMS indicated product formation (m/z 349, 293, 249). 
The mixture was concentrated under reduced pressure and water (4 mL) was added. The 
mixture was extracted four times with ethyl acetate (4 × 40 mL). The combined organic phases 
were washed with water (40 mL) and brine (40 mL) then dried over MgSO4, filtered and 
concentrated under reduced pressure (848 mg). The crude was purified via flash column 
chromatography (30 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl N-[(3R)-
1-(7-chloro-1,6-naphthyridin-5-yl)pyrrolidin-3-yl]carbamate (284 mg, 77%) as an off-white solid.  
Rf 0.70 (100% ethyl acetate); m.p. 147–148 °C; νmax (thin film)/cm-1 3211 (N-H, br), 2968 (aliphatic 
C-H, w), 1698 (C=O, s), 1579 (aromatic C-H, s), 1468 (aliphatic C-H, s), 876 (N-H, s); 1H NMR 
(600 MHz, DMSO-d6) δ 8.87 (d, J = 4.2 Hz, 1H, H-7), 8.62 (d, J = 8.6 Hz, 1H, H-9), 7.47–7.39 (m, 1, 
H-8), 7.23 (d, J = 5.4 Hz, 1H, H-16), 7.05 (s, 1H, H-4), 4.17–4.06 (m, 1H, H-14), 3.98 (dd, J = 11.1, 
6.0 Hz, 1H, H-15), 3.91 (dt, J = 11.0, 7.2 Hz, 1H, H-12), 3.79 (ddd, J = 10.9, 7.5, 5.5 Hz, 1H, H-12), 
3.61 (dd, J = 11.1, 4.5 Hz, 1H, H-15), 2.11–2.08 (m, 1H, H-13), 1.93 (m, 1H, H-13), 1.38 (s, 9H, H-
21); 13C NMR (151 MHz, DMSO-d6) δ 156.2 (C-1), 155.2 (C-17/3), 154.4 (C-3/17), 153.8 (C-7), 
146.4 (C-5), 134.9 (C-9), 119.9 (C-8), 112.8 (C-10), 108.7 (C-4), 77.9 (C-20), 56.2 (C-15), 49.8 (C-
14), 49.0 (C-12), 30.5 (C-13), 28.2 (C-21); HRMS m/z (ESI+) [Found: 371.1240, C17H21ClN4NaO2 
requires (M+H)+ 371.1245]; LCMS (LCQ) Rt = 1.4 min, (4 min method); m/z (ESI+) 349.1 (M+H)+, 
293.2 (M-t-Bu+H)+ and 249.3 (M-Boc+H)+. 
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Tert-Butyl N-[(3R)-1-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]pyrrolidin-3-yl]carbamate 
 
Potassium carbonate (169 mg, 1.23 mmol), pyridine-4-boronic acid hydrate (196) (50 mg, 
0.4100mmol),  bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(13 mg, 0.02 mmol) and tert-butyl N-[(3R)-1-(7-chloro-1,6-naphthyridin-5-yl)pyrrolidin-3-yl]-
carbamate (150 mg, 0.41 mmol) in acetonitrile (9.6 mL) and water (2.4 mL) were degassed under 
a flow of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS indicated 
product had formed (m/z 392). Water (15 mL) was added to the reaction mixture and the 
mixture was extracted three times with ethyl acetate (3 × 20 mL). The organic phase was dried 
over MgSO4, filtered and concentrated under reduced pressure (75 mg). The crude was purified 
via flash column chromatography (4 g silica, petroleum ether:ethyl acetate 1:0 to 0:1) to 
give tert-butyl N-[(3R)-1-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]pyrrolidin-3-yl]carbamate (38 mg, 
23%) as a yellow gum. 
1H NMR (600 MHz, DMSO-d6) δ 8.94 (dd, J = 4.2, 1.5 Hz, 1H, H-9), 8.68 (d, J = 6.0 Hz, 2H, H-2' and 
H-6'), 8.65 (d, J = 8.5 Hz, 1H, H-7), 8.16 (d, J = 6.0 Hz, 2H, H-3' and H-5'), 7.85 (s, 1H, H-4), 7.49 
(dd, J = 8.5, 4.2 Hz, 1H, H-8), 7.25 (d, J = 6.4 Hz, 1H, H-16), 4.20–4.14 (m, 1H, H-14), 4.08 (dd, J = 
10.9, 6.1 Hz, 1H, H-15), 4.05–4.00 (m, 1H, H-12), 3.95–3.88 (m, 1H, H-12), 3.74 (dd, J = 10.9, 
4.5 Hz, 1H, H-15), 2.21–2.10 (m, 1H, H-13), 2.03–1.91 (m, 1H, H-13), 1.38 (s, 9H, H-21); LCMS 
(MDAP) Rt = 2.3 min (Ana 5–95 over 5 min), m/z (ESI+) 392.2 (M+H)+. Further characterisation 
pending. 
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(3R)-1-[7-(4-Pyridyl)-1,6-naphthyridin-5-yl]pyrrolidin-3-amine (309) 
 
Tert-Butyl N-[(3R)-1-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]pyrrolidin-3-yl]carbamate (30 mg, 
0.07 mmol) was dissolved in dichloromethane (1 mL) and cooled to 0 °C. Trifluoro acetic acid 
(0.3 mL, 3.92 mmol) was added dropwise and the reaction mixture was allowed to stir at room 
temperature overnight. LCMS (LCQ) indicated product formation (m/z 292). The reaction 
mixture was concentrated under reduced pressure to give a yellow solid. The crude was purified 
via SCX cartridge by elution with methanol then 2 M ammonia in methanol to give (3R)-1-[7-(4-
pyridyl)-1,6-naphthyridin-5-yl]pyrrolidin-3-amine (309) (14 mg, 63%) as a yellow solid.  
Rf 0.07 (9:1 dichloromethane:methanol); m.p. 165–166 °C; νmax (thin film)/cm-1 2938 (aliphatic 
C-H, m), 1593 (C=C, s), 1560 (aromatic C-C, s), 1410 (aliphatic C-H, s), 1032 (C-N, s), 699 (N-H, 
s); 1H NMR (600 MHz, DMSO-d6) δ 8.92 (d, J = 4.0 Hz, 1H, H-7), 8.67 (d, J = 5.4 Hz, 3H, H-2', H-6' 
and H-9), 8.14 (d, J = 5.6 Hz, 2H, H-3' and H-5'), 7.83 (s, 1H, H-4), 7.49 (s, 1H, H-8), 6.21 (s, 2H, 
H-16), 4.09 (s, 2H, H-12), 3.90 (s, 1H, H-14), 3.80 (s, 2H, H-15), 2.23 (s, 1H, H-13) ,2.01 (s, 2H, H-
13); 13C NMR (151 MHz, DMSO-d6) δ 156.1 (C-1), 154.0 (C-5), 153.5 (C-7), 150.1 (C-2' and C-6'), 
148.2 (C-3), 145.9 (C-4'), 134.5 (C-9), 121.3 (C-8), 120.6 (C-3' and C-5'), 114.4 (C-10), 108.8 (C-4), 
55.9 (C-12), 49.8 (C-14), 48.9 (C-15), 31.2 (C-13); HRMS m/z (ESI+) [Found: 
292.1549, C17H18N5 requires (M+H)+ 292.1557]; LCMS (MDAP)  Rt = 0.5 min (Ana 5–95 over 
5 min), m/z (ESI+) 292.1 (M+H)+. 
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Tert-Butyl N-[(3S)-1-(7-chloro-1,6-naphthyridin-5-yl)pyrrolidin-3-yl]carbamate 
 
N,N-diisopropylethylamine (0.7 mL, 4.04 mmol), 5,7-dichloro-1,6-naphthyridine (284) (200 mg, 
1 mmol) and  (3S)-(-)-3-(tert-butoxycarbonylamino)pyrrolidine (1.11 g, 5.96 mmol)  in ethanol 
(7 mL) were stirred at 100 °C overnight. LCMS indicated product formation (m/z 349, 293, 249). 
The mixture was concentrated under reduced pressure and water (4 mL) was added. The 
mixture was extracted four time with ethyl acetate (4 × 40 mL). The combined organic phases 
were washed with water (40 mL) and brine (40 mL) then dried over MgSO4, filtered and 
concentrated under reduced pressure (899 mg). The crude was purified via flash column 
chromatography (25 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl N-[(3S)-
1-(7-chloro-1,6-naphthyridin-5-yl)pyrrolidin-3-yl]carbamate (301 mg, 82%) as an off-white solid.  
Rf 0.68 (100% ethyl acetate); m.p. 150–151 °C; νmax (thin film)/cm-1 3209 (N-H, br), 2969 (aliphatic 
C-H, w), 1698 (C=O, s), 1580 (aromatic C-C, m), 1438 (aliphatic C-H, s), 1246 (C-N, s), 830 (N-H, 
s); 1H NMR (600 MHz, DMSO-d6) δ 8.87 (dd, J = 5.2, 1.0 Hz, 1H, H-7), 8.62 (d, J = 8.6 Hz, 1H, H-9), 
7.43 (dd, J = 8.6, 4.2 Hz, 1H, H-8), 7.23 (d, J = 5.8 Hz, 1H, H-16), 7.05 (s, 1H, H-4), 4.15–4.08 (m, 
1H, H-14), 4.01–3.95 (m, 1H, H-15), 3.91 (dt, J = 10.7, 7.1 Hz, 1H, H-12), 3.83–3.75 (m, 1H, H-12), 
3.61 (dd, J = 11.0, 4.5 Hz, 1H, H-15), 2.11 (app.sept., J = 13.3, 7.1 Hz, 1H, H-13), 1.93 (app. sept, 
J = 12.4, 6.2 Hz, 1H, H-13), 1.38 (s, 9H, H-21). 13C NMR (151 MHz, DMSO-d6) δ 156.2 (C-1), 155.3 
(C-17), 154.4 (C-5), 153.8 (C-7), 146.4 (C-3), 134.9 (C-9), 119.9 (C-8), 112.8 (C-10), 108.7 (C-4), 
77.9 (C-20), 56.3 (C-15), 49.9 (C-14), 49.1 (C-12), 30.5 (C-13), 28.2 (C-21); HRMS m/z (ESI+) 
[Found: 371.1237, C17H21ClN4NaO2 requires (M+H)+ 371.1245]; LCMS (MDAP) Rt = 19.5 min (Ana 
5–95 over 20 min), m/z (ESI+) 349.1 (M+H)+. 
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Tert-Butyl N-[(3S)-1-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]pyrrolidin-3-yl]carbamate 
 
Potassium carbonate (178 mg, 1.29 mmol), pyridine-4-boronic acid hydrate (196) (53 mg, 
0.43 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(14 mg, 0.02 mmol) and tert-butyl N-[(3S)-1-(7-chloro-1,6-naphthyridin-5-yl)pyrrolidin-3-yl]-
carbamate (150 mg, 0.43 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow 
of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed 
reaction completion (m/z 392, 336, 292). The reaction mixture was diluted with water (20 ml) 
and extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were dried 
over MgSO4, filtered and concentrated under reduced pressure to give a brown foam (151 mg). 
The crude was purified via flash column chromatography  (4 g petroleum ether:ethyl acetate, 
1:0 to 0:1) to give tert-butyl N-[(3S)-1-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]pyrrolidin-3-yl]-
carbamate (64 mg, 36%) as a pale brown solid.  
Rf 0.13 (100% ethyl acetate); m.p. 206–208 °C; νmax (thin film)/cm-1 3199 (N-H, br), 2983 (aliphatic 
C-H, br), 1697 (C=O, s), 1592 (aromatic C-C, m), 1067 (C-N, s), 827 (N-H, s); 1H NMR (600 MHz, 
DMSO-d6) δ 8.95–8.93 (m, 1H, H-7), 8.68 (d, J = 6.0 Hz, 2H, H-2' and H-6'), 8.65 (d, J = 8.5 Hz, 1H, 
H-9), 8.16 (d, J = 6.0 Hz, 2H, H-3' and H-5'), 7.85 (s, 1H, H-4), 7.49 (dd, J = 8.5, 4.2 Hz, 1H, H-8), 
7.25 (d, J = 6.4 Hz, 1H, H-16), 4.20–4.13 (m, 1H, H-14), 4.11–4.05 (m, 1H, H-15), 4.05–4.00 (m, 
1H, H-12), 3.95–3.88 (m, 1H, H-12), 3.74 (dd, J = 10.8, 4.6 Hz, 1H, H-15), 2.20–2.11 (m, 1H, H-13), 
2.00–1.93 (m, 1H, H-13), 1.38 (s, 9H, H-21); 13C NMR (151 MHz, DMSO-d6) δ 156.4 (C-1), 155.3 
(C-17), 154.0 (C-7), 153.5 (C-5), 150.2 (C-2' and C-6'), 148.3 (C-3), 146.0 (C-4'), 134.5 (C-9), 120.7 
(C-3' and C-5'), 120.5 (C-8), 114.4 (C-10), 108.6 (C-4), 77.9 (C-20), 56.0 (C-15), 50.0 (C-14), 49.0 
(C-12), 30.7 (C-13), 28.3 (C-21); HRMS m/z (ESI+) [Found: 392.2079, C22H26N5O2 requires (M+H)+ 
392.2081]; LCMS (MDAP) Rt = 13.4 min (Ana 5–95 over 20 min), m/z (ESI+) 392.2 (M+H)+ and 
336.1 (M+H-t-Bu)+. 
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Tert-Butyl N-[(3S)-1-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]pyrrolidin-3-yl]carbamate (310) 
 
Tert-Butyl N-[(3S)-1-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]pyrrolidin-3-yl]carbamate (25 mg, 
0.06 mmol) was stirred in dichloromethane (0.54 mL) and cooled to 0 °C. Trifluoro acetic acid 
(0.25 mL, 3.26 mmol) was added dropwise and the reaction was allowed to stir at room 
temperature for 4 h. The reaction mixture was concentrated under reduced pressure 
and purified via SCX cartridge by elution with methanol then 2 M ammonia in methanol to give 
tert-butyl N-[(3S)-1-[7-(4-pyridyl)-1,6-naphthyridin-5-yl]pyrrolidin-3-yl]carbamate (310) (25 mg, 
97%) as a yellow solid.  
Rf 0.10 (9:1 dichloromethane:methanol); m.p. 79–80 °C; νmax (thin film)/cm-1 2937 (aliphatic C-
H, w), 1592 (C=C, m), 1560 (aromatic C-C, s), 1490 (aliphatic C-H, m), 1001 (C-N, s) 697 (N-H, s); 
1H NMR (600 MHz, DMSO-d6) δ 8.93 (dd, J = 4.2, 1.4 Hz, 1H, H-7), 8.69–8.66 (m, 3H, H-9, H-2' 
and H-6'), 8.18–8.12 (m, 2H, H-3' and H-5'), 7.84 (s, 1H, H-4), 7.49 (dd, J = 8.6, 4.2 Hz, 1H, H-8), 
4.11–4.03 (m, 2H, H-15), 3.94–3.87 (m, 1H, H-14), 3.75–3.67 (m, 2H, H-12), 2.20–2.12 (m, 1H, 
H-13), 1.93–1.86 (m, 1H, H-13); 13C NMR (151 MHz, DMSO-d6) δ 156.2 (C-1), 154.0 (C-5), 153.5 
(C-7), 150.2 (C-2' and C-6'), 148.3 (C-3), 146.0 (C-4'), 134.5 (C-9), 120.7 (C-3' and C-5'), 120.5 
(C-8), 114.4 (C-10), 108.6 (C-4), 57.1 (C-15), 50.2 (C-12), 49.0 (C-14), 32.2 (C-13); HRMS m/z (ESI+) 
[Found: 292.1545, C17H18N5 requires (M+H)+ 292.1557]; LCMS (MDAP) Rt = 6.8 min (Ana 30–95 
over 20 min), m/z (ESI+) 292.9 (M+H)+. 
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Tert-Butyl (3S)-3-[(7-chloro-1,6-naphthyridin-5-yl)amino]pyrrolidine-1-carboxylate 
 
N,N-Diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (200 mg, 
1 mmol) and (S)-3-amino-1-N-Boc-pyrrolidine (1.11 g, 5.97 mmol) in ethanol (7mL) were stirred 
at 100 °C overnight. LCMS indicated product formation (m/z 349, 293, 249). The mixture was 
concentrated under reduced pressure and water (4 mL) was added. The mixture was extracted 
four times with ethyl acetate (4 × 40 mL). The combined organic phases were washed with water 
(40 mL) and brine (40 mL) then dried over MgSO4, filtered and concentrated under reduced 
pressure (922 mg). The crude was purified via flash column chromatography (30 g silica, 
petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-butyl (3S)-3-[(7-chloro-1,6-naphthyridin-
5-yl)amino]pyrrolidine-1-carboxylate (278 mg, 75%) as a white solid.  
Rf 0.58 (100% ethyl acetate); m.p. 209–210 °C; νmax (thin film)/cm-1 331 (N-H, m), 3093 (aromatic 
C-H, w), 2976 (aliphatic C-H, m), 1678 (C=O, s), 1576 (aromatic C-C, s), 876 (N-H, s); 1H NMR 
(600 MHz, DMSO-d6) δ 8.92 (dd, J = 4.3, 1.5 Hz, 1H, H-7), 8.78 (d, J = 8.7 Hz, 1H, H-9), 8.00 (d, J = 
5.7 Hz, 1H, H-11), 7.51 (dd, J = 8.4, 4.3 Hz, 1H, H-8), 7.03 (s, 1H, H-4), 4.70–4.44 (m, 1H, H-12), 
3.68 (t, J = 8.8 Hz, 1H, H-H-13), 3.53–3.41 (m, 1H, H-15), 3.42–3.31 (m, 1H, H-15), 3.29–3.21 (m, 
1H, H-13), 2.30–2.09 (m, 1H, H-16), 2.09–1.87 (m, 1H, H-16), 1.40–1.33 (m, 9H, H-21); 13C NMR 
(151 MHz, DMSO-d6) δ 155.7 (C-1), 154.4 (C-7), 153.5 (C-17), 153.0 (C-5), 147.3 (C-3), 132.3 (C-
9), 120.8 (C-8), 111.9 (C-10), 108.5 (C-4), 78.3 (C-20), 51.2 (C-12), 50.7 (C-12), 50.5 (C-13), 50.4 
(C-13), 44.1 (C-15), 44.0 (C-15), 30.6 (C-16), 29.8 (C-16), 28.2 (C-21). Presence of rotamers 
accounts for additional peaks in aliphatic region; HRMS m/z (ESI+) [Found: 371.1239, 
C17H21ClN4NaO2 requires (M+H)+ 371.1245]; LCMS (LCQ) Rt = 2.9 min, (4 min method), m/z (ESI+) 
349.1 (M+H)+, 293.2 (M-tBu+H)+ and 249.2 (M-Boc+H)+. 
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Tert-Butyl (3S)-3-[[7-(4-pyridyl)-1,6-naphthyridin-5-yl]amino]pyrrolidine-1-carboxylate 
 
Potassium carbonate (169 mg, 1.23 mmol), pyridine-4-boronic acid hydrate (196) (50 mg, 
0.41 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(13 mg, 0.02 mmol) and tert-butyl (3S)-3-[(7-chloro-1,6-naphthyridin-5-yl)amino]pyrrolidine-1-
carboxylate (150 mg, 0.41 mmol) in 4:1 acetonitrile:water (12 mL) were degassed under a flow 
of nitrogen and heated in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed 
reaction completion (m/z 392, 336, 292). The reaction mixture was diluted with water (20 ml) 
and extracted twice with ethyl acetate (2 × 25 mL). The combined organic phases were dried 
over MgSO4, filtered and concentrated under reduced pressure to give a yellow oil (167 mg). The 
crude was purified via flash column chromatography  (5 g petroleum ether:ethyl acetate, 1:0 to 
0:1) to give tert-butyl (3S)-3-[[7-(4-pyridyl)-1,6-naphthyridin-5-yl]amino]pyrrolidine-1-
carboxylate (110 mg, 65%) as an off-white solid.  
Rf 0.38 (9:1 ethyl acetate:methanol); m.p. 120–122 °C; νmax (thin film)/cm-1 3330 (N-H, br), 2974 
(aliphatic C-H, w), 1668 (C=O, m), 1601 (C=C, m), 1532 (aromatic C-H, s), 1131 (C-N, m), 825 (N-H, 
s); 1H NMR (600 MHz, DMSO-d6) δ 9.02–8.92 (m, 1H, H-7), 8.81 (t, J = 6.7 Hz, 1H, H-9), 8.68 (d, J = 6.1 Hz, 
2H, H-2' and H-6'), 8.16 (d, J = 6.2 Hz, 2H), H-3' and H-5', 7.80 (s, 1H, H-4), 7.79–7.74 (m, 1H, H-11), 7.56 
(dd, J = 8.4, 4.3 Hz, 1H, H-8), 4.89–4.69 (m, 1H, H-12), 3.91–3.67 (m, 1H, H-13), 3.57–3.44 (m, 1H, H-14), 
3.46–3.33 (m, 2H, H-14), 3.35–3.31 (m, 1H, H-13), 2.35–2.21 (m, 1H, H-16), 2.17–2.00 (m, 1H, H-16), 1.53–
1.31 (m, 9H, H-21); 13C NMR (151 MHz, DMSO-d6) δ 155.4 (C-1), 154.1 (C-7), 153.6 (C-17), 152.6 
(C-5), 150.1 (C-2' and C-6'), 148.9 (C-1'), 146.2 (C-3), 132.0 (C-9), 121.9 (C-8), 119.9 (C-3' and C-
5'), 114.4 (C-10), 108.3 (C-4), 78.3 (C-20), 51.4 (C-12), 51.1 (C-12), 50.9 (C-13), 50.7 (C-13), 44.3 
(C-14), 44.1 (C-14), 30.8(C-16), 30.0 (C-16), 28.2 (C-21). Presence of rotamers accounts for 
multiple peaks; HRMS m/z (ESI+) [Found: 392.2076, C22H26N5O2 requires (M+H)+ 392.2081]; LCMS 
(MDAP) Rt = 8.3 min (Ana 30–95 over 20 min), m/z (ESI+) 392.1 (M+H)+, 336.0 (M+H-t-Bu)+, 292.0 
(M+H-Boc)+. 
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7-(4-Pyridyl)-N-[(3S)-pyrrolidin-3-yl]-1,6-naphthyridin-5-amine (311) 
 
Tert-Butyl (3S)-3-[[7-(4-pyridyl)-1,6-naphthyridin-5-yl]amino]pyrrolidine-1-carboxylate (50 mg, 
0.13 mmol) was dissolved in dichloromethane (1 mL) and cooled to 0 °C. Trifluoro acetic acid 
(0.5 mL, 5.17 mmol) was added dropwise and the reaction mixture was allowed to stir at room 
temperature overnight. LCMS (LCQ) indicated product formation (m/z 292). The reaction 
mixture was concentrated under reduced pressure to give a yellow solid. The crude was purified 
via SCX cartridge by elution with methanol then 2 M ammonia in methanol to give 7-(4-pyridyl)-
N-[(3S)-pyrrolidin-3-yl]-1,6-naphthyridin-5-amine (311) (39 mg, 99%) as a yellow solid.  
Rf 0.75 (100% ethyl acetate); m.p. 163–164 °C; νmax (thin film)/cm-1 3308 (N-H, br), 3085 
(aromatic C-H, w), 2974 (aliphatic C-H, w), 1677 (C=C, m), 1588 (aromatic C-C, s), 1407 (aliphatic 
C-H, s), 767 (N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.97 (dd, J = 4.1, 1.3 Hz, 1H, H-7), 8.78 (d, 
J = 8.4 Hz, 1H, H-9), 8.68 (d, J = 6.0 Hz, 2H, H-2' and H-6'), 8.15 (d, J = 6.0 Hz, 2H, H-3' and H-5'), 
7.83–7.79 (m, 2H, H-11 and H-4), 7.56 (dd, J = 8.4, 4.3 Hz, 1H, H-8), 4.80 (app. sept, J = 5.7 Hz, 
1H, H-12), 3.54 (dd, J = 11.8, 6.7 Hz, 1H, H-16), 3.23–3.12 (m, 3H, H-14 and H-16), 2.30 (h, J = 
14.5, 7.4 Hz, 1H, H-13), 2.10 (app. sept, J = 13.1, 6.4 Hz, 1H, H-13); 13C NMR (151 MHz, DMSO-
d6) δ 155.7 (C-1), 154.5 (C-7), 152.9 (C-5), 150.6 (C-2' and C-6'), 149.3 (C-3), 146.4 (C-4'), 132.4 
(C-9), 121.9 (C-8), 121.1 (C-3' and C-5'), 114.0 (C-10), 108.9 (C-4), 51.5 (C-12), 50.7 (C-16), 44.6 
(C-14), 30.7 (C-13); HRMS m/z (ESI+) [Found: 292.1549, C17H17N5 requires (M+H)+ 292.1557]; 
LCMS (MDAP) Rt = 6.8 min (Ana 30–95 over 20 min), m/z (ESI+) 292.0 (M+H)+. 
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tert-Butyl (3R)-3-[(7-chloro-1,6-naphthyridin-5-yl)amino]pyrrolidine-1-carboxylate 
 
N,N-diisopropylethylamine (0.71 mL, 4.06 mmol), 5,7-dichloro-1,6-naphthyridine (200 mg, 
1 mmol), and (R)-1-Boc-3-Aminopyrrolidine (1 mL, 5.98 mmol) in ethanol (7mL) were heated at 
100 °C overnight. LCMS  indicated product formation (m/z 349). The reaction mixture was 
concentrated under reduced pressure and water (4 mL) was added. The mixture was extracted 
three times with ethyl acetate (3 × 40 mL). The combined organic phases were washed with 
water (40 mL), brine (40 mL), dried over MgSO4, filtered and concentrated under reduced 
pressure to give a brown mixture (931 mg). The crude was purified via flash column 
chromatography (30 g silica, petroleum ether:ethyl acetate, 1:0 to 0:1) to give  tert-butyl (3R)-3-
[(7-chloro-1,6-naphthyridin-5-yl)amino]-pyrrolidine-1-carboxylate (300 mg, 81%) as an off-
white solid.  
Rf 0.54 (100% ethyl acetate); m.p. 210–211 °C; νmax (thin film)/cm-1 3345 (N-H, br), 3075 
(aromatic C-H, w), 1976 (aliphatic C-H, m), 1678 (C=O, s), 1576 (C=C, s), 1529 (aromatic C-C, s), 
1111 (C-N, s), 874 (N-H, s); 1H NMR (600 MHz, DMSO-d6) δ 8.92 (dd, J = 4.2, 1.3 Hz, 1H, H-7), 8.78 
(d, J = 8.0 Hz, 1H, H-9), 8.01 (d, J = 5.9 Hz, 1H, H-11), 7.51 (dd, J = 8.4, 4.3 Hz, 1H, H-8), 7.03 (s, 
1H, H-4), 4.67–4.45 (m, 1, H-12), 3.74–3.58 (m, 1H, H-13), 3.51–3.40 (m, 1H, H-15), 3.39–3.31 
(m, 1H, H-15), 3.28–3.21 (m, 1H, H-13), 2.25–2.15 (m, 1H, H-16), 2.07–1.92 (m, 1H, H-16), 1.40 
(d, J = 9.0 Hz, 9H, H-21); 13C NMR (151 MHz, DMSO-d6) δ 155.7 (C-1), 154.5 (C-7), 153.6 (C-17), 
153.0 (C-5), 147.3 (C-3), 132.4 (C-9), 120.8 (C-8), 112.0 (C-10), 108.5 (C-4), 78.3 (C-20), 78.3 
(C-20), 51.3 (C-12), 50.7 (C-12), 50.6 (C-13), 50.5 (C-13), 44.2 (C-15), 44.0 (C-15), 30.7 (C-16), 29.9 
(C-16), 28.2 (C-21); HRMS m/z (ESI+) [Found: 371.1238, C17H21ClN4NaO2 requires (M+H)+ 
371.1245]; LCMS (MDAP) Rt = 22.1 min (Ana 30–95 over 20 min), m/z (ESI+) 347.1 [35Cl] and 349.0 
[37Cl] (M+H)+. 
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Tert-Butyl (3R)-3-[[7-(4-pyridyl)-1,6-naphthyridin-5-yl]amino]pyrrolidine-1-carboxylate (313) 
 
Potassium carbonate (169 mg, 1.23 mmol), pyridine-4-boronic acid hydrate (196) (50 mg, 
0.41 mmol),   bis[2-(di-tert-butylphosphanyl)cyclopenta-2,4-dien-1-yl]iron; dichloropalladium 
(13 mg, 0.02 mmol) and tert-butyl (3R)-3-[(7-chloro-1,6-naphthyridin-5-yl)amino]pyrrolidine-1-
carboxylate (150 mg, 0.41 mmol) in 4:1 acetonitrile:water (12 mL) under a flow of nitrogen were 
heated in a microwave reactor at 140 °C for 15 minutes. LCMS confirmed reaction completion 
(m/z 392, 336, 292). The reaction mixture was diluted with water (20 ml) and extracted twice 
with ethyl acetate (2 × 25 mL). The combined organic phases were dried over MgSO4, filtered 
and concentrated under reduced pressure to give a brown oil (141 mg). The crude was purified 
via flash column chromatography  (4 g petroleum ether:ethyl acetate, 1:0 to 0:1) to give tert-
butyl (3R)-3-[[7-(4-pyridyl)-1,6-naphthyridin-5-yl]amino]pyrrolidine-1-carboxylate (313) 
(117 mg, 66%) as an orange solid. 
Rf 0.37 (9:1 ethyl acetate:methanol); m.p. 110–112 °C; νmax (thin film)/cm-1 3320 (N-H, br), 2972 
(aliphatic C-H, w), 1668 (C=O, m), 1602 (C=C, m), 1575 (aromatic C-C, m), 1404 (aliphatic C-H, s), 
1112 (C-N, m), 722 (N-H, m); 1H NMR (600 MHz, DMSO-d6) δ 8.98 (dd, J = 4.3, 1.7 Hz, 1H, H-7), 
8.82 (t, J = 7.6 Hz, 1H, H-9), 8.69 (d, J = 6.2 Hz, 1H, H-2' and H-6'), 8.17 (d, J = 6.2 Hz, 2H, H-3' and 
H-5'), 7.85–7.78 (m, 2H, H-4 and H-11), 7.57 (dd, J = 8.4, 4.2 Hz, 1H, H-8), 4.81 (m, 1H, H-12), 
3.79 (m, 1H, H-13), 3.54–3.47 (m, 1H, H-15), 3.45–3.37 (m, 1H, H-15), 3.32 (s, 1 H, H-13), 2.34–
2.20 (m, 1H, H-16), 2.18–2.00 (m, 1H, H-16), 1.41 (d, J = 16.3 Hz, 9H, H-21); 13C NMR (151 MHz, 
DMSO-d6) δ 155.4 (C-1), 154.1 (C-7), 152.6 (C-5), 150.2 (C-2' and C-6'), 149.0 (C-3), 146.1 (C-4'), 
132.0 (C-9), 121.4 (C-8), 120.6 (C-3' and C-5'), 113.6 (C-10), 108.3 (C-4), 78.3 (C-20), 51.4 (C-12), 
51.1 (C-12), 50.9 (C-13), 50.7 (C-13), 44.3 (C-15), 44.1 (C-15), 30.8 (C-16), 30.0 (C-16), 28.2 (C-21); 
HRMS m/z (ESI+) [Found: 392.2079, C22H26N5O2 requires (M+H)+ 392.2081]; LCMS (MDAP)  Rt = 
8.2 min (method), m/z (ESI+) 392.0 (M+H)+. 
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7-(4-Pyridyl)-N-[(3R)-pyrrolidin-3-yl]-1,6-naphthyridin-5-amine (312) 
 
Tert-Butyl (3R)-3-[[7-(4-pyridyl)-1,6-naphthyridin-5-yl]amino]pyrrolidine-1-carboxylate (313) 
(50 mg, 0.11 mmol) was stirred in dichloromethane (1 mL) and cooled to 0 °C. Trifluoro acetic 
acid (0.5 mL, 6.53 mmol) was added dropwise and the reaction was allowed to stir at room 
temperature for 4 h. The reaction mixture was concentrated under reduced pressure 
and purified via SCX cartridge by elution with methanol then 2 M ammonia in methanol to 
give 7-(4-pyridyl)-N-[(3R)-pyrrolidin-3-yl]-1,6-naphthyridin-5-amine (312) (30 mg, 85%) as a 
yellow solid.161 
Rf 0 (9:1 dichloromethane:methanol); m.p. 156–158 °C; νmax (thin film)/cm-1 3281 (N-H, br), 2973 
(aliphatic C-H, br), 1603 (C=C, m), 1575 (aromatic C-C, s), 1062 (C-N, s), 766 (N-H, s); 1H NMR 
(600 MHz, DMSO-d6) δ 8.96 (dd, J = 4.3, 1.5 Hz, 1H, H-7), 8.80 (d, J = 8.3 Hz, 1H, H-9), 8.69–8.66 
(m, 2H, H-2' and H-6'), 8.17–8.14 (m, 2H, H-3' and H-5'), 7.84 (d, J = 5.5 Hz, 1H, H-11), 7.78 (s, 
1H, H-4), 7.55 (dd, J = 8.4, 4.3 Hz, 1H, H-8), 4.81–4.75 (m, 1H, H-12), 3.46 (dd, J = 11.6, 6.5 Hz, 
1H, H-16), 3.26–3.19 (m, 1H, H-15), 3.15–3.03 (m, 2H, H-15 and H-16), 2.30–2.23 (m, 1H, H-13), 
2.08–2.00 (m, 1H, H-13); 13C NMR (151 MHz, DMSO-d6) δ 155.4 (C-1), 154.1 (C-7), 152.6 (C-5), 
150.2 (C-2' and C-6'), 149.0 (C-3), 146.1 (C-4'), 132.1 (C-9), 121.4 (C-8), 120.7 (C-3' and C-5'), 
113.6 (C-10), 108.2 (C-4), 51.7 (C-12), 51.2 (C-16), 44.7 (C-15), 31.1 (C-13); HRMS m/z (ESI+) 
[Found: 292.1543, C17H18N5 requires (M+H)+ 292.1557]; LCMS (MDAP) Rt = 7.1 min (Ana 30–95 
over 20 min), m/z (ESI+) 291.90 (M+H)+. 
6.2 Biology 
The following section describes work carried out by Dr. Angela Fala. 
6.2.1 Cloning, protein expression and purification 
PKN2- UniProt ID Q16513 (Ser646-Cys984) and PKN1-UniProt ID Q16512 (Pro604-Cys942) were 
cloned fused to an N-terminal GST tag and C-terminal biotin tag attachment site 
(SSKGGYGLNDIFEAQKIEWHE). 
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Bacmid DNA containing the construct sequence was prepared from DH10Bac cells and used to 
transfect Sf9 insect cells for the preparation of baculovirus. The prepared baculovirus was used 
to infect a new batch of Sf9 cells cultivated in Sf-900 II SFM media (Thermo Fisher) in the 
presence of 20 U/mL of penicillin/streptomycin. Both proteins were expressed for 48 hours at 
27°C. Additional biotin (Sigma-Aldrich) was added to the culture (200 mM/L) for biotinylation by 
co-expressed BirA. After incubation the cells were harvested (900 x g, 30 min, 4°C) and were re-
suspended in lysis buffer (50 mM HEPES pH 7.5, 300 mM NaCl, 5% glycerol, 0.5 mM TCEP, 5 µL 
per 1 mL protease inhibitor cocktail Set III EDTA-free (Merck Millipore), frozen in liquid nitrogen 
and stored for later purification. The cells were thawed, re-suspended in approximately 150 mL 
lysis buffer, sonicated for 2 min in total (5 s ON, 10 s OFF) on ice. After sonication, the lysate was 
supplemented with 0.7% of Tween20 and benzonase (50 μg/100 mL of lysate) and incubated on 
ice for 15 min. The cell lysates were centrifuged at 50000 x g for 30 min at 4 °C. The supernatant 
was loaded on a pre-equilibrated (with lysis buffer) gravity column with 5 mL of glutathione-
Sepharose resin and then purified by affinity chromatography. After loading the sample, the 
resin was washed with 40 CV of lysis buffer. The sample was eluted with 10 CV of lysis buffer 
containing 10 mM reduced glutathione. The elution fraction was concentrated to 2 mL using a 
30 kDa molecular weight cut-off centrifugal concentrator (Millipore) at 4 °C and injected onto 
an S75 16/600 column (pre-equilibrated in 20 mM HEPES pH 7.5, 300 mM NaCl, 5% glycerol, 1 
mM TCEP) at 1.0 mL/min. 1.5 mL fractions were collected and analysed on a 12% SDS-PAGE. One 
sample of the protein was separated to confirm its identity and the biotinylation by intact mass 
analysis. The main peak fractions were concentrated, and the protein was flash-frozen in a liquid 
nitrogen bath and stored at -80 °C until use. 
6.2.2 Binding Displacement Assay 
The time resolved fluorescence resonance energy transfer (TR-FRET) method was used to 
measure the binding of a fluorescent tracer molecule in the ATP binding site. Displacement of 
the tracer by varying concentrations of an inhibitor allows the IC50 value for the inhibitor to be 
calculated.  Compounds were serially diluted from 50 μM to 0.85 nM for a 12-point (1:3) in 
DMSO and then diluted in assay buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% 
Brij-35). The dissociation constants of the tracer were measured for both kinases (PKN2 KD = 5 ± 
0.2 nM and PKN1 KD = 2.8 ± 0.2 nM, Supplementary Figure 1). The final assay contained 5 nM 
biotinylated PKN2 or 15 nM biotinylated PKN1 ligated to streptavidin-Tb-cryptate (Cisbio), 5 nM 
or 2.8 nM Kinase Tracer 236 (Thermo Fisher Scientific) respectively for PKN2 and PKN1 and serial 
dilutions of the compounds. Final assay volume of each data point was 15 µL and final DMSO 
concentration was 1.25%. Black 384 well plates (Greiner) were used. The assay was incubated 
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at room temperature for 1 hour and then TR-FRET data was measured on a CLARIOstar Plus 
(BMG Labtech). Data was normalized to 0% and 100% inhibition values and fit to a four 
parameter dose-response binding curve in GraphPad 7 Software (version 7.04). All the points 
were measured in triplicate with two biological replicates. 10 µM of Staurosporine was used as 
a control for 100% inhibition and calculation of the Z’ value.216  
 
Figure S1. Determination of dissociation constant of Tracer 236 (ThermoFisher) when titrated over 5 nM of PKN2 
or 15 nM of PKN1 
6.2.3 Crystallography 
Conditions: 2 M ammonium sulfate, 0.2 M sodium/potassium tartrate and 0.1 M of citrate 
pH 5.50 
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Appendices 
Appendix 1 DiscoverX Panel Results 
Table A DiscoverX panel results for compounds 11, 120, 187, 191, 220 and 220, ranked by potency. % represents % of immobilised ligand remaining. 
Compound 11 Compound 187 Compound 191 Compound 120 Compound 220 Compound 222 
Target 
name 
% ligand 
remaining 
Target 
name 
% ligand 
remaining 
Target name 
% ligand 
remaining 
Target 
name 
% ligand 
remaining 
Target 
name 
% ligand 
remaining 
Target 
name 
% ligand 
remaining 
PAK3 0 ROCK1 0 HASPIN 1.5 YSK4 0.8 HASPIN 21 
AMPK-
alpha1 
44 
LTK 0 PRKCE 0 ROCK2 6.9 HASPIN 4.2 
FLT3 
(ITD,D835V
) 
21 YSK4 48 
CIT 0 ROCK2 0.2 ROCK1 13 PRKCQ 11 NIK 41 EPHA5 52 
HASPIN 1.5 HASPIN 0.5 YSK4 28 IRAK1 12 
FLT3 
(D835V) 
41 TRKB 53 
PRKG2 3.5 MEK5 14 MEK5 32 HIPK3 12 PIP5K1C 48 JNK2 53 
DYRK1A 5 HIPK2 19 
FLT3 
(D835V) 
35 DYRK2 12 GRK2 48 ROCK2 54 
DYRK1B 6.1 CIT 21 HIPK4 39 CLK4 14 MYLK 49 PRKX 54 
YSK4 8.9 PRKG2 26 BMPR1B 40 CLK1 15 ANKK1 49 
JAK2(JH1 
domain-
catalytic) 
55 
CLK4 9.3 PKN2 27 
FLT3 (ITD, 
F691L) 
44 CSNK1E 16 ASK2 50 GRK2 55 
DRAK1 13 CDK7 30 PRKCE 46 CSNK1A1 16 LRRK2 52 CDK5 56 
ROCK1 15 YSK4 40 MARK3 49 HIPK2 17 
RSK2(Kin. 
Dom.2-C-
terminal) 
53 BMPR1B 56 
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DYRK2 15 TRKB 40 PIP5K1C 51 CDK9 17 PDGFRA 54 
FLT3 
(D835V) 
57 
CLK1 17 PRKX 40 CDK7 51 LATS2 18 MKNK1 54 CDK7 57 
IRAK1 19 DMPK 42 
FLT3 (ITD, 
D835V) 
53 HIPK1 19 
FLT3 (ITD, 
F691L) 
54 CASK 57 
CSNK1A1 19 CAMK1B 44 
TYK2(JH1 
domain-
catalytic) 
54 DYRK1A 22 
FLT3 
(R834Q) 
55 NEK3 58 
ROCK2 23 
RSK2(Kin. 
Dom.2-C-
terminal) 
45 
ABL1 
(Q252H) 
54 PRKCE 26 SNARK 56 HIPK2 58 
TRKB 25 PKN1 46 CDKL1 56 PRKG1 29 
FLT3-auto-
inhibited 
56 ERK2 58 
TAOK1 27 PKAC-beta 46 CLK4 58 DYRK1B 29 SGK3 57 
PFPK5(P. 
falciparum) 
60 
PKN2 27 PRKCH 47 PFTAIRE2 60 BMPR1B 29 LATS2 57 MEK2 60 
HIPK3 29 GRK2 49 CSNK2A1 60 CSNK1D 30 CASK 57 LRRK2 60 
CDK9 30 
FLT3 (ITD, 
F691L) 
49 MAP3K15 61 PKN2 31 BTK 57 
BRAF 
(V600E) 
60 
JAK3(JH1 
domain-
catalytic) 
31 PRKCD 50 PRKD3 62 CIT 34 
ABL1 
(M351T)  
-(PO4)3- 
57 BRAF 60 
BMPR1B 38 CAMK1 50 PRKCI 62 GSK3A 35 
ABL1 
(E255K) 
-(PO4)3- 
57 MAP3K15 61 
DRAK2 39 DYRK2 51 PKN2 62 CDK7 38 TRKB 58 LATS2 61 
HIPK1 41 PRKD1 52 MKNK1 62 ERK8 39 SRMS 58 PRKCE 62 
TTK 43 CTK 52 EIF2AK1 62 PRKG2 40 HIPK1 58 JNK3 62 
NEK10 43 PRKG1 53 
ABL1 
(E255K) 
(PO4)3- 
62 MINK 40 SBK1 59 S6K1 64 
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CSNK1E 44 
FLT3 
(D835V) 
54 SRPK2 63 ROCK1 41 NEK3 59 MST3 64 
ALK 
(C1156Y) 
44 ALK 54 SGK2 63 PKN1 41 IKK-epsilon 60 
CDK4-
cyclinD1 
64 
HIPK2 46 
CSF1R-auto-
inhibited 
55 IKK-alpha 63 EPHB6 43 EPHB6 60 
RSK2(Kin. 
Dom.2-C-
terminal) 
65 
PRKCE 47 PRKD3 57 DCAMKL1 63 CLK2 44 
ABL1 
(F317I)  
-(PO4)3- 
60 NIM1 65 
RSK2(Kin. 
Dom.2-C-
terminal) 
48 DCAMKL1 57 CAMKK1 63 IKK-epsilon 46 VEGFR2 61 HASPIN 65 
IKK-alpha 48 CDK9 57 
ABL1 
(H396P)  
-(PO4)3- 
63 
PFPK5(P. 
falciparum) 
48 TAOK1 61 BMPR2 65 
PFPK5(P. 
falciparum) 
49 NEK10 58 
TYK2 (JH2 
domain-
pseudokinas
e) 
64 SNARK 49 
KIT-auto-
inhibited 
61 
TYK2 (JH2 
domain-
pseudokina
se) 
66 
CDK7 49 PLK3 59 PIKFYVE 64 PLK3 49 
CSF1R-
auto-
inhibited 
61 MAPKAPK5 66 
PRKG1 50 JNK2 59 DYRK1A 64 GRK7 49 
ALK(C1156
Y) 
61 
EGFR 
(L747-
S752del, 
P753S) 
66 
CDK4-
cyclinD1 
50 ERN1 59 RIPK5 65 DAPK3 49 ACVR1B 61 
EGFR 
(E746-
A750del) 
66 
PLK1 51 SgK110 60 PRKG2 65 TAOK1 51 
ABL1 
(F317L) -
(PO4)3- 
61 DDR2 66 
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NEK3 51 MAST1 60 MKNK2 65 TAK1 51 MAPKAPK5 62 ROCK1 67 
GSK3B 51 GRK3 61 CLK1 65 PRKCH 51 IRAK1 62 SRMS 68 
ERK8 51 TNNI3K 62 ULK2 66 DCAMKL1 51 CDK7 62 MKNK2 68 
RPS6KA4 
 (Kin. 
Dom.2-C-
terminal) 
52 SRMS 62 SNRK 66 CSNK2A1 51 
ABL1 
(T315I) 
62 
FLT3 
(ITD,D835V
) 
68 
CSNK1D 52 KIT (A829P) 62 NEK7 66 
EGFR (E746-
A750del) 
53 QSK 63 CAMK1B 68 
MAP3K1 52 MAPKAPK2 62 
PIK3CA 
(I800L) 
66 
GCN2 (Kin. 
Dom.2,S808
G) 
53 ROCK2 63 FGFR1 68 
CLK2 53 AKT3 62 ACVRL1 66 
ABL1 
(E255K)- 
(PO4)3- 
54 
PFPK5(P. 
falciparum) 
63 ALK 68 
RSK3(Kin. 
Dom.2-C-
terminal) 
53 
EGFR 
(T790M) 
62 
JAK2(JH1 
domain-
catalytic) 
66 
PKNB(M.tu
berculosis) 
54 
PIK3CA 
(I800L) 
63 
ALK 
(C1156Y) 
68 
ASK2 53 DYRK1B 63 RIOK2 67 
EGFR 
(T790M) 
55 MAP4K2 63 DCAMKL1 69 
CDC2L5 53 
RPS6KA4 
(Kin. 
Dom.1-N-
terminal) 
63 YANK1 67 GRK2 55 MINK 63 PIK3CB 69 
KIT-auto-
inhibited 
54 VPS34 64 PLK3 67 NEK4 56 EPHB4 63 IKK-epsilon 70 
SNARK 55 NIK 64 MYO3B 67 
JAK3(JH1 
domain-
catalytic) 
56 ALK 63 
FLT3 
(R834Q) 
70 
RIPK4 55 
FLT3 (ITD, 
D835V) 
64 KIT (D816H) 67 
ABL1 
(Y253F)-
phosphoryl
ated 
56 RIPK5 64 
FLT3 (ITD, 
F691L) 
70 
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MKNK1 55 p38-gamma 65 HIPK1 67 MAP3K15 57 DCAMKL1 64 DLK 70 
NIK 56 CAMKK2 65 
EGFR (E746-
A750del) 
67 
EGFR (L747-
S752del, 
P753S) 
57 BMPR1B 64 
PFCDPK1(P.
falciparum) 
71 
JAK2(JH1 
domain-
catalytic) 
56 
PIK3CA 
(H1047L) 
66 CAMK1B 67 
CSF1R-auto-
inhibited 
57 TAOK2 65 NIK 71 
GRK2 56 
GCN2 (Kin. 
Dom.2,S808
G) 
66 
ABL1-
(PO4)3- 
67 SGK3 58 PLK2 65 LOK 71 
WNK2 57 DRAK2 66 TTK 68 p38-delta 58 MEK5 65 BUB1 71 
VPS34 57 CDC2L5 66 SRMS 68 MYLK 58 MAP3K3 65 
PIK3CA 
(Q546K) 
72 
ICK 57 TAK1 67 CAMKK2 68 
PFCDPK1(P.
falciparum) 
59 
ABL1 
(T315I)  
-(PO4)3- 
65 MEK5 72 
ABL1 
(T315I) -
(PO4)3- 
57 
PFCDPK1(P.
falciparum) 
67 
PFCDPK1(P.f
alciparum) 
69 
FLT3 
(D835V) 
59 PIK3CB 66 BTK 72 
MAPKAPK5 58 MKNK2 67 MEK2 69 CDC2L5 59 ERBB3 66 RIOK2 73 
BRAF 58 
CDK4-
cyclinD1 
67 DYRK2 69 
RET 
(V804M) 
60 S6K1 67 MAP3K2 73 
LATS2 58 CLK1 67 FYN 69 TSSK1B 60 SgK110 67 MEK1 73 
LRRK2 59 
PIK3CA 
(I800L) 
68 
ABL1-
nonphospho
rylated 
69 EPHA4 60 MYLK2 67 JNK1 73 
DCAMKL3 59 MAP3K1 68 
PIK3CA 
(C420R) 
70 
ALK 
(C1156Y) 
60 ULK3 68 WNK3 74 
HPK1 60 
ABL1 
(E255K)-
phosphoryl
ated 
68 NEK9 70 
KIT-auto-
inhibited 
61 MTOR 68 TAOK2 74 
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PIP5K2C 60 BMPR1B 68 NIM1 70 
RSK2(Kin. 
Dom.2-C-
terminal) 
61 PIK4CB 68 TTK 74 
QSK 61 AAK1 68 MINK 70 
EGFR (S752-
I759del) 
61 
KIT 
(D816H) 
68 SGK2 74 
MYLK 61 TGFBR1 69 ALK 70 AAK1 61 
EGFR 
(L858R, 
T790M) 
68 RIPK4 74 
FLT3 (ITD, 
F691L) 
61 
PFPK5(P. 
falciparum) 
69 TNNI3K 71 ROCK2 62 CDKL1 68 MKNK1 74 
CASK 61 STK39 70 RAF1 71 KIT (A829P) 62 WNK3 69 MINK 74 
KIT (A829P) 62 SGK2 70 
PIK3CA 
(E542K) 
71 BUB1 62 TAOK3 69 
JAK3(JH1 
domain-
catalytic) 
74 
BMPR2 62 
KIT-auto-
inhibited 
70 MRCKA 71 LKB1 63 IKK-alpha 69 HIPK3 74 
CAMK1B 62 MAP3K15 70 NDR1 71 MEK2 63 
RSK4(Kin. 
Dom.1-N-
terminal) 
69 IRAK1 74 
ABL1 
(Q252H) 
62 INSR 70 PLK1 72 
JAK2(JH1 
domain-
catalytic) 
63 DYRK1A 69 CSNK2A1 74 
ABL1 
(M351T) -
(PO4)3- 
62 
ABL1 
(Y253F) -
(PO4)3- 
70 
PIK3CA 
(Q546K) 
72 
RPS6KA4  
(Kin. 
Dom.2-C-
terminal) 
64 YSK4 70 CDKL5 74 
ABL1 
(H396P)-
(PO4)3- 
62 SNRK 71 MEK3 72 FLT3 64 TBK1 70 CDKL2 74 
MEK5 63 PRKCQ 71 
EGFR (L747-
S752del, 
P753S) 
72 
EGFR 
(L861Q) 
64 NIM1 70 TAK1 75 
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ABL1 
(E255K)-
(PO4)3- 
63 HPK1 71 TAOK2 73 
RSK3 (Kin. 
Dom.1-N-
terminal) 
65 
JAK2(JH1 
domain-
catalytic) 
70 
RPS6KA4  
(Kin. 
Dom.2-C-
terminal) 
75 
DDR2 63 PIK3CD 71 ULK3 73 TNNI3K 65 MAP3K2 70 
RSK4(Kin. 
Dom.1-N-
terminal) 
75 
MINK 64 RIPK5 72 LATS2 73 EPHB3 65 CAMK1B 70 
PIK3CA 
(C420R) 
75 
MKNK2 64 TAOK2 72 SGK 73 MEK1 65 
EGFR 
(L747-
S752del, 
P753S) 
70 PKN2 75 
FLT3 (ITD, 
D835V) 
64 PRKCI 72 JNK3 73 
CDK4-
cyclinD3 
65 ULK2 71 PCTK1 75 
ABL1 
(F317L)- 
(PO4)3 
65 MKK7 72 CSNK2A2 73 PRKCI 66 NDR1 71 GRK3 75 
MAP4K2 65 MYO3B 72 GRK4 73 SgK110 66 PRKCE 71 HIPK1 75 
PRKD1 66 MAP4K2 72 CSNK1G2 73 PIK3CA 66 CDKL3 71 
ABL1 
(T315I)- 
75 
MAP3K2 66 JNK3 72 
CSF1R-auto-
inhibited 
73 NEK3 66 BMPR2 71 SGK 76 
CLK3 66 HIPK1 72 
ALK 
(L1196M) 
73 EPHA6 66 PLK3 72 
KIT-auto-
inhibited 
76 
HUNK 66 
JAK2(JH1 
domain-
catalytic) 
72 CAMK1 73 MAPKAPK5 66 RIOK2 72 MKK7 76 
BRAF 
(V600E) 
66 BMX 72 p38-gamma 74 CDKL1 66 
PIK3CA 
(E545K) 
72 IKK-alpha 76 
ULK2 67 ADCK3 72 NLK 74 CDK11 66 
PIK3CA 
(C420R) 
72 GRK7 76 
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TYK2(JH1 
domain-
catalytic) 
67 PIK3CA 73 MST1 74 NDR1 67 PIK3CA 72 
ABL1 
(T315I)-
(PO4)3- 
76 
EPHB6 67 PAK2 73 
KIT-auto-
inhibited 
74 RIPK4 68 CSNK2A1 72 STK39 77 
JNK2 67 PIK3C2G 73 MLK1 74 TTK 68 MEK2 72 TRPM6 77 
ABL1-
(PO4)3- 
67 FYN 73 STK16 75 PRKX 68 CDK11 72 NEK11 77 
SGK2 68 CDKL1 73 
PFPK5(P. 
falciparum) 
75 NEK10 68 
TYK2(JH2 
domain-
ps.kinase) 
73 NEK10 77 
AAK1 68 MEK2 74 AURKB 75 DDR2 68 GRK7 73 DYRK1A 77 
PFCDPK1(P.
falciparum) 
68 NEK3 74 BTK 75 INSR 68 
JAK1(JH2 
domain-
ps.kinase) 
73 FYN 77 
PKNB(M.tu
berculosis) 
68 ULK2 74 IKK-beta 75 MYO3B 68 MST4 73 IRAK4 77 
MEK2 68 FLT3 74 SgK110 76 DAPK2 68 DLK 73 
CSF1R-
auto-
inhibited 
77 
FLT3 
(D835V) 
68 FGFR4 74 PIK3CB 76 CSNK1A1L 68 CTK 73 SGK3 78 
CSNK1G2 68 EPHB2 74 NEK10 76 
TYK2(JH1 
domain-
catalytic) 
69 CSNK1A1 73 SgK110 78 
IKK-epsilon 69 MKNK1 75 HIPK3 76 CLK3 69 
BRAF(V600
E) 
73 
ABL1 
(E255K)-
(PO4)3- 
78 
SgK110 69 
PIK3CA 
(C420R) 
75 MAP3K3 76 TGFBR1 69 CDKL5 73 MAP3K3 78 
CSNK1G3 69 MARK1 75 DLK 76 AKT2 69 
TYK2(JH1 
domain-
catalytic) 
74 QSK 79 
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ABL1 
(Y253F)-
(PO4)3- 
69 WNK1 76 
ABL1 
(T315I)- 
76 ADCK4 69 TRKA 74 PLK1 79 
CDK4-
cyclinD3 
70 TTK 76 
PIK3CA 
(E545K) 
77 
ABL1 
(Q252H)- 
69 
PIK3CA 
(E542K) 
74 PIP5K2C 79 
GSK3A 71 PLK2 76 LRRK2 77 MAPKAPK2 70 
EGFR 
(T790M) 
74 CSNK1A1 79 
SRMS 71 RIPK2 76 NEK3 77 MYO3A 70 EIF2AK1 74 DYRK1B 79 
WNK4 71 S6K1 76 PIK3C2G 77 STK39 70 MKK7 74 MYLK 79 
ABL1 
(H396P)- 
71 MRCKB 76 
ABL1 
(H396P)- 
77 PLK2 71 RIPK4 75 SBK1 80 
CSF1R-
auto-
inhibited 
71 
PKNB(M.tu
berculosis) 
76 
EGFR 
(L861Q) 
77 RIPK2 71 VPS34 75 ZAP70 80 
PLK3 72 
KIT 
(V559D,V65
4A) 
76 AAK1 77 MEK4 71 PLK1 75 
RSK3(Kin. 
Dom.2-C-
terminal) 
80 
MLCK 72 EPHA2 76 MAPKAPK5 78 DDR1 71 GRK3 75 MAP3K1 80 
NIM1 72 GRK7 76 PLK2 78 HPK1 71 IKK-beta 75 MEK3 80 
PIKFYVE 72 IKK-alpha 76 
RSK2(Kin. 
Dom.1-N-
terminal) 
78 
JAK1(JH1 
domain-
catalytic) 
71 PCTK1 75 
PIK3CA 
(E545A) 
80 
LZK 72 
ALK(L1196
M) 
76 FLT3 (N841I) 78 CAMK1B 71 MEK3 76 
KIT 
(D816H) 
80 
MEK1 72 BMPR2 76 MAP4K2 78 CSNK1G2 71 
PIK3CA 
(E545A) 
76 
LRRK2 
(G2019S) 
80 
IKK-beta 72 ZAP70 77 DMPK 78 TBK1 72 JNK1 76 KIT (A829P) 80 
BUB1 72 
PIK3CA 
(E545K) 
77 BMPR2 78 STK36 72 
ABL1 
(F317I)- 
76 VRK2 81 
DAPK3 72 PIP5K1C 77 CDKL3 78 SYK 72 ERN1 76 WNK4 81 
ALK 72 JNK1 77 TGFBR1 79 PIK3CG 72 ZAP70 77 VPS34 81 
PKN1 73 HIPK3 77 TAOK1 79 GSK3B 72 ULK1 77 PLK3 81 
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PIK3CA 
(C420R) 
73 
ABL1 
(T315I)-
(PO4)3- 
77 SBK1 79 EPHB2 73 SNRK 77 NEK4 81 
PIK4CB 73 
EGFR (E746-
A750del) 
77 STK33 79 SRPK3 73 TAK1 77 NLK 81 
MST4 73 WNK3 78 RIOK1 79 
CDK4-
cyclinD1 
73 
PFCDPK1(P.
falciparum) 
77 NDR1 81 
JNK1 73 NIM1 78 PIK3CD 79 SGK2 74 MEK1 77 CDC2L5 81 
MAP3K15 73 
RSK3(Kin. 
Dom.1-N-
terminal) 
78 PRKD1 79 STK35 74 MKNK2 77 CDKL1 81 
ABL1 
(T315I)- 
73 CSNK1A1 78 JNK1 79 JNK2 74 ICK 77 
PIK3CA 
(H1047L) 
82 
EGFR 
(T790M) 
73 EPHB1 78 MARK2 79 PLK1 74 JNK2 77 
RSK2(Kin. 
Dom.1-N-
terminal) 
82 
FLT3-auto-
inhibited 
73 EPHB3 78 MYLK 79 PRKCD 74 MAP3K15 77 
TYK2(JH1 
domain-
catalytic) 
82 
WNK3 74 ABL2 78 DDR2 79 
JAK1(JH2 
domain-
ps.kinase) 
74 HPK1 77 
PIK3CA 
(E545K) 
82 
SGK 74 
ABL1 
(T315I) 
78 CHEK1 79 
FLT3 
(ITD,F691L) 
74 TRKC 78 MST4 82 
ERBB4 74 PHKG2 79 EPHA8 80 BMX 74 HIPK2 78 EPHB6 82 
KIT 
(D816H) 
74 PKAC-alpha 79 EPHB2 80 
BRAF(V600E
) 
74 
RPS6KA4  
(Kin. 
Dom.2-C-
terminal) 
78 ERBB2 82 
PLK2 74 YANK1 79 SNARK 80 
EGFR 
(G719C) 
74 
RSK2(Kin. 
Dom.1-N-
terminal) 
78 LZK 82 
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DLK 74 
CDK4-
cyclinD3 
79 CAMK1D 80 RAF1 75 AURKB 78 
ALK 
(L1196M) 
82 
ERBB3 74 DDR2 79 CASK 80 RIPK5 75 BRAF 78 ASK2 82 
CDKL1 74 
ALK 
(C1156Y) 
79 BRAF 80 PIK3CD 75 
ABL1-
(PO4)3- 
78 ULK3 83 
CAMK2B 74 KIT (D816V) 80 
ABL1 
(F317I)- 
80 MAP3K1 75 
ABL1 
(Y253F)-
(PO4)3- 
78 ULK2 83 
TAK1 75 IRAK1 80 TAK1 81 
EGFR 
(G719S) 
75 
ABL1 
(H396P)-
(PO4)3- 
78 SNRK 83 
FGFR3 75 CDKL3 80 
PIK3CA 
(H1047L) 
81 AXL 75 PRKCI 79 AURKB 83 
MST1R 75 ERK8 80 PRKG1 81 BRAF 75 STK39 79 EIF2AK1 83 
PIK3CA 
(H1047L) 
75 FGFR3 80 
RSK4(Kin. 
Dom.1-N-
terminal) 
81 CSNK1G3 75 WNK2 79 SIK2 83 
CSNK2A1 75 CDK11 80 PDGFRA 81 ARK5 75 NEK10 79 RIPK5 84 
ZAP70 76 
ABL1 
(Q252H)- 
80 LATS1 81 
ABL1-
(PO4)3- 
75 HIPK3 79 
RET 
(V804L) 
84 
TAOK3 76 SBK1 81 ERK1 81 WNK3 76 GRK1 79 PLK2 84 
SNRK 76 PIK3CG 81 
EGFR 
(T790M) 
81 
RSK3(Kin. 
Dom.2-C-
terminal) 
76 OSR1 80 IKK-beta 84 
RSK3(Kin. 
Dom.1-N-
terminal) 
76 MYO3A 81 
EGFR L747-
T751delSins 
81 ROS1 76 JNK3 80 VEGFR2 85 
PRP4 76 MLK2 81 CAMK4 81 PKAC-beta 76 SGK2 81 TRKA 85 
MARK3 76 EPHA4 81 MEK1 82 BIKE 76 DDR2 81 CAMK1 85 
p38-delta 76 EPHB4 81 PKAC-alpha 82 DAPK1 76 
FLT3 
(D835H) 
81 CDKL3 85 
PDGFRA 76 GSK3B 81 S6K1 82 FER 76 LZK 81 GRK1 85 
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PRKCI 76 
JAK3(JH1 
domain-
catalytic) 
81 TBK1 82 MEK5 76 SGK 81 
PIK3CA 
(I800L) 
85 
DCAMKL1 76 DYRK1A 81 LOK 82 PKAC-alpha 77 
ABL1 
(Q252H)-
(PO4)3- 
81 GSK3B 86 
FGFR2 76 
EGFR (L747-
S752del, 
P753S) 
81 MAP4K5 82 TESK1 77 
CDK4-
cyclinD1 
81 TAOK1 86 
ACVR2B 76 CAMK4 81 
FLT3-auto-
inhibited 
82 MAP3K2 77 ROCK1 82 
ABL1 
(F317L)-
(PO4)3- 
86 
CDK8 76 CSNK1G1 81 GSK3B 82 p38-gamma 77 TGFBR1 82 ACVRL1 86 
DAPK2 76 DCAMKL3 81 
KIT (V559D, 
V654A) 
82 
PIK3CA 
(C420R) 
77 TNK1 82 
EGFR 
(T790M) 
86 
MEK4 77 BUB1 81 EPHA7 82 GRK4 77 EPHA5 82 
ABL1 
(F317I)- 
86 
EGFR 
(L858R,T79
0M) 
77 ADCK4 81 
ALK 
(C1156Y) 
82 FGFR4 77 CDC2L5 82 TIE1 87 
EPHB4 77 AXL 81 CLK3 82 FGR 77 DYRK1B 82 ULK1 87 
AURKB 77 
TYK2(JH2 
domain-
ps.kinase) 
82 VEGFR2 83 CASK 77 MAP3K4 83 TGFBR1 87 
PRKD3 78 RIOK2 82 TAOK3 83 ANKK1 77 ACVRL1 83 ERBB3 87 
TIE1 78 SGK 82 ULK1 83 BRSK1 77 BUB1 83 
FLT3 
(D835H) 
87 
MKK7 78 
PIK3CA 
(E545A) 
82 PCTK1 83 AKT3 77 PRKX 84 
ABL1 
(Y253F)-
(PO4)3- 
87 
CSNK1A1L 78 
ABL1-
(PO4)3- 
82 EPHB1 83 RET 78 MAP3K1 84 
FLT3-auto-
inhibited 
88 
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ERBB2 78 CAMK2D 82 
FLT3 
(D835H) 
83 SNRK 78 MRCKB 84 FRK 88 
GRK7 78 FRK 82 FLT3 (ITD) 83 SRMS 78 NEK4 84 PIK4CB 88 
JNK3 78 PDGFRA 82 MAP3K2 83 VPS34 78 
PIK3CA 
(Q546K) 
84 PKAC-alpha 88 
RPS6KA5 
(Kin. 
Dom.2-C-
terminal) 
79 PDPK1 83 CAMK2B 83 GRK1 78 CAMK1 84 ADCK4 88 
RSK4 (Kin. 
Dom.1-N-
terminal) 
79 RET 83 CDKL5 83 MEK6 78 
CDK4-
cyclinD3 
84 CDK4 88 
VEGFR2 79 
RPS6KA5 
(Kin. 
Dom.2-C-
terminal) 
83 DDR1 83 PRKD2 78 
FLT3 
(D835Y) 
84 EPHA2 88 
ACVR1B 79 GAK 83 
ABL1 
(Y253F)-
(PO4)3- 
83 ERK4 78 VRK2 85 PIK3C2G 89 
ACVR2A 79 MYLK2 83 
AMPK-
alpha1 
83 FYN 78 YANK1 85 WNK2 89 
ABL1- 79 
FLT3-auto-
inhibited 
83 WEE2 84 BTK 78 TIE2 85 IRAK3 89 
TBK1 80 
EGFR 
(L858R, 
T790M) 
83 PYK2 84 BMPR2 78 PKN2 85 
EGFR 
(L861Q) 
89 
WNK1 80 FGFR2 83 SGK3 84 BRK 78 
PKNB(M.tu
berculosis) 
85 ICK 89 
IRAK4 80 
ABL1 
(F317I)-
(PO4)3- 
83 MLCK 84 IKK-alpha 79 FGFR2 85 
ABL1 
(Q252H)- 
89 
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PCTK1 80 
ABL1 
(F317L)-
(PO4)3- 
83 NIK 84 TIE1 79 PIK3C2B 85 
ABL1-
(PO4)3- 
89 
SRPK2 80 DDR1 83 PKAC-beta 84 TRKB 79 PIP5K2C 85 DMPK 89 
AMPK-
alpha1 
80 TRPM6 84 GRK7 84 CDKL3 79 DYRK2 85 
ABL1 
(H396P)-
(PO4)3- 
89 
EPHA2 80 WNK4 84 IRAK4 84 EPHA2 79 EPHA2 85 
ABL1 
(M351T)-
(PO4)3- 
89 
ULK3 81 MAPKAPK5 84 ERK3 84 AURKA 79 
ABL1 
(F317L)- 
85 TRKC 90 
RIOK2 81 LATS2 84 ACVR2B 84 ACVR1B 79 PRKG2 86 MAPKAPK2 90 
NEK4 81 IRAK3 84 TRKB 85 
ABL1 
(Q252H)-
(PO4)3- 
79 MARK3 86 HPK1 90 
JAK1(JH2 
domain-
ps.kinase) 
81 ERBB3 84 IRAK1 85 TIE2 80 
ABL1 
(Q252H)- 
86 CLK2 90 
LRRK2(G20
19S) 
81 ERK4 84 JNK2 85 ULK2 80 KIT (A829P) 86 DAPK3 90 
INSR 81 CSNK2A1 84 HCK 85 SIK2 80 NEK1 87 CAMK4 90 
CDKL2 81 
ABL1 
(Q252H)-
(PO4)3- 
84 ERBB4 85 PIP5K1C 80 ABL1- 87 TLK2 91 
FLT3 
(R834Q) 
81 CLK4 84 FLT4 85 
RPS6KA4 
(Kin. 
Dom.1-N-
terminal) 
80 
JAK3(JH1 
domain-
catalytic) 
87 YANK1 91 
CAMK2D 81 PRKD2 85 TEC 86 p38-alpha 80 
PIK3CA 
(H1047L) 
88 PRKCI 91 
CAMK4 81 VEGFR2 85 ZAP70 86 PAK3 80 
RPS6KA4 
(Kin. 
88 SNARK 91 
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Dom.1-N-
terminal) 
PHKG2 82 ABL1- 85 LTK 86 
ABL1 
(H396P)-
(PO4)3- 
80 AKT3 88 ACVR1B 91 
PIK3CB 82 CAMK1G 85 MST4 86 DCAMKL3 80 CDK3 88 CAMK1D 91 
PIK3CD 82 
PIK3CA 
(E542K) 
85 
RPS6KA4 
(Kin. Dom.1-
N-terminal) 
86 ERBB3 80 FYN 88 MLCK 91 
TRKC 82 PIKFYVE 85 SRPK3 86 IRAK3 80 MEK4 88 
PKNB(M.tu
berculosis) 
91 
NEK11 82 
ABL1 
(H396P)- 
85 DYRK1B 86 STK16 81 INSR 89 PRP4 92 
NLK 82 
ABL1 
(M351T)-
(PO4)3- 
85 EPHB6 86 WNK2 81 YSK1 89 SRC 92 
ADCK4 82 PLK4 86 CAMK1G 86 PIM3 81 
EGFR 
(S752-
I759del) 
89 MARK3 92 
ASK1 82 
RSK3 (Kin. 
Dom.2-C-
terminal) 
86 CIT 86 RIOK2 81 EPHA1 89 MEK4 92 
EGFR 
(L861Q) 
82 TAOK1 86 CSNK1E 86 
RSK2 (Kin. 
Dom.1-N-
terminal) 
81 FLT3 89 PRKG2 92 
ADCK3 82 MEK1 86 AURKC 86 NLK 81 RET(V804L) 90 LKB1 92 
TYK2(JH2 
domain-
pskinase) 
83 
FLT3 
(D835Y) 
86 ARK5 86 HIPK4 81 WNK4 91 
JAK1(JH2 
domain-
pskinase) 
92 
PIP5K1C 83 
EGFR 
(L858R) 
86 
RSK2 (Kin. 
Dom.2-C-
terminal) 
87 CAMKK2 81 
RSK3 (Kin. 
Dom.1-N-
terminal) 
91 FGR 92 
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RSK2 (Kin. 
Dom.1-N-
terminal) 
83 
EGFR 
(L861Q) 
86 WNK1 87 ERK3 81 TGFBR2 91 FLT3 92 
MAST1 83 CDKL2 86 RET(M918T) 87 
RPS6KA5 
(Kin. 
Dom.2-C-
terminal) 
82 IRAK4 91 DRAK2 92 
CDKL3 83 
RSK1 (Kin. 
Dom.2-C-
terminal) 
87 MAPKAPK2 87 PIK3CB 82 BMPR1A 91 AKT3 92 
DAPK1 83 STK16 87 PKMYT1 87 PRKD1 82 CSK 91 BIKE 92 
ABL1 
(F317L)- 
83 RAF1 87 KIT (A829P) 87 MST1 82 AXL 91 WNK1 93 
MAP3K3 84 IKK-beta 87 
BRAF 
(V600E) 
87 CHEK1 82 NLK 92 ERBB4 93 
SGK3 84 
LRRK2 
(G2019S) 
87 CSNK1G1 87 FES 82 PAK3 92 FLT4 93 
TSSK3 84 LTK 87 EPHA2 87 
FLT3 
(R834Q) 
82 PIP5K1A 92 MYLK2 93 
YANK1 84 MAP4K3 87 GRK3 87 MAP4K3 82 STK16 92 PIP5K1A 93 
DDR1 84 ERK1 87 
RPS6KA4 
(Kin. Dom.2-
C-terminal) 
88 
AMPK-
alpha1 
82 NEK11 92 
EGFR 
(G719C) 
93 
LOK 85 EIF2AK1 87 PIK3CA 88 
ABL1 
(F317I)-
(PO4)3- 
83 FLT3 (ITD) 92 
CDK4-
cyclinD3 
93 
PIK3CA 
(E545A) 
85 EPHA5 87 
PIK3CA 
(E545A) 
88 PCTK1 83 LOK 92 CLK3 93 
ULK1 85 EPHA6 87 RET 88 S6K1 83 MEK6 92 DCAMKL3 93 
CTK 85 BRK 87 GRK2 88 
PIK3CA 
(E545A) 
84 
AMPK-
alpha1 
92 
ABL1 
(F317L)- 
93 
GRK1 85 CDK8 87 INSR 88 
PIK3CA 
(E545K) 
84 CDK4 92 ANKK1 93 
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KIT 
(D816V) 
85 CSK 87 MET 88 VEGFR2 84 FES 92 CDK3 93 
CAMK1G 85 BRAF 87 ERN1 88 p38-beta 84 TSSK1B 93 TIE2 94 
ABL1 
(Q252H)-
(PO4)3- 
86 MARK4 88 BRK 88 CTK 84 MLCK 93 MAP4K2 94 
ACVRL1 86 NLK 88 BUB1 88 FRK 84 MST2 93 RIPK1 94 
FLT3 86 PIM3 88 CLK2 88 MLCK 84 RET 93 STK35 94 
PIP5K1A 86 
RSK4 (Kin. 
Dom.2-C-
terminal) 
88 CSK 88 NEK1 84 TIE1 93 TBK1 94 
VRK2 87 LZK 88 ANKK1 88 CAMK4 84 LKB1 93 CSNK1G1 94 
STK35 87 LOK 88 TYRO3 89 ASK1 84 PRKG1 94 
ABL1 
(F317I)-
(PO4)3- 
94 
PRKCH 87 ITK 88 
RSK1 (Kin. 
Dom.2-C-
terminal) 
89 
ABL1 
(T315I)-
(PO4)3- 
84 PKAC-alpha 94 TNK1 95 
GRK3 87 CSNK1E 88 IGF1R 89 PRKD3 85 FLT4 94 PAK4 95 
HCK 87 ERK3 88 QSK 89 SGK 85 INSRR 94 PDGFRA 95 
BIKE 87 
TYK2(JH1 
domain-
catalytic) 
89 ERK8 89 PKMYT1 85 
EGFR 
(G719S) 
94 NEK5 95 
TRKA 88 PIP5K1A 89 CAMK2A 89 PAK1 85 
EGFR 
(G719C) 
94 
KIT 
(V559D,V6
54A) 
95 
PRKX 88 
PIK3CA 
(M1043I) 
89 AXL 89 NIK 85 TYRO3 95 ERK3 95 
PIK3CA 
(Q546K) 
88 GRK1 89 SIK2 90 MKNK2 85 ADCK3 95 DAPK2 95 
PIM1 88 LRRK2 89 WNK3 90 MYLK2 85 PIK3CG 95 
EGFR 
(G719S) 
95 
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MST3 88 
EGFR (S752-
I759del) 
89 RIOK3 90 MKK7 85 PKAC-beta 96 BRK 95 
CAMK2A 88 BRSK2 89 PIM1 90 ICK 85 EPHA3 96 PKN1 96 
EGFR 
(S752-
I759del) 
88 CAMK1D 89 RET(V804L) 90 MAP4K2 85 p38-beta 96 PRKD1 96 
S6K1 89 
ABL1 
(H396P)-
(PO4)3- 
89 
PIK3CA 
(M1043I) 
90 GAK 85 SRPK1 97 PIP5K1C 96 
MRCKB 89 
RET(V804M
) 
90 
JAK3(JH1 
domain-
catalytic) 
90 
ABL1 
(M351T)-
(PO4)3- 
85 
EGFR 
(E746-
A750del) 
97 ARK5 96 
PIK3CA 
(E542K) 
89 
RSK4 (Kin. 
Dom.1-N-
terminal) 
90 OSR1 90 BMPR1A 85 MST1 97 CAMK2G 96 
RIPK5 89 TGFBR2 90 PAK3 90 CSNK2A2 85 PIM3 97 
MET 
(Y1235D) 
96 
MLK2 89 PLK1 90 FLT1 90 ZAK 86 TNK2 98 
AMPK-
alpha2 
96 
CDK4 89 AURKB 90 DAPK3 90 TRPM6 86 ACVR1 98 
RET 
(M918T) 
97 
EPHB3 89 
BRAF(V600
E) 
90 
EGFR 
(G719C) 
90 
TYK2(JH2 
domain-
pskinase) 
86 AURKA 98 SRPK1 97 
FGR 89 EPHA3 90 
EGFR 
(L858R, 
T790M) 
90 YANK3 86 BLK 98 TSSK3 97 
TRPM6 90 
ABL1 
(F317I)- 
90 CSNK1A1 90 PIM1 86 
ABL1 
(H396P)- 
98 PHKG2 97 
CAMKK2 90 TIE1 91 STK36 91 LTK 86 FGR 99 
KIT 
(D816V) 
97 
TAOK2 90 ULK1 91 TSSK3 91 MST4 86 WNK1 99 PHKG1 97 
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PIK3CA 
(E545K) 
91 NEK2 91 PAK1 91 CAMK2G 86 
ALK 
(L1196M) 
99 
EGFR 
(L747-
T751del,Sin
s) 
97 
PKAC-beta 91 PAK7 91 
PKNB(M.tub
erculosis) 
91 
EGFR (L747-
E749del, 
A750P) 
86 ASK1 99 
EGFR 
(L858R, 
T790M) 
97 
TGFBR1 91 PIK3CB 91 PRKD2 91 HCK 86 BRSK1 99 FES 97 
TGFBR2 91 PIK4CB 91 RIPK2 91 LOK 86 CAMK2G 99 HCK 97 
CDK11 91 CHEK1 91 IRAK3 91 PDGFRA 87 YANK2 100 AKT1 97 
EPHA5 91 
FLT3 
(N841I) 
91 LYN 91 PIK3C2G 87 YANK3 100 BMX 97 
ERK3 91 MLCK 91 MAP4K4 91 QSK 87 YES 100 CDK11 97 
MAPKAPK2 91 MST1 91 MKK7 91 YSK1 87 ZAK 100 CSNK1E 97 
BRSK1 91 CASK 91 FLT3 (D835Y) 91 NIM1 87 WEE2 100 TGFBR2 98 
SBK1 92 ACVRL1 91 BIKE 91 EPHA1 87 TXK 100 
RET 
(V804M) 
98 
TSSK1B 92 BMPR1A 91 CTK 91 MAK 87 WEE1 100 
RSK4 (Kin. 
Dom.2-C-
terminal) 
98 
MET 
(Y1235D) 
92 STK36 92 AKT3 91 AURKC 87 TRPM6 100 MRCKA 98 
PIK3CA 92 TAOK3 92 
AMPK-
alpha2 
91 DRAK1 87 TSSK3 100 p38-beta 98 
PKMYT1 92 TSSK3 92 ASK2 91 EGFR 87 TTK 100 PDGFRB 98 
FLT3 
(N841I) 
92 SGK3 92 TNK2 92 TNK1 88 TNNI3K 100 BLK 98 
EPHA1 93 EGFR 92 CDK8 92 CDKL5 88 STK33 100 ADCK3 99 
FGFR3(G69
7C) 
93 EPHB6 92 
FLT3 
(K663Q) 
92 DRAK2 88 STK35 100 AXL 99 
FLT3 
(K663Q) 
93 
FLT3 
(K663Q) 
92 
FLT3 
(R834Q) 
92 EPHB4 88 STK36 100 CAMKK1 99 
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GCN2 (Kin. 
Dom.2,S80
8G) 
93 LYN 92 FRK 92 
FLT3 (ITD, 
D835V) 
88 SYK 100 CIT 99 
INSRR 93 MAP3K3 92 ITK 92 MARK1 88 TEC 100 EPHB4 99 
MEK6 93 MINK 92 MRCKB 92 
MET 
(Y1235D) 
88 TESK1 100 FGFR2 99 
MUSK 93 MLK1 92 NEK5 92 PDGFRB 88 TLK1 100 
GCN2 (Kin. 
Dom.2,S80
8G) 
99 
p38-
gamma 
93 p38-beta 92 STK35 92 TAOK3 88 TLK2 100 MERTK 99 
PRKCD 93 PRP4 92 STK39 92 TNIK 88 TNIK 100 STK16 99 
EGFR 
(L747-
T751del,Sin
s) 
93 ACVR1B 92 ABL2 92 
ALK 
(L1196M) 
88 SRPK2 100 YSK1 100 
EIF2AK1 93 DAPK3 92 CDK3 92 CAMK1D 88 SRPK3 100 ZAK 100 
ABL1 
(F317I)- 
93 MEK4 93 DCAMKL3 93 MKNK1 89 
RSK4 (Kin. 
Dom.2-C-
terminal) 
100 WEE1 100 
BMX 93 MRCKA 93 DMPK2 93 PHKG2 89 SIK 100 WEE2 100 
CAMK1D 93 NEK1 93 MAP3K4 93 PIK4CB 89 SIK2 100 YANK2 100 
CDK3 93 TBK1 93 PIM3 93 
RET 
(M918T) 
89 SLK 100 YANK3 100 
CSNK1G1 93 WNK2 93 SRPK1 93 YANK1 89 SRC 100 YES 100 
FLT3 
(D835Y) 
94 BRSK1 93 ACVR2A 93 
ABL1 
(T315I)- 
89 
RPS6KA5 
(Kin. 
Dom.1-N-
terminal) 
100 TNK2 100 
FLT4 94 CLK2 93 BMX 93 ADCK3 89 
RPS6KA5 
(Kin. 
100 TNNI3K 100 
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Dom.2-C-
terminal) 
LKB1 94 CSNK2A2 93 CAMK2D 93 ALK 89 
RSK1 (Kin. 
Dom.1-N-
terminal) 
100 TSSK1B 100 
NEK1 94 HCK 93 CDC2L5 93 CAMKK1 89 
RSK1 (Kin. 
Dom.2-C-
terminal) 
100 TXK 100 
PKAC-alpha 94 MAP3K2 93 CSF1R 93 GRK3 89 
RSK3 (Kin. 
Dom.2-C-
terminal) 
100 TYRO3 100 
ALK 
(L1196M) 
94 TEC 94 
ABL1 
(F317L)- 
93 
ABL1 
(F317L)-
(PO4)3- 
89 ROS1 100 TNIK 100 
RPS6KA5 
(Kin. 
Dom.1-N-
terminal) 
95 SRC 94 WNK4 94 ZAP70 90 RIPK2 100 TLK1 100 
BTK 96 MEK6 94 FGFR4 94 PCTK2 90 
RET 
(V804M) 
100 SYK 100 
CAMK2G 96 p38-alpha 94 MAP3K1 94 RET(V804L) 90 RIOK1 100 TAOK3 100 
RET 
(V804L) 
96 PFTAIRE2 94 PIP5K2B 94 RIOK1 90 RIOK3 100 TEC 100 
STK39 96 SIK2 94 RIPK1 94 
RSK4 (Kin. 
Dom.1-N-
terminal) 
90 RIPK1 100 TESK1 100 
STK33 97 CAMKK1 94 AURKA 94 MST3 90 PYK2 100 SRPK3 100 
YSK1 97 MAP4K5 94 CSNK1A1L 94 MTOR 90 RAF1 100 STK33 100 
ZAK 97 MEK3 94 DAPK1 94 MUSK 90 
RET 
(M918T) 
100 STK36 100 
BRK 97 CDK3 95 FGFR2 95 ABL1- 90 PRKCH 100 
RPS6KA5 
(Kin. 
100 
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Dom.2-C-
terminal) 
CDKL5 97 
EGFR (L747-
E749del, 
A750P) 
95 NEK11 95 ASK2 90 PRKCQ 100 
RSK1 (Kin. 
Dom.1-N-
terminal) 
100 
DMPK 97 GRK4 95 PDGFRB 95 CSNK1G1 90 PRKD1 100 
RSK1 (Kin. 
Dom.2-C-
terminal) 
100 
EPHA4 97 PAK1 95 TLK1 95 
FLT3 
(D835Y) 
90 PRKD2 100 
RSK3 (Kin. 
Dom.1-N-
terminal) 
100 
MEK3 97 PAK3 95 TNK1 95 HUNK 90 PRKD3 100 SIK 100 
NDR1 97 PRKR 95 VRK2 95 MAP3K3 90 PRKR 100 SLK 100 
p38-alpha 97 
RSK2 (Kin. 
Dom.1-N-
terminal) 
95 WNK2 95 MLK3 90 PRP4 100 SRPK2 100 
ARK5 97 BIKE 95 ERBB3 95 TAOK2 91 PRKCD 100 
RPS6KA5 
(Kin. 
Dom.1-N-
terminal) 
100 
SIK2 98 ASK1 95 CDK5 95 
RSK1 (Kin. 
Dom.2-C-
terminal) 
91 PLK4 100 
RPS6KA4 
(Kin. 
Dom.1-N-
terminal) 
100 
PIK3CG 98 ULK3 96 
ABL1 
(F317L)-
(PO4)3- 
95 MARK4 91 PKMYT1 100 RIPK2 100 
RET 98 YSK1 96 
ABL1 
(T315I)-
(PO4)3- 
95 RIOK3 91 PKN1 100 ROS1 100 
CAMKK1 98 DLK 96 TIE1 96 
FGFR3 
(G697C) 
91 PIK3CD 100 PYK2 100 
CSNK2A2 98 ERBB4 96 TIE2 96 FLT1 91 PIKFYVE 100 RAF1 100 
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MST1 98 LKB1 96 TRKA 96 JNK1 91 PIM1 100 RET 100 
MYO3A 98 PHKG1 96 YANK3 96 LIMK2 91 PIM2 100 RIOK1 100 
OSR1 98 TLK1 96 YES 96 LYN 91 PIP5K2B 100 RIOK3 100 
STK16 99 
AMPK-
alpha1 
96 DRAK1 96 CSK 91 
PIK3CA 
(H1047Y) 
100 PRKG1 100 
TNIK 99 CLK3 96 
KIT (V559D, 
T670I) 
96 EPHA5 91 
PIK3CA 
(M1043I) 
100 PRKR 100 
ABL1 
(F317I)-
(PO4)3- 
99 
JAK1(JH2 
domain-
pskinase) 
97 MEK4 97 LZK 92 PFTK1 100 PRKCH 100 
MYO3B 99 NEK7 97 PCTK3 97 MLK2 92 PHKG1 100 PRKCQ 100 
RET 
(V804M) 
99 NEK9 97 TESK1 97 
RSK4 (Kin. 
Dom.2-C-
terminal) 
92 PHKG2 100 PRKD2 100 
RPS6KA4 
(Kin. Dom. 
1-N-
terminal) 
99 TNIK 97 TNIK 97 SRC 92 PIK3C2G 100 PRKD3 100 
TYRO3 100 
ABL1 
(F317L)- 
97 BLK 97 CAMK2D 92 PAK7 100 PIM3 100 
WEE1 100 CAMK2G 97 BMPR1A 97 CDKL2 92 PCTK2 100 PIP5K2B 100 
WEE2 100 DMPK2 97 
EGFR (L747-
E749del, 
A750P) 
97 
EGFR 
(L858R) 
92 PCTK3 100 PKAC-beta 100 
YANK2 100 ERBB2 97 FGR 97 EPHA3 92 PDGFRB 100 PKMYT1 100 
YANK3 100 FER 97 FLT3 97 FLT4 92 PDPK1 100 PLK4 100 
YES 100 IGF1R 97 LIMK2 97 JNK3 92 PFTAIRE2 100 PRKCD 100 
TXK 100 STK35 98 
ABL1 
(M351T)-
(PO4)3- 
97 VRK2 93 PAK6 100 PIM2 100 
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TESK1 100 DAPK1 98 
ABL1 
(F317I)-
(PO4)3- 
98 
FLT3 
(K663Q) 
93 NEK9 100 
PIK3CA 
(E542K) 
100 
TIE2 100 
EGFR 
(G719S) 
98 DAPK2 98 
FLT3-auto-
inhibited 
93 p38-alpha 100 
PIK3CA 
(H1047Y) 
100 
TLK1 100 FGR 98 EPHA4 98 MARK2 93 p38-delta 100 
PIK3CA 
(M1043I) 
100 
TLK2 100 
PIK3CA 
(Q546K) 
98 NEK1 98 MAST1 93 
p38-
gamma 
100 PIK3CD 100 
TNK1 100 ROS1 98 PAK4 98 PIP5K2C 93 PAK1 100 PIK3CG 100 
TNK2 100 SLK 98 PCTK2 98 SLK 93 PAK2 100 PIKFYVE 100 
TNNI3K 100 SNARK 98 VPS34 98 TSSK3 93 PAK4 100 PIM1 100 
SYK 100 AKT1 98 PRKCD 99 DMPK2 93 NEK6 100 PIK3C2B 100 
TEC 100 CDK4 98 WEE1 99 FGFR2 93 NEK7 100 PIK3CA 100 
SRPK1 100 LIMK2 99 NEK4 99 
ABL1 
(H396P)- 
93 NDR2 100 PDPK1 100 
SRPK3 100 p38-delta 99 PAK7 99 ACVR1 93 NEK2 100 PFTAIRE2 100 
STK36 100 
RPS6KA4 
(Kin.Dom. 
2-C-
terminal) 
99 PFTK1 99 ACVRL1 93 NEK5 100 PFTK1 100 
SIK 100 AURKA 99 GRK1 99 LCK 94 MYLK4 100 PAK7 100 
SLK 100 FES 99 
JAK1(JH1 
domain-
catalytic) 
99 SBK1 94 MYO3A 100 PCTK2 100 
SRC 100 FLT3 (ITD) 99 
MET 
(Y1235D) 
99 TXK 94 MYO3B 100 PCTK3 100 
RSK4 (Kin. 
Dom.2-C-
terminal) 
100 ZAK 100 EPHA1 99 FLT3 (ITD) 94 MUSK 100 PAK6 100 
RIPK2 100 WEE2 100 ACVR1 99 EIF2AK1 95 MLK3 100 
p38-
gamma 
100 
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ROS1 100 YANK2 100 CAMK2G 99 LRRK2 95 MRCKA 100 PAK1 100 
RSK1 (Kin. 
Dom.1-N-
terminal) 
100 YANK3 100 CDC2L1 99 SRPK1 95 MST1R 100 PAK2 100 
RSK1 (Kin. 
Dom.2-C-
terminal) 
100 YES 100 DRAK2 99 WNK1 95 MST3 100 PAK3 100 
RIOK3 100 VRK2 100 YSK1 100 
AMPK-
alpha2 
95 MLK1 100 p38-alpha 100 
RIPK1 100 WEE1 100 ZAK 100 DMPK 95 MLK2 100 p38-delta 100 
PIK3CA 
(M1043I) 
100 STK33 100 
RSK4 (Kin. 
Dom.2-C-
terminal) 
100 AURKB 96 MAP4K4 100 MTOR 100 
PIM2 100 SYK 100 SIK 100 CDC2L1 96 MAP4K5 100 MUSK 100 
PIM3 100 TESK1 100 SLK 100 CDK3 96 MAPKAPK2 100 MYLK4 100 
PIP5K2B 100 TIE2 100 SRC 100 ERN1 96 MARK1 100 MYO3A 100 
PLK4 100 TLK2 100 SYK 100 FGFR3 96 MARK2 100 MYO3B 100 
PRKCQ 100 TNK1 100 TGFBR2 100 INSRR 96 MARK4 100 NDR2 100 
PRKD2 100 TNK2 100 TLK2 100 
KIT 
(V559D,V65
4A) 
96 MAST1 100 NEK1 100 
PRKR 100 TRKA 100 TRKC 100 MLK1 96 MELK 100 NEK2 100 
PYK2 100 TRKC 100 TRPM6 100 
PIK3CA 
(H1047L) 
96 MERTK 100 NEK6 100 
RAF1 100 TSSK1B 100 TSSK1B 100 TGFBR2 96 MET 100 NEK7 100 
RET(M918T
) 
100 TXK 100 TXK 100 TRKA 96 
MET 
(M1250T) 
100 NEK9 100 
RIOK1 100 TYRO3 100 YANK2 100 WNK4 96 
MET 
(Y1235D) 
100 OSR1 100 
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PHKG1 100 
RSK1 (Kin. 
Dom.1-N-
terminal) 
100 
RPS6KA5 
(Kin. Dom.1-
N-terminal) 
100 CAMK2A 97 
LRRK2 
(G2019S) 
100 MLK3 100 
PIK3C2B 100 SIK 100 
RPS6KA5 
(Kin. Dom.2-
C-terminal) 
100 CAMK2B 97 LTK 100 MRCKB 100 
PIK3C2G 100 SRPK1 100 
RSK1 (Kin. 
Dom.1-N-
terminal) 
100 DLK 97 LYN 100 MST1 100 
PIK3CA 
(H1047Y) 
100 SRPK2 100 
RSK3 (Kin. 
Dom.1-N-
terminal) 
100 KIT (D816V) 97 MAK 100 MST1R 100 
PIK3CA 
(I800L) 
100 SRPK3 100 
RSK3 (Kin. 
Dom.2-C-
terminal) 
100 
PIK3CA 
(Q546K) 
97 MAP4K3 100 MST2 100 
PAK7 100 
RET 
(M918T) 
100 PRKCQ 100 CAMK1G 98 
KIT 
(V559D) 
100 MAST1 100 
PCTK2 100 RET(V804L) 100 PRKR 100 
EGFR (L747-
T751 
del,Sins) 
98 
KIT (V559D, 
T670I) 
100 MEK6 100 
PCTK3 100 RIOK1 100 PRKX 100 KIT 98 
KIT (V559D, 
V654A) 
100 MELK 100 
PDGFRB 100 RIOK3 100 PRP4 100 MST2 98 LATS1 100 MET 100 
PDPK1 100 RIPK1 100 RET(V804M) 100 PIK3C2B 98 LCK 100 
MET 
(M1250T) 
100 
PFTAIRE2 100 RIPK4 100 RIPK4 100 PIKFYVE 98 LIMK1 100 MLK1 100 
PFTK1 100 
RPS6KA5 
(Kin. 
Dom.1-N-
terminal) 
100 ROS1 100 TLK2 98 LIMK2 100 MLK2 100 
NEK9 100 PIM2 100 PIM2 100 ERK2 99 IRAK3 100 MAP4K3 100 
p38-beta 100 PIP5K2B 100 PIP5K1A 100 MERTK 99 ITK 100 MAP4K4 100 
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PAK1 100 PIP5K2C 100 PIP5K2C 100 PAK2 99 
JAK1(JH1 
domain-
catalytic) 
100 MAP4K5 100 
PAK2 100 PKMYT1 100 PKN1 100 PHKG1 99 KIT 100 MARK1 100 
PAK4 100 PYK2 100 PLK4 100 PRP4 99 
KIT 
(D816V) 
100 MARK2 100 
PAK6 100 QSK 100 PRKCH 100 ULK1 99 KIT (L576P) 100 MARK4 100 
ABL2 100 ACVR1 100 
ABL1 
(Q252H)-
(PO4)3- 
100 
ABL1 
(F317I)- 
100 AAK1 100 AAK1 100 
ACVR1 100 ACVR2A 100 ACVR1B 100 
ABL1 
(F317L)- 
100 ABL2 100 
ABL1 
(H396P)- 
100 
AKT1 100 ACVR2B 100 ADCK3 100 ABL2 100 ACVR2A 100 
ABL1 
(Q252H)-
(PO4)3- 
100 
AKT2 100 AKT2 100 ADCK4 100 ACVR2A 100 ACVR2B 100 ABL1- 100 
AKT3 100 
AMPK-
alpha2 
100 AKT1 100 ACVR2B 100 ADCK4 100 ABL2 100 
AMPK-
alpha2 
100 ANKK1 100 AKT2 100 AKT1 100 AKT1 100 ACVR1 100 
ANKK1 100 ARK5 100 ASK1 100 BLK 100 AKT2 100 ACVR2A 100 
AURKA 100 ASK2 100 BRSK1 100 BRSK2 100 
AMPK-
alpha2 
100 ACVR2B 100 
AURKC 100 AURKC 100 BRSK2 100 CAMK1 100 ARK5 100 AKT2 100 
AXL 100 BLK 100 CDC2L2 100 CDC2L2 100 AURKC 100 ASK1 100 
BLK 100 BTK 100 CDK11 100 CDK2 100 BIKE 100 AURKA 100 
BMPR1A 100 CAMK2A 100 CDK2 100 CDK4 100 BMX 100 AURKC 100 
BRSK2 100 CAMK2B 100 CDK4 100 CDK5 100 BRK 100 BMPR1A 100 
CAMK1 100 CDC2L1 100 
CDK4-
cyclinD1 
100 CDK8 100 BRSK2 100 BRSK1 100 
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CDC2L1 100 CDC2L2 100 
CDK4-
cyclinD3 
100 CHEK2 100 CAMK1D 100 BRSK2 100 
CDC2L2 100 CDK2 100 CDK9 100 CSF1R 100 CAMK1G 100 CAMK1G 100 
CDK2 100 CDK5 100 CDKL2 100 DCAMKL2 100 CAMK2A 100 CAMK2A 100 
CDK5 100 CDKL5 100 CHEK2 100 
EGFR 
(L858R,T79
0M) 
100 CAMK2B 100 CAMK2B 100 
CHEK1 100 CHEK2 100 CSNK1D 100 EPHA7 100 CAMK2D 100 CAMK2D 100 
CHEK2 100 CSF1R 100 CSNK1G3 100 EPHA8 100 CAMK4 100 CAMKK2 100 
CSF1R 100 CSNK1A1L 100 DCAMKL2 100 EPHB1 100 CAMKK1 100 CDC2L1 100 
CSK 100 CSNK1D 100 EGFR 100 ERBB2 100 CAMKK2 100 CDC2L2 100 
DCAMKL2 100 CSNK1G2 100 
EGFR 
(G719S) 
100 ERBB4 100 CDC2L1 100 CDK2 100 
DMPK2 100 CSNK1G3 100 
EGFR 
(L858R) 
100 ERK1 100 CDC2L2 100 CDK8 100 
EGFR 100 DAPK2 100 
EGFR (S752-
I759del) 
100 ERK5 100 CDK2 100 CDK9 100 
EGFR 
(E746-
A750del) 
100 DCAMKL2 100 EPHA3 100 FAK 100 CDK5 100 CHEK1 100 
EGFR 
(G719C) 
100 DRAK1 100 EPHA5 100 FGFR1 100 CDK8 100 CHEK2 100 
EGFR 
(G719S) 
100 
EGFR 
(G719C) 
100 EPHA6 100 
FLT3 
(D835H) 
100 CDK9 100 CLK1 100 
EGFR 
(L747-
E749del, 
A750P) 
100 
EGFR (L747-
T751 
del,Sins) 
100 EPHB3 100 
FLT3 
(N841I) 
100 CDKL2 100 CLK4 100 
EGFR 
(L747-S752 
del, P753S) 
100 EPHA1 100 EPHB4 100 IGF1R 100 CHEK1 100 CSF1R 100 
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EGFR 
(L858R) 
100 EPHA7 100 ERBB2 100 IKK-beta 100 CHEK2 100 CSK 100 
EPHA3 100 EPHA8 100 ERK2 100 IRAK4 100 CIT 100 CSNK1A1L 100 
EPHA6 100 ERK2 100 ERK4 100 ITK 100 CLK1 100 CSNK1D 100 
EPHA7 100 ERK5 100 ERK5 100 KIT (D816H) 100 CLK2 100 CSNK1G2 100 
EPHA8 100 FAK 100 FAK 100 KIT (L576P) 100 CLK3 100 CSNK1G3 100 
EPHB1 100 FGFR1 100 FER 100 KIT (V559D) 100 CLK4 100 CSNK2A2 100 
EPHB2 100 
FGFR3 
(G697C) 
100 FES 100 
KIT (V559D, 
T670I) 
100 CSF1R 100 CTK 100 
ERK1 100 FLT1 100 FGFR1 100 LATS1 100 CSNK1A1L 100 DAPK1 100 
ERK2 100 
FLT3 
(D835H) 
100 FGFR3 100 LIMK1 100 CSNK1D 100 DCAMKL2 100 
ERK4 100 
FLT3 
(R834Q) 
100 
FGFR3 
(G697C) 
100 
LRRK2 
(G2019S) 
100 CSNK1E 100 DDR1 100 
ERK5 100 FLT4 100 GAK 100 MAP3K4 100 CSNK1G1 100 DMPK2 100 
ERN1 100 GSK3A 100 
GCN2 (Kin. 
Dom.2,S808
G) 
100 MAP4K4 100 CSNK1G2 100 DRAK1 100 
FAK 100 HIPK4 100 GSK3A 100 MAP4K5 100 CSNK1G3 100 DYRK2 100 
FER 100 HUNK 100 HIPK2 100 MARK3 100 CSNK2A2 100 EGFR 100 
FES 100 ICK 100 HPK1 100 MEK3 100 DAPK1 100 
EGFR 
(L747-
E749del, 
A750P) 
100 
FGFR1 100 IKK-epsilon 100 HUNK 100 MELK 100 DAPK2 100 
EGFR 
(L858R) 
100 
FGFR4 100 INSRR 100 ICK 100 MET 100 DAPK3 100 
EGFR 
(S752-
I759del) 
100 
FLT1 100 IRAK4 100 IKK-epsilon 100 
MET 
(M1250T) 
100 DCAMKL2 100 EPHA1 100 
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FLT3 
(D835H) 
100 
JAK1(JH1 
domain-
catalytic) 
100 INSRR 100 MRCKA 100 DCAMKL3 100 EPHA3 100 
FLT3 (ITD) 100 KIT 100 
JAK1(JH2 
domain-
ps.kinase) 
100 MRCKB 100 DDR1 100 EPHA4 100 
FRK 100 KIT (D816H) 100 KIT 100 MST1R 100 DMPK 100 EPHA6 100 
FYN 100 KIT (L576P) 100 KIT (D816V) 100 MYLK4 100 DMPK2 100 EPHA7 100 
GAK 100 KIT (V559D) 100 KIT (L576P) 100 NDR2 100 DRAK1 100 EPHA8 100 
GRK4 100 
KIT (V559D, 
T670I) 
100 KIT (V559D) 100 NEK11 100 DRAK2 100 EPHB1 100 
HIPK4 100 LATS1 100 LCK 100 NEK2 100 EGFR 100 EPHB2 100 
IGF1R 100 LCK 100 LIMK1 100 NEK5 100 
EGFR 
(L747-
E749del, 
A750P) 
100 EPHB3 100 
IRAK3 100 LIMK1 100 LKB1 100 NEK6 100 
EGFR 
(L747-
T751del,Sin
s) 
100 ERK1 100 
ITK 100 MAK 100 
LRRK2 
(G2019S) 
100 NEK7 100 
EGFR 
(L858R) 
100 ERK4 100 
JAK1(JH1 
domain-
catalytic) 
100 MAP3K4 100 LZK 100 NEK9 100 
EGFR 
(L861Q) 
100 ERK5 100 
KIT 100 MAP4K4 100 MAK 100 OSR1 100 EPHA4 100 ERK8 100 
KIT (L576P) 100 MARK2 100 MAP4K3 100 PAK4 100 EPHA6 100 ERN1 100 
KIT 
(V559D) 
100 MARK3 100 MARK1 100 PAK6 100 EPHA7 100 FAK 100 
KIT 
(V559D,T6
70I) 
100 MELK 100 MARK4 100 PAK7 100 EPHA8 100 FER 100 
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KIT 
(V559D,V6
54A) 
100 MERTK 100 MAST1 100 PCTK3 100 EPHB1 100 FGFR3 100 
LATS1 100 MET 100 MEK6 100 PDPK1 100 EPHB2 100 
FGFR3 
(G697C) 
100 
LCK 100 
MET 
(M1250T) 
100 MELK 100 PFTAIRE2 100 EPHB3 100 FGFR4 100 
LIMK1 100 
MET 
(Y1235D) 
100 MERTK 100 PFTK1 100 ERBB2 100 FLT1 100 
LIMK2 100 MLK3 100 
MET 
(M1250T) 
100 
PIK3CA 
(E542K) 
100 ERBB4 100 
FLT3 
(D835Y) 
100 
LYN 100 MST1R 100 MLK2 100 
PIK3CA 
(H1047Y) 
100 ERK1 100 FLT3 (ITD) 100 
MAK 100 MST2 100 MLK3 100 
PIK3CA 
(I800L) 
100 ERK2 100 
FLT3 
(K663Q) 
100 
MAP3K4 100 MST3 100 MST1R 100 
PIK3CA 
(M1043I) 
100 ERK3 100 
FLT3 
(N841I) 
100 
MAP4K3 100 MST4 100 MST2 100 PIM2 100 ERK4 100 GAK 100 
MAP4K4 100 MTOR 100 MST3 100 PIP5K1A 100 ERK5 100 GRK4 100 
MAP4K5 100 MUSK 100 MTOR 100 PIP5K2B 100 ERK8 100 GSK3A 100 
MARK1 100 MYLK 100 MUSK 100 PLK4 100 FAK 100 HIPK4 100 
MARK2 100 MYLK4 100 MYLK2 100 PRKR 100 FER 100 HUNK 100 
MARK4 100 NDR1 100 MYLK4 100 PYK2 100 FGFR1 100 IGF1R 100 
MELK 100 NDR2 100 MYO3A 100 RIPK1 100 FGFR3 100 INSR 100 
MERTK 100 NEK11 100 NDR2 100 
RPS6KA5 
(Kin. 
Dom.1-N-
terminal) 
100 
FGFR3 
(G697C) 
100 INSRR 100 
MET 100 NEK4 100 NEK2 100 
RSK1 (Kin. 
Dom.1-N-
terminal) 
100 FGFR4 100 ITK 100 
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MET 
(M1250T) 
100 NEK5 100 NEK6 100 SIK 100 FLT1 100 
JAK1(JH1 
domain-
catalytic) 
100 
MLK1 100 NEK6 100 p38-alpha 100 SRPK2 100 
FLT3 
(K663Q) 
100 KIT 100 
MLK3 100 OSR1 100 p38-beta 100 STK33 100 
FLT3 
(N841I) 
100 KIT (L576P) 100 
MRCKA 100 PAK4 100 p38-delta 100 TEC 100 FRK 100 
KIT 
(V559D) 
100 
MST2 100 PAK6 100 PAK2 100 TLK1 100 GAK 100 
KIT 
(V559D,T67
0I) 
100 
MTOR 100 PCTK1 100 PAK6 100 TNK2 100 
GCN2 (Kin. 
Dom.2,S80
8G) 
100 LATS1 100 
MYLK2 100 PCTK2 100 PDPK1 100 TRKC 100 GRK4 100 LCK 100 
MYLK4 100 PCTK3 100 PHKG1 100 TYRO3 100 GSK3A 100 LIMK1 100 
NDR2 100 PDGFRB 100 PHKG2 100 ULK3 100 GSK3B 100 LIMK2 100 
NEK2 100 PFTK1 100 PIK3C2B 100 WEE1 100 HCK 100 LTK 100 
NEK5 100 PIK3C2B 100 
PIK3CA 
(H1047Y) 
100 WEE2 100 HIPK4 100 LYN 100 
NEK6 100 
PIK3CA 
(H1047Y) 
100 PIK3CG 100 YANK2 100 HUNK 100 MAK 100 
NEK7 100 PIM1 100 PIK4CB 100 YES 100 IGF1R 100 MAP3K4 100 
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Appendix 2 Crystal structures used in X-Docking Studies 
Table B List of DiscoverX targets with corresponding physiologically relevant PDB codes used in XDocking 
experiments 
KINASE HIT FROM DISCOVERX PDB CODE 
PI3Ka 4FA6 
ROCK1 3TV7 
ROCK1 3V8S 
GSK3 3L1S 
VEGFR2 3VHE 
JNK1 4AWI 
p38 5WJJ 
AurA 5DN3 
MELK 5K00 
FLT3 4XUF 
PKN2 4CRS 
PKN1 4OTH 
CHEK2 2CN5 
RSK1(Kin.Dom.1-N-terminal) 2Z7Q 
LIMK1 3S95 
CDK2 4EK4 
FAK 4I4E 
PIK3CA(H1047Y) 4JPS 
PAK6 4KS7 
MET(M1250T) 4MXC 
PIM2 4X7Q 
MELK 5K00 
ERK5/MAPK7 5O7I 
KIT(L576P) 6GQJ 
 
